[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSXOPjqHt2-jGWUZHT5-_L8j3fmubrOz2QnACi1kUIV8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University of Michigan",[4,6],"University of Michigan Rogel Cancer Center",1784,false,296,46,620801,84,1346,[15,18,21,24,26,29,32,35],{"name":16,"count":17},"Depression",52,{"name":19,"count":20},"Breast Cancer",50,{"name":22,"count":23},"Healthy",38,{"name":25,"count":23},"Prostate Cancer",{"name":27,"count":28},"Obesity",28,{"name":30,"count":31},"Hypertension",23,{"name":33,"count":34},"Anxiety",21,{"name":36,"count":37},"Chronic Pain",19,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03787680","Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","2023-01-26","Olaparib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05351164","Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)","2024-04-08","Metreleptin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04140162","Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy","2024-05-02","Daratumumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04477200","Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","2025-01-06","Mycophenolate Mofetil",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04848337","Pembrolizumab and Lenvatinib in Advanced\u002FMetastatic Neuroendocrine Prostate Cancer","2025-01-08","Pembrolizumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03842696","Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","2025-07-30","Vorinostat",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05988918","Multicenter Trial of ESK981 in Patients With Select Solid Tumors","2026-02-21","ESK981",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05574400","The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study","2026-04-16","Dextrose Water",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04748042","Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","2026-05","Abiraterone",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT06840470","Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia","2026-05-06","Imiquimod 5% Topical Cream",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,154,176,198,364,410,432,468,493,511,540,563,589,625,649,674,699,811,883,922,964,991,1017,1059,1181,1208,1342,1412,1452,1506,1556,1591,1617,1666,1698,1733,1755,1781,1812,1830,1848,1866,1889,1907,1933,1956,1980,2004,2028,2046,2064,2082,2100,2125,2143,2161,2179,2205,2223,2249,2267,2296,2314,2340,2430,2497,2545,2569,2593,2621,2639,2657,2679,2704,2730,2756,2774,2792,2810,2834,2860,2878,2896,2914,2939,3001,3055,3083,3120,3157,3189,3214,3239,3263,3285,3309,3335,3361,3384,3410,3437,3455,3481,3499,3517,3535,3561,3579,3604,3632,3654,3677,3701,3726,3744,3766,3789,3813,3836,3863,3881,3899,3917,3941,3968,3995,4017,4035,4058,4081,4105,4129,4154,4172,4198,4216,4234,4252,4270,4294,4316,4340,4363,4387,4410,4433,4457,4475,4498,4522,4540,4564,4582,4607,4625,4657,4690,4725,4748,4766,4793,4811,4836,4860,4888,4912,4936,4954,4972,4990,5015,5040,5064,5087,5105,5128,5153,5171,5195,5221,5320,5378,5424,5458,5484,5516,5552,5590,5616,5638,5665,5687,5709,5731,5764,5786,5813,5843,5878,5900,5932,5970,5996,6022,6055,6082,6111,6133,6168,6191,6213,6231,6255,6273,6301,6323,6341,6363,6388,6406,6428,6452,6470,6495,6513,6531,6558,6576,6594,6612,6630,6648,6671,6689,6716,6734,6757,6780,6805,6823,6850,6868,6886,6909,6927,6950,6972,6997,7015,7039,7057,7080,7104,7122,7140,7158,7176,7200,7226,7249,7267,7285,7310,7332,7350,7376,7394,7415,7438,7456,7474,7495,7516,7540,7566,7589,7607,7630,7654,7672,7690,7713,7736,7754,7777,7801,7826,7848,7866,7889,7907,7933,7957,7975,7993,8016,8040,8058,8080,8101,8119,8142,8165,8183,8205,8229,8247,8271,8295,8317,8340,8364,8385,8408,8433,8451,8476,8498,8521,8539,8563,8587,8610,8633,8651,8673,8697,8715,8733,8758,8776,8800,8822,8847,8877,8901,8924,8949,8972,9000,9018,9040,9062,9080,9098,9116,9139,9164,9182,9204,9226,9244,9269,9287,9309,9331,9354,9376,9401,9428,9446,9474,9492,9510,9528,9550,9574,9592,9615,9636,9668,9690,9717,9735,9753,9771,9789,9807,9830,9852,9876,9894,9918,9936,9961,9983,10006,10024,10053,10071,10089,10107,10125,10143,10161,10185,10261,10308,10346,10393,10447,10473,10514,10540,10572,10599,10621,10647,10677,10709,10727,10745,10763,10781,10799,10817,10835,10858,10883,10905,10927,10949,10972,10994,11020,11044,11062,11085,11103,11121,11144,11162,11185,11207,11233,11251,11276,11302,11328,11350,11376,11394,11417,11435,11461,11479,11497,11519,11542,11567,11585,11603,11621,11639,11662,11686,11708,11731,11749,11772,11798,11816,11834,11852,11876,11897,11918,11939,11966,11988,12011,12035,12060,12078,12096,12118,12136,12161,12179,12197,12220,12238,12261,12279,12303,12325,12346],{"intervention":98,"totalTrials":99,"cells":100},"Acetaminophen",3,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":152},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[],{"trials":109,"activeCount":103},[],{"trials":111,"activeCount":151,"soonestReadout":145},[112,126,141],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":124},"NCT02891174","The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy","COMPLETED",[94],"2018-03-31","2018-06-20","2016-12-01",74,[122,123],"Hypertension, Pregnancy-Induced","Pre-eclampsia",[125,98],"Ibuprofen",{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":138},"NCT05722002","Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial","RECRUITING",[94],"2026-12","2027-07","2023-02-06",900,[136,137],"Surgery","Pain, Postoperative",[139,140,98],"NSAID","Opioid",{"nctId":142,"briefTitle":143,"status":129,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":134,"conditions":148,"interventions":150},"NCT06671002","Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial",[94],"2026-10-16","2027-10-31","2025-01-10",[136,149],"Pain, Post Operative",[139,140,98,125],2,{"trials":153,"activeCount":103},[],{"intervention":139,"totalTrials":151,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":174},{"trials":157,"activeCount":103},[],{"trials":159,"activeCount":103},[],{"trials":161,"activeCount":103},[],{"trials":163,"activeCount":103},[],{"trials":165,"activeCount":151,"soonestReadout":145},[166,170],{"nctId":127,"briefTitle":128,"status":129,"phases":167,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":168,"interventions":169},[94],[136,137],[139,140,98],{"nctId":142,"briefTitle":143,"status":129,"phases":171,"primaryCompletion":145,"completion":146,"start":147,"enrollment":134,"conditions":172,"interventions":173},[94],[136,149],[139,140,98,125],{"trials":175,"activeCount":103},[],{"intervention":140,"totalTrials":151,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":196},{"trials":179,"activeCount":103},[],{"trials":181,"activeCount":103},[],{"trials":183,"activeCount":103},[],{"trials":185,"activeCount":103},[],{"trials":187,"activeCount":151,"soonestReadout":145},[188,192],{"nctId":127,"briefTitle":128,"status":129,"phases":189,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":190,"interventions":191},[94],[136,137],[139,140,98],{"nctId":142,"briefTitle":143,"status":129,"phases":193,"primaryCompletion":145,"completion":146,"start":147,"enrollment":134,"conditions":194,"interventions":195},[94],[136,149],[139,140,98,125],{"trials":197,"activeCount":103},[],{"intervention":199,"totalTrials":200,"cells":201},"Paclitaxel",13,{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":326,"PHASE4":328,"NA":340},{"trials":203,"activeCount":103},[],{"trials":205,"activeCount":103},[],{"trials":207,"activeCount":241,"soonestReadout":317},[208,223,235,245,256,266,278,291,302,313],{"nctId":209,"briefTitle":210,"status":211,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT00570531","Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma","TERMINATED",[92],"2010-10","2013-06","2007-06",6,[218],"Loco-regional Esophageal Cancer",[220,199,221,222],"Bevacizumab","Cisplatin","5-Fluorouracil",{"nctId":224,"briefTitle":225,"status":115,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT03416153","Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer",[92],"2023-05-05","2025-05-05","2018-05-21",91,[232],"Oropharynx Cancer",[234,199],"Carboplatin",{"nctId":236,"briefTitle":237,"status":211,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT00161278","Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling",[92],"2006-08","2004-12",1,[243],"Advanced Non-Small Cell Lung Cancer",[234,199],{"nctId":246,"briefTitle":247,"status":115,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT03829722","Radiotherapy, Carboplatin\u002FPaclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer",[92],"2024-06-11","2019-09-05",26,[253],"Oropharynx Squamous Cell Carcinoma",[255,234,199],"Nivolumab",{"nctId":257,"briefTitle":258,"status":115,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"conditions":263,"interventions":265},"NCT00230451","Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma",[92],"1999-12","2008-07","1997-11",[264],"Esophageal Cancer",[199,221,222],{"nctId":267,"briefTitle":268,"status":115,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT00136175","Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder",[92],"2005-12","2007-10","1999-11",68,[275],"Bladder Cancer",[199,234,277],"Gemcitabine",{"nctId":279,"briefTitle":280,"status":281,"phases":282,"primaryCompletion":283,"start":284,"enrollment":103,"conditions":285,"interventions":287},"NCT02013453","A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer","WITHDRAWN",[92],"2016-12","2013-12",[286],"Cancer of Head and Neck",[288,234,289,199,290],"Omeprazole","5FU","Pemetrexed",{"nctId":292,"briefTitle":293,"status":115,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":28,"conditions":298,"interventions":299},"NCT00151060","Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate",[92],"2004-11","2006-06","1998-12",[25],[300,301,199],"Estramustine","Etoposide",{"nctId":303,"briefTitle":304,"status":115,"phases":305,"primaryCompletion":306,"completion":271,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT00151034","Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer",[92],"2004-08","2000-09",33,[310],"Urologic Neoplasms",[312,199,234,277],"Trastuzumab",{"nctId":314,"briefTitle":315,"status":129,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":20,"conditions":319,"interventions":325},"NCT07121595","Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial",[92],"2030-07-01","2025-07-17",[320,321,322,323,324],"Oral Cavity Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8",[234,221,199],{"trials":327,"activeCount":103},[],{"trials":329,"activeCount":241,"soonestReadout":334},[330],{"nctId":331,"briefTitle":332,"status":129,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT05183126","Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer",[94],"2026-06","2022-03-28",22,[19,338,264],"Metastatic Gastric Cancer",[199,199],{"trials":341,"activeCount":103},[342,354],{"nctId":343,"briefTitle":344,"status":115,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT02492867","A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer",[95],"2021-11-28","2022-04-21","2016-01-14",49,[351],"Carcinoma, Non-Small-Cell Lung",[234,199,353],"Durvalumab",{"nctId":355,"briefTitle":356,"status":115,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":363},"NCT00580983","Optimized Intensity Modulated Irradiation for Head and Neck Cancer",[95],"2010-06","2003-08",90,[362],"Head and Neck Cancer",[199,234,221,222],{"intervention":365,"totalTrials":99,"cells":366},"Dupilumab",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":408},{"trials":368,"activeCount":103},[],{"trials":370,"activeCount":103},[],{"trials":372,"activeCount":103},[],{"trials":374,"activeCount":103},[],{"trials":376,"activeCount":241,"soonestReadout":131},[377,388,398],{"nctId":378,"briefTitle":379,"status":115,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT06012448","The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction",[94],"2025-01-07","2025-03-25","2023-10-02",10,[386],"Dermal Hypersensitivity Reaction",[365],{"nctId":389,"briefTitle":390,"status":115,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT05036733","Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma",[94],"2023-06-29","2022-02-22",15,[396],"Asthma",[365],{"nctId":399,"briefTitle":400,"status":129,"phases":401,"primaryCompletion":131,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},"NCT05268107","Ethnic Differences in Mechanisms of Action of Dupilumab",[94],"2027-06","2023-01-25",30,[406],"Atopic Dermatitis",[365],{"trials":409,"activeCount":103},[],{"intervention":125,"totalTrials":151,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":430},{"trials":413,"activeCount":103},[],{"trials":415,"activeCount":103},[],{"trials":417,"activeCount":103},[],{"trials":419,"activeCount":103},[],{"trials":421,"activeCount":241,"soonestReadout":145},[422,426],{"nctId":113,"briefTitle":114,"status":115,"phases":423,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":424,"interventions":425},[94],[122,123],[125,98],{"nctId":142,"briefTitle":143,"status":129,"phases":427,"primaryCompletion":145,"completion":146,"start":147,"enrollment":134,"conditions":428,"interventions":429},[94],[136,149],[139,140,98,125],{"trials":431,"activeCount":103},[],{"intervention":433,"totalTrials":151,"cells":434},"Warfarin",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":466},{"trials":436,"activeCount":103},[],{"trials":438,"activeCount":103},[],{"trials":440,"activeCount":103},[],{"trials":442,"activeCount":103},[],{"trials":444,"activeCount":241,"soonestReadout":449},[445,456],{"nctId":446,"briefTitle":447,"status":129,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT07515664","Vitamin K for Perioperative Warfarin Management",[94],"2026-08","2025-07-03",20,[453],"Anticoagulant Therapy",[455,433,433],"Vitamin K",{"nctId":457,"briefTitle":458,"status":281,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":103,"conditions":462,"interventions":464},"NCT02054936","Evaluation of Wound Drainage After Knee or Hip Arthroplasty",[94],"2016-02","2014-03",[463],"Complications; Arthroplasty",[465,433],"Rivaroxaban",{"trials":467,"activeCount":103},[],{"intervention":469,"totalTrials":241,"cells":470},"cephalexin",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":491},{"trials":472,"activeCount":103},[],{"trials":474,"activeCount":103},[],{"trials":476,"activeCount":103},[],{"trials":478,"activeCount":103},[],{"trials":480,"activeCount":241,"soonestReadout":485},[481],{"nctId":482,"briefTitle":483,"status":129,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT01912651","The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery",[94],"2028-09","2013-07",300,[489],"Facial Defect",[469],{"trials":492,"activeCount":103},[],{"intervention":455,"totalTrials":241,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":509},{"trials":496,"activeCount":103},[],{"trials":498,"activeCount":103},[],{"trials":500,"activeCount":103},[],{"trials":502,"activeCount":103},[],{"trials":504,"activeCount":241,"soonestReadout":449},[505],{"nctId":446,"briefTitle":447,"status":129,"phases":506,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":507,"interventions":508},[94],[453],[455,433,433],{"trials":510,"activeCount":103},[],{"intervention":512,"totalTrials":241,"cells":513},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":538},{"trials":515,"activeCount":103},[],{"trials":517,"activeCount":103},[],{"trials":519,"activeCount":103},[],{"trials":521,"activeCount":103},[],{"trials":523,"activeCount":241,"soonestReadout":528},[524],{"nctId":525,"briefTitle":526,"status":129,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":537},"NCT06785116","A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)",[94],"2028-08","2025-03-02",200,[532,533,534,535,536],"Gestational Hypertension","Hypertension in Pregnancy","Pre-Eclampsia","Superimposed Pre-Eclampsia","Cardiovascular Complication",[512],{"trials":539,"activeCount":103},[],{"intervention":88,"totalTrials":241,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":561},{"trials":543,"activeCount":103},[],{"trials":545,"activeCount":103},[],{"trials":547,"activeCount":103},[],{"trials":549,"activeCount":103},[],{"trials":551,"activeCount":241,"soonestReadout":87},[552],{"nctId":85,"briefTitle":86,"status":553,"phases":554,"primaryCompletion":87,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"ACTIVE_NOT_RECRUITING",[94],"2026-05-31","2025-03-11",40,[559],"Sebaceous Hyperplasia",[88],{"trials":562,"activeCount":103},[],{"intervention":564,"totalTrials":241,"cells":565},"SGLT2 inhibitor",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":587},{"trials":567,"activeCount":103},[],{"trials":569,"activeCount":103},[],{"trials":571,"activeCount":103},[],{"trials":573,"activeCount":103},[],{"trials":575,"activeCount":241,"soonestReadout":580},[576],{"nctId":577,"briefTitle":578,"status":129,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":451,"conditions":583,"interventions":586},"NCT06291155","Mechanism of SGLT2 Inhibition in the Kidney",[94],"2026-12-31","2028-06-30","2024-01-01",[584,585],"Type 2 Diabetes","Diabetic Kidney Disease",[564],{"trials":588,"activeCount":103},[],{"intervention":590,"totalTrials":151,"cells":591},"Metoprolol Succinate",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":612},{"trials":593,"activeCount":103},[],{"trials":595,"activeCount":103},[],{"trials":597,"activeCount":103},[],{"trials":599,"activeCount":103},[],{"trials":601,"activeCount":241,"soonestReadout":606},[602],{"nctId":603,"briefTitle":604,"status":129,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":611},"NCT07490067","Mechanistic Clinical Trial Comparing the Pharmacokinetics\u002FPharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score",[94],"2029-07","2026-04",100,[610],"Heart Failure With Reduced Ejection Fraction",[590],{"trials":613,"activeCount":103},[614],{"nctId":615,"briefTitle":616,"status":115,"phases":617,"primaryCompletion":618,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":624},"NCT03612180","Evaluation of Metoprolol Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis",[],"2019-05-31","2018-06-30",8,[622,623],"Hemodialysis","Pharmacokinetics",[590],{"intervention":626,"totalTrials":241,"cells":627},"Cyclobenzaprine",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":645,"NA":647},{"trials":629,"activeCount":103},[],{"trials":631,"activeCount":103},[],{"trials":633,"activeCount":103},[],{"trials":635,"activeCount":241,"soonestReadout":131},[636],{"nctId":637,"briefTitle":638,"status":129,"phases":639,"primaryCompletion":131,"completion":131,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT07404397","Comparing Adjuvant Treatments for High Tone Pelvic Floor Dysfunction",[92,93],"2026-02-18",60,[643],"High Tone Pelvic Floor Dysfunction",[626],{"trials":646,"activeCount":103},[],{"trials":648,"activeCount":103},[],{"intervention":650,"totalTrials":241,"cells":651},"Relugolix CT",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":670,"NA":672},{"trials":653,"activeCount":103},[],{"trials":655,"activeCount":103},[],{"trials":657,"activeCount":103},[],{"trials":659,"activeCount":241,"soonestReadout":528},[660],{"nctId":661,"briefTitle":662,"status":129,"phases":663,"primaryCompletion":528,"completion":485,"start":664,"enrollment":665,"conditions":666,"interventions":669},"NCT07100782","Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain",[93],"2025-12-08",130,[667,668],"Endometriosis","Pelvic Pain",[650],{"trials":671,"activeCount":103},[],{"trials":673,"activeCount":103},[],{"intervention":675,"totalTrials":241,"cells":676},"Lexapro",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":695,"NA":697},{"trials":678,"activeCount":103},[],{"trials":680,"activeCount":103},[],{"trials":682,"activeCount":103},[],{"trials":684,"activeCount":241,"soonestReadout":689},[685],{"nctId":686,"briefTitle":687,"status":129,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT05519683","Home Transcutaneous Electrical Acustimulation (TEA)",[92,93],"2026-09","2022-11-02",160,[693],"Irritable Bowel Syndrome With Constipation",[675],{"trials":696,"activeCount":103},[],{"trials":698,"activeCount":103},[],{"intervention":63,"totalTrials":700,"cells":701},9,{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":719,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":703,"activeCount":103},[],{"trials":705,"activeCount":103},[706],{"nctId":707,"briefTitle":708,"status":211,"phases":709,"primaryCompletion":710,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":718},"NCT03286114","Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab",[91],"2020-10-22","2021-04-28","2017-12-21",16,[715,716,717],"Myelodysplastic Syndromes","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia",[63],{"trials":720,"activeCount":804,"soonestReadout":62},[721,732,743,752,762,772,784,793],{"nctId":722,"briefTitle":723,"status":129,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":730},"NCT06356155","Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer",[92],"2028-03","2025-07-22",32,[729],"Urothelial Carcinoma",[731,63],"Enfortumab vedotin",{"nctId":733,"briefTitle":734,"status":211,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":741},"NCT03559049","Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer",[91,92],"2025-05-01","2018-12-24",25,[740],"Stage IV Non-small Cell Lung Cancer",[63,290,234,742],"Rucaparib",{"nctId":744,"briefTitle":745,"status":211,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":216,"conditions":750,"interventions":751},"NCT03287050","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",[92],"2019-03-13","2020-11-10","2018-01-24",[729],[63],{"nctId":753,"briefTitle":754,"status":115,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT03240016","Abraxane With Anti-PD1\u002FPDL1 in Patients With Advanced Urothelial Cancer",[92],"2023-06-23","2018-02-08",36,[729],[63,761],"Abraxane",{"nctId":60,"briefTitle":61,"status":553,"phases":763,"primaryCompletion":62,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":770},[92],"2027-04","2021-05-25",45,[768,769],"Prostate Cancer Metastatic","Neuroendocrine Tumors",[63,771],"Lenvatinib",{"nctId":773,"briefTitle":774,"status":129,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":336,"conditions":779,"interventions":783},"NCT06580054","Pembrolizumab for the Treatment of Locally Advanced and\u002For Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma",[92],"2028-03-01","2030-03-01","2025-03-05",[780,781,782],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",[63],{"nctId":785,"briefTitle":786,"status":115,"phases":787,"primaryCompletion":788,"completion":788,"start":789,"enrollment":308,"conditions":790,"interventions":792},"NCT03242915","Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents",[92],"2025-02-20","2017-10-03",[791],"Non-small Cell Lung Cancer",[63,234,290],{"nctId":794,"briefTitle":795,"status":129,"phases":796,"primaryCompletion":131,"completion":797,"start":798,"enrollment":31,"conditions":799,"interventions":802},"NCT05956041","Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed\u002FRefractory Cutaneous T-cell Lymphomas",[92],"2027-12","2023-12-06",[800,801],"Cutaneous T Cell Lymphoma","Fungoides Mycosis Sezary Syndrome",[63,803],"Mogamulizumab",4,{"trials":806,"activeCount":103},[],{"trials":808,"activeCount":103},[],{"trials":810,"activeCount":103},[],{"intervention":58,"totalTrials":804,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":830,"PHASE3":865,"PHASE4":867,"NA":881},{"trials":814,"activeCount":103},[],{"trials":816,"activeCount":241,"soonestReadout":57},[817],{"nctId":55,"briefTitle":56,"status":553,"phases":818,"primaryCompletion":57,"completion":819,"start":820,"enrollment":273,"conditions":821,"interventions":828},[91],"2027-11-05","2020-08-05",[822,823,824,825,826,827],"Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Astrocytoma, Grade IV","Newly Diagnosed Glioblastoma","Newly Diagnosed Gliosarcoma","Newly Diagnosed Astrocytoma, Grade IV",[58,829,58,58],"Temozolomide",{"trials":831,"activeCount":241,"soonestReadout":67},[832,853],{"nctId":65,"briefTitle":66,"status":553,"phases":833,"primaryCompletion":67,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":849},[91,92],"2026-04-01","2020-02-04",43,[838,839,840,841,842,715,843,844,845,846,847,848],"Hematologic Diseases","Acute Leukemia in Remission","Chronic Myelogenous Leukemia - Chronic Phase","Chronic Myelogenous Leukemia, Accelerated Phase","Chronic Myelogenous Leukemia, Blastic Phase","Mantle Cell Lymphoma","Follicular Lymphoma","Diffuse Large B Cell Lymphoma","Non Hodgkin Lymphoma","Graft Vs Host Disease","Graft-versus-host-disease",[68,850,851,58,852],"Tacrolimus","Methotrexate","Cyclophosphamide",{"nctId":854,"briefTitle":855,"status":115,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":451,"conditions":860,"interventions":862},"NCT00763490","Trial Of Double Umbilical Cord Blood Transplantation",[92],"2013-03","2015-10","2008-12",[861],"Hematological Malignancies",[863,864,58],"Flu\u002FBu4 conditioning regimen","Graft versus Host Disease prevention",{"trials":866,"activeCount":103},[],{"trials":868,"activeCount":103},[869],{"nctId":870,"briefTitle":871,"status":115,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":713,"conditions":875,"interventions":878},"NCT00189150","Pharmacokinetics of Mmf and Valganciclovir",[94],"2007-08","2005-04",[876,877],"Kidney Transplant Recipient","Heart Transplant Recipient",[879,880],"Mycophenolate mofetil","Valganciclovir",{"trials":882,"activeCount":103},[],{"intervention":829,"totalTrials":99,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":893,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":886,"activeCount":103},[],{"trials":888,"activeCount":241,"soonestReadout":57},[889],{"nctId":55,"briefTitle":56,"status":553,"phases":890,"primaryCompletion":57,"completion":819,"start":820,"enrollment":273,"conditions":891,"interventions":892},[91],[822,823,824,825,826,827],[58,829,58,58],{"trials":894,"activeCount":241,"soonestReadout":909},[895,905],{"nctId":896,"briefTitle":897,"status":115,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":251,"conditions":902,"interventions":904},"NCT02805179","A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma",[92],"2020-02-06","2020-11-18","2016-09-22",[903],"Glioma",[829],{"nctId":906,"briefTitle":907,"status":553,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":404,"conditions":912,"interventions":914},"NCT04574856","Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma",[92],"2026-11-19","2027-11-19","2020-11-04",[913],"Glioblastoma",[829,915],"Adjuvant temozolomide",{"trials":917,"activeCount":103},[],{"trials":919,"activeCount":103},[],{"trials":921,"activeCount":103},[],{"intervention":43,"totalTrials":99,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":925,"activeCount":103},[],{"trials":927,"activeCount":103},[],{"trials":929,"activeCount":151,"soonestReadout":42},[930,943,952],{"nctId":931,"briefTitle":932,"status":115,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":941},"NCT04076579","Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma",[92],"2023-01-30","2024-09-26","2020-03-17",29,[939,940],"Sarcoma","Sarcoma Metastatic",[43,942],"Trabectedin",{"nctId":80,"briefTitle":81,"status":553,"phases":944,"primaryCompletion":82,"completion":82,"start":945,"enrollment":34,"conditions":946,"interventions":949},[92],"2021-05-28",[25,947,948],"Castrate Sensitive Prostate Cancer","Oligometastatic Disease",[83,950,951,43],"Prednisone","Androgen Deprivation Therapy",{"nctId":40,"briefTitle":41,"status":553,"phases":953,"primaryCompletion":42,"completion":528,"start":954,"enrollment":349,"conditions":955,"interventions":956},[92],"2019-10-31",[25],[43,957],"AZD6738",{"trials":959,"activeCount":103},[],{"trials":961,"activeCount":103},[],{"trials":963,"activeCount":103},[],{"intervention":852,"totalTrials":151,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":967,"activeCount":103},[],{"trials":969,"activeCount":103},[],{"trials":971,"activeCount":151,"soonestReadout":67},[972,976],{"nctId":65,"briefTitle":66,"status":553,"phases":973,"primaryCompletion":67,"completion":834,"start":835,"enrollment":836,"conditions":974,"interventions":975},[91,92],[838,839,840,841,842,715,843,844,845,846,847,848],[68,850,851,58,852],{"nctId":977,"briefTitle":978,"status":129,"phases":979,"primaryCompletion":131,"completion":131,"start":980,"enrollment":336,"conditions":981,"interventions":983},"NCT03099356","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",[92],"2017-04-27",[982],"Metastatic Thyroid Cancer",[852,984],"Sirolimus",{"trials":986,"activeCount":103},[],{"trials":988,"activeCount":103},[],{"trials":990,"activeCount":103},[],{"intervention":950,"totalTrials":151,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":994,"activeCount":103},[],{"trials":996,"activeCount":103},[],{"trials":998,"activeCount":151,"soonestReadout":82},[999,1003],{"nctId":80,"briefTitle":81,"status":553,"phases":1000,"primaryCompletion":82,"completion":82,"start":945,"enrollment":34,"conditions":1001,"interventions":1002},[92],[25,947,948],[83,950,951,43],{"nctId":1004,"briefTitle":1005,"status":129,"phases":1006,"primaryCompletion":449,"completion":449,"start":1007,"enrollment":451,"conditions":1008,"interventions":1010},"NCT05901519","A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma",[92],"2024-02-16",[1009],"Hepatocellular Carcinoma",[950],{"trials":1012,"activeCount":103},[],{"trials":1014,"activeCount":103},[],{"trials":1016,"activeCount":103},[],{"intervention":1018,"totalTrials":151,"cells":1019},"Leuprolide",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1021,"activeCount":103},[],{"trials":1023,"activeCount":103},[],{"trials":1025,"activeCount":151,"soonestReadout":1030},[1026,1038],{"nctId":1027,"briefTitle":1028,"status":553,"phases":1029,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1035},"NCT04194554","A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer",[91,92],"2027-05","2029-05","2020-11-06",102,[25],[1036,1018,1037],"Niraparib","Abiraterone Acetate",{"nctId":1039,"briefTitle":1040,"status":129,"phases":1041,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1051},"NCT07158021","Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial",[92],"2028-01-01","2026-01-22",75,[1046,1047,1048,1049,1050],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma",[1052,1018],"Goserelin",{"trials":1054,"activeCount":103},[],{"trials":1056,"activeCount":103},[],{"trials":1058,"activeCount":103},[],{"intervention":234,"totalTrials":1060,"cells":1061},17,{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1063,"activeCount":103},[],{"trials":1065,"activeCount":103},[],{"trials":1067,"activeCount":151,"soonestReadout":1081},[1068,1077,1090,1094,1098,1102,1106,1110,1120,1130,1142,1151,1155,1159,1163],{"nctId":1069,"briefTitle":1070,"status":115,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":937,"conditions":1074,"interventions":1075},"NCT00585689","Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer",[92],"2013-04","2007-12",[275],[1076,234,277],"ABI-007",{"nctId":1078,"briefTitle":1079,"status":553,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1088},"NCT03781986","APG-115 in Salivary Gland Cancer Trial",[91,92],"2026-07","2027-01","2019-10-28",41,[1086,1087],"Malignant Salivary Gland Cancer","Salivary Gland Cancer",[1089,234],"APG-115",{"nctId":224,"briefTitle":225,"status":115,"phases":1091,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":1092,"interventions":1093},[92],[232],[234,199],{"nctId":236,"briefTitle":237,"status":211,"phases":1095,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":1096,"interventions":1097},[92],[243],[234,199],{"nctId":733,"briefTitle":734,"status":211,"phases":1099,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":1100,"interventions":1101},[91,92],[740],[63,290,234,742],{"nctId":246,"briefTitle":247,"status":115,"phases":1103,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":1104,"interventions":1105},[92],[253],[255,234,199],{"nctId":267,"briefTitle":268,"status":115,"phases":1107,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":1108,"interventions":1109},[92],[275],[199,234,277],{"nctId":1111,"briefTitle":1112,"status":211,"phases":1113,"primaryCompletion":1114,"completion":271,"start":1115,"conditions":1116,"interventions":1118},"NCT00148135","Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site",[92],"2006-04","2001-05",[1117],"Carcinoma of Unknown Primary",[234,277,1119],"Capecitabine",{"nctId":1121,"briefTitle":1122,"status":115,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT02031250","Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer",[92],"2023-02-22","2014-02",106,[1128],"Squamous Cell Carcinoma of the Head and Neck",[221,234],{"nctId":1131,"briefTitle":1132,"status":115,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT01633541","Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer",[92],"2021-11-06","2012-03",55,[1138],"Laryngeal Cancer",[1140,1141,221,234],"AT-101","Docetaxel",{"nctId":1143,"briefTitle":1144,"status":115,"phases":1145,"primaryCompletion":1146,"completion":936,"start":1147,"enrollment":34,"conditions":1148,"interventions":1149},"NCT03194373","Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[92],"2019-02-01","2017-10-12",[1128],[1150,234],"Palbociclib",{"nctId":279,"briefTitle":280,"status":281,"phases":1152,"primaryCompletion":283,"start":284,"enrollment":103,"conditions":1153,"interventions":1154},[92],[286],[288,234,289,199,290],{"nctId":303,"briefTitle":304,"status":115,"phases":1156,"primaryCompletion":306,"completion":271,"start":307,"enrollment":308,"conditions":1157,"interventions":1158},[92],[310],[312,199,234,277],{"nctId":785,"briefTitle":786,"status":115,"phases":1160,"primaryCompletion":788,"completion":788,"start":789,"enrollment":308,"conditions":1161,"interventions":1162},[92],[791],[63,234,290],{"nctId":314,"briefTitle":315,"status":129,"phases":1164,"primaryCompletion":317,"completion":317,"start":318,"enrollment":20,"conditions":1165,"interventions":1166},[92],[320,321,322,323,324],[234,221,199],{"trials":1168,"activeCount":103},[],{"trials":1170,"activeCount":103},[],{"trials":1172,"activeCount":103},[1173,1177],{"nctId":343,"briefTitle":344,"status":115,"phases":1174,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":1175,"interventions":1176},[95],[351],[234,199,353],{"nctId":355,"briefTitle":356,"status":115,"phases":1178,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":1179,"interventions":1180},[95],[362],[199,234,221,222],{"intervention":984,"totalTrials":151,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1193,"PHASE4":1204,"NA":1206},{"trials":1184,"activeCount":103},[],{"trials":1186,"activeCount":103},[],{"trials":1188,"activeCount":241,"soonestReadout":131},[1189],{"nctId":977,"briefTitle":978,"status":129,"phases":1190,"primaryCompletion":131,"completion":131,"start":980,"enrollment":336,"conditions":1191,"interventions":1192},[92],[982],[852,984],{"trials":1194,"activeCount":103},[1195],{"nctId":1196,"briefTitle":1197,"status":115,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":306,"enrollment":349,"conditions":1200,"interventions":1203},"NCT00189202","Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans",[92,93],"2008-07-01",[1201,1202],"End Stage Renal Disease","Kidney Transplantation",[984],{"trials":1205,"activeCount":103},[],{"trials":1207,"activeCount":103},[],{"intervention":255,"totalTrials":1209,"cells":1210},11,{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1241,"PHASE3":1336,"PHASE4":1338,"NA":1340},{"trials":1212,"activeCount":103},[],{"trials":1214,"activeCount":103},[1215,1226],{"nctId":1216,"briefTitle":1217,"status":211,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":216,"conditions":1221,"interventions":1223},"NCT04431635","Dose De-escalation Study of the PI3k Alpha\u002FDelta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed\u002FRefractory Indolent Lymphoma",[91],"2023-11-14","2020-06-15",[1222],"Indolent Lymphoma",[1224,255,1225],"Copanlisib","Rituximab",{"nctId":1227,"briefTitle":1228,"status":115,"phases":1229,"primaryCompletion":1230,"completion":1231,"start":1232,"enrollment":151,"conditions":1233,"interventions":1239},"NCT05169957","Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)",[91],"2023-06-13","2024-07-17","2022-08-09",[1234,1235,1236,1237,1238],"Melanoma, Ocular","Melanoma, Cutaneous","Metastatic Melanoma","Melanoma, Mucosal","Liver Metastases",[1240,255],"Ipilimumab",{"trials":1242,"activeCount":241,"soonestReadout":1283},[1243,1255,1264,1268,1279,1293,1302,1312,1323],{"nctId":1244,"briefTitle":1245,"status":115,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1252},"NCT03785873","Phase Ib\u002FII Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer",[91,92],"2024-11-15","2019-05-22",34,[1251],"Biliary Tract Cancer",[255,1253,222,1254],"Nanoliposomal-Irinotecan","Leucovorin",{"nctId":1256,"briefTitle":1257,"status":115,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":727,"conditions":1262,"interventions":1263},"NCT03639935","Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy",[92],"2023-02-07","2024-04-30","2019-03-28",[1251],[742,255],{"nctId":246,"briefTitle":247,"status":115,"phases":1265,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":1266,"interventions":1267},[92],[253],[255,234,199],{"nctId":1269,"briefTitle":1270,"status":115,"phases":1271,"primaryCompletion":1272,"completion":1273,"start":1274,"enrollment":200,"conditions":1275,"interventions":1277},"NCT02989714","Phase Ib\u002FII Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",[91,92],"2019-02-25","2020-06-23","2017-03-16",[1276],"Renal Cell Carcinoma",[1278,255],"Interleukin-2",{"nctId":1280,"briefTitle":1281,"status":129,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1136,"conditions":1285,"interventions":1292},"NCT06866262","Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial",[91,92],"2031-08-01","2025-08-15",[1286,1287,1288,1289,1290,1291],"Locally Advanced Clear Cell Renal Cell Carcinoma","Locally Advanced Sarcomatoid Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[1240,255],{"nctId":1294,"briefTitle":1295,"status":211,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":620,"conditions":1299,"interventions":1301},"NCT03562507","Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma",[92],"2022-10-18","2019-04-11",[1300],"Renal Cell Carcinoma, Metastatic",[73,255],{"nctId":1303,"briefTitle":1304,"status":115,"phases":1305,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1044,"conditions":1309,"interventions":1311},"NCT03101566","Study of Nivolumab in Combination With Gemcitabine\u002FCisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer",[92],"2019-12-03","2021-06-07","2017-09-08",[1310],"Biliary Tract Neoplasms",[277,221,1240,255],{"nctId":1313,"briefTitle":1314,"status":115,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":804,"conditions":1319,"interventions":1321},"NCT03927105","Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed\u002FRefractory Peripheral T Cell Lymphoma",[92],"2019-11-01","2023-07-06","2019-04-25",[1320],"Peripheral T Cell Lymphoma",[255,1322],"cabiralizumab",{"nctId":1324,"briefTitle":1325,"status":115,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1335},"NCT03570619","Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations",[92],"2022-12-22","2024-03-26","2018-12-14",56,[1332,1333,1334],"Metastatic Castration Resistant Prostate Cancer","Metastatic Cancer","Solid Tumor",[255,1240],{"trials":1337,"activeCount":103},[],{"trials":1339,"activeCount":103},[],{"trials":1341,"activeCount":103},[],{"intervention":850,"totalTrials":1343,"cells":1344},5,{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1346,"activeCount":103},[],{"trials":1348,"activeCount":103},[],{"trials":1350,"activeCount":241,"soonestReadout":67},[1351,1355,1370,1384,1394],{"nctId":65,"briefTitle":66,"status":553,"phases":1352,"primaryCompletion":67,"completion":834,"start":835,"enrollment":836,"conditions":1353,"interventions":1354},[91,92],[838,839,840,841,842,715,843,844,845,846,847,848],[68,850,851,58,852],{"nctId":1356,"briefTitle":1357,"status":115,"phases":1358,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT00639717","Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant",[92],"2012-01","2016-04","2009-03",48,[1364],"Graft Versus Host Disease",[1366,1367,1368,1369],"tacrolimus","mycophenolate","etanercept","methoxsalen",{"nctId":1371,"briefTitle":1372,"status":115,"phases":1373,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1382},"NCT02145403","Phase 1\u002F2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies",[91,92],"2018-11-26","2020-10-16","2014-10",53,[1379,1380,1381],"Hematologic Malignancies","Relapse","Graft-Versus-Host Disease",[1383,850],"Carfilzomib",{"nctId":1385,"briefTitle":1386,"status":115,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},"NCT02328755","Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia",[91,92],"2019-03-25","2015-01",37,[716],[1393,850,851],"peg-IFN-α",{"nctId":1395,"briefTitle":1396,"status":115,"phases":1397,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":251,"conditions":1401,"interventions":1405},"NCT01790568","Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant",[92],"2017-01-01","2017-10-31","2014-12",[1402,1403,1404],"Graft vs Host Disease","Hematologic Neoplasms","Non-Neoplastic Hematologic and Lymphocytic Disorder",[68,850,851],{"trials":1407,"activeCount":103},[],{"trials":1409,"activeCount":103},[],{"trials":1411,"activeCount":103},[],{"intervention":1240,"totalTrials":1343,"cells":1413},{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1422,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1415,"activeCount":103},[],{"trials":1417,"activeCount":103},[1418],{"nctId":1227,"briefTitle":1228,"status":115,"phases":1419,"primaryCompletion":1230,"completion":1231,"start":1232,"enrollment":151,"conditions":1420,"interventions":1421},[91],[1234,1235,1236,1237,1238],[1240,255],{"trials":1423,"activeCount":241,"soonestReadout":1283},[1424,1428,1432,1442],{"nctId":1280,"briefTitle":1281,"status":129,"phases":1425,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1136,"conditions":1426,"interventions":1427},[91,92],[1286,1287,1288,1289,1290,1291],[1240,255],{"nctId":1303,"briefTitle":1304,"status":115,"phases":1429,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1044,"conditions":1430,"interventions":1431},[92],[1310],[277,221,1240,255],{"nctId":1433,"briefTitle":1434,"status":211,"phases":1435,"primaryCompletion":1436,"completion":1437,"start":1438,"enrollment":804,"conditions":1439,"interventions":1441},"NCT02097732","Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery",[92],"2016-08","2020-07","2014-04",[1236,1440],"Brain Metastases",[1240],{"nctId":1324,"briefTitle":1325,"status":115,"phases":1443,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1444,"interventions":1445},[92],[1332,1333,1334],[255,1240],{"trials":1447,"activeCount":103},[],{"trials":1449,"activeCount":103},[],{"trials":1451,"activeCount":103},[],{"intervention":1453,"totalTrials":804,"cells":1454},"Bortezomib",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1469,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1456,"activeCount":103},[],{"trials":1458,"activeCount":103},[1459],{"nctId":1460,"briefTitle":1461,"status":115,"phases":1462,"primaryCompletion":1307,"completion":1307,"start":1463,"enrollment":394,"conditions":1464,"interventions":1467},"NCT02613598","Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma",[91],"2016-05-12",[1465,1466],"Hodgkin's Lymphoma","Lymphoma, Non-Hodgkin",[1453,1468],"Ruxolitinib",{"trials":1470,"activeCount":241,"soonestReadout":52},[1471,1480,1490],{"nctId":1472,"briefTitle":1473,"status":281,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1437,"enrollment":103,"conditions":1477,"interventions":1478},"NCT03617484","Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma",[92],"2023-01","2030-07",[843],[1453,1479],"Ibrutinib",{"nctId":50,"briefTitle":51,"status":553,"phases":1481,"primaryCompletion":52,"completion":1482,"start":1483,"enrollment":1484,"conditions":1485,"interventions":1487},[92],"2026-05-02","2020-10-05",57,[1486],"Multiple Myeloma",[53,1488,1453,1489],"Lenalidomide","Dexamethasone",{"nctId":1491,"briefTitle":1492,"status":115,"phases":1493,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":120,"conditions":1497,"interventions":1498},"NCT00724568","Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma",[91,92],"2009-04","2014-09-03","2008-05",[1486],[1488,1453,1489,1499],"Doxil",{"trials":1501,"activeCount":103},[],{"trials":1503,"activeCount":103},[],{"trials":1505,"activeCount":103},[],{"intervention":1468,"totalTrials":804,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1516,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1509,"activeCount":103},[],{"trials":1511,"activeCount":103},[1512],{"nctId":1460,"briefTitle":1461,"status":115,"phases":1513,"primaryCompletion":1307,"completion":1307,"start":1463,"enrollment":394,"conditions":1514,"interventions":1515},[91],[1465,1466],[1453,1468],{"trials":1517,"activeCount":241,"soonestReadout":1522},[1518,1530,1540],{"nctId":1519,"briefTitle":1520,"status":129,"phases":1521,"primaryCompletion":1522,"completion":1523,"start":334,"enrollment":451,"conditions":1524,"interventions":1528},"NCT06616155","Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[91,92],"2028-06","2030-06",[1525,1526,1527],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8",[1529,1468],"Enzalutamide",{"nctId":1531,"briefTitle":1532,"status":115,"phases":1533,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":216,"conditions":1537,"interventions":1539},"NCT02400463","A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome",[92],"2019-10-10","2020-01-07","2016-02-05",[1538],"Hemophagocytic Syndrome (HPS)",[1468],{"nctId":1541,"briefTitle":1542,"status":281,"phases":1543,"primaryCompletion":1544,"completion":1544,"start":1545,"enrollment":103,"conditions":1546,"interventions":1548},"NCT02973711","A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",[91,92],"2021-08","2018-01",[1547],"Leukemia, Chronic Myeloid",[1549,1468],"Nilotinib",{"trials":1551,"activeCount":103},[],{"trials":1553,"activeCount":103},[],{"trials":1555,"activeCount":103},[],{"intervention":68,"totalTrials":99,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1575,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1559,"activeCount":103},[],{"trials":1561,"activeCount":103},[1562],{"nctId":1563,"briefTitle":1564,"status":211,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT00565227","Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.",[91],"2008-11","2009-09","2007-04",12,[1571,25,275,729],"Non-Small-Cell Lung Carcinoma",[1573,1574],"vorinostat","docetaxel",{"trials":1576,"activeCount":241,"soonestReadout":67},[1577,1581],{"nctId":65,"briefTitle":66,"status":553,"phases":1578,"primaryCompletion":67,"completion":834,"start":835,"enrollment":836,"conditions":1579,"interventions":1580},[91,92],[838,839,840,841,842,715,843,844,845,846,847,848],[68,850,851,58,852],{"nctId":1395,"briefTitle":1396,"status":115,"phases":1582,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":251,"conditions":1583,"interventions":1584},[92],[1402,1403,1404],[68,850,851],{"trials":1586,"activeCount":103},[],{"trials":1588,"activeCount":103},[],{"trials":1590,"activeCount":103},[],{"intervention":851,"totalTrials":99,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1594,"activeCount":103},[],{"trials":1596,"activeCount":103},[],{"trials":1598,"activeCount":241,"soonestReadout":67},[1599,1603,1607],{"nctId":65,"briefTitle":66,"status":553,"phases":1600,"primaryCompletion":67,"completion":834,"start":835,"enrollment":836,"conditions":1601,"interventions":1602},[91,92],[838,839,840,841,842,715,843,844,845,846,847,848],[68,850,851,58,852],{"nctId":1385,"briefTitle":1386,"status":115,"phases":1604,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1605,"interventions":1606},[91,92],[716],[1393,850,851],{"nctId":1395,"briefTitle":1396,"status":115,"phases":1608,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":251,"conditions":1609,"interventions":1610},[92],[1402,1403,1404],[68,850,851],{"trials":1612,"activeCount":103},[],{"trials":1614,"activeCount":103},[],{"trials":1616,"activeCount":103},[],{"intervention":1618,"totalTrials":99,"cells":1619},"Pacritinib",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1639,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1621,"activeCount":103},[],{"trials":1623,"activeCount":103},[1624],{"nctId":1625,"briefTitle":1626,"status":211,"phases":1627,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":804,"conditions":1631,"interventions":1638},"NCT03601819","Pacritinib in Relapsed\u002FRefractory Lymphoproliferative Disorders",[91],"2020-03-07","2020-07-17","2019-05-15",[1632,1633,1634,1635,1636,1637,843],"Lymphoma, T-Cell, Cutaneous","Lymphoma, T-Cell, Peripheral","Chronic Lymphocytic Leukemia","Lymphoproliferative Disorders","Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[1618],{"trials":1640,"activeCount":241,"soonestReadout":1654},[1641,1650],{"nctId":1642,"briefTitle":1643,"status":281,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":103,"conditions":1647,"interventions":1649},"NCT02677948","Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)",[91,92],"2018-10","2016-10",[1634,1648],"Lymphoma, Small Lymphocytic",[1618,1479],{"nctId":1651,"briefTitle":1652,"status":129,"phases":1653,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":608,"conditions":1657,"interventions":1659},"NCT04858256","Pacritinib in Relapsed\u002FRefractory T-cell Lymphoproliferative Neoplasms",[92],"2027-11","2028-11","2023-03-29",[1658,1635],"T-Cell Neoplasm",[1618],{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":103},[],{"trials":1665,"activeCount":103},[],{"intervention":1488,"totalTrials":99,"cells":1667},{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1669,"activeCount":103},[],{"trials":1671,"activeCount":103},[],{"trials":1673,"activeCount":241,"soonestReadout":52},[1674,1678,1688],{"nctId":50,"briefTitle":51,"status":553,"phases":1675,"primaryCompletion":52,"completion":1482,"start":1483,"enrollment":1484,"conditions":1676,"interventions":1677},[92],[1486],[53,1488,1453,1489],{"nctId":1679,"briefTitle":1680,"status":115,"phases":1681,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":727,"conditions":1684,"interventions":1685},"NCT02331368","Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT\u002FASCT for Multiple Myeloma",[92],"2017-06","2015-06",[1486],[1686,1488,1687],"Melphalan","MK-3475",{"nctId":1491,"briefTitle":1492,"status":115,"phases":1689,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":120,"conditions":1690,"interventions":1691},[91,92],[1486],[1488,1453,1489,1499],{"trials":1693,"activeCount":103},[],{"trials":1695,"activeCount":103},[],{"trials":1697,"activeCount":103},[],{"intervention":1699,"totalTrials":151,"cells":1700},"Caffeine Citrate",{"EARLY_PHASE1":1701,"PHASE1":1713,"PHASE2":1715,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1702,"activeCount":103},[1703],{"nctId":1704,"briefTitle":1705,"status":115,"phases":1706,"primaryCompletion":1707,"completion":1708,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1712},"NCT03577730","Caffeine and Neurologic Recovery Following Surgery and General Anesthesia",[90],"2019-11-21","2020-01-17","2018-07-10",71,[137],[1699,78],{"trials":1714,"activeCount":103},[],{"trials":1716,"activeCount":241,"soonestReadout":77},[1717],{"nctId":75,"briefTitle":76,"status":553,"phases":1718,"primaryCompletion":77,"completion":555,"start":1719,"enrollment":1720,"conditions":1721,"interventions":1725},[92],"2023-02-20",250,[1722,1723,1724],"Postoperative Delirium","Postoperative Cognitive Dysfunction","Mild Cognitive Impairment",[78,1726,1726],"Caffeine citrate",{"trials":1728,"activeCount":103},[],{"trials":1730,"activeCount":103},[],{"trials":1732,"activeCount":103},[],{"intervention":78,"totalTrials":151,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1741,"PHASE2":1743,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1736,"activeCount":103},[1737],{"nctId":1704,"briefTitle":1705,"status":115,"phases":1738,"primaryCompletion":1707,"completion":1708,"start":1709,"enrollment":1710,"conditions":1739,"interventions":1740},[90],[137],[1699,78],{"trials":1742,"activeCount":103},[],{"trials":1744,"activeCount":241,"soonestReadout":77},[1745],{"nctId":75,"briefTitle":76,"status":553,"phases":1746,"primaryCompletion":77,"completion":555,"start":1719,"enrollment":1720,"conditions":1747,"interventions":1748},[92],[1722,1723,1724],[78,1726,1726],{"trials":1750,"activeCount":103},[],{"trials":1752,"activeCount":103},[],{"trials":1754,"activeCount":103},[],{"intervention":1529,"totalTrials":151,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1769,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1758,"activeCount":103},[],{"trials":1760,"activeCount":103},[1761],{"nctId":1762,"briefTitle":1763,"status":211,"phases":1764,"primaryCompletion":1765,"completion":1765,"start":618,"enrollment":700,"conditions":1766,"interventions":1767},"NCT03300505","ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer",[91],"2023-01-24",[25],[1768,1529],"ARRx",{"trials":1770,"activeCount":241,"soonestReadout":1522},[1771],{"nctId":1519,"briefTitle":1520,"status":129,"phases":1772,"primaryCompletion":1522,"completion":1523,"start":334,"enrollment":451,"conditions":1773,"interventions":1774},[91,92],[1525,1526,1527],[1529,1468],{"trials":1776,"activeCount":103},[],{"trials":1778,"activeCount":103},[],{"trials":1780,"activeCount":103},[],{"intervention":73,"totalTrials":151,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1784,"activeCount":103},[],{"trials":1786,"activeCount":103},[],{"trials":1788,"activeCount":241,"soonestReadout":72},[1789,1802],{"nctId":70,"briefTitle":71,"status":553,"phases":1790,"primaryCompletion":72,"completion":1791,"start":1792,"enrollment":1060,"conditions":1793,"interventions":1801},[92],"2027-08","2024-04-19",[1794,1795,1796,1797,1798,1799,1800],"Pancreatic Adenocarcinoma","Adenosquamous Carcinoma","Pancreatic Neuroendocrine Tumor","Pancreatic Neuroendocrine Carcinoma","Gastrointestinal Neuroendocrine Tumor","Gastrointestinal Neuroendocrine Carcinoma","Neuroendocrine Prostate Carcinoma",[73],{"nctId":1294,"briefTitle":1295,"status":211,"phases":1803,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":620,"conditions":1804,"interventions":1805},[92],[1300],[73,255],{"trials":1807,"activeCount":103},[],{"trials":1809,"activeCount":103},[],{"trials":1811,"activeCount":103},[],{"intervention":1089,"totalTrials":241,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":103},[],{"trials":1817,"activeCount":103},[],{"trials":1819,"activeCount":241,"soonestReadout":1081},[1820],{"nctId":1078,"briefTitle":1079,"status":553,"phases":1821,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":1084,"conditions":1822,"interventions":1823},[91,92],[1086,1087],[1089,234],{"trials":1825,"activeCount":103},[],{"trials":1827,"activeCount":103},[],{"trials":1829,"activeCount":103},[],{"intervention":731,"totalTrials":241,"cells":1831},{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1833,"activeCount":103},[],{"trials":1835,"activeCount":103},[],{"trials":1837,"activeCount":241,"soonestReadout":725},[1838],{"nctId":722,"briefTitle":723,"status":129,"phases":1839,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":1840,"interventions":1841},[92],[729],[731,63],{"trials":1843,"activeCount":103},[],{"trials":1845,"activeCount":103},[],{"trials":1847,"activeCount":103},[],{"intervention":53,"totalTrials":241,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1851,"activeCount":103},[],{"trials":1853,"activeCount":103},[],{"trials":1855,"activeCount":241,"soonestReadout":52},[1856],{"nctId":50,"briefTitle":51,"status":553,"phases":1857,"primaryCompletion":52,"completion":1482,"start":1483,"enrollment":1484,"conditions":1858,"interventions":1859},[92],[1486],[53,1488,1453,1489],{"trials":1861,"activeCount":103},[],{"trials":1863,"activeCount":103},[],{"trials":1865,"activeCount":103},[],{"intervention":1867,"totalTrials":241,"cells":1868},"Sodium Nitrate",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1870,"activeCount":103},[],{"trials":1872,"activeCount":103},[],{"trials":1874,"activeCount":241,"soonestReadout":1081},[1875],{"nctId":1876,"briefTitle":1877,"status":129,"phases":1878,"primaryCompletion":1081,"completion":1081,"start":1879,"enrollment":608,"conditions":1880,"interventions":1882},"NCT07016074","Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury",[92],"2025-06-30",[1881],"Kidney Injury, Acute",[1867],{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":103},[],{"trials":1888,"activeCount":103},[],{"intervention":915,"totalTrials":241,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":103},[],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":241,"soonestReadout":909},[1897],{"nctId":906,"briefTitle":907,"status":553,"phases":1898,"primaryCompletion":909,"completion":910,"start":911,"enrollment":404,"conditions":1899,"interventions":1900},[92],[913],[829,915],{"trials":1902,"activeCount":103},[],{"trials":1904,"activeCount":103},[],{"trials":1906,"activeCount":103},[],{"intervention":1908,"totalTrials":241,"cells":1909},"Starch, Potato",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1911,"activeCount":103},[],{"trials":1913,"activeCount":103},[],{"trials":1915,"activeCount":241,"soonestReadout":1920},[1916],{"nctId":1917,"briefTitle":1918,"status":129,"phases":1919,"primaryCompletion":1920,"completion":1921,"start":1922,"enrollment":451,"conditions":1923,"interventions":1926},"NCT07443943","A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial",[92],"2027-09","2028-04","2026-04-22",[1924,1046,1047,1048,1925],"Anatomic Stage 0 Breast Cancer AJCC v8","Localized Breast Carcinoma",[1908],{"trials":1928,"activeCount":103},[],{"trials":1930,"activeCount":103},[],{"trials":1932,"activeCount":103},[],{"intervention":1934,"totalTrials":241,"cells":1935},"Aquamin",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1950,"PHASE4":1952,"NA":1954},{"trials":1937,"activeCount":103},[],{"trials":1939,"activeCount":103},[],{"trials":1941,"activeCount":241,"soonestReadout":131},[1942],{"nctId":1943,"briefTitle":1944,"status":553,"phases":1945,"primaryCompletion":131,"completion":131,"start":1946,"enrollment":394,"conditions":1947,"interventions":1949},"NCT05058638","Effectiveness of Aquamin® in Mitigating Halitosis",[92],"2022-08-15",[22,1948],"Halitosis",[1934],{"trials":1951,"activeCount":103},[],{"trials":1953,"activeCount":103},[],{"trials":1955,"activeCount":103},[],{"intervention":1957,"totalTrials":241,"cells":1958},"Platinum based chemotherapy",{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1960,"activeCount":103},[],{"trials":1962,"activeCount":103},[],{"trials":1964,"activeCount":241,"soonestReadout":1969},[1965],{"nctId":1966,"briefTitle":1967,"status":553,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":37,"conditions":1971,"interventions":1973},"NCT06234748","Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer",[92],"2028-07","2023-12-20",[232,1972],"HPV-Related Carcinoma",[1957],{"trials":1975,"activeCount":103},[],{"trials":1977,"activeCount":103},[],{"trials":1979,"activeCount":103},[],{"intervention":1981,"totalTrials":241,"cells":1982},"Freeze-Dried California Table Grape",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1984,"activeCount":103},[],{"trials":1986,"activeCount":103},[],{"trials":1988,"activeCount":241,"soonestReadout":1791},[1989],{"nctId":1990,"briefTitle":1991,"status":129,"phases":1992,"primaryCompletion":1791,"completion":1791,"start":1993,"enrollment":1994,"conditions":1995,"interventions":1997},"NCT05991700","Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation",[91,92],"2026-03-23",70,[1996],"Post-operative Atrial Fibrillation (POAF)",[1981],{"trials":1999,"activeCount":103},[],{"trials":2001,"activeCount":103},[],{"trials":2003,"activeCount":103},[],{"intervention":2005,"totalTrials":241,"cells":2006},"Amitriptyline",{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2022,"PHASE4":2024,"NA":2026},{"trials":2008,"activeCount":103},[],{"trials":2010,"activeCount":103},[],{"trials":2012,"activeCount":241,"soonestReadout":2018},[2013],{"nctId":2014,"briefTitle":2015,"status":2016,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":607,"enrollment":608,"conditions":2019,"interventions":2021},"NCT07556718","Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease","NOT_YET_RECRUITING",[92],"2029-12",[2020],"Quiescent Crohn's Disease (CD)",[2005],{"trials":2023,"activeCount":103},[],{"trials":2025,"activeCount":103},[],{"trials":2027,"activeCount":103},[],{"intervention":83,"totalTrials":241,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2031,"activeCount":103},[],{"trials":2033,"activeCount":103},[],{"trials":2035,"activeCount":241,"soonestReadout":82},[2036],{"nctId":80,"briefTitle":81,"status":553,"phases":2037,"primaryCompletion":82,"completion":82,"start":945,"enrollment":34,"conditions":2038,"interventions":2039},[92],[25,947,948],[83,950,951,43],{"trials":2041,"activeCount":103},[],{"trials":2043,"activeCount":103},[],{"trials":2045,"activeCount":103},[],{"intervention":951,"totalTrials":241,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2049,"activeCount":103},[],{"trials":2051,"activeCount":103},[],{"trials":2053,"activeCount":241,"soonestReadout":82},[2054],{"nctId":80,"briefTitle":81,"status":553,"phases":2055,"primaryCompletion":82,"completion":82,"start":945,"enrollment":34,"conditions":2056,"interventions":2057},[92],[25,947,948],[83,950,951,43],{"trials":2059,"activeCount":103},[],{"trials":2061,"activeCount":103},[],{"trials":2063,"activeCount":103},[],{"intervention":1036,"totalTrials":241,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":103},[],{"trials":2069,"activeCount":103},[],{"trials":2071,"activeCount":241,"soonestReadout":1030},[2072],{"nctId":1027,"briefTitle":1028,"status":553,"phases":2073,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":2074,"interventions":2075},[91,92],[25],[1036,1018,1037],{"trials":2077,"activeCount":103},[],{"trials":2079,"activeCount":103},[],{"trials":2081,"activeCount":103},[],{"intervention":1037,"totalTrials":241,"cells":2083},{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2088,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2085,"activeCount":103},[],{"trials":2087,"activeCount":103},[],{"trials":2089,"activeCount":241,"soonestReadout":1030},[2090],{"nctId":1027,"briefTitle":1028,"status":553,"phases":2091,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":2092,"interventions":2093},[91,92],[25],[1036,1018,1037],{"trials":2095,"activeCount":103},[],{"trials":2097,"activeCount":103},[],{"trials":2099,"activeCount":103},[],{"intervention":2101,"totalTrials":241,"cells":2102},"Tirzepatide",{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2104,"activeCount":103},[],{"trials":2106,"activeCount":103},[],{"trials":2108,"activeCount":241,"soonestReadout":2113},[2109],{"nctId":2110,"briefTitle":2111,"status":129,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":727,"conditions":2115,"interventions":2117},"NCT07091734","Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024",[92],"2029-09","2025-09-08",[2116],"Lipodystrophy, Partial",[2101,2118],"Usual care medications",{"trials":2120,"activeCount":103},[],{"trials":2122,"activeCount":103},[],{"trials":2124,"activeCount":103},[],{"intervention":2118,"totalTrials":241,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":103},[],{"trials":2130,"activeCount":103},[],{"trials":2132,"activeCount":241,"soonestReadout":2113},[2133],{"nctId":2110,"briefTitle":2111,"status":129,"phases":2134,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":727,"conditions":2135,"interventions":2136},[92],[2116],[2101,2118],{"trials":2138,"activeCount":103},[],{"trials":2140,"activeCount":103},[],{"trials":2142,"activeCount":103},[],{"intervention":1052,"totalTrials":241,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2146,"activeCount":103},[],{"trials":2148,"activeCount":103},[],{"trials":2150,"activeCount":241,"soonestReadout":1042},[2151],{"nctId":1039,"briefTitle":1040,"status":129,"phases":2152,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":2153,"interventions":2154},[92],[1046,1047,1048,1049,1050],[1052,1018],{"trials":2156,"activeCount":103},[],{"trials":2158,"activeCount":103},[],{"trials":2160,"activeCount":103},[],{"intervention":771,"totalTrials":241,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":103},[],{"trials":2166,"activeCount":103},[],{"trials":2168,"activeCount":241,"soonestReadout":62},[2169],{"nctId":60,"briefTitle":61,"status":553,"phases":2170,"primaryCompletion":62,"completion":764,"start":765,"enrollment":766,"conditions":2171,"interventions":2172},[92],[768,769],[63,771],{"trials":2174,"activeCount":103},[],{"trials":2176,"activeCount":103},[],{"trials":2178,"activeCount":103},[],{"intervention":2180,"totalTrials":241,"cells":2181},"Calcium Gluconate",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2183,"activeCount":103},[],{"trials":2185,"activeCount":103},[],{"trials":2187,"activeCount":241,"soonestReadout":1081},[2188],{"nctId":2189,"briefTitle":2190,"status":129,"phases":2191,"primaryCompletion":1081,"completion":449,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2198},"NCT07217899","Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony",[92],"2025-10-20",140,[2195,2196,2197],"Blood Loss, Surgical","Blood Loss, Postoperative","Uterine Atony",[2180],{"trials":2200,"activeCount":103},[],{"trials":2202,"activeCount":103},[],{"trials":2204,"activeCount":103},[],{"intervention":957,"totalTrials":241,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2208,"activeCount":103},[],{"trials":2210,"activeCount":103},[],{"trials":2212,"activeCount":241,"soonestReadout":42},[2213],{"nctId":40,"briefTitle":41,"status":553,"phases":2214,"primaryCompletion":42,"completion":528,"start":954,"enrollment":349,"conditions":2215,"interventions":2216},[92],[25],[43,957],{"trials":2218,"activeCount":103},[],{"trials":2220,"activeCount":103},[],{"trials":2222,"activeCount":103},[],{"intervention":2224,"totalTrials":241,"cells":2225},"Iron chelation",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2227,"activeCount":103},[],{"trials":2229,"activeCount":103},[],{"trials":2231,"activeCount":241,"soonestReadout":2236},[2232],{"nctId":2233,"briefTitle":2234,"status":129,"phases":2235,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":20,"conditions":2239,"interventions":2241},"NCT06784336","Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation",[92],"2028-10","2029-10","2025-10-15",[2240],"Allogeneic Stem Cell Transplant",[2224,2242],"Potato Resistant Starch",{"trials":2244,"activeCount":103},[],{"trials":2246,"activeCount":103},[],{"trials":2248,"activeCount":103},[],{"intervention":2242,"totalTrials":241,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2252,"activeCount":103},[],{"trials":2254,"activeCount":103},[],{"trials":2256,"activeCount":241,"soonestReadout":2236},[2257],{"nctId":2233,"briefTitle":2234,"status":129,"phases":2258,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":20,"conditions":2259,"interventions":2260},[92],[2240],[2224,2242],{"trials":2262,"activeCount":103},[],{"trials":2264,"activeCount":103},[],{"trials":2266,"activeCount":103},[],{"intervention":2268,"totalTrials":241,"cells":2269},"Ivonescimab",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2271,"activeCount":103},[],{"trials":2273,"activeCount":103},[],{"trials":2275,"activeCount":241,"soonestReadout":2280},[2276],{"nctId":2277,"briefTitle":2278,"status":129,"phases":2279,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":28,"conditions":2283,"interventions":2289},"NCT07094685","Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",[92],"2027-08-01","2030-11-01","2025-11-18",[2284,2285,2286,2287,2288],"Advanced Head and Neck Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma","Stage II Head and Neck Cutaneous Squamous Cell Carcinoma","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma",[2268],{"trials":2291,"activeCount":103},[],{"trials":2293,"activeCount":103},[],{"trials":2295,"activeCount":103},[],{"intervention":803,"totalTrials":241,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":103},[],{"trials":2301,"activeCount":103},[],{"trials":2303,"activeCount":241,"soonestReadout":131},[2304],{"nctId":794,"briefTitle":795,"status":129,"phases":2305,"primaryCompletion":131,"completion":797,"start":798,"enrollment":31,"conditions":2306,"interventions":2307},[92],[800,801],[63,803],{"trials":2309,"activeCount":103},[],{"trials":2311,"activeCount":103},[],{"trials":2313,"activeCount":103},[],{"intervention":2315,"totalTrials":241,"cells":2316},"Chemoradiation",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2318,"activeCount":103},[],{"trials":2320,"activeCount":103},[],{"trials":2322,"activeCount":241,"soonestReadout":131},[2323],{"nctId":2324,"briefTitle":2325,"status":129,"phases":2326,"primaryCompletion":131,"completion":2327,"start":2328,"enrollment":2329,"conditions":2330,"interventions":2333},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[92],"2030-12","2023-04-27",150,[2331,2332],"Oropharyngeal Cancer","Squamous Cell Carcinoma of the Oropharynx",[2315],{"trials":2335,"activeCount":103},[],{"trials":2337,"activeCount":103},[],{"trials":2339,"activeCount":103},[],{"intervention":221,"totalTrials":1569,"cells":2341},{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2346,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2343,"activeCount":103},[],{"trials":2345,"activeCount":103},[],{"trials":2347,"activeCount":241,"soonestReadout":317},[2348,2352,2362,2366,2377,2381,2385,2392,2396,2405,2416],{"nctId":209,"briefTitle":210,"status":211,"phases":2349,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":2350,"interventions":2351},[92],[218],[220,199,221,222],{"nctId":2353,"briefTitle":2354,"status":115,"phases":2355,"primaryCompletion":1438,"completion":1683,"start":2356,"enrollment":2357,"conditions":2358,"interventions":2359},"NCT00645593","Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer",[92],"2008-03",89,[275],[2360,221,2361],"Gemcitabine,","Cetuximab",{"nctId":257,"briefTitle":258,"status":115,"phases":2363,"primaryCompletion":260,"completion":261,"start":262,"conditions":2364,"interventions":2365},[92],[264],[199,221,222],{"nctId":2367,"briefTitle":2368,"status":115,"phases":2369,"primaryCompletion":2370,"completion":2371,"start":2372,"enrollment":1343,"conditions":2373,"interventions":2375},"NCT00176813","Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer",[92],"2003-11","2006-11","2003-03",[2374],"Pancreatic Cancer",[277,221,2376],"Celecoxib",{"nctId":1121,"briefTitle":1122,"status":115,"phases":2378,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":2379,"interventions":2380},[92],[1128],[221,234],{"nctId":1131,"briefTitle":1132,"status":115,"phases":2382,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1136,"conditions":2383,"interventions":2384},[92],[1138],[1140,1141,221,234],{"nctId":2386,"briefTitle":2387,"status":211,"phases":2388,"primaryCompletion":261,"completion":213,"start":873,"enrollment":804,"conditions":2389,"interventions":2391},"NCT00599131","Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)",[92],[2390],"Cancer of Larynx",[221,2361,222,1141],{"nctId":1303,"briefTitle":1304,"status":115,"phases":2393,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1044,"conditions":2394,"interventions":2395},[92],[1310],[277,221,1240,255],{"nctId":2397,"briefTitle":2398,"status":211,"phases":2399,"primaryCompletion":2400,"completion":2401,"start":1273,"enrollment":1044,"conditions":2402,"interventions":2403},"NCT04203160","Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)",[91,92],"2024-04-16","2024-04-29",[1251],[2404,277,221],"CPI 613",{"nctId":2406,"briefTitle":2407,"status":115,"phases":2408,"primaryCompletion":1400,"completion":2409,"start":2410,"enrollment":2411,"conditions":2412,"interventions":2414},"NCT01661114","A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers",[92],"2016-03","2011-07",39,[2374,2413],"Biliary Cancer",[277,2415,221],"5-FU",{"nctId":314,"briefTitle":315,"status":129,"phases":2417,"primaryCompletion":317,"completion":317,"start":318,"enrollment":20,"conditions":2418,"interventions":2419},[92],[320,321,322,323,324],[234,221,199],{"trials":2421,"activeCount":103},[],{"trials":2423,"activeCount":103},[],{"trials":2425,"activeCount":103},[2426],{"nctId":355,"briefTitle":356,"status":115,"phases":2427,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":2428,"interventions":2429},[95],[362],[199,234,221,222],{"intervention":1489,"totalTrials":216,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2449,"PHASE3":2468,"PHASE4":2485,"NA":2487},{"trials":2433,"activeCount":103},[],{"trials":2435,"activeCount":103},[2436],{"nctId":2437,"briefTitle":2438,"status":115,"phases":2439,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":2443,"interventions":2445},"NCT01673087","Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures",[91],"2017-08-15","2012-10",256,[2444],"Stress",[2446,1489,2447,2448],"Metyrapone","Cortrosyn","Corticorelin ovine triflutate",{"trials":2450,"activeCount":241,"soonestReadout":52},[2451,2455,2464],{"nctId":50,"briefTitle":51,"status":553,"phases":2452,"primaryCompletion":52,"completion":1482,"start":1483,"enrollment":1484,"conditions":2453,"interventions":2454},[92],[1486],[53,1488,1453,1489],{"nctId":2456,"briefTitle":2457,"status":115,"phases":2458,"primaryCompletion":2459,"completion":1073,"start":2460,"enrollment":557,"conditions":2461,"interventions":2462},"NCT00116961","Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma",[92],"2007-01","2005-06",[1486],[2463,1499,1489],"Velcade",{"nctId":1491,"briefTitle":1492,"status":115,"phases":2465,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":120,"conditions":2466,"interventions":2467},[91,92],[1486],[1488,1453,1489,1499],{"trials":2469,"activeCount":103},[2470],{"nctId":2471,"briefTitle":2472,"status":211,"phases":2473,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":2477,"conditions":2478,"interventions":2480},"NCT04503668","Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients",[93],"2024-01-03","2024-03-11","2020-12-28",62,[2479],"Gynecologic Cancer",[2481,1489,2482,2483,2484],"Ondansetron","Neurokinin-1 Receptor Antagonist","Olanzapine","Compazine",{"trials":2486,"activeCount":103},[],{"trials":2488,"activeCount":103},[2489],{"nctId":2490,"briefTitle":2491,"status":115,"phases":2492,"primaryCompletion":239,"completion":1073,"start":2493,"enrollment":404,"conditions":2494,"interventions":2495},"NCT00135187","Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma",[95],"2004-07",[1486],[2496,1499,1489],"VELCADE",{"intervention":48,"totalTrials":804,"cells":2498},{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2532,"PHASE4":2534,"NA":2536},{"trials":2500,"activeCount":103},[],{"trials":2502,"activeCount":103},[],{"trials":2504,"activeCount":241,"soonestReadout":47},[2505,2516,2522],{"nctId":2506,"briefTitle":2507,"status":115,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":1209,"conditions":2511,"interventions":2515},"NCT02654977","CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy",[92],"2019-11-14","2015-09-29",[2512,2513,2514],"Familial Partial Lipodystrophy","Nonalcoholic Steatohepatitis","NAFLD",[48],{"nctId":45,"briefTitle":46,"status":553,"phases":2517,"primaryCompletion":47,"completion":2236,"start":2518,"enrollment":804,"conditions":2519,"interventions":2521},[92],"2023-08-01",[2520],"Lipomatosis, Multiple Symmetrical",[48],{"nctId":2523,"briefTitle":2524,"status":115,"phases":2525,"primaryCompletion":2526,"completion":2526,"start":2527,"enrollment":31,"conditions":2528,"interventions":2531},"NCT01679197","Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy",[92],"2016-07-13","2012-10-08",[2529,2513,2530],"Fatty Liver Disease, Nonalcoholic","Lipodystrophy",[48],{"trials":2533,"activeCount":103},[],{"trials":2535,"activeCount":103},[],{"trials":2537,"activeCount":103},[2538],{"nctId":2539,"briefTitle":2540,"status":2541,"phases":2542,"conditions":2543,"interventions":2544},"NCT02404896","Expanded Access Metreleptin Study","AVAILABLE",[],[2512],[48],{"intervention":2546,"totalTrials":241,"cells":2547},"Yttrium-90",{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2561,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2549,"activeCount":103},[],{"trials":2551,"activeCount":241,"soonestReadout":2556},[2552],{"nctId":2553,"briefTitle":2554,"status":129,"phases":2555,"primaryCompletion":2556,"completion":1655,"start":2557,"enrollment":1994,"conditions":2558,"interventions":2560},"NCT04518748","Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.",[91],"2028-05","2020-09-16",[2559],"Liver Malignancy",[2546],{"trials":2562,"activeCount":103},[],{"trials":2564,"activeCount":103},[],{"trials":2566,"activeCount":103},[],{"trials":2568,"activeCount":103},[],{"intervention":2570,"totalTrials":241,"cells":2571},"Gilteritinib",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2585,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2573,"activeCount":103},[],{"trials":2575,"activeCount":241,"soonestReadout":1030},[2576],{"nctId":2577,"briefTitle":2578,"status":129,"phases":2579,"primaryCompletion":1030,"completion":1030,"start":2580,"enrollment":404,"conditions":2581,"interventions":2584},"NCT06225427","Gilteritinib for the Treatment of ALK NSCLC",[91],"2024-07-25",[2582,2583],"Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8",[2570],{"trials":2586,"activeCount":103},[],{"trials":2588,"activeCount":103},[],{"trials":2590,"activeCount":103},[],{"trials":2592,"activeCount":103},[],{"intervention":2594,"totalTrials":241,"cells":2595},"Ad-hCMV-Flt3L",{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2597,"activeCount":103},[],{"trials":2599,"activeCount":241,"soonestReadout":2604},[2600],{"nctId":2601,"briefTitle":2602,"status":129,"phases":2603,"primaryCompletion":2604,"completion":2604,"start":2605,"enrollment":1209,"conditions":2606,"interventions":2610},"NCT06914479","Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors",[91],"2031-05","2026-05-22",[2607,2608,2609],"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant","Recurrent Malignant Brain Neoplasm","Resectable Brain Neoplasm",[2594,2611,2612],"Ad-hCMV-TK","Valacyclovir",{"trials":2614,"activeCount":103},[],{"trials":2616,"activeCount":103},[],{"trials":2618,"activeCount":103},[],{"trials":2620,"activeCount":103},[],{"intervention":2611,"totalTrials":241,"cells":2622},{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2631,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2624,"activeCount":103},[],{"trials":2626,"activeCount":241,"soonestReadout":2604},[2627],{"nctId":2601,"briefTitle":2602,"status":129,"phases":2628,"primaryCompletion":2604,"completion":2604,"start":2605,"enrollment":1209,"conditions":2629,"interventions":2630},[91],[2607,2608,2609],[2594,2611,2612],{"trials":2632,"activeCount":103},[],{"trials":2634,"activeCount":103},[],{"trials":2636,"activeCount":103},[],{"trials":2638,"activeCount":103},[],{"intervention":2612,"totalTrials":241,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2649,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2642,"activeCount":103},[],{"trials":2644,"activeCount":241,"soonestReadout":2604},[2645],{"nctId":2601,"briefTitle":2602,"status":129,"phases":2646,"primaryCompletion":2604,"completion":2604,"start":2605,"enrollment":1209,"conditions":2647,"interventions":2648},[91],[2607,2608,2609],[2594,2611,2612],{"trials":2650,"activeCount":103},[],{"trials":2652,"activeCount":103},[],{"trials":2654,"activeCount":103},[],{"trials":2656,"activeCount":103},[],{"intervention":2658,"totalTrials":241,"cells":2659},"Ribociclib",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2671,"PHASE3":2673,"PHASE4":2675,"NA":2677},{"trials":2661,"activeCount":103},[],{"trials":2663,"activeCount":241,"soonestReadout":334},[2664],{"nctId":2665,"briefTitle":2666,"status":129,"phases":2667,"primaryCompletion":334,"completion":1523,"start":2668,"enrollment":404,"conditions":2669,"interventions":2670},"NCT05996107","Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+\u002FHER2- Breast Cancer",[91],"2024-02-27",[19],[2658],{"trials":2672,"activeCount":103},[],{"trials":2674,"activeCount":103},[],{"trials":2676,"activeCount":103},[],{"trials":2678,"activeCount":103},[],{"intervention":2680,"totalTrials":241,"cells":2681},"Cefoxitin",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2683,"activeCount":103},[],{"trials":2685,"activeCount":241,"soonestReadout":2690},[2686],{"nctId":2687,"briefTitle":2688,"status":129,"phases":2689,"primaryCompletion":2690,"completion":2691,"start":2692,"enrollment":10,"conditions":2693,"interventions":2695},"NCT06860802","Precision Antibiotic Dosing for Appendectomy",[91],"2026-06-30","2026-09-30","2025-02-28",[2694],"Appendicitis (Diagnosis)",[2680],{"trials":2697,"activeCount":103},[],{"trials":2699,"activeCount":103},[],{"trials":2701,"activeCount":103},[],{"trials":2703,"activeCount":103},[],{"intervention":2705,"totalTrials":241,"cells":2706},"Pomalidomide",{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2722,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2708,"activeCount":103},[],{"trials":2710,"activeCount":241,"soonestReadout":132},[2711],{"nctId":2712,"briefTitle":2713,"status":2016,"phases":2714,"primaryCompletion":132,"completion":1969,"start":2715,"enrollment":1569,"conditions":2716,"interventions":2721},"NCT07532525","Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma",[91],"2026-05-01",[2717,2718,2719,2720],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B-Cell Non-Hodgkin Lymphoma",[2705],{"trials":2723,"activeCount":103},[],{"trials":2725,"activeCount":103},[],{"trials":2727,"activeCount":103},[],{"trials":2729,"activeCount":103},[],{"intervention":2731,"totalTrials":241,"cells":2732},"Glucotrol XL 5Mg Extended-Release",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2748,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2734,"activeCount":103},[],{"trials":2736,"activeCount":241,"soonestReadout":689},[2737],{"nctId":2738,"briefTitle":2739,"status":129,"phases":2740,"primaryCompletion":689,"completion":689,"start":2741,"enrollment":557,"conditions":2742,"interventions":2744},"NCT05159427","Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers",[91],"2022-03-15",[2743],"Human Gastrointestinal Physiology Data",[2731,2745,2746,2747],"Glipizide ER 5 MG 24 HR Extended Release Oral","Rifaximin 200Mg Tab","13C6-Glipizide",{"trials":2749,"activeCount":103},[],{"trials":2751,"activeCount":103},[],{"trials":2753,"activeCount":103},[],{"trials":2755,"activeCount":103},[],{"intervention":2745,"totalTrials":241,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2766,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":103},[],{"trials":2761,"activeCount":241,"soonestReadout":689},[2762],{"nctId":2738,"briefTitle":2739,"status":129,"phases":2763,"primaryCompletion":689,"completion":689,"start":2741,"enrollment":557,"conditions":2764,"interventions":2765},[91],[2743],[2731,2745,2746,2747],{"trials":2767,"activeCount":103},[],{"trials":2769,"activeCount":103},[],{"trials":2771,"activeCount":103},[],{"trials":2773,"activeCount":103},[],{"intervention":2746,"totalTrials":241,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2777,"activeCount":103},[],{"trials":2779,"activeCount":241,"soonestReadout":689},[2780],{"nctId":2738,"briefTitle":2739,"status":129,"phases":2781,"primaryCompletion":689,"completion":689,"start":2741,"enrollment":557,"conditions":2782,"interventions":2783},[91],[2743],[2731,2745,2746,2747],{"trials":2785,"activeCount":103},[],{"trials":2787,"activeCount":103},[],{"trials":2789,"activeCount":103},[],{"trials":2791,"activeCount":103},[],{"intervention":2747,"totalTrials":241,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2795,"activeCount":103},[],{"trials":2797,"activeCount":241,"soonestReadout":689},[2798],{"nctId":2738,"briefTitle":2739,"status":129,"phases":2799,"primaryCompletion":689,"completion":689,"start":2741,"enrollment":557,"conditions":2800,"interventions":2801},[91],[2743],[2731,2745,2746,2747],{"trials":2803,"activeCount":103},[],{"trials":2805,"activeCount":103},[],{"trials":2807,"activeCount":103},[],{"trials":2809,"activeCount":103},[],{"intervention":2811,"totalTrials":241,"cells":2812},"Gallium Ga 68-DOTA-FAPI-04",{"EARLY_PHASE1":2813,"PHASE1":2824,"PHASE2":2826,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2814,"activeCount":241,"soonestReadout":2819},[2815],{"nctId":2816,"briefTitle":2817,"status":129,"phases":2818,"primaryCompletion":2819,"completion":2819,"start":2820,"enrollment":404,"conditions":2821,"interventions":2823},"NCT07132645","An Investigational Scan ([68Ga] Ga-FAPI-04 PET\u002FCT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer",[90],"2027-09-01","2025-09-16",[2822],"Neuroendocrine Tumor",[2811],{"trials":2825,"activeCount":103},[],{"trials":2827,"activeCount":103},[],{"trials":2829,"activeCount":103},[],{"trials":2831,"activeCount":103},[],{"trials":2833,"activeCount":103},[],{"intervention":2835,"totalTrials":241,"cells":2836},"Sotagliflozin (SOTA) followed by 3 drugs in a random order",{"EARLY_PHASE1":2837,"PHASE1":2850,"PHASE2":2852,"PHASE3":2854,"PHASE4":2856,"NA":2858},{"trials":2838,"activeCount":241,"soonestReadout":689},[2839],{"nctId":2840,"briefTitle":2841,"status":129,"phases":2842,"primaryCompletion":689,"completion":689,"start":2843,"enrollment":451,"conditions":2844,"interventions":2846},"NCT06933056","Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs",[90],"2025-09-02",[2845],"Platelet Function and Reactivity Tests",[2835,2847,2848,2849],"Aspirin followed by 3 drugs in a random order","Clopidogrel followed by 3 drugs in a random order","Eliquis followed by 3 drugs in a random order",{"trials":2851,"activeCount":103},[],{"trials":2853,"activeCount":103},[],{"trials":2855,"activeCount":103},[],{"trials":2857,"activeCount":103},[],{"trials":2859,"activeCount":103},[],{"intervention":2847,"totalTrials":241,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2874,"NA":2876},{"trials":2863,"activeCount":241,"soonestReadout":689},[2864],{"nctId":2840,"briefTitle":2841,"status":129,"phases":2865,"primaryCompletion":689,"completion":689,"start":2843,"enrollment":451,"conditions":2866,"interventions":2867},[90],[2845],[2835,2847,2848,2849],{"trials":2869,"activeCount":103},[],{"trials":2871,"activeCount":103},[],{"trials":2873,"activeCount":103},[],{"trials":2875,"activeCount":103},[],{"trials":2877,"activeCount":103},[],{"intervention":2848,"totalTrials":241,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2886,"PHASE2":2888,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2881,"activeCount":241,"soonestReadout":689},[2882],{"nctId":2840,"briefTitle":2841,"status":129,"phases":2883,"primaryCompletion":689,"completion":689,"start":2843,"enrollment":451,"conditions":2884,"interventions":2885},[90],[2845],[2835,2847,2848,2849],{"trials":2887,"activeCount":103},[],{"trials":2889,"activeCount":103},[],{"trials":2891,"activeCount":103},[],{"trials":2893,"activeCount":103},[],{"trials":2895,"activeCount":103},[],{"intervention":2849,"totalTrials":241,"cells":2897},{"EARLY_PHASE1":2898,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2899,"activeCount":241,"soonestReadout":689},[2900],{"nctId":2840,"briefTitle":2841,"status":129,"phases":2901,"primaryCompletion":689,"completion":689,"start":2843,"enrollment":451,"conditions":2902,"interventions":2903},[90],[2845],[2835,2847,2848,2849],{"trials":2905,"activeCount":103},[],{"trials":2907,"activeCount":103},[],{"trials":2909,"activeCount":103},[],{"trials":2911,"activeCount":103},[],{"trials":2913,"activeCount":103},[],{"intervention":2915,"totalTrials":241,"cells":2916},"Osilodrostat",{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2923,"PHASE4":2925,"NA":2927},{"trials":2918,"activeCount":103},[],{"trials":2920,"activeCount":103},[],{"trials":2922,"activeCount":103},[],{"trials":2924,"activeCount":103},[],{"trials":2926,"activeCount":103},[],{"trials":2928,"activeCount":241,"soonestReadout":1030},[2929],{"nctId":2930,"briefTitle":2931,"status":129,"phases":2932,"primaryCompletion":1030,"completion":1791,"start":2933,"enrollment":1569,"conditions":2934,"interventions":2938},"NCT06430528","A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement",[],"2024-07-19",[2935,2936,2937],"Endogenous Cushing Syndrome","Adrenal Insufficiency","Hypercortisolism",[2915],{"intervention":2940,"totalTrials":216,"cells":2941},"Etanercept",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2978,"PHASE4":2988,"NA":2999},{"trials":2943,"activeCount":103},[],{"trials":2945,"activeCount":103},[],{"trials":2947,"activeCount":103},[2948,2956,2960,2971],{"nctId":2949,"briefTitle":2950,"status":115,"phases":2951,"primaryCompletion":2952,"completion":2953,"start":306,"enrollment":608,"conditions":2954,"interventions":2955},"NCT00141739","Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)",[92],"2011-08","2012-09",[1381],[2940],{"nctId":1356,"briefTitle":1357,"status":115,"phases":2957,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":2958,"interventions":2959},[92],[1364],[1366,1367,1368,1369],{"nctId":2961,"briefTitle":2962,"status":115,"phases":2963,"primaryCompletion":261,"completion":2964,"start":2965,"enrollment":1249,"conditions":2966,"interventions":2970},"NCT00141726","Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant",[92],"2009-02","2003-10",[2967,2968,2969],"Lung Injury, Acute","Respiratory Distress Syndrome, Adult","Bronchiolitis Obliterans",[2940],{"nctId":2972,"briefTitle":2973,"status":115,"phases":2974,"primaryCompletion":2371,"completion":2975,"start":2965,"enrollment":557,"conditions":2976,"interventions":2977},"NCT00141713","The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease",[92],"2006-12",[1381],[2940],{"trials":2979,"activeCount":103},[2980],{"nctId":2981,"briefTitle":2982,"status":115,"phases":2983,"primaryCompletion":486,"completion":2984,"start":1496,"enrollment":1249,"conditions":2985,"interventions":2987},"NCT00726375","The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease",[93],"2014-09",[2986],"Acute Graft Versus Host Disease",[2940],{"trials":2989,"activeCount":103},[2990],{"nctId":2991,"briefTitle":2992,"status":115,"phases":2993,"primaryCompletion":2994,"completion":2994,"start":2995,"enrollment":20,"conditions":2996,"interventions":2998},"NCT01971346","The Immunological Basis for Treatment Resistance to Anti-TNF Treatments",[94],"2017-11-01","2014-03-13",[2997],"Psoriasis",[1368],{"trials":3000,"activeCount":103},[],{"intervention":3002,"totalTrials":804,"cells":3003},"Pioglitazone",{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3029,"PHASE4":3043,"NA":3053},{"trials":3005,"activeCount":103},[],{"trials":3007,"activeCount":103},[],{"trials":3009,"activeCount":103},[3010,3020],{"nctId":3011,"briefTitle":3012,"status":115,"phases":3013,"primaryCompletion":284,"completion":284,"start":1566,"enrollment":3014,"conditions":3015,"interventions":3019},"NCT00782795","Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality",[92],64,[3016,3017,3018],"Chronic Pancreatitis","Insulin Resistance","Normal or Mildly Abnormal Stool Fat Levels",[3002],{"nctId":3021,"briefTitle":3022,"status":115,"phases":3023,"primaryCompletion":3024,"completion":3024,"start":3025,"enrollment":241,"conditions":3026,"interventions":3028},"NCT01655719","Pioglitazone in Thyroid Cancers",[92],"2017-03-31","2012-04",[3027],"Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene",[3002],{"trials":3030,"activeCount":103},[3031],{"nctId":3032,"briefTitle":3033,"status":115,"phases":3034,"primaryCompletion":2441,"completion":3035,"start":3036,"enrollment":3037,"conditions":3038,"interventions":3040},"NCT00554853","PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease",[93],"2013-01","2007-11",143,[3039],"Rheumatoid Arthritis",[3041,3042],"pioglitazone","Sublingual nitroglycerine",{"trials":3044,"activeCount":103},[3045],{"nctId":3046,"briefTitle":3047,"status":115,"phases":3048,"primaryCompletion":1073,"start":3049,"enrollment":557,"conditions":3050,"interventions":3052},"NCT00189163","Pioglitazone in Hepatitis C",[94],"2005-01",[3051],"Chronic Hepatitis C",[3002],{"trials":3054,"activeCount":103},[],{"intervention":2481,"totalTrials":151,"cells":3056},{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3063,"PHASE4":3069,"NA":3081},{"trials":3058,"activeCount":103},[],{"trials":3060,"activeCount":103},[],{"trials":3062,"activeCount":103},[],{"trials":3064,"activeCount":103},[3065],{"nctId":2471,"briefTitle":2472,"status":211,"phases":3066,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":2477,"conditions":3067,"interventions":3068},[93],[2479],[2481,1489,2482,2483,2484],{"trials":3070,"activeCount":103},[3071],{"nctId":3072,"briefTitle":3073,"status":211,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":10,"conditions":3077,"interventions":3080},"NCT03262038","Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?",[94],"2019-08-20","2017-12-07",[3078,3079],"Pruritus","Nausea\u002FVomiting",[2481],{"trials":3082,"activeCount":103},[],{"intervention":3084,"totalTrials":151,"cells":3085},"Abemaciclib 150 MG",{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3102,"PHASE4":3104,"NA":3118},{"trials":3087,"activeCount":103},[],{"trials":3089,"activeCount":103},[],{"trials":3091,"activeCount":103},[3092],{"nctId":3093,"briefTitle":3094,"status":281,"phases":3095,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":103,"conditions":3098,"interventions":3099},"NCT04272645","Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer",[92],"2022-10","2020-10",[25],[3100,3101,3084],"Abemaciclib 200 MG","Atezolizumab 1200 MG in 20 ML",{"trials":3103,"activeCount":103},[],{"trials":3105,"activeCount":103},[3106],{"nctId":3107,"briefTitle":3108,"status":281,"phases":3109,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":103,"conditions":3112,"interventions":3114},"NCT05691400","Phase IV Multi-arm Study of CDK4\u002F6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype",[94],"2027-03","2024-03",[3113],"CYP3A4*22",[3115,3116,3117],"Palbociclib 125Mg Tab","Ribociclib 200Mg Oral","Abemaciclib 150 MG Oral",{"trials":3119,"activeCount":103},[],{"intervention":3121,"totalTrials":151,"cells":3122},"Vancomycin",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3155},{"trials":3124,"activeCount":103},[],{"trials":3126,"activeCount":103},[3127],{"nctId":3128,"briefTitle":3129,"status":115,"phases":3130,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3136},"NCT06601257","Vancomycin Dose Optimization in Obesity",[91],"2026-04-27","2025-04-01",35,[3135],"Pharmacokinetics and Pharmacodynamics",[3121],{"trials":3138,"activeCount":103},[],{"trials":3140,"activeCount":103},[],{"trials":3142,"activeCount":103},[3143],{"nctId":3144,"briefTitle":3145,"status":115,"phases":3146,"primaryCompletion":3147,"completion":3148,"start":3149,"enrollment":3150,"conditions":3151,"interventions":3153},"NCT02692651","A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections",[94],"2021-05-23","2021-06-23","2017-05-01",144,[3152],"Clostridium Difficile Infection (CDI)",[3154,3121],"Fidaxomicin",{"trials":3156,"activeCount":103},[],{"intervention":3158,"totalTrials":151,"cells":3159},"Aspirin",{"EARLY_PHASE1":3160,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3177,"NA":3187},{"trials":3161,"activeCount":103},[3162],{"nctId":3163,"briefTitle":3164,"status":115,"phases":3165,"primaryCompletion":3166,"completion":3166,"start":3167,"enrollment":34,"conditions":3168,"interventions":3170},"NCT06378398","A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy",[90],"2026-02-17","2024-06-14",[3169],"Colorectal Neoplasia",[288,3158],{"trials":3172,"activeCount":103},[],{"trials":3174,"activeCount":103},[],{"trials":3176,"activeCount":103},[],{"trials":3178,"activeCount":103},[3179],{"nctId":3180,"briefTitle":3181,"status":211,"phases":3182,"primaryCompletion":3183,"completion":3183,"start":1360,"enrollment":700,"conditions":3184,"interventions":3186},"NCT02966002","Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients",[94],"2017-05-25",[3185],"Fontan Procedure",[3158],{"trials":3188,"activeCount":103},[],{"intervention":3190,"totalTrials":241,"cells":3191},"Cosopt",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3212},{"trials":3193,"activeCount":103},[],{"trials":3195,"activeCount":103},[],{"trials":3197,"activeCount":103},[],{"trials":3199,"activeCount":103},[],{"trials":3201,"activeCount":103},[3202],{"nctId":3203,"briefTitle":3204,"status":115,"phases":3205,"primaryCompletion":3206,"completion":3206,"start":3207,"enrollment":3208,"conditions":3209,"interventions":3211},"NCT00906087","Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions",[94],"2012-07-18","2009-08-04",14,[3210],"Glaucoma",[3190],{"trials":3213,"activeCount":103},[],{"intervention":3215,"totalTrials":241,"cells":3216},"Insulin treatment for hyperglycemia",{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3223,"PHASE4":3225,"NA":3237},{"trials":3218,"activeCount":103},[],{"trials":3220,"activeCount":103},[],{"trials":3222,"activeCount":103},[],{"trials":3224,"activeCount":103},[],{"trials":3226,"activeCount":103},[3227],{"nctId":3228,"briefTitle":3229,"status":115,"phases":3230,"primaryCompletion":3231,"completion":3231,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},"NCT01683331","A Clinical Trial to Prevent New Onset Diabetes After Transplantation",[94],"2018-02-27","2012-08",251,[3235],"Prevention of New Onset Diabetes Among Kidney Transplant Patients",[3215],{"trials":3238,"activeCount":103},[],{"intervention":3240,"totalTrials":241,"cells":3241},"Eplerenone 50mg",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3261},{"trials":3243,"activeCount":103},[],{"trials":3245,"activeCount":103},[],{"trials":3247,"activeCount":103},[],{"trials":3249,"activeCount":103},[],{"trials":3251,"activeCount":103},[3252],{"nctId":3253,"briefTitle":3254,"status":281,"phases":3255,"primaryCompletion":3256,"completion":3257,"start":3258,"enrollment":103,"conditions":3259,"interventions":3260},"NCT04746495","Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)",[94],"2023-07-01","2023-12-01","2023-02",[30],[3240],{"trials":3262,"activeCount":103},[],{"intervention":3264,"totalTrials":241,"cells":3265},"Vitamin D3",{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3283},{"trials":3267,"activeCount":103},[],{"trials":3269,"activeCount":103},[],{"trials":3271,"activeCount":103},[],{"trials":3273,"activeCount":103},[],{"trials":3275,"activeCount":103},[3276],{"nctId":3277,"briefTitle":3278,"status":211,"phases":3279,"primaryCompletion":1400,"completion":1400,"start":213,"enrollment":28,"conditions":3280,"interventions":3282},"NCT01230307","Vitamin D Supplementation for Treatment of Heart Failure",[94],[3281],"Heart Failure",[3264],{"trials":3284,"activeCount":103},[],{"intervention":3286,"totalTrials":241,"cells":3287},"Iopamidol 300",{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3307},{"trials":3289,"activeCount":103},[],{"trials":3291,"activeCount":103},[],{"trials":3293,"activeCount":103},[],{"trials":3295,"activeCount":103},[],{"trials":3297,"activeCount":103},[3298],{"nctId":3299,"briefTitle":3300,"status":211,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":3303,"enrollment":241,"conditions":3304,"interventions":3306},"NCT02467075","Double-Blind Placebo-Controlled CIN Trial",[94],"2015-09","2015-07",[3305],"Acute Kidney Injury",[3286],{"trials":3308,"activeCount":103},[],{"intervention":3310,"totalTrials":241,"cells":3311},"Modafinil",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3333},{"trials":3313,"activeCount":103},[],{"trials":3315,"activeCount":103},[],{"trials":3317,"activeCount":103},[],{"trials":3319,"activeCount":103},[],{"trials":3321,"activeCount":103},[3322],{"nctId":3323,"briefTitle":3324,"status":115,"phases":3325,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3332},"NCT03621761","Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue",[94],"2021-08-24","2021-11-30","2018-11-15",343,[3331],"Multiple Sclerosis",[3310],{"trials":3334,"activeCount":103},[],{"intervention":3336,"totalTrials":241,"cells":3337},"Levetiracetam",{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3342,"PHASE3":3344,"PHASE4":3346,"NA":3359},{"trials":3339,"activeCount":103},[],{"trials":3341,"activeCount":103},[],{"trials":3343,"activeCount":103},[],{"trials":3345,"activeCount":103},[],{"trials":3347,"activeCount":103},[3348],{"nctId":3349,"briefTitle":3350,"status":115,"phases":3351,"primaryCompletion":3352,"completion":3352,"start":3353,"enrollment":3354,"conditions":3355,"interventions":3358},"NCT01801072","Seizure Prophylaxis in Aneurysm Repair",[94],"2023-10-06","2013-02",82,[3356,3357],"Intracranial Aneurysms","Seizure",[3336],{"trials":3360,"activeCount":103},[],{"intervention":3362,"totalTrials":241,"cells":3363},"Lactobacillus",{"EARLY_PHASE1":3364,"PHASE1":3366,"PHASE2":3368,"PHASE3":3370,"PHASE4":3372,"NA":3382},{"trials":3365,"activeCount":103},[],{"trials":3367,"activeCount":103},[],{"trials":3369,"activeCount":103},[],{"trials":3371,"activeCount":103},[],{"trials":3373,"activeCount":103},[3374],{"nctId":3375,"briefTitle":3376,"status":281,"phases":3377,"primaryCompletion":3353,"start":3378,"enrollment":103,"conditions":3379,"interventions":3381},"NCT01497743","Probiotics in Patients With Moderate-to-severe Distention\u002F Bloating From Systemic Sclerosis",[94],"2012-02",[3380],"Scleroderma",[3362],{"trials":3383,"activeCount":103},[],{"intervention":3385,"totalTrials":241,"cells":3386},"Naltrexone",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3408},{"trials":3388,"activeCount":103},[],{"trials":3390,"activeCount":103},[],{"trials":3392,"activeCount":103},[],{"trials":3394,"activeCount":103},[],{"trials":3396,"activeCount":103},[3397],{"nctId":3398,"briefTitle":3399,"status":115,"phases":3400,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":31,"conditions":3404,"interventions":3406},"NCT01993108","Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))",[94],"2015-12","2017-02","2013-10",[22,3405],"Attention Deficit Hyperactivity Disorder",[3407,3385],"Methylphenidate",{"trials":3409,"activeCount":103},[],{"intervention":3411,"totalTrials":241,"cells":3412},"Pfizer-BioNTech mRNA COVID-19 vaccine",{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3417,"PHASE3":3419,"PHASE4":3421,"NA":3435},{"trials":3414,"activeCount":103},[],{"trials":3416,"activeCount":103},[],{"trials":3418,"activeCount":103},[],{"trials":3420,"activeCount":103},[],{"trials":3422,"activeCount":103},[3423],{"nctId":3424,"briefTitle":3425,"status":115,"phases":3426,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":3429,"conditions":3430,"interventions":3433},"NCT05212610","Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction",[94],"2025-03-07","2022-03-21",137,[3431,3432],"COVID-19","Corona Virus Infection",[3411,3434],"Moderna mRNA COVID-19 vaccine",{"trials":3436,"activeCount":103},[],{"intervention":3434,"totalTrials":241,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3453},{"trials":3440,"activeCount":103},[],{"trials":3442,"activeCount":103},[],{"trials":3444,"activeCount":103},[],{"trials":3446,"activeCount":103},[],{"trials":3448,"activeCount":103},[3449],{"nctId":3424,"briefTitle":3425,"status":115,"phases":3450,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":3429,"conditions":3451,"interventions":3452},[94],[3431,3432],[3411,3434],{"trials":3454,"activeCount":103},[],{"intervention":3456,"totalTrials":241,"cells":3457},"Pliaglis",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3464,"PHASE4":3466,"NA":3479},{"trials":3459,"activeCount":103},[],{"trials":3461,"activeCount":103},[],{"trials":3463,"activeCount":103},[],{"trials":3465,"activeCount":103},[],{"trials":3467,"activeCount":103},[3468],{"nctId":3469,"briefTitle":3470,"status":115,"phases":3471,"primaryCompletion":3472,"completion":3472,"start":3473,"enrollment":3014,"conditions":3474,"interventions":3476},"NCT01951820","Comparison of Two Topical Anesthetics: Benzocaine Versus Pliaglis",[94],"2014-06","2013-08",[3475],"Anesthesia of Mucous Membrane",[3456,3477,3478],"Benzocaine","Articaine",{"trials":3480,"activeCount":103},[],{"intervention":3477,"totalTrials":241,"cells":3482},{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3489,"PHASE4":3491,"NA":3497},{"trials":3484,"activeCount":103},[],{"trials":3486,"activeCount":103},[],{"trials":3488,"activeCount":103},[],{"trials":3490,"activeCount":103},[],{"trials":3492,"activeCount":103},[3493],{"nctId":3469,"briefTitle":3470,"status":115,"phases":3494,"primaryCompletion":3472,"completion":3472,"start":3473,"enrollment":3014,"conditions":3495,"interventions":3496},[94],[3475],[3456,3477,3478],{"trials":3498,"activeCount":103},[],{"intervention":3478,"totalTrials":241,"cells":3500},{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3507,"PHASE4":3509,"NA":3515},{"trials":3502,"activeCount":103},[],{"trials":3504,"activeCount":103},[],{"trials":3506,"activeCount":103},[],{"trials":3508,"activeCount":103},[],{"trials":3510,"activeCount":103},[3511],{"nctId":3469,"briefTitle":3470,"status":115,"phases":3512,"primaryCompletion":3472,"completion":3472,"start":3473,"enrollment":3014,"conditions":3513,"interventions":3514},[94],[3475],[3456,3477,3478],{"trials":3516,"activeCount":103},[],{"intervention":465,"totalTrials":241,"cells":3518},{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3525,"PHASE4":3527,"NA":3533},{"trials":3520,"activeCount":103},[],{"trials":3522,"activeCount":103},[],{"trials":3524,"activeCount":103},[],{"trials":3526,"activeCount":103},[],{"trials":3528,"activeCount":103},[3529],{"nctId":457,"briefTitle":458,"status":281,"phases":3530,"primaryCompletion":460,"completion":460,"start":461,"enrollment":103,"conditions":3531,"interventions":3532},[94],[463],[465,433],{"trials":3534,"activeCount":103},[],{"intervention":3536,"totalTrials":241,"cells":3537},"Dapagliflozin",{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3559},{"trials":3539,"activeCount":103},[],{"trials":3541,"activeCount":103},[],{"trials":3543,"activeCount":103},[],{"trials":3545,"activeCount":103},[],{"trials":3547,"activeCount":103},[3548],{"nctId":3549,"briefTitle":3550,"status":115,"phases":3551,"primaryCompletion":3552,"completion":3552,"start":3553,"enrollment":766,"conditions":3554,"interventions":3557},"NCT02973477","Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)",[94],"2019-08-22","2017-01-12",[3555,3556],"Type2 Diabetes","Cardiovascular Diseases",[3536,3558],"Glimepiride",{"trials":3560,"activeCount":103},[],{"intervention":3558,"totalTrials":241,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3569,"PHASE4":3571,"NA":3577},{"trials":3564,"activeCount":103},[],{"trials":3566,"activeCount":103},[],{"trials":3568,"activeCount":103},[],{"trials":3570,"activeCount":103},[],{"trials":3572,"activeCount":103},[3573],{"nctId":3549,"briefTitle":3550,"status":115,"phases":3574,"primaryCompletion":3552,"completion":3552,"start":3553,"enrollment":766,"conditions":3575,"interventions":3576},[94],[3555,3556],[3536,3558],{"trials":3578,"activeCount":103},[],{"intervention":3580,"totalTrials":241,"cells":3581},"probiotic containing L.rhamnosus R0011 strain",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3590,"NA":3602},{"trials":3583,"activeCount":103},[],{"trials":3585,"activeCount":103},[],{"trials":3587,"activeCount":103},[],{"trials":3589,"activeCount":103},[],{"trials":3591,"activeCount":103},[3592],{"nctId":3593,"briefTitle":3594,"status":115,"phases":3595,"primaryCompletion":3596,"completion":3597,"start":2371,"enrollment":3598,"conditions":3599,"interventions":3601},"NCT00396162","Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis",[94],"2008-01","2008-02",77,[3600],"Chronic Rhinosinusitis",[3580],{"trials":3603,"activeCount":103},[],{"intervention":3605,"totalTrials":241,"cells":3606},"Lorazepam and fMRI",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3630},{"trials":3608,"activeCount":103},[],{"trials":3610,"activeCount":103},[],{"trials":3612,"activeCount":103},[],{"trials":3614,"activeCount":103},[],{"trials":3616,"activeCount":103},[3617],{"nctId":3618,"briefTitle":3619,"status":115,"phases":3620,"primaryCompletion":2692,"completion":2692,"start":3621,"enrollment":3037,"conditions":3622,"interventions":3629},"NCT04004416","Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis",[94],"2020-01-16",[3623,3624,22,3625,3626,3627,3628],"Schizophrenia","Bipolar Disorder","Psychosis","Schizophreniform Disorders","Schizo Affective Disorder","Major Depression With Psychotic Features",[3605],{"trials":3631,"activeCount":103},[],{"intervention":3633,"totalTrials":241,"cells":3634},"Tolvaptan",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3652},{"trials":3636,"activeCount":103},[],{"trials":3638,"activeCount":103},[],{"trials":3640,"activeCount":103},[],{"trials":3642,"activeCount":103},[],{"trials":3644,"activeCount":103},[3645],{"nctId":3646,"briefTitle":3647,"status":281,"phases":3648,"primaryCompletion":3649,"completion":3649,"start":3232,"enrollment":103,"conditions":3650,"interventions":3651},"NCT01663662","The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study",[94],"2013-11",[3281],[3633],{"trials":3653,"activeCount":103},[],{"intervention":3655,"totalTrials":241,"cells":3656},"ertapenem",{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3663,"PHASE4":3665,"NA":3675},{"trials":3658,"activeCount":103},[],{"trials":3660,"activeCount":103},[],{"trials":3662,"activeCount":103},[],{"trials":3664,"activeCount":103},[],{"trials":3666,"activeCount":103},[3667],{"nctId":3668,"briefTitle":3669,"status":115,"phases":3670,"primaryCompletion":3671,"completion":3671,"start":2964,"enrollment":620,"conditions":3672,"interventions":3674},"NCT00877370","Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis",[94],"2011-03",[3673],"Acute Kidney Failure",[3655],{"trials":3676,"activeCount":103},[],{"intervention":3678,"totalTrials":241,"cells":3679},"Indomethacin",{"EARLY_PHASE1":3680,"PHASE1":3682,"PHASE2":3684,"PHASE3":3686,"PHASE4":3688,"NA":3699},{"trials":3681,"activeCount":103},[],{"trials":3683,"activeCount":103},[],{"trials":3685,"activeCount":103},[],{"trials":3687,"activeCount":103},[],{"trials":3689,"activeCount":103},[3690],{"nctId":3691,"briefTitle":3692,"status":211,"phases":3693,"primaryCompletion":2410,"completion":2410,"start":3694,"enrollment":3695,"conditions":3696,"interventions":3698},"NCT00820612","Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients",[94],"2009-01",602,[3697],"Post-ERCP Pancreatitis",[3678],{"trials":3700,"activeCount":103},[],{"intervention":3702,"totalTrials":241,"cells":3703},"Cholecalciferol 10,000 IU",{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3724},{"trials":3705,"activeCount":103},[],{"trials":3707,"activeCount":103},[],{"trials":3709,"activeCount":103},[],{"trials":3711,"activeCount":103},[],{"trials":3713,"activeCount":103},[3714],{"nctId":3715,"briefTitle":3716,"status":211,"phases":3717,"primaryCompletion":1360,"completion":1360,"start":3718,"enrollment":1209,"conditions":3719,"interventions":3722},"NCT02208310","Trial of High Dose Vitamin D in Patient's With Crohn's Disease",[94],"2015-04",[3720,3721],"Crohn's Disease","Vitamin D Deficiency",[3702,3723],"Cholecalciferol 400 IU",{"trials":3725,"activeCount":103},[],{"intervention":3723,"totalTrials":241,"cells":3727},{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3742},{"trials":3729,"activeCount":103},[],{"trials":3731,"activeCount":103},[],{"trials":3733,"activeCount":103},[],{"trials":3735,"activeCount":103},[],{"trials":3737,"activeCount":103},[3738],{"nctId":3715,"briefTitle":3716,"status":211,"phases":3739,"primaryCompletion":1360,"completion":1360,"start":3718,"enrollment":1209,"conditions":3740,"interventions":3741},[94],[3720,3721],[3702,3723],{"trials":3743,"activeCount":103},[],{"intervention":3745,"totalTrials":241,"cells":3746},"generic bupropion",{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3751,"PHASE3":3753,"PHASE4":3755,"NA":3764},{"trials":3748,"activeCount":103},[],{"trials":3750,"activeCount":103},[],{"trials":3752,"activeCount":103},[],{"trials":3754,"activeCount":103},[],{"trials":3756,"activeCount":103},[3757],{"nctId":3758,"briefTitle":3759,"status":115,"phases":3760,"primaryCompletion":3761,"completion":3761,"start":1438,"enrollment":1249,"conditions":3762,"interventions":3763},"NCT02078180","Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns",[94],"2016-11",[16],[3745],{"trials":3765,"activeCount":103},[],{"intervention":3767,"totalTrials":241,"cells":3768},"Daptomycin",{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3773,"PHASE3":3775,"PHASE4":3777,"NA":3787},{"trials":3770,"activeCount":103},[],{"trials":3772,"activeCount":103},[],{"trials":3774,"activeCount":103},[],{"trials":3776,"activeCount":103},[],{"trials":3778,"activeCount":103},[3779],{"nctId":3780,"briefTitle":3781,"status":115,"phases":3782,"primaryCompletion":1494,"completion":1494,"start":3783,"enrollment":620,"conditions":3784,"interventions":3786},"NCT00663403","Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)",[94],"2007-02",[3785,622],"Critically Ill",[3767],{"trials":3788,"activeCount":103},[],{"intervention":3790,"totalTrials":241,"cells":3791},"Enalapril",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3811},{"trials":3793,"activeCount":103},[],{"trials":3795,"activeCount":103},[],{"trials":3797,"activeCount":103},[],{"trials":3799,"activeCount":103},[],{"trials":3801,"activeCount":103},[3802],{"nctId":3803,"briefTitle":3804,"status":115,"phases":3805,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":34,"conditions":3808,"interventions":3810},"NCT03051282","Genetic Determinants of ACEI Prodrug Activation",[94],"2026-01-01","2017-04-01",[3809],"Healthy Volunteers",[3790],{"trials":3812,"activeCount":103},[],{"intervention":3814,"totalTrials":241,"cells":3815},"milnacipran",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3834},{"trials":3817,"activeCount":103},[],{"trials":3819,"activeCount":103},[],{"trials":3821,"activeCount":103},[],{"trials":3823,"activeCount":103},[],{"trials":3825,"activeCount":103},[3826],{"nctId":3827,"briefTitle":3828,"status":115,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":358,"enrollment":336,"conditions":3831,"interventions":3833},"NCT01173055","A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia",[94],"2012-06",[3832],"Fibromyalgia",[3814],{"trials":3835,"activeCount":103},[],{"intervention":3837,"totalTrials":241,"cells":3838},"Bone Graft Placement",{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3861},{"trials":3840,"activeCount":103},[],{"trials":3842,"activeCount":103},[],{"trials":3844,"activeCount":103},[],{"trials":3846,"activeCount":103},[],{"trials":3848,"activeCount":103},[3849],{"nctId":3850,"briefTitle":3851,"status":115,"phases":3852,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":727,"conditions":3855,"interventions":3857},"NCT01628367","Guided Bone Regeneration Around Immediate Implants",[94],"2014-05","2012-07",[3856],"Missing Tooth",[3837,3858,3859,3860],"Membrane placement","Collagen plug placement","Medications",{"trials":3862,"activeCount":103},[],{"intervention":3858,"totalTrials":241,"cells":3864},{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3879},{"trials":3866,"activeCount":103},[],{"trials":3868,"activeCount":103},[],{"trials":3870,"activeCount":103},[],{"trials":3872,"activeCount":103},[],{"trials":3874,"activeCount":103},[3875],{"nctId":3850,"briefTitle":3851,"status":115,"phases":3876,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":727,"conditions":3877,"interventions":3878},[94],[3856],[3837,3858,3859,3860],{"trials":3880,"activeCount":103},[],{"intervention":3859,"totalTrials":241,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3897},{"trials":3884,"activeCount":103},[],{"trials":3886,"activeCount":103},[],{"trials":3888,"activeCount":103},[],{"trials":3890,"activeCount":103},[],{"trials":3892,"activeCount":103},[3893],{"nctId":3850,"briefTitle":3851,"status":115,"phases":3894,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":727,"conditions":3895,"interventions":3896},[94],[3856],[3837,3858,3859,3860],{"trials":3898,"activeCount":103},[],{"intervention":3860,"totalTrials":241,"cells":3900},{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3915},{"trials":3902,"activeCount":103},[],{"trials":3904,"activeCount":103},[],{"trials":3906,"activeCount":103},[],{"trials":3908,"activeCount":103},[],{"trials":3910,"activeCount":103},[3911],{"nctId":3850,"briefTitle":3851,"status":115,"phases":3912,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":727,"conditions":3913,"interventions":3914},[94],[3856],[3837,3858,3859,3860],{"trials":3916,"activeCount":103},[],{"intervention":3918,"totalTrials":241,"cells":3919},"Rifaximin 550 MG",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3939},{"trials":3921,"activeCount":103},[],{"trials":3923,"activeCount":103},[],{"trials":3925,"activeCount":103},[],{"trials":3927,"activeCount":103},[],{"trials":3929,"activeCount":103},[3930],{"nctId":3931,"briefTitle":3932,"status":115,"phases":3933,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":120,"conditions":3936,"interventions":3938},"NCT03219528","A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing",[94],"2024-02-28","2018-02-13",[3937],"Irritable Bowel Syndrome",[3918],{"trials":3940,"activeCount":103},[],{"intervention":3942,"totalTrials":241,"cells":3943},"Protamine Sulfate",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3952,"NA":3966},{"trials":3945,"activeCount":103},[],{"trials":3947,"activeCount":103},[],{"trials":3949,"activeCount":103},[],{"trials":3951,"activeCount":103},[],{"trials":3953,"activeCount":103},[3954],{"nctId":3955,"briefTitle":3956,"status":115,"phases":3957,"primaryCompletion":3958,"completion":3959,"start":3960,"enrollment":3961,"conditions":3962,"interventions":3965},"NCT03140631","Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation",[94],"2017-11-16","2018-04-03","2017-03-23",153,[3963,3964],"Atrial Fibrillation","Catheter Ablation",[3942],{"trials":3967,"activeCount":103},[],{"intervention":3969,"totalTrials":241,"cells":3970},"Antibiotics",{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3993},{"trials":3972,"activeCount":103},[],{"trials":3974,"activeCount":103},[],{"trials":3976,"activeCount":103},[],{"trials":3978,"activeCount":103},[],{"trials":3980,"activeCount":103},[3981],{"nctId":3982,"briefTitle":3983,"status":115,"phases":3984,"primaryCompletion":3985,"completion":3985,"start":3986,"enrollment":557,"conditions":3987,"interventions":3992},"NCT03159754","Optimal Care of Complicated Appendicitis",[94],"2020-03-26","2017-06-29",[3988,3989,3990,3991],"Appendicitis","Perforated Appendicitis","Ruptured Appendicitis","Complicated Appendicitis",[3969],{"trials":3994,"activeCount":103},[],{"intervention":3996,"totalTrials":241,"cells":3997},"insulin",{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4004,"PHASE4":4006,"NA":4015},{"trials":3999,"activeCount":103},[],{"trials":4001,"activeCount":103},[],{"trials":4003,"activeCount":103},[],{"trials":4005,"activeCount":103},[],{"trials":4007,"activeCount":103},[4008],{"nctId":4009,"briefTitle":4010,"status":115,"phases":4011,"primaryCompletion":1567,"completion":1567,"start":261,"enrollment":608,"conditions":4012,"interventions":4014},"NCT00780026","Intraoperative Glucose Control in Liver Transplant",[94],[4013],"Liver Transplant",[3996],{"trials":4016,"activeCount":103},[],{"intervention":3154,"totalTrials":241,"cells":4018},{"EARLY_PHASE1":4019,"PHASE1":4021,"PHASE2":4023,"PHASE3":4025,"PHASE4":4027,"NA":4033},{"trials":4020,"activeCount":103},[],{"trials":4022,"activeCount":103},[],{"trials":4024,"activeCount":103},[],{"trials":4026,"activeCount":103},[],{"trials":4028,"activeCount":103},[4029],{"nctId":3144,"briefTitle":3145,"status":115,"phases":4030,"primaryCompletion":3147,"completion":3148,"start":3149,"enrollment":3150,"conditions":4031,"interventions":4032},[94],[3152],[3154,3121],{"trials":4034,"activeCount":103},[],{"intervention":4036,"totalTrials":241,"cells":4037},"Telavancin",{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4046,"NA":4056},{"trials":4039,"activeCount":103},[],{"trials":4041,"activeCount":103},[],{"trials":4043,"activeCount":103},[],{"trials":4045,"activeCount":103},[],{"trials":4047,"activeCount":103},[4048],{"nctId":4049,"briefTitle":4050,"status":115,"phases":4051,"primaryCompletion":2409,"completion":2409,"start":3303,"enrollment":620,"conditions":4052,"interventions":4055},"NCT02392208","Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5",[94],[4053,4054],"End-Stage Renal Disease","Stage 5 Chronic Kidney Disease",[4036],{"trials":4057,"activeCount":103},[],{"intervention":4059,"totalTrials":241,"cells":4060},"Variation in eye pressure response to timolol and latanoprost treatment",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4067,"PHASE4":4069,"NA":4079},{"trials":4062,"activeCount":103},[],{"trials":4064,"activeCount":103},[],{"trials":4066,"activeCount":103},[],{"trials":4068,"activeCount":103},[],{"trials":4070,"activeCount":103},[4071],{"nctId":4072,"briefTitle":4073,"status":115,"phases":4074,"primaryCompletion":4075,"completion":4075,"start":3232,"enrollment":4076,"conditions":4077,"interventions":4078},"NCT01677507","Glaucoma Biomarkers",[94],"2016-08-30",135,[3210,22],[4059],{"trials":4080,"activeCount":103},[],{"intervention":4082,"totalTrials":241,"cells":4083},"carbidopa\u002Flevodopa, as prescribed by treating physician",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4090,"PHASE4":4092,"NA":4103},{"trials":4085,"activeCount":103},[],{"trials":4087,"activeCount":103},[],{"trials":4089,"activeCount":103},[],{"trials":4091,"activeCount":103},[],{"trials":4093,"activeCount":103},[4094],{"nctId":4095,"briefTitle":4096,"status":115,"phases":4097,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":37,"conditions":4100,"interventions":4102},"NCT04821830","Vigor and the LDR in Parkinson Disease",[94],"2024-04-25","2020-02-12",[4101],"Parkinson Disease",[4082],{"trials":4104,"activeCount":103},[],{"intervention":4106,"totalTrials":241,"cells":4107},"Cefazolin for",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4127},{"trials":4109,"activeCount":103},[],{"trials":4111,"activeCount":103},[],{"trials":4113,"activeCount":103},[],{"trials":4115,"activeCount":103},[],{"trials":4117,"activeCount":103},[4118],{"nctId":4119,"briefTitle":4120,"status":115,"phases":4121,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":1484,"conditions":4124,"interventions":4126},"NCT06005168","Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis",[94],"2025-10-01","2023-03-08",[4125],"Surgical Prophylaxis",[4106],{"trials":4128,"activeCount":103},[],{"intervention":4130,"totalTrials":241,"cells":4131},"platelet-rich plasma",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4152},{"trials":4133,"activeCount":103},[],{"trials":4135,"activeCount":103},[],{"trials":4137,"activeCount":103},[],{"trials":4139,"activeCount":103},[],{"trials":4141,"activeCount":103},[4142],{"nctId":4143,"briefTitle":4144,"status":211,"phases":4145,"primaryCompletion":4146,"completion":4146,"start":4147,"enrollment":804,"conditions":4148,"interventions":4150},"NCT02920177","Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement",[94],"2018-08-10","2016-08-01",[4149],"Femoroacetabular Impingement",[4130,4151],"Kenalog 10 MG\u002FML Injectable Suspension",{"trials":4153,"activeCount":103},[],{"intervention":4151,"totalTrials":241,"cells":4155},{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4164,"NA":4170},{"trials":4157,"activeCount":103},[],{"trials":4159,"activeCount":103},[],{"trials":4161,"activeCount":103},[],{"trials":4163,"activeCount":103},[],{"trials":4165,"activeCount":103},[4166],{"nctId":4143,"briefTitle":4144,"status":211,"phases":4167,"primaryCompletion":4146,"completion":4146,"start":4147,"enrollment":804,"conditions":4168,"interventions":4169},[94],[4149],[4130,4151],{"trials":4171,"activeCount":103},[],{"intervention":4173,"totalTrials":241,"cells":4174},"IANB Articaine",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4183,"NA":4196},{"trials":4176,"activeCount":103},[],{"trials":4178,"activeCount":103},[],{"trials":4180,"activeCount":103},[],{"trials":4182,"activeCount":103},[],{"trials":4184,"activeCount":103},[4185],{"nctId":4186,"briefTitle":4187,"status":115,"phases":4188,"primaryCompletion":460,"completion":460,"start":4189,"enrollment":4190,"conditions":4191,"interventions":4193},"NCT01496846","Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars",[94],"2011-09",201,[4192],"Irreversible Pulpitis",[4173,4194,4195],"SUP Articaine","SUP Lidocaine",{"trials":4197,"activeCount":103},[],{"intervention":4194,"totalTrials":241,"cells":4199},{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4208,"NA":4214},{"trials":4201,"activeCount":103},[],{"trials":4203,"activeCount":103},[],{"trials":4205,"activeCount":103},[],{"trials":4207,"activeCount":103},[],{"trials":4209,"activeCount":103},[4210],{"nctId":4186,"briefTitle":4187,"status":115,"phases":4211,"primaryCompletion":460,"completion":460,"start":4189,"enrollment":4190,"conditions":4212,"interventions":4213},[94],[4192],[4173,4194,4195],{"trials":4215,"activeCount":103},[],{"intervention":4195,"totalTrials":241,"cells":4217},{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4222,"PHASE3":4224,"PHASE4":4226,"NA":4232},{"trials":4219,"activeCount":103},[],{"trials":4221,"activeCount":103},[],{"trials":4223,"activeCount":103},[],{"trials":4225,"activeCount":103},[],{"trials":4227,"activeCount":103},[4228],{"nctId":4186,"briefTitle":4187,"status":115,"phases":4229,"primaryCompletion":460,"completion":460,"start":4189,"enrollment":4190,"conditions":4230,"interventions":4231},[94],[4192],[4173,4194,4195],{"trials":4233,"activeCount":103},[],{"intervention":3115,"totalTrials":241,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4242,"PHASE4":4244,"NA":4250},{"trials":4237,"activeCount":103},[],{"trials":4239,"activeCount":103},[],{"trials":4241,"activeCount":103},[],{"trials":4243,"activeCount":103},[],{"trials":4245,"activeCount":103},[4246],{"nctId":3107,"briefTitle":3108,"status":281,"phases":4247,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":103,"conditions":4248,"interventions":4249},[94],[3113],[3115,3116,3117],{"trials":4251,"activeCount":103},[],{"intervention":3116,"totalTrials":241,"cells":4253},{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4260,"PHASE4":4262,"NA":4268},{"trials":4255,"activeCount":103},[],{"trials":4257,"activeCount":103},[],{"trials":4259,"activeCount":103},[],{"trials":4261,"activeCount":103},[],{"trials":4263,"activeCount":103},[4264],{"nctId":3107,"briefTitle":3108,"status":281,"phases":4265,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":103,"conditions":4266,"interventions":4267},[94],[3113],[3115,3116,3117],{"trials":4269,"activeCount":103},[],{"intervention":4271,"totalTrials":241,"cells":4272},"Rifaximin",{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4292},{"trials":4274,"activeCount":103},[],{"trials":4276,"activeCount":103},[],{"trials":4278,"activeCount":103},[],{"trials":4280,"activeCount":103},[],{"trials":4282,"activeCount":103},[4283],{"nctId":4284,"briefTitle":4285,"status":115,"phases":4286,"primaryCompletion":3806,"completion":3806,"start":4287,"enrollment":4288,"conditions":4289,"interventions":4291},"NCT03729271","Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea",[94],"2020-01-09",148,[3937,4290],"Irritable Bowel Syndrome With Diarrhea",[4271],{"trials":4293,"activeCount":103},[],{"intervention":4295,"totalTrials":241,"cells":4296},"leptin",{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4314},{"trials":4298,"activeCount":103},[],{"trials":4300,"activeCount":103},[],{"trials":4302,"activeCount":103},[],{"trials":4304,"activeCount":103},[],{"trials":4306,"activeCount":103},[4307],{"nctId":4308,"briefTitle":4309,"status":115,"phases":4310,"completion":240,"start":4311,"enrollment":394,"conditions":4312,"interventions":4313},"NCT00121433","Leptin and Endothelial Function",[94],"2004-09",[22],[4295],{"trials":4315,"activeCount":103},[],{"intervention":4317,"totalTrials":241,"cells":4318},"Vismodegib",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4338},{"trials":4320,"activeCount":103},[],{"trials":4322,"activeCount":103},[],{"trials":4324,"activeCount":103},[],{"trials":4326,"activeCount":103},[],{"trials":4328,"activeCount":103},[4329],{"nctId":4330,"briefTitle":4331,"status":115,"phases":4332,"primaryCompletion":4333,"completion":4333,"start":4334,"enrollment":3133,"conditions":4335,"interventions":4337},"NCT02436408","VISmodegib for ORbital and Periocular Basal Cell Carcinoma",[94],"2020-09","2015-07-15",[4336],"Carcinoma, Basal Cell",[4317],{"trials":4339,"activeCount":103},[],{"intervention":4341,"totalTrials":241,"cells":4342},"Nitrous Oxide Gas for Inhalation",{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4361},{"trials":4344,"activeCount":103},[],{"trials":4346,"activeCount":103},[],{"trials":4348,"activeCount":103},[],{"trials":4350,"activeCount":103},[],{"trials":4352,"activeCount":103},[4353],{"nctId":4354,"briefTitle":4355,"status":115,"phases":4356,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":34,"conditions":4359,"interventions":4360},"NCT03435055","Network-Level Effects of Nitrous Oxide in the Human Brain",[94],"2019-10-11","2017-07-21",[22],[4341],{"trials":4362,"activeCount":103},[],{"intervention":4364,"totalTrials":241,"cells":4365},"Spironolactone",{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4370,"PHASE3":4372,"PHASE4":4374,"NA":4385},{"trials":4367,"activeCount":103},[],{"trials":4369,"activeCount":103},[],{"trials":4371,"activeCount":103},[],{"trials":4373,"activeCount":103},[],{"trials":4375,"activeCount":103},[4376],{"nctId":4377,"briefTitle":4378,"status":281,"phases":4379,"primaryCompletion":4380,"completion":4380,"start":4381,"enrollment":103,"conditions":4382,"interventions":4384},"NCT04205136","Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients",[94],"2023-04","2022-03",[4383],"Obstructive Sleep Apnea",[4364],{"trials":4386,"activeCount":103},[],{"intervention":4388,"totalTrials":241,"cells":4389},"Propofol",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4408},{"trials":4391,"activeCount":103},[],{"trials":4393,"activeCount":103},[],{"trials":4395,"activeCount":103},[],{"trials":4397,"activeCount":103},[],{"trials":4399,"activeCount":103},[4400],{"nctId":4401,"briefTitle":4402,"status":115,"phases":4403,"primaryCompletion":4404,"completion":4404,"start":4405,"enrollment":404,"conditions":4406,"interventions":4407},"NCT03361605","Neuroimaging of Anesthetic Modulation of Human Consciousness",[94],"2019-07-12","2017-04-12",[22],[4388],{"trials":4409,"activeCount":103},[],{"intervention":4411,"totalTrials":241,"cells":4412},"Celexa or other antidepressant as clinically indicated",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4421,"NA":4431},{"trials":4414,"activeCount":103},[],{"trials":4416,"activeCount":103},[],{"trials":4418,"activeCount":103},[],{"trials":4420,"activeCount":103},[],{"trials":4422,"activeCount":103},[4423],{"nctId":4424,"briefTitle":4425,"status":115,"phases":4426,"primaryCompletion":858,"completion":858,"start":4427,"enrollment":4428,"conditions":4429,"interventions":4430},"NCT02178696","Predictors of Antidepressant Response",[94],"2011-01",44,[16],[4411],{"trials":4432,"activeCount":103},[],{"intervention":4434,"totalTrials":241,"cells":4435},"LOVAZA Omega 3-acid ethyl esters",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4455},{"trials":4437,"activeCount":103},[],{"trials":4439,"activeCount":103},[],{"trials":4441,"activeCount":103},[],{"trials":4443,"activeCount":103},[],{"trials":4445,"activeCount":103},[4446],{"nctId":4447,"briefTitle":4448,"status":211,"phases":4449,"primaryCompletion":4450,"completion":4451,"start":1566,"enrollment":1569,"conditions":4452,"interventions":4453},"NCT00791089","Effects of Fish Oil on Post Ablation Arrhythmias",[94],"2009-12","2011-10",[3963],[4434,4454],"LOVAZA",{"trials":4456,"activeCount":103},[],{"intervention":4454,"totalTrials":241,"cells":4458},{"EARLY_PHASE1":4459,"PHASE1":4461,"PHASE2":4463,"PHASE3":4465,"PHASE4":4467,"NA":4473},{"trials":4460,"activeCount":103},[],{"trials":4462,"activeCount":103},[],{"trials":4464,"activeCount":103},[],{"trials":4466,"activeCount":103},[],{"trials":4468,"activeCount":103},[4469],{"nctId":4447,"briefTitle":4448,"status":211,"phases":4470,"primaryCompletion":4450,"completion":4451,"start":1566,"enrollment":1569,"conditions":4471,"interventions":4472},[94],[3963],[4434,4454],{"trials":4474,"activeCount":103},[],{"intervention":4476,"totalTrials":241,"cells":4477},"Ranolazine",{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4496},{"trials":4479,"activeCount":103},[],{"trials":4481,"activeCount":103},[],{"trials":4483,"activeCount":103},[],{"trials":4485,"activeCount":103},[],{"trials":4487,"activeCount":103},[4488],{"nctId":4489,"briefTitle":4490,"status":115,"phases":4491,"primaryCompletion":857,"completion":857,"start":4451,"enrollment":1060,"conditions":4492,"interventions":4495},"NCT01435174","Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients",[94],[4493,4494],"End-stage Renal Disease","Cardiovascular Disease",[4476],{"trials":4497,"activeCount":103},[],{"intervention":4499,"totalTrials":241,"cells":4500},"AirDuo Digihaler",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4507,"PHASE4":4509,"NA":4520},{"trials":4502,"activeCount":103},[],{"trials":4504,"activeCount":103},[],{"trials":4506,"activeCount":103},[],{"trials":4508,"activeCount":103},[],{"trials":4510,"activeCount":103},[4511],{"nctId":4512,"briefTitle":4513,"status":115,"phases":4514,"primaryCompletion":4515,"completion":4515,"start":4516,"enrollment":608,"conditions":4517,"interventions":4518},"NCT04997304","Teva Asthma Predictive Analytics Study",[94],"2023-12-14","2021-07-09",[396],[4499,4519],"ProAir Digihaler",{"trials":4521,"activeCount":103},[],{"intervention":4519,"totalTrials":241,"cells":4523},{"EARLY_PHASE1":4524,"PHASE1":4526,"PHASE2":4528,"PHASE3":4530,"PHASE4":4532,"NA":4538},{"trials":4525,"activeCount":103},[],{"trials":4527,"activeCount":103},[],{"trials":4529,"activeCount":103},[],{"trials":4531,"activeCount":103},[],{"trials":4533,"activeCount":103},[4534],{"nctId":4512,"briefTitle":4513,"status":115,"phases":4535,"primaryCompletion":4515,"completion":4515,"start":4516,"enrollment":608,"conditions":4536,"interventions":4537},[94],[396],[4499,4519],{"trials":4539,"activeCount":103},[],{"intervention":4541,"totalTrials":241,"cells":4542},"Tranexamic acid",{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4549,"PHASE4":4551,"NA":4562},{"trials":4544,"activeCount":103},[],{"trials":4546,"activeCount":103},[],{"trials":4548,"activeCount":103},[],{"trials":4550,"activeCount":103},[],{"trials":4552,"activeCount":103},[4553],{"nctId":4554,"briefTitle":4555,"status":115,"phases":4556,"primaryCompletion":4557,"completion":4557,"start":1946,"enrollment":4558,"conditions":4559,"interventions":4561},"NCT05441592","A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery",[94],"2024-10-22",107,[4560],"Hematoma Postoperative",[4541],{"trials":4563,"activeCount":103},[],{"intervention":880,"totalTrials":241,"cells":4565},{"EARLY_PHASE1":4566,"PHASE1":4568,"PHASE2":4570,"PHASE3":4572,"PHASE4":4574,"NA":4580},{"trials":4567,"activeCount":103},[],{"trials":4569,"activeCount":103},[],{"trials":4571,"activeCount":103},[],{"trials":4573,"activeCount":103},[],{"trials":4575,"activeCount":103},[4576],{"nctId":870,"briefTitle":871,"status":115,"phases":4577,"primaryCompletion":873,"completion":873,"start":874,"enrollment":713,"conditions":4578,"interventions":4579},[94],[876,877],[879,880],{"trials":4581,"activeCount":103},[],{"intervention":4583,"totalTrials":241,"cells":4584},"Fluzone",{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4605},{"trials":4586,"activeCount":103},[],{"trials":4588,"activeCount":103},[],{"trials":4590,"activeCount":103},[],{"trials":4592,"activeCount":103},[],{"trials":4594,"activeCount":103},[4595],{"nctId":4596,"briefTitle":4597,"status":115,"phases":4598,"primaryCompletion":1496,"completion":1496,"start":4599,"enrollment":4600,"conditions":4601,"interventions":4603},"NCT00538512","Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4",[94],"2007-09",1952,[4602],"Influenza",[4583,4604],"Flumist",{"trials":4606,"activeCount":103},[],{"intervention":4604,"totalTrials":241,"cells":4608},{"EARLY_PHASE1":4609,"PHASE1":4611,"PHASE2":4613,"PHASE3":4615,"PHASE4":4617,"NA":4623},{"trials":4610,"activeCount":103},[],{"trials":4612,"activeCount":103},[],{"trials":4614,"activeCount":103},[],{"trials":4616,"activeCount":103},[],{"trials":4618,"activeCount":103},[4619],{"nctId":4596,"briefTitle":4597,"status":115,"phases":4620,"primaryCompletion":1496,"completion":1496,"start":4599,"enrollment":4600,"conditions":4621,"interventions":4622},[94],[4602],[4583,4604],{"trials":4624,"activeCount":103},[],{"intervention":4626,"totalTrials":151,"cells":4627},"Salsalate",{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4643,"PHASE4":4653,"NA":4655},{"trials":4629,"activeCount":103},[],{"trials":4631,"activeCount":103},[],{"trials":4633,"activeCount":103},[4634],{"nctId":4635,"briefTitle":4636,"status":115,"phases":4637,"primaryCompletion":3025,"completion":2984,"start":4638,"enrollment":620,"conditions":4639,"interventions":4642},"NCT01480297","Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy",[92],"2011-11",[4640,4641],"Peripheral Neuropathy","Type 1 Diabetes",[4626],{"trials":4644,"activeCount":103},[4645],{"nctId":4646,"briefTitle":4647,"status":115,"phases":4648,"primaryCompletion":4649,"completion":4649,"start":1646,"enrollment":4650,"conditions":4651,"interventions":4652},"NCT02936843","Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy",[92,93],"2023-05-01",61,[4641,4640],[4626],{"trials":4654,"activeCount":103},[],{"trials":4656,"activeCount":103},[],{"intervention":4658,"totalTrials":151,"cells":4659},"Lactulose",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4666,"PHASE4":4686,"NA":4688},{"trials":4661,"activeCount":103},[],{"trials":4663,"activeCount":103},[],{"trials":4665,"activeCount":103},[],{"trials":4667,"activeCount":103},[4668,4677],{"nctId":4669,"briefTitle":4670,"status":115,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":1330,"conditions":4674,"interventions":4676},"NCT05061992","A Trial to Improve Quality of Life in People With Cirrhosis",[92,93],"2022-11-01","2021-11-10",[4675],"Cirrhosis",[4658],{"nctId":4678,"briefTitle":4679,"status":115,"phases":4680,"primaryCompletion":3427,"completion":3427,"start":1230,"enrollment":4681,"conditions":4682,"interventions":4685},"NCT05794555","LiveSMART Trial to Prevent Falls in Patients With Cirrhosis",[93],230,[4683,4684],"Cirrhosis, Liver","Portal Hypertension",[4658],{"trials":4687,"activeCount":103},[],{"trials":4689,"activeCount":103},[],{"intervention":4691,"totalTrials":151,"cells":4692},"N-acetylcysteine",{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4709,"PHASE4":4721,"NA":4723},{"trials":4694,"activeCount":103},[],{"trials":4696,"activeCount":103},[],{"trials":4698,"activeCount":103},[4699],{"nctId":4700,"briefTitle":4701,"status":115,"phases":4702,"primaryCompletion":4703,"completion":4703,"start":4704,"enrollment":34,"conditions":4705,"interventions":4708},"NCT00374088","N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)",[92],"2008-06","2005-02",[4706,4707],"Transposition of Great Vessels","Congenital Heart Disease",[4691],{"trials":4710,"activeCount":103},[4711],{"nctId":4712,"briefTitle":4713,"status":211,"phases":4714,"primaryCompletion":3353,"start":4715,"enrollment":1343,"conditions":4716,"interventions":4719},"NCT01424033","A Clinical Trial for CTD-ILD Treatment",[92,93],"2011-12",[4717,4718],"Interstitial Lung Disease","Connective Tissue Disease",[4720],"N-Acetylcysteine",{"trials":4722,"activeCount":103},[],{"trials":4724,"activeCount":103},[],{"intervention":4726,"totalTrials":241,"cells":4727},"ORAL ANTIOXIDANT",{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4732,"PHASE3":4734,"PHASE4":4744,"NA":4746},{"trials":4729,"activeCount":103},[],{"trials":4731,"activeCount":103},[],{"trials":4733,"activeCount":103},[],{"trials":4735,"activeCount":103},[4736],{"nctId":4737,"briefTitle":4738,"status":115,"phases":4739,"primaryCompletion":1567,"completion":4450,"start":4740,"enrollment":4428,"conditions":4741,"interventions":4743},"NCT00116207","An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes",[93],"2000-01",[4742],"Diabetic Autonomic Neuropathy",[4726],{"trials":4745,"activeCount":103},[],{"trials":4747,"activeCount":103},[],{"intervention":3042,"totalTrials":241,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4762,"NA":4764},{"trials":4751,"activeCount":103},[],{"trials":4753,"activeCount":103},[],{"trials":4755,"activeCount":103},[],{"trials":4757,"activeCount":103},[4758],{"nctId":3032,"briefTitle":3033,"status":115,"phases":4759,"primaryCompletion":2441,"completion":3035,"start":3036,"enrollment":3037,"conditions":4760,"interventions":4761},[93],[3039],[3041,3042],{"trials":4763,"activeCount":103},[],{"trials":4765,"activeCount":103},[],{"intervention":4767,"totalTrials":241,"cells":4768},"colistin and meropenem",{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4775,"PHASE4":4789,"NA":4791},{"trials":4770,"activeCount":103},[],{"trials":4772,"activeCount":103},[],{"trials":4774,"activeCount":103},[],{"trials":4776,"activeCount":103},[4777],{"nctId":4778,"briefTitle":4779,"status":115,"phases":4780,"primaryCompletion":4781,"completion":4781,"start":4782,"enrollment":4783,"conditions":4784,"interventions":4787},"NCT01597973","Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)",[93],"2020-08-09","2012-10-06",467,[4785,4786],"Pneumonia","Blood Stream Infection",[4767,4788],"colistin and placebo",{"trials":4790,"activeCount":103},[],{"trials":4792,"activeCount":103},[],{"intervention":4788,"totalTrials":241,"cells":4794},{"EARLY_PHASE1":4795,"PHASE1":4797,"PHASE2":4799,"PHASE3":4801,"PHASE4":4807,"NA":4809},{"trials":4796,"activeCount":103},[],{"trials":4798,"activeCount":103},[],{"trials":4800,"activeCount":103},[],{"trials":4802,"activeCount":103},[4803],{"nctId":4778,"briefTitle":4779,"status":115,"phases":4804,"primaryCompletion":4781,"completion":4781,"start":4782,"enrollment":4783,"conditions":4805,"interventions":4806},[93],[4785,4786],[4767,4788],{"trials":4808,"activeCount":103},[],{"trials":4810,"activeCount":103},[],{"intervention":4812,"totalTrials":241,"cells":4813},"Colchicine",{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4818,"PHASE3":4820,"PHASE4":4832,"NA":4834},{"trials":4815,"activeCount":103},[],{"trials":4817,"activeCount":103},[],{"trials":4819,"activeCount":103},[],{"trials":4821,"activeCount":103},[4822],{"nctId":4823,"briefTitle":4824,"status":211,"phases":4825,"primaryCompletion":4826,"completion":4826,"start":4827,"enrollment":1209,"conditions":4828,"interventions":4831},"NCT03575572","Colchicine in Postoperative Fontan Patients",[92,93],"2021-01-13","2018-08-29",[4829,4830],"Single-ventricle","Heart Diseases",[4812],{"trials":4833,"activeCount":103},[],{"trials":4835,"activeCount":103},[],{"intervention":4837,"totalTrials":241,"cells":4838},"Dehydroepiandrosterone",{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4843,"PHASE3":4845,"PHASE4":4856,"NA":4858},{"trials":4840,"activeCount":103},[],{"trials":4842,"activeCount":103},[],{"trials":4844,"activeCount":103},[],{"trials":4846,"activeCount":103},[4847],{"nctId":4848,"briefTitle":4849,"status":115,"phases":4850,"primaryCompletion":270,"completion":4851,"start":4852,"enrollment":200,"conditions":4853,"interventions":4855},"NCT00189124","Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention",[92,93],"2006-07","2003-09",[4854],"Systemic Lupus Erythematosus",[4837],{"trials":4857,"activeCount":103},[],{"trials":4859,"activeCount":103},[],{"intervention":4861,"totalTrials":241,"cells":4862},"Gentamicin Sulfate",{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4884,"NA":4886},{"trials":4864,"activeCount":103},[],{"trials":4866,"activeCount":103},[],{"trials":4868,"activeCount":103},[],{"trials":4870,"activeCount":103},[4871],{"nctId":4872,"briefTitle":4873,"status":115,"phases":4874,"primaryCompletion":4875,"completion":4876,"start":4877,"enrollment":31,"conditions":4878,"interventions":4883},"NCT03503513","Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury",[92,93],"2023-09-08","2023-09-30","2018-08-24",[4879,4880,4881,4882],"Urinary Tract Infections","Spinal Cord Injuries","Spinal Cord Diseases","Neurogenic Bladder",[4861],{"trials":4885,"activeCount":103},[],{"trials":4887,"activeCount":103},[],{"intervention":4889,"totalTrials":241,"cells":4890},"Melatonin 0.5 MG",{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4895,"PHASE3":4897,"PHASE4":4908,"NA":4910},{"trials":4892,"activeCount":103},[],{"trials":4894,"activeCount":103},[],{"trials":4896,"activeCount":103},[],{"trials":4898,"activeCount":103},[4899],{"nctId":4900,"briefTitle":4901,"status":115,"phases":4902,"primaryCompletion":4903,"completion":4903,"start":4904,"enrollment":4428,"conditions":4905,"interventions":4907},"NCT03715465","The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder",[93],"2021-11-05","2019-02-15",[4906],"Delayed Sleep Phase Syndrome",[4889],{"trials":4909,"activeCount":103},[],{"trials":4911,"activeCount":103},[],{"intervention":4913,"totalTrials":241,"cells":4914},"EPA-rich fish oil supplement",{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4919,"PHASE3":4921,"PHASE4":4932,"NA":4934},{"trials":4916,"activeCount":103},[],{"trials":4918,"activeCount":103},[],{"trials":4920,"activeCount":103},[],{"trials":4922,"activeCount":103},[4923],{"nctId":4924,"briefTitle":4925,"status":115,"phases":4926,"primaryCompletion":3232,"completion":3035,"start":4927,"enrollment":4928,"conditions":4929,"interventions":4930},"NCT00711971","Does Fish Oil Prevent Depression in Pregnancy and Postpartum?",[92,93],"2008-09",126,[16],[4913,4931],"DHA-rich fish oil supplement",{"trials":4933,"activeCount":103},[],{"trials":4935,"activeCount":103},[],{"intervention":4931,"totalTrials":241,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4944,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":103},[],{"trials":4941,"activeCount":103},[],{"trials":4943,"activeCount":103},[],{"trials":4945,"activeCount":103},[4946],{"nctId":4924,"briefTitle":4925,"status":115,"phases":4947,"primaryCompletion":3232,"completion":3035,"start":4927,"enrollment":4928,"conditions":4948,"interventions":4949},[92,93],[16],[4913,4931],{"trials":4951,"activeCount":103},[],{"trials":4953,"activeCount":103},[],{"intervention":2482,"totalTrials":241,"cells":4955},{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4960,"PHASE3":4962,"PHASE4":4968,"NA":4970},{"trials":4957,"activeCount":103},[],{"trials":4959,"activeCount":103},[],{"trials":4961,"activeCount":103},[],{"trials":4963,"activeCount":103},[4964],{"nctId":2471,"briefTitle":2472,"status":211,"phases":4965,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":2477,"conditions":4966,"interventions":4967},[93],[2479],[2481,1489,2482,2483,2484],{"trials":4969,"activeCount":103},[],{"trials":4971,"activeCount":103},[],{"intervention":2484,"totalTrials":241,"cells":4973},{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4978,"PHASE3":4980,"PHASE4":4986,"NA":4988},{"trials":4975,"activeCount":103},[],{"trials":4977,"activeCount":103},[],{"trials":4979,"activeCount":103},[],{"trials":4981,"activeCount":103},[4982],{"nctId":2471,"briefTitle":2472,"status":211,"phases":4983,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":2477,"conditions":4984,"interventions":4985},[93],[2479],[2481,1489,2482,2483,2484],{"trials":4987,"activeCount":103},[],{"trials":4989,"activeCount":103},[],{"intervention":4991,"totalTrials":241,"cells":4992},"Silver Diamine Fluoride",{"EARLY_PHASE1":4993,"PHASE1":4995,"PHASE2":4997,"PHASE3":4999,"PHASE4":5011,"NA":5013},{"trials":4994,"activeCount":103},[],{"trials":4996,"activeCount":103},[],{"trials":4998,"activeCount":103},[],{"trials":5000,"activeCount":103},[5001],{"nctId":5002,"briefTitle":5003,"status":211,"phases":5004,"primaryCompletion":5005,"completion":2328,"start":5006,"enrollment":5007,"conditions":5008,"interventions":5010},"NCT03649659","Effectiveness of Silver Diamine Fluoride (SDF) in Arresting Cavitated Caries Lesions",[93],"2023-04-11","2018-10-08",830,[5009],"Cavities of Teeth",[4991],{"trials":5012,"activeCount":103},[],{"trials":5014,"activeCount":103},[],{"intervention":5016,"totalTrials":241,"cells":5017},"Indacaterol\u002FGlycopyrrolate",{"EARLY_PHASE1":5018,"PHASE1":5020,"PHASE2":5022,"PHASE3":5024,"PHASE4":5036,"NA":5038},{"trials":5019,"activeCount":103},[],{"trials":5021,"activeCount":103},[],{"trials":5023,"activeCount":103},[],{"trials":5025,"activeCount":103},[5026],{"nctId":5027,"briefTitle":5028,"status":115,"phases":5029,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":5033,"interventions":5035},"NCT02867761","RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative",[93],"2021-07-07","2017-08-29",780,[5034],"COPD (Chronic Obstructive Pulmonary Disease)",[5016],{"trials":5037,"activeCount":103},[],{"trials":5039,"activeCount":103},[],{"intervention":5041,"totalTrials":241,"cells":5042},"pulmicort",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5049,"PHASE4":5060,"NA":5062},{"trials":5044,"activeCount":103},[],{"trials":5046,"activeCount":103},[],{"trials":5048,"activeCount":103},[],{"trials":5050,"activeCount":103},[5051],{"nctId":5052,"briefTitle":5053,"status":115,"phases":5054,"primaryCompletion":3830,"completion":3830,"start":5055,"enrollment":31,"conditions":5056,"interventions":5059},"NCT01197612","Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis",[93],"2010-09",[5057,5058],"Chronic Sinusitis","Polyposis",[5041],{"trials":5061,"activeCount":103},[],{"trials":5063,"activeCount":103},[],{"intervention":5065,"totalTrials":241,"cells":5066},"Fluticasone",{"EARLY_PHASE1":5067,"PHASE1":5069,"PHASE2":5071,"PHASE3":5073,"PHASE4":5083,"NA":5085},{"trials":5068,"activeCount":103},[],{"trials":5070,"activeCount":103},[],{"trials":5072,"activeCount":103},[],{"trials":5074,"activeCount":103},[5075],{"nctId":5076,"briefTitle":5077,"status":211,"phases":5078,"primaryCompletion":3472,"completion":3472,"start":2953,"enrollment":384,"conditions":5079,"interventions":5081},"NCT01748162","Management of Recurrent Croup",[93],[5080],"Croup",[5065,5082],"Prednisolone IF needed",{"trials":5084,"activeCount":103},[],{"trials":5086,"activeCount":103},[],{"intervention":5082,"totalTrials":241,"cells":5088},{"EARLY_PHASE1":5089,"PHASE1":5091,"PHASE2":5093,"PHASE3":5095,"PHASE4":5101,"NA":5103},{"trials":5090,"activeCount":103},[],{"trials":5092,"activeCount":103},[],{"trials":5094,"activeCount":103},[],{"trials":5096,"activeCount":103},[5097],{"nctId":5076,"briefTitle":5077,"status":211,"phases":5098,"primaryCompletion":3472,"completion":3472,"start":2953,"enrollment":384,"conditions":5099,"interventions":5100},[93],[5080],[5065,5082],{"trials":5102,"activeCount":103},[],{"trials":5104,"activeCount":103},[],{"intervention":5106,"totalTrials":241,"cells":5107},"Multiprofen",{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5114,"PHASE4":5124,"NA":5126},{"trials":5109,"activeCount":103},[],{"trials":5111,"activeCount":103},[],{"trials":5113,"activeCount":103},[],{"trials":5115,"activeCount":103},[5116],{"nctId":5117,"briefTitle":5118,"status":211,"phases":5119,"primaryCompletion":5120,"completion":5120,"start":3149,"enrollment":20,"conditions":5121,"interventions":5123},"NCT03199417","Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL)",[92,93],"2018-05-30",[5122],"Knee Osteoarthritis",[5106],{"trials":5125,"activeCount":103},[],{"trials":5127,"activeCount":103},[],{"intervention":5129,"totalTrials":241,"cells":5130},"Silver Nitrate",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5149,"NA":5151},{"trials":5132,"activeCount":103},[],{"trials":5134,"activeCount":103},[],{"trials":5136,"activeCount":103},[],{"trials":5138,"activeCount":103},[5139],{"nctId":5140,"briefTitle":5141,"status":211,"phases":5142,"primaryCompletion":5143,"completion":5143,"start":5144,"enrollment":17,"conditions":5145,"interventions":5147},"NCT02519738","Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion",[93],"2018-11-13","2015-01-15",[5146],"Other Abnormal Granulation Tissue Nos",[5129,5148],"Kenalog",{"trials":5150,"activeCount":103},[],{"trials":5152,"activeCount":103},[],{"intervention":5148,"totalTrials":241,"cells":5154},{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5159,"PHASE3":5161,"PHASE4":5167,"NA":5169},{"trials":5156,"activeCount":103},[],{"trials":5158,"activeCount":103},[],{"trials":5160,"activeCount":103},[],{"trials":5162,"activeCount":103},[5163],{"nctId":5140,"briefTitle":5141,"status":211,"phases":5164,"primaryCompletion":5143,"completion":5143,"start":5144,"enrollment":17,"conditions":5165,"interventions":5166},[93],[5146],[5129,5148],{"trials":5168,"activeCount":103},[],{"trials":5170,"activeCount":103},[],{"intervention":5172,"totalTrials":241,"cells":5173},"Intralipid 20% I.V. Fat Emulsion",{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5180,"PHASE4":5191,"NA":5193},{"trials":5175,"activeCount":103},[],{"trials":5177,"activeCount":103},[],{"trials":5179,"activeCount":103},[],{"trials":5181,"activeCount":103},[5182],{"nctId":5183,"briefTitle":5184,"status":115,"phases":5185,"primaryCompletion":1147,"completion":5186,"start":5187,"enrollment":336,"conditions":5188,"interventions":5190},"NCT02357576","Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD",[93],"2019-11-08","2016-05-21",[5189],"Cholestasis",[5172],{"trials":5192,"activeCount":103},[],{"trials":5194,"activeCount":103},[],{"intervention":5196,"totalTrials":241,"cells":5197},"Tamsulosin",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5204,"PHASE4":5217,"NA":5219},{"trials":5199,"activeCount":103},[],{"trials":5201,"activeCount":103},[],{"trials":5203,"activeCount":103},[],{"trials":5205,"activeCount":103},[5206],{"nctId":5207,"briefTitle":5208,"status":211,"phases":5209,"primaryCompletion":5210,"completion":5211,"start":5212,"enrollment":5213,"conditions":5214,"interventions":5216},"NCT02518971","Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients",[93],"2018-06-05","2018-12-19","2015-08",176,[5215],"Postoperative Urinary Retention",[5196],{"trials":5218,"activeCount":103},[],{"trials":5220,"activeCount":103},[],{"intervention":277,"totalTrials":3208,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5235,"PHASE2":5246,"PHASE3":5314,"PHASE4":5316,"NA":5318},{"trials":5224,"activeCount":103},[5225],{"nctId":5226,"briefTitle":5227,"status":281,"phases":5228,"primaryCompletion":5229,"completion":5229,"start":5230,"enrollment":103,"conditions":5231,"interventions":5234},"NCT04051047","Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma",[90],"2021-12","2019-11-30",[5232,5233,903],"Glial Tumor of Brain","Diffuse Intrinsic Pontine Glioma",[277],{"trials":5236,"activeCount":103},[5237],{"nctId":5238,"briefTitle":5239,"status":115,"phases":5240,"primaryCompletion":1389,"completion":5241,"start":3854,"enrollment":1569,"conditions":5242,"interventions":5243},"NCT01663272","A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer",[91],"2017-03-01",[2374],[5244,5245],"CABOZANTINIB","gemcitabine",{"trials":5247,"activeCount":103},[5248,5252,5263,5267,5271,5275,5285,5289,5296,5300,5304,5310],{"nctId":1069,"briefTitle":1070,"status":115,"phases":5249,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":937,"conditions":5250,"interventions":5251},[92],[275],[1076,234,277],{"nctId":5253,"briefTitle":5254,"status":115,"phases":5255,"primaryCompletion":5256,"completion":5257,"start":5258,"enrollment":557,"conditions":5259,"interventions":5261},"NCT00242190","Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer",[91,92],"2006-03","2010-02","2004-06",[5260],"Pancreatic Neoplasms",[5262,5245],"oxaliplatin",{"nctId":267,"briefTitle":268,"status":115,"phases":5264,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":5265,"interventions":5266},[92],[275],[199,234,277],{"nctId":1111,"briefTitle":1112,"status":211,"phases":5268,"primaryCompletion":1114,"completion":271,"start":1115,"conditions":5269,"interventions":5270},[92],[1117],[234,277,1119],{"nctId":2367,"briefTitle":2368,"status":115,"phases":5272,"primaryCompletion":2370,"completion":2371,"start":2372,"enrollment":1343,"conditions":5273,"interventions":5274},[92],[2374],[277,221,2376],{"nctId":5276,"briefTitle":5277,"status":115,"phases":5278,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":1249,"conditions":5281,"interventions":5283},"NCT02037230","Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas",[91,92],"2018-08","2014-01",[5282],"Adenocarcinoma of the Pancreas",[5284,277],"MK-1775",{"nctId":1303,"briefTitle":1304,"status":115,"phases":5286,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1044,"conditions":5287,"interventions":5288},[92],[1310],[277,221,1240,255],{"nctId":5290,"briefTitle":5291,"status":115,"phases":5292,"primaryCompletion":5293,"completion":3035,"start":1568,"enrollment":1710,"conditions":5294,"interventions":5295},"NCT00456599","Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer",[92],"2012-05",[2374],[5245,5262],{"nctId":303,"briefTitle":304,"status":115,"phases":5297,"primaryCompletion":306,"completion":271,"start":307,"enrollment":308,"conditions":5298,"interventions":5299},[92],[310],[312,199,234,277],{"nctId":2397,"briefTitle":2398,"status":211,"phases":5301,"primaryCompletion":2400,"completion":2401,"start":1273,"enrollment":1044,"conditions":5302,"interventions":5303},[91,92],[1251],[2404,277,221],{"nctId":5305,"briefTitle":5306,"status":115,"phases":5307,"primaryCompletion":5293,"completion":1376,"start":296,"enrollment":20,"conditions":5308,"interventions":5309},"NCT00593866","Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer",[91,92],[2374],[277],{"nctId":2406,"briefTitle":2407,"status":115,"phases":5311,"primaryCompletion":1400,"completion":2409,"start":2410,"enrollment":2411,"conditions":5312,"interventions":5313},[92],[2374,2413],[277,2415,221],{"trials":5315,"activeCount":103},[],{"trials":5317,"activeCount":103},[],{"trials":5319,"activeCount":103},[],{"intervention":5321,"totalTrials":1343,"cells":5322},"Tetrathiomolybdate",{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5327,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5324,"activeCount":103},[],{"trials":5326,"activeCount":103},[],{"trials":5328,"activeCount":103},[5329,5341,5347,5355,5366],{"nctId":5330,"briefTitle":5331,"status":115,"phases":5332,"primaryCompletion":5333,"completion":5334,"start":5335,"enrollment":5336,"conditions":5337,"interventions":5339},"NCT00176774","Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",[92],"2004-02","2004-04","2001-02",24,[5338],"Colorectal Carcinoma",[5340,222,1254,5321],"Irinotecan",{"nctId":5342,"briefTitle":5343,"status":115,"phases":5344,"completion":2460,"start":5258,"enrollment":384,"conditions":5345,"interventions":5346},"NCT00113542","A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris",[92],[2997],[5321],{"nctId":5348,"briefTitle":5349,"status":115,"phases":5350,"primaryCompletion":5351,"completion":5351,"start":2372,"enrollment":31,"conditions":5352,"interventions":5354},"NCT00189176","Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis",[91,92],"2006-05",[5353],"Idiopathic Pulmonary Fibrosis",[5321],{"nctId":5356,"briefTitle":5357,"status":115,"phases":5358,"primaryCompletion":5359,"completion":5360,"start":5361,"enrollment":5362,"conditions":5363,"interventions":5365},"NCT00176800","Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma",[92],"2006-02","2013-05","2001-11",69,[5364],"Esophageal Carcinoma",[5321],{"nctId":5367,"briefTitle":5368,"status":115,"phases":5369,"primaryCompletion":2965,"completion":1114,"start":1115,"enrollment":37,"conditions":5370,"interventions":5371},"NCT00150995","Tetrathiomolybdate in Hormone Refractory Prostate Cancer",[92],[25],[5321],{"trials":5373,"activeCount":103},[],{"trials":5375,"activeCount":103},[],{"trials":5377,"activeCount":103},[],{"intervention":312,"totalTrials":804,"cells":5379},{"EARLY_PHASE1":5380,"PHASE1":5382,"PHASE2":5395,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5381,"activeCount":103},[],{"trials":5383,"activeCount":103},[5384],{"nctId":5385,"briefTitle":5386,"status":115,"phases":5387,"primaryCompletion":5388,"completion":5389,"start":5390,"enrollment":1209,"conditions":5391,"interventions":5392},"NCT03135171","Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab",[91],"2020-03-16","2020-03-20","2017-07-26",[19],[312,5393,5394],"Pertuzumab","Tocilizumab",{"trials":5396,"activeCount":103},[5397,5404,5408],{"nctId":5398,"briefTitle":5399,"status":211,"phases":5400,"primaryCompletion":358,"completion":213,"start":261,"enrollment":241,"conditions":5401,"interventions":5402},"NCT00726180","Use of Trastuzumab to Induce Increased ER Expression in ER-negative\u002FLow, Her-2\u002FNeu Positive Breast Cancer",[91,92],[19],[5403],"trastuzumab",{"nctId":303,"briefTitle":304,"status":115,"phases":5405,"primaryCompletion":306,"completion":271,"start":307,"enrollment":308,"conditions":5406,"interventions":5407},[92],[310],[312,199,234,277],{"nctId":5409,"briefTitle":5410,"status":115,"phases":5411,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":336,"conditions":5415,"interventions":5417},"NCT00146042","UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer",[92],"2004-03","2005-03","1999-03",[5416],"HER-2 Positive Metastatic Breast Cancer",[1141,312],{"trials":5419,"activeCount":103},[],{"trials":5421,"activeCount":103},[],{"trials":5423,"activeCount":103},[],{"intervention":5425,"totalTrials":99,"cells":5426},"Cabozantinib",{"EARLY_PHASE1":5427,"PHASE1":5429,"PHASE2":5435,"PHASE3":5452,"PHASE4":5454,"NA":5456},{"trials":5428,"activeCount":103},[],{"trials":5430,"activeCount":103},[5431],{"nctId":5238,"briefTitle":5239,"status":115,"phases":5432,"primaryCompletion":1389,"completion":5241,"start":3854,"enrollment":1569,"conditions":5433,"interventions":5434},[91],[2374],[5244,5245],{"trials":5436,"activeCount":103},[5437,5446],{"nctId":5438,"briefTitle":5439,"status":211,"phases":5440,"primaryCompletion":5441,"completion":5441,"start":5442,"enrollment":99,"conditions":5443,"interventions":5445},"NCT04497038","Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy",[91,92],"2023-05-02","2021-08-06",[5444],"Advanced Adult Hepatocellular Carcinoma",[5425],{"nctId":5447,"briefTitle":5448,"status":211,"phases":5449,"primaryCompletion":1376,"completion":3302,"start":3378,"enrollment":738,"conditions":5450,"interventions":5451},"NCT01428219","Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone",[92],[768],[5425],{"trials":5453,"activeCount":103},[],{"trials":5455,"activeCount":103},[],{"trials":5457,"activeCount":103},[],{"intervention":290,"totalTrials":99,"cells":5459},{"EARLY_PHASE1":5460,"PHASE1":5462,"PHASE2":5464,"PHASE3":5478,"PHASE4":5480,"NA":5482},{"trials":5461,"activeCount":103},[],{"trials":5463,"activeCount":103},[],{"trials":5465,"activeCount":103},[5466,5470,5474],{"nctId":733,"briefTitle":734,"status":211,"phases":5467,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":5468,"interventions":5469},[91,92],[740],[63,290,234,742],{"nctId":279,"briefTitle":280,"status":281,"phases":5471,"primaryCompletion":283,"start":284,"enrollment":103,"conditions":5472,"interventions":5473},[92],[286],[288,234,289,199,290],{"nctId":785,"briefTitle":786,"status":115,"phases":5475,"primaryCompletion":788,"completion":788,"start":789,"enrollment":308,"conditions":5476,"interventions":5477},[92],[791],[63,234,290],{"trials":5479,"activeCount":103},[],{"trials":5481,"activeCount":103},[],{"trials":5483,"activeCount":103},[],{"intervention":1225,"totalTrials":99,"cells":5485},{"EARLY_PHASE1":5486,"PHASE1":5488,"PHASE2":5494,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5487,"activeCount":103},[],{"trials":5489,"activeCount":103},[5490],{"nctId":1216,"briefTitle":1217,"status":211,"phases":5491,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":216,"conditions":5492,"interventions":5493},[91],[1222],[1224,255,1225],{"trials":5495,"activeCount":103},[5496,5504],{"nctId":5497,"briefTitle":5498,"status":115,"phases":5499,"primaryCompletion":2975,"completion":2459,"start":5500,"enrollment":3133,"conditions":5501,"interventions":5503},"NCT00143871","Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma",[92],"2001-04",[5502],"Lymphoma, Non-Hodgkin's",[1225],{"nctId":5505,"briefTitle":5506,"status":211,"phases":5507,"primaryCompletion":5413,"completion":270,"start":2372,"enrollment":404,"conditions":5508,"interventions":5509},"NCT00141700","Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma",[92],[5502],[1225],{"trials":5511,"activeCount":103},[],{"trials":5513,"activeCount":103},[],{"trials":5515,"activeCount":103},[],{"intervention":300,"totalTrials":99,"cells":5517},{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5519,"activeCount":103},[],{"trials":5521,"activeCount":103},[],{"trials":5523,"activeCount":103},[5524,5532,5542],{"nctId":5525,"briefTitle":5526,"status":115,"phases":5527,"primaryCompletion":5412,"completion":239,"start":5528,"enrollment":308,"conditions":5529,"interventions":5530},"NCT00151086","Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer",[91,92],"2001-12",[25],[300,5531],"Vinorelbine",{"nctId":5533,"briefTitle":5534,"status":115,"phases":5535,"primaryCompletion":5536,"completion":4599,"start":5537,"enrollment":28,"conditions":5538,"interventions":5540},"NCT00151073","Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate",[92],"2005-09","2002-04",[5539],"Hormone-Refractory Prostate Cancer",[5541,300,1141],"Zoledronic acid",{"nctId":292,"briefTitle":293,"status":115,"phases":5543,"primaryCompletion":295,"completion":296,"start":297,"enrollment":28,"conditions":5544,"interventions":5545},[92],[25],[300,301,199],{"trials":5547,"activeCount":103},[],{"trials":5549,"activeCount":103},[],{"trials":5551,"activeCount":103},[],{"intervention":5553,"totalTrials":99,"cells":5554},"Sunitinib",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5559,"PHASE3":5584,"PHASE4":5586,"NA":5588},{"trials":5556,"activeCount":103},[],{"trials":5558,"activeCount":103},[],{"trials":5560,"activeCount":103},[5561,5569,5576],{"nctId":5562,"briefTitle":5563,"status":115,"phases":5564,"primaryCompletion":5565,"completion":5565,"start":3694,"enrollment":836,"conditions":5566,"interventions":5568},"NCT00794950","Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma",[92],"2016-08-22",[5567],"Urinary Tract Urothelial Carcinoma",[5553],{"nctId":5570,"briefTitle":5571,"status":211,"phases":5572,"primaryCompletion":3025,"completion":3035,"start":1567,"enrollment":5573,"conditions":5574,"interventions":5575},"NCT01042795","Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy",[92],7,[729,275],[5553],{"nctId":5577,"briefTitle":5578,"status":115,"phases":5579,"primaryCompletion":4450,"completion":4427,"start":4599,"enrollment":713,"conditions":5580,"interventions":5582},"NCT00616109","Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC",[92],[5581],"Extensive-Stage Small Cell Lung Cancer",[5583],"sunitinib",{"trials":5585,"activeCount":103},[],{"trials":5587,"activeCount":103},[],{"trials":5589,"activeCount":103},[],{"intervention":1076,"totalTrials":151,"cells":5591},{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5596,"PHASE3":5610,"PHASE4":5612,"NA":5614},{"trials":5593,"activeCount":103},[],{"trials":5595,"activeCount":103},[],{"trials":5597,"activeCount":103},[5598,5602],{"nctId":1069,"briefTitle":1070,"status":115,"phases":5599,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":937,"conditions":5600,"interventions":5601},[92],[275],[1076,234,277],{"nctId":5603,"briefTitle":5604,"status":211,"phases":5605,"primaryCompletion":3649,"completion":3649,"start":5606,"enrollment":713,"conditions":5607,"interventions":5609},"NCT00995488","Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer",[92],"2009-10",[5608,275],"Urothelial Cancer",[1076],{"trials":5611,"activeCount":103},[],{"trials":5613,"activeCount":103},[],{"trials":5615,"activeCount":103},[],{"intervention":5262,"totalTrials":151,"cells":5617},{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5622,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5619,"activeCount":103},[],{"trials":5621,"activeCount":103},[],{"trials":5623,"activeCount":103},[5624,5628],{"nctId":5253,"briefTitle":5254,"status":115,"phases":5625,"primaryCompletion":5256,"completion":5257,"start":5258,"enrollment":557,"conditions":5626,"interventions":5627},[91,92],[5260],[5262,5245],{"nctId":5290,"briefTitle":5291,"status":115,"phases":5629,"primaryCompletion":5293,"completion":3035,"start":1568,"enrollment":1710,"conditions":5630,"interventions":5631},[92],[2374],[5245,5262],{"trials":5633,"activeCount":103},[],{"trials":5635,"activeCount":103},[],{"trials":5637,"activeCount":103},[],{"intervention":5340,"totalTrials":151,"cells":5639},{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5644,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5641,"activeCount":103},[],{"trials":5643,"activeCount":103},[],{"trials":5645,"activeCount":103},[5646,5650],{"nctId":5330,"briefTitle":5331,"status":115,"phases":5647,"primaryCompletion":5333,"completion":5334,"start":5335,"enrollment":5336,"conditions":5648,"interventions":5649},[92],[5338],[5340,222,1254,5321],{"nctId":5651,"briefTitle":5652,"status":115,"phases":5653,"primaryCompletion":5654,"completion":2356,"start":5655,"enrollment":394,"conditions":5656,"interventions":5658},"NCT00230399","Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer",[92],"2006-01","2003-06",[5657],"Colorectal Cancer",[2376,1119,5340],{"trials":5660,"activeCount":103},[],{"trials":5662,"activeCount":103},[],{"trials":5664,"activeCount":103},[],{"intervention":1254,"totalTrials":151,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5668,"activeCount":103},[],{"trials":5670,"activeCount":103},[],{"trials":5672,"activeCount":103},[5673,5677],{"nctId":5330,"briefTitle":5331,"status":115,"phases":5674,"primaryCompletion":5333,"completion":5334,"start":5335,"enrollment":5336,"conditions":5675,"interventions":5676},[92],[5338],[5340,222,1254,5321],{"nctId":1244,"briefTitle":1245,"status":115,"phases":5678,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":5679,"interventions":5680},[91,92],[1251],[255,1253,222,1254],{"trials":5682,"activeCount":103},[],{"trials":5684,"activeCount":103},[],{"trials":5686,"activeCount":103},[],{"intervention":742,"totalTrials":151,"cells":5688},{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5690,"activeCount":103},[],{"trials":5692,"activeCount":103},[],{"trials":5694,"activeCount":103},[5695,5699],{"nctId":1256,"briefTitle":1257,"status":115,"phases":5696,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":727,"conditions":5697,"interventions":5698},[92],[1251],[742,255],{"nctId":733,"briefTitle":734,"status":211,"phases":5700,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":5701,"interventions":5702},[91,92],[740],[63,290,234,742],{"trials":5704,"activeCount":103},[],{"trials":5706,"activeCount":103},[],{"trials":5708,"activeCount":103},[],{"intervention":1479,"totalTrials":151,"cells":5710},{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5715,"PHASE3":5725,"PHASE4":5727,"NA":5729},{"trials":5712,"activeCount":103},[],{"trials":5714,"activeCount":103},[],{"trials":5716,"activeCount":103},[5717,5721],{"nctId":1472,"briefTitle":1473,"status":281,"phases":5718,"primaryCompletion":1475,"completion":1476,"start":1437,"enrollment":103,"conditions":5719,"interventions":5720},[92],[843],[1453,1479],{"nctId":1642,"briefTitle":1643,"status":281,"phases":5722,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":103,"conditions":5723,"interventions":5724},[91,92],[1634,1648],[1618,1479],{"trials":5726,"activeCount":103},[],{"trials":5728,"activeCount":103},[],{"trials":5730,"activeCount":103},[],{"intervention":5732,"totalTrials":151,"cells":5733},"Carbidopa 25 mg",{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5758,"PHASE4":5760,"NA":5762},{"trials":5735,"activeCount":103},[],{"trials":5737,"activeCount":103},[],{"trials":5739,"activeCount":103},[5740,5750],{"nctId":5741,"briefTitle":5742,"status":115,"phases":5743,"primaryCompletion":5744,"completion":5744,"start":5745,"enrollment":1343,"conditions":5746,"interventions":5748},"NCT06587217","Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm",[91,92],"2025-04-03","2024-10-29",[5747],"Parkinsonian Signs in Older Persons",[5732,5749],"Carbidopa-Levodopa 25\u002F100 mg",{"nctId":5751,"briefTitle":5752,"status":115,"phases":5753,"primaryCompletion":5754,"completion":5754,"start":5755,"enrollment":200,"conditions":5756,"interventions":5757},"NCT06219915","Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm",[91,92],"2024-05-30","2024-03-15",[5747],[5732,5749],{"trials":5759,"activeCount":103},[],{"trials":5761,"activeCount":103},[],{"trials":5763,"activeCount":103},[],{"intervention":5749,"totalTrials":151,"cells":5765},{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5770,"PHASE3":5780,"PHASE4":5782,"NA":5784},{"trials":5767,"activeCount":103},[],{"trials":5769,"activeCount":103},[],{"trials":5771,"activeCount":103},[5772,5776],{"nctId":5741,"briefTitle":5742,"status":115,"phases":5773,"primaryCompletion":5744,"completion":5744,"start":5745,"enrollment":1343,"conditions":5774,"interventions":5775},[91,92],[5747],[5732,5749],{"nctId":5751,"briefTitle":5752,"status":115,"phases":5777,"primaryCompletion":5754,"completion":5754,"start":5755,"enrollment":200,"conditions":5778,"interventions":5779},[91,92],[5747],[5732,5749],{"trials":5781,"activeCount":103},[],{"trials":5783,"activeCount":103},[],{"trials":5785,"activeCount":103},[],{"intervention":1278,"totalTrials":151,"cells":5787},{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5807,"PHASE4":5809,"NA":5811},{"trials":5789,"activeCount":103},[],{"trials":5791,"activeCount":103},[],{"trials":5793,"activeCount":103},[5794,5798],{"nctId":1269,"briefTitle":1270,"status":115,"phases":5795,"primaryCompletion":1272,"completion":1273,"start":1274,"enrollment":200,"conditions":5796,"interventions":5797},[91,92],[1276],[1278,255],{"nctId":5799,"briefTitle":5800,"status":211,"phases":5801,"completion":5351,"start":5802,"enrollment":5803,"conditions":5804,"interventions":5806},"NCT00176761","Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine",[92],"2000-03",27,[5805],"Metastatic Colorectal Cancer",[1278],{"trials":5808,"activeCount":103},[],{"trials":5810,"activeCount":103},[],{"trials":5812,"activeCount":103},[],{"intervention":5814,"totalTrials":151,"cells":5815},"Varenicline",{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5837,"PHASE4":5839,"NA":5841},{"trials":5817,"activeCount":103},[],{"trials":5819,"activeCount":103},[],{"trials":5821,"activeCount":103},[5822,5831],{"nctId":5823,"briefTitle":5824,"status":115,"phases":5825,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":738,"conditions":5828,"interventions":5830},"NCT02933372","Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3",[92],"2019-06-26","2015-10-05",[5829],"Parkinson's Disease",[5814],{"nctId":5832,"briefTitle":5833,"status":115,"phases":5834,"primaryCompletion":5826,"completion":5826,"start":3986,"enrollment":1249,"conditions":5835,"interventions":5836},"NCT04403399","Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])",[92],[5829],[5814],{"trials":5838,"activeCount":103},[],{"trials":5840,"activeCount":103},[],{"trials":5842,"activeCount":103},[],{"intervention":5844,"totalTrials":151,"cells":5845},"Amlexanox",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5850,"PHASE3":5872,"PHASE4":5874,"NA":5876},{"trials":5847,"activeCount":103},[],{"trials":5849,"activeCount":103},[],{"trials":5851,"activeCount":103},[5852,5862],{"nctId":5853,"briefTitle":5854,"status":211,"phases":5855,"primaryCompletion":5856,"completion":5856,"start":5857,"enrollment":5573,"conditions":5858,"interventions":5861},"NCT01842282","Amlexanox for Type 2 Diabetes and Obesity",[92],"2014-02-25","2013-07-19",[5859,5860,27],"Diabetes Mellitus Type 2","Non Alcoholic Fatty Liver Disease",[5844],{"nctId":5863,"briefTitle":5864,"status":115,"phases":5865,"primaryCompletion":5866,"completion":5867,"start":5280,"enrollment":5868,"conditions":5869,"interventions":5871},"NCT01975935","Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients",[92],"2016-04-25","2017-08-18",42,[5859,5870,27],"Non-alcoholic Fatty Liver Disease",[5844],{"trials":5873,"activeCount":103},[],{"trials":5875,"activeCount":103},[],{"trials":5877,"activeCount":103},[],{"intervention":2376,"totalTrials":151,"cells":5879},{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5881,"activeCount":103},[],{"trials":5883,"activeCount":103},[],{"trials":5885,"activeCount":103},[5886,5890],{"nctId":2367,"briefTitle":2368,"status":115,"phases":5887,"primaryCompletion":2370,"completion":2371,"start":2372,"enrollment":1343,"conditions":5888,"interventions":5889},[92],[2374],[277,221,2376],{"nctId":5651,"briefTitle":5652,"status":115,"phases":5891,"primaryCompletion":5654,"completion":2356,"start":5655,"enrollment":394,"conditions":5892,"interventions":5893},[92],[5657],[2376,1119,5340],{"trials":5895,"activeCount":103},[],{"trials":5897,"activeCount":103},[],{"trials":5899,"activeCount":103},[],{"intervention":5901,"totalTrials":151,"cells":5902},"68Ga-PSMA",{"EARLY_PHASE1":5903,"PHASE1":5905,"PHASE2":5907,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5904,"activeCount":103},[],{"trials":5906,"activeCount":103},[],{"trials":5908,"activeCount":103},[5909,5919],{"nctId":5910,"briefTitle":5911,"status":115,"phases":5912,"primaryCompletion":1232,"completion":1232,"start":5913,"enrollment":5914,"conditions":5915,"interventions":5918},"NCT03396874","Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence",[92],"2018-02-09",1435,[25,5916,768,5917],"Prostate Adenocarcinoma","Prostate Cancer Recurrent",[5901],{"nctId":5920,"briefTitle":5921,"status":211,"phases":5922,"primaryCompletion":5923,"completion":5923,"start":5143,"enrollment":1209,"conditions":5924,"interventions":5925},"NCT03689582","Radiolabeled Gallium-68 (68Ga-PSMA) for PET\u002FCT Imaging to Detect Prostate Cancer",[92],"2020-02-27",[25],[5901],{"trials":5927,"activeCount":103},[],{"trials":5929,"activeCount":103},[],{"trials":5931,"activeCount":103},[],{"intervention":5933,"totalTrials":151,"cells":5934},"Dasatinib",{"EARLY_PHASE1":5935,"PHASE1":5937,"PHASE2":5939,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5936,"activeCount":103},[],{"trials":5938,"activeCount":103},[],{"trials":5940,"activeCount":103},[5941,5953],{"nctId":5942,"briefTitle":5943,"status":281,"phases":5944,"primaryCompletion":5945,"completion":5946,"start":5947,"enrollment":103,"conditions":5948,"interventions":5949},"NCT04845035","Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[92],"2026-01","2029-01","2024-01",[717],[5933,5950,5951,5952],"Ponatinib","Berlin-Frankfurt-Münster Chemotherapy","Methotrexate and Cytarabine",{"nctId":5954,"briefTitle":5955,"status":211,"phases":5956,"primaryCompletion":5957,"completion":1630,"start":5958,"enrollment":99,"conditions":5959,"interventions":5962},"NCT03352427","Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations",[92],"2019-04-17","2017-12-06",[903,5960,5961],"High Grade Glioma","Pontine Tumors",[5933,5963],"Everolimus",{"trials":5965,"activeCount":103},[],{"trials":5967,"activeCount":103},[],{"trials":5969,"activeCount":103},[],{"intervention":1140,"totalTrials":151,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5976,"PHASE3":5990,"PHASE4":5992,"NA":5994},{"trials":5973,"activeCount":103},[],{"trials":5975,"activeCount":103},[],{"trials":5977,"activeCount":103},[5978,5982],{"nctId":1131,"briefTitle":1132,"status":115,"phases":5979,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1136,"conditions":5980,"interventions":5981},[92],[1138],[1140,1141,221,234],{"nctId":5983,"briefTitle":5984,"status":211,"phases":5985,"primaryCompletion":5986,"completion":3302,"start":358,"enrollment":3133,"conditions":5987,"interventions":5989},"NCT01285635","A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck",[92],"2012-12",[5988],"Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[1140,1141],{"trials":5991,"activeCount":103},[],{"trials":5993,"activeCount":103},[],{"trials":5995,"activeCount":103},[],{"intervention":5394,"totalTrials":151,"cells":5997},{"EARLY_PHASE1":5998,"PHASE1":6000,"PHASE2":6006,"PHASE3":6016,"PHASE4":6018,"NA":6020},{"trials":5999,"activeCount":103},[],{"trials":6001,"activeCount":103},[6002],{"nctId":5385,"briefTitle":5386,"status":115,"phases":6003,"primaryCompletion":5388,"completion":5389,"start":5390,"enrollment":1209,"conditions":6004,"interventions":6005},[91],[19],[312,5393,5394],{"trials":6007,"activeCount":103},[6008],{"nctId":6009,"briefTitle":6010,"status":281,"phases":6011,"primaryCompletion":1437,"completion":6012,"start":6013,"enrollment":103,"conditions":6014,"interventions":6015},"NCT02997956","Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)",[91,92],"2022-07","2017-07",[1009],[5394],{"trials":6017,"activeCount":103},[],{"trials":6019,"activeCount":103},[],{"trials":6021,"activeCount":103},[],{"intervention":6023,"totalTrials":151,"cells":6024},"Imatinib",{"EARLY_PHASE1":6025,"PHASE1":6027,"PHASE2":6029,"PHASE3":6049,"PHASE4":6051,"NA":6053},{"trials":6026,"activeCount":103},[],{"trials":6028,"activeCount":103},[],{"trials":6030,"activeCount":103},[6031,6039],{"nctId":6032,"briefTitle":6033,"status":211,"phases":6034,"primaryCompletion":1496,"completion":6035,"start":5333,"enrollment":1209,"conditions":6036,"interventions":6038},"NCT00115739","Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma",[92],"2010-08",[6037],"Thyroid Cancer",[6023],{"nctId":6040,"briefTitle":6041,"status":281,"phases":6042,"primaryCompletion":283,"completion":6043,"start":6044,"enrollment":103,"conditions":6045,"interventions":6047},"NCT01188889","RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w\u002F Molecular Disease.",[91,92],"2017-12","2013-09",[6046],"Chronic Myeloid Leukemia",[6048,6023],"RAD001",{"trials":6050,"activeCount":103},[],{"trials":6052,"activeCount":103},[],{"trials":6054,"activeCount":103},[],{"intervention":5963,"totalTrials":151,"cells":6056},{"EARLY_PHASE1":6057,"PHASE1":6059,"PHASE2":6061,"PHASE3":6076,"PHASE4":6078,"NA":6080},{"trials":6058,"activeCount":103},[],{"trials":6060,"activeCount":103},[],{"trials":6062,"activeCount":103},[6063,6067],{"nctId":5954,"briefTitle":5955,"status":211,"phases":6064,"primaryCompletion":5957,"completion":1630,"start":5958,"enrollment":99,"conditions":6065,"interventions":6066},[92],[903,5960,5961],[5933,5963],{"nctId":6068,"briefTitle":6069,"status":281,"phases":6070,"primaryCompletion":6071,"completion":6071,"start":6072,"enrollment":103,"conditions":6073,"interventions":6074},"NCT03632317","A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas",[92],"2025-10","2019-10",[903,5233],[6075,5963],"Panobinostat",{"trials":6077,"activeCount":103},[],{"trials":6079,"activeCount":103},[],{"trials":6081,"activeCount":103},[],{"intervention":6083,"totalTrials":151,"cells":6084},"Axitinib",{"EARLY_PHASE1":6085,"PHASE1":6087,"PHASE2":6089,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6086,"activeCount":103},[],{"trials":6088,"activeCount":103},[],{"trials":6090,"activeCount":103},[6091,6098],{"nctId":6092,"briefTitle":6093,"status":115,"phases":6094,"primaryCompletion":6095,"completion":6095,"start":4075,"enrollment":937,"conditions":6096,"interventions":6097},"NCT02762513","Expansion Trial for Axitinib In Head And Neck Cancer",[92],"2020-04-09",[1128],[6083],{"nctId":6099,"briefTitle":6100,"status":115,"phases":6101,"primaryCompletion":3718,"completion":2409,"start":1359,"enrollment":5868,"conditions":6102,"interventions":6104},"NCT01469546","Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer",[92],[6103],"Head and Neck Squamous Cell Carcinoma",[6083],{"trials":6106,"activeCount":103},[],{"trials":6108,"activeCount":103},[],{"trials":6110,"activeCount":103},[],{"intervention":288,"totalTrials":151,"cells":6112},{"EARLY_PHASE1":6113,"PHASE1":6119,"PHASE2":6121,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6114,"activeCount":103},[6115],{"nctId":3163,"briefTitle":3164,"status":115,"phases":6116,"primaryCompletion":3166,"completion":3166,"start":3167,"enrollment":34,"conditions":6117,"interventions":6118},[90],[3169],[288,3158],{"trials":6120,"activeCount":103},[],{"trials":6122,"activeCount":103},[6123],{"nctId":279,"briefTitle":280,"status":281,"phases":6124,"primaryCompletion":283,"start":284,"enrollment":103,"conditions":6125,"interventions":6126},[92],[286],[288,234,289,199,290],{"trials":6128,"activeCount":103},[],{"trials":6130,"activeCount":103},[],{"trials":6132,"activeCount":103},[],{"intervention":6134,"totalTrials":151,"cells":6135},"Clofarabine\u002FBusulfan x 4",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6137,"activeCount":103},[],{"trials":6139,"activeCount":103},[],{"trials":6141,"activeCount":103},[6142,6151],{"nctId":6143,"briefTitle":6144,"status":115,"phases":6145,"primaryCompletion":6146,"completion":6147,"start":4638,"enrollment":1044,"conditions":6148,"interventions":6150},"NCT01457885","Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen",[92],"2014-11","2016-06-14",[6149],"Acute Myeloblastic Leukemia",[6134],{"nctId":6152,"briefTitle":6153,"status":115,"phases":6154,"primaryCompletion":6155,"completion":2953,"start":271,"enrollment":10,"conditions":6156,"interventions":6161},"NCT00556452","Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen",[91,92],"2011-06",[6157,6158,6159,1486,6160],"Leukemia","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Myelodysplastic Syndrome",[6134],{"trials":6163,"activeCount":103},[],{"trials":6165,"activeCount":103},[],{"trials":6167,"activeCount":103},[],{"intervention":6169,"totalTrials":241,"cells":6170},"MK-0752, Docetaxel, Pegfilgrastim",{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6172,"activeCount":103},[],{"trials":6174,"activeCount":103},[],{"trials":6176,"activeCount":103},[6177],{"nctId":6178,"briefTitle":6179,"status":115,"phases":6180,"primaryCompletion":6181,"completion":2441,"start":2356,"enrollment":404,"conditions":6182,"interventions":6184},"NCT00645333","Phase I\u002FII Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer",[91,92],"2010-01",[6183],"Metastatic Breast Cancer",[6169],{"trials":6186,"activeCount":103},[],{"trials":6188,"activeCount":103},[],{"trials":6190,"activeCount":103},[],{"intervention":6192,"totalTrials":241,"cells":6193},"Citalopram",{"EARLY_PHASE1":6194,"PHASE1":6196,"PHASE2":6198,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6195,"activeCount":103},[],{"trials":6197,"activeCount":103},[],{"trials":6199,"activeCount":103},[6200],{"nctId":6201,"briefTitle":6202,"status":281,"phases":6203,"primaryCompletion":3472,"completion":3472,"start":486,"enrollment":103,"conditions":6204,"interventions":6205},"NCT02000726","Neuroimaging Predictors of Antidepressant Treatment Outcome",[92],[16],[6192,6206],"Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session",{"trials":6208,"activeCount":103},[],{"trials":6210,"activeCount":103},[],{"trials":6212,"activeCount":103},[],{"intervention":6206,"totalTrials":241,"cells":6214},{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6219,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6216,"activeCount":103},[],{"trials":6218,"activeCount":103},[],{"trials":6220,"activeCount":103},[6221],{"nctId":6201,"briefTitle":6202,"status":281,"phases":6222,"primaryCompletion":3472,"completion":3472,"start":486,"enrollment":103,"conditions":6223,"interventions":6224},[92],[16],[6192,6206],{"trials":6226,"activeCount":103},[],{"trials":6228,"activeCount":103},[],{"trials":6230,"activeCount":103},[],{"intervention":6232,"totalTrials":241,"cells":6233},"Lapatinib and Paclitaxel",{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6238,"PHASE3":6249,"PHASE4":6251,"NA":6253},{"trials":6235,"activeCount":103},[],{"trials":6237,"activeCount":103},[],{"trials":6239,"activeCount":103},[6240],{"nctId":6241,"briefTitle":6242,"status":281,"phases":6243,"primaryCompletion":6244,"completion":6245,"start":6246,"enrollment":103,"conditions":6247,"interventions":6248},"NCT01700010","Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer",[92],"2017-01","2019-01","2012-11",[5608,275],[6232],{"trials":6250,"activeCount":103},[],{"trials":6252,"activeCount":103},[],{"trials":6254,"activeCount":103},[],{"intervention":220,"totalTrials":241,"cells":6256},{"EARLY_PHASE1":6257,"PHASE1":6259,"PHASE2":6261,"PHASE3":6267,"PHASE4":6269,"NA":6271},{"trials":6258,"activeCount":103},[],{"trials":6260,"activeCount":103},[],{"trials":6262,"activeCount":103},[6263],{"nctId":209,"briefTitle":210,"status":211,"phases":6264,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":6265,"interventions":6266},[92],[218],[220,199,221,222],{"trials":6268,"activeCount":103},[],{"trials":6270,"activeCount":103},[],{"trials":6272,"activeCount":103},[],{"intervention":6274,"totalTrials":241,"cells":6275},"adalimumab",{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6280,"PHASE3":6295,"PHASE4":6297,"NA":6299},{"trials":6277,"activeCount":103},[],{"trials":6279,"activeCount":103},[],{"trials":6281,"activeCount":103},[6282],{"nctId":6283,"briefTitle":6284,"status":115,"phases":6285,"primaryCompletion":6286,"completion":6287,"start":6288,"enrollment":5573,"conditions":6289,"interventions":6294},"NCT04009668","Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease",[92],"2023-09-05","2023-10-03","2019-10-02",[6290,6291,6292,6293],"FSGS","MCD","Focal Segmental Glomerulosclerosis","Minimal Change Disease",[6274],{"trials":6296,"activeCount":103},[],{"trials":6298,"activeCount":103},[],{"trials":6300,"activeCount":103},[],{"intervention":6302,"totalTrials":241,"cells":6303},"SUTENT",{"EARLY_PHASE1":6304,"PHASE1":6306,"PHASE2":6308,"PHASE3":6317,"PHASE4":6319,"NA":6321},{"trials":6305,"activeCount":103},[],{"trials":6307,"activeCount":103},[],{"trials":6309,"activeCount":103},[6310],{"nctId":6311,"briefTitle":6312,"status":211,"phases":6313,"primaryCompletion":4715,"completion":5986,"start":5351,"enrollment":6314,"conditions":6315,"interventions":6316},"NCT00393796","Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma",[92],54,[275],[6302],{"trials":6318,"activeCount":103},[],{"trials":6320,"activeCount":103},[],{"trials":6322,"activeCount":103},[],{"intervention":1253,"totalTrials":241,"cells":6324},{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6335,"PHASE4":6337,"NA":6339},{"trials":6326,"activeCount":103},[],{"trials":6328,"activeCount":103},[],{"trials":6330,"activeCount":103},[6331],{"nctId":1244,"briefTitle":1245,"status":115,"phases":6332,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":6333,"interventions":6334},[91,92],[1251],[255,1253,222,1254],{"trials":6336,"activeCount":103},[],{"trials":6338,"activeCount":103},[],{"trials":6340,"activeCount":103},[],{"intervention":6342,"totalTrials":241,"cells":6343},"recombinant human keratinocyte growth factor",{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6348,"PHASE3":6357,"PHASE4":6359,"NA":6361},{"trials":6345,"activeCount":103},[],{"trials":6347,"activeCount":103},[],{"trials":6349,"activeCount":103},[6350],{"nctId":6351,"briefTitle":6352,"status":115,"phases":6353,"completion":2460,"start":6354,"enrollment":20,"conditions":6355,"interventions":6356},"NCT00056875","Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants",[91,92],"2002-09",[1364],[6342],{"trials":6358,"activeCount":103},[],{"trials":6360,"activeCount":103},[],{"trials":6362,"activeCount":103},[],{"intervention":6364,"totalTrials":241,"cells":6365},"Fezolinetant",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6382,"PHASE4":6384,"NA":6386},{"trials":6367,"activeCount":103},[],{"trials":6369,"activeCount":103},[],{"trials":6371,"activeCount":103},[6372],{"nctId":6373,"briefTitle":6374,"status":211,"phases":6375,"primaryCompletion":6376,"completion":6377,"start":6378,"enrollment":700,"conditions":6379,"interventions":6381},"NCT06617455","Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial",[92],"2025-10-22","2025-11-21","2024-10-31",[1046,1047,1048,6380,1925],"Breast Ductal Carcinoma In Situ",[6364],{"trials":6383,"activeCount":103},[],{"trials":6385,"activeCount":103},[],{"trials":6387,"activeCount":103},[],{"intervention":2360,"totalTrials":241,"cells":6389},{"EARLY_PHASE1":6390,"PHASE1":6392,"PHASE2":6394,"PHASE3":6400,"PHASE4":6402,"NA":6404},{"trials":6391,"activeCount":103},[],{"trials":6393,"activeCount":103},[],{"trials":6395,"activeCount":103},[6396],{"nctId":2353,"briefTitle":2354,"status":115,"phases":6397,"primaryCompletion":1438,"completion":1683,"start":2356,"enrollment":2357,"conditions":6398,"interventions":6399},[92],[275],[2360,221,2361],{"trials":6401,"activeCount":103},[],{"trials":6403,"activeCount":103},[],{"trials":6405,"activeCount":103},[],{"intervention":6407,"totalTrials":241,"cells":6408},"Calcitriol",{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6413,"PHASE3":6422,"PHASE4":6424,"NA":6426},{"trials":6410,"activeCount":103},[],{"trials":6412,"activeCount":103},[],{"trials":6414,"activeCount":103},[6415],{"nctId":6416,"briefTitle":6417,"status":211,"phases":6418,"primaryCompletion":4451,"completion":3473,"start":859,"enrollment":1249,"conditions":6419,"interventions":6421},"NCT00794547","Phase I\u002FII Calcitriol in Lung Cancer",[91,92],[6420],"Non Small Cell Lung Cancer",[6407,6407],{"trials":6423,"activeCount":103},[],{"trials":6425,"activeCount":103},[],{"trials":6427,"activeCount":103},[],{"intervention":6429,"totalTrials":241,"cells":6430},"Loratadine",{"EARLY_PHASE1":6431,"PHASE1":6433,"PHASE2":6435,"PHASE3":6446,"PHASE4":6448,"NA":6450},{"trials":6432,"activeCount":103},[],{"trials":6434,"activeCount":103},[],{"trials":6436,"activeCount":103},[6437],{"nctId":6438,"briefTitle":6439,"status":211,"phases":6440,"primaryCompletion":6441,"completion":6441,"start":6442,"enrollment":99,"conditions":6443,"interventions":6445},"NCT03883386","Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use",[92],"2019-10-18","2019-06-24",[6444],"Bone Pain",[6429],{"trials":6447,"activeCount":103},[],{"trials":6449,"activeCount":103},[],{"trials":6451,"activeCount":103},[],{"intervention":5531,"totalTrials":241,"cells":6453},{"EARLY_PHASE1":6454,"PHASE1":6456,"PHASE2":6458,"PHASE3":6464,"PHASE4":6466,"NA":6468},{"trials":6455,"activeCount":103},[],{"trials":6457,"activeCount":103},[],{"trials":6459,"activeCount":103},[6460],{"nctId":5525,"briefTitle":5526,"status":115,"phases":6461,"primaryCompletion":5412,"completion":239,"start":5528,"enrollment":308,"conditions":6462,"interventions":6463},[91,92],[25],[300,5531],{"trials":6465,"activeCount":103},[],{"trials":6467,"activeCount":103},[],{"trials":6469,"activeCount":103},[],{"intervention":6471,"totalTrials":241,"cells":6472},"Definity contrast during ultrasound",{"EARLY_PHASE1":6473,"PHASE1":6475,"PHASE2":6477,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6474,"activeCount":103},[],{"trials":6476,"activeCount":103},[],{"trials":6478,"activeCount":103},[6479],{"nctId":6480,"briefTitle":6481,"status":115,"phases":6482,"primaryCompletion":6483,"completion":6483,"start":6484,"enrollment":384,"conditions":6485,"interventions":6488},"NCT05090800","Contrast Enhanced Ultrasound for Renal Obstruction",[92],"2025-09-23","2021-12-03",[6486,6487],"Kidney; Obstruction","Renal Obstruction",[6471],{"trials":6490,"activeCount":103},[],{"trials":6492,"activeCount":103},[],{"trials":6494,"activeCount":103},[],{"intervention":1686,"totalTrials":241,"cells":6496},{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6501,"PHASE3":6507,"PHASE4":6509,"NA":6511},{"trials":6498,"activeCount":103},[],{"trials":6500,"activeCount":103},[],{"trials":6502,"activeCount":103},[6503],{"nctId":1679,"briefTitle":1680,"status":115,"phases":6504,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":727,"conditions":6505,"interventions":6506},[92],[1486],[1686,1488,1687],{"trials":6508,"activeCount":103},[],{"trials":6510,"activeCount":103},[],{"trials":6512,"activeCount":103},[],{"intervention":1687,"totalTrials":241,"cells":6514},{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6519,"PHASE3":6525,"PHASE4":6527,"NA":6529},{"trials":6516,"activeCount":103},[],{"trials":6518,"activeCount":103},[],{"trials":6520,"activeCount":103},[6521],{"nctId":1679,"briefTitle":1680,"status":115,"phases":6522,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":727,"conditions":6523,"interventions":6524},[92],[1486],[1686,1488,1687],{"trials":6526,"activeCount":103},[],{"trials":6528,"activeCount":103},[],{"trials":6530,"activeCount":103},[],{"intervention":6532,"totalTrials":241,"cells":6533},"Ibrance",{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6538,"PHASE3":6552,"PHASE4":6554,"NA":6556},{"trials":6535,"activeCount":103},[],{"trials":6537,"activeCount":103},[],{"trials":6539,"activeCount":103},[6540],{"nctId":6541,"briefTitle":6542,"status":115,"phases":6543,"primaryCompletion":6544,"completion":6545,"start":3472,"enrollment":6546,"conditions":6547,"interventions":6548},"NCT02059213","A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer",[92],"2017-09-09","2019-06-04",72,[25],[6532,6549,6550,6551],"Bicalutamide","Zoladex","Lupron Depot",{"trials":6553,"activeCount":103},[],{"trials":6555,"activeCount":103},[],{"trials":6557,"activeCount":103},[],{"intervention":6549,"totalTrials":241,"cells":6559},{"EARLY_PHASE1":6560,"PHASE1":6562,"PHASE2":6564,"PHASE3":6570,"PHASE4":6572,"NA":6574},{"trials":6561,"activeCount":103},[],{"trials":6563,"activeCount":103},[],{"trials":6565,"activeCount":103},[6566],{"nctId":6541,"briefTitle":6542,"status":115,"phases":6567,"primaryCompletion":6544,"completion":6545,"start":3472,"enrollment":6546,"conditions":6568,"interventions":6569},[92],[25],[6532,6549,6550,6551],{"trials":6571,"activeCount":103},[],{"trials":6573,"activeCount":103},[],{"trials":6575,"activeCount":103},[],{"intervention":6550,"totalTrials":241,"cells":6577},{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6588,"PHASE4":6590,"NA":6592},{"trials":6579,"activeCount":103},[],{"trials":6581,"activeCount":103},[],{"trials":6583,"activeCount":103},[6584],{"nctId":6541,"briefTitle":6542,"status":115,"phases":6585,"primaryCompletion":6544,"completion":6545,"start":3472,"enrollment":6546,"conditions":6586,"interventions":6587},[92],[25],[6532,6549,6550,6551],{"trials":6589,"activeCount":103},[],{"trials":6591,"activeCount":103},[],{"trials":6593,"activeCount":103},[],{"intervention":6551,"totalTrials":241,"cells":6595},{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6606,"PHASE4":6608,"NA":6610},{"trials":6597,"activeCount":103},[],{"trials":6599,"activeCount":103},[],{"trials":6601,"activeCount":103},[6602],{"nctId":6541,"briefTitle":6542,"status":115,"phases":6603,"primaryCompletion":6544,"completion":6545,"start":3472,"enrollment":6546,"conditions":6604,"interventions":6605},[92],[25],[6532,6549,6550,6551],{"trials":6607,"activeCount":103},[],{"trials":6609,"activeCount":103},[],{"trials":6611,"activeCount":103},[],{"intervention":863,"totalTrials":241,"cells":6613},{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6624,"PHASE4":6626,"NA":6628},{"trials":6615,"activeCount":103},[],{"trials":6617,"activeCount":103},[],{"trials":6619,"activeCount":103},[6620],{"nctId":854,"briefTitle":855,"status":115,"phases":6621,"primaryCompletion":857,"completion":858,"start":859,"enrollment":451,"conditions":6622,"interventions":6623},[92],[861],[863,864,58],{"trials":6625,"activeCount":103},[],{"trials":6627,"activeCount":103},[],{"trials":6629,"activeCount":103},[],{"intervention":864,"totalTrials":241,"cells":6631},{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6642,"PHASE4":6644,"NA":6646},{"trials":6633,"activeCount":103},[],{"trials":6635,"activeCount":103},[],{"trials":6637,"activeCount":103},[6638],{"nctId":854,"briefTitle":855,"status":115,"phases":6639,"primaryCompletion":857,"completion":858,"start":859,"enrollment":451,"conditions":6640,"interventions":6641},[92],[861],[863,864,58],{"trials":6643,"activeCount":103},[],{"trials":6645,"activeCount":103},[],{"trials":6647,"activeCount":103},[],{"intervention":6649,"totalTrials":241,"cells":6650},"Adenosine",{"EARLY_PHASE1":6651,"PHASE1":6653,"PHASE2":6655,"PHASE3":6665,"PHASE4":6667,"NA":6669},{"trials":6652,"activeCount":103},[],{"trials":6654,"activeCount":103},[],{"trials":6656,"activeCount":103},[6657],{"nctId":6658,"briefTitle":6659,"status":115,"phases":6660,"primaryCompletion":3303,"completion":3303,"start":4451,"enrollment":6661,"conditions":6662,"interventions":6663},"NCT03032965","Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation",[92],131,[3963],[6649,6664],"Isoproterenol",{"trials":6666,"activeCount":103},[],{"trials":6668,"activeCount":103},[],{"trials":6670,"activeCount":103},[],{"intervention":6664,"totalTrials":241,"cells":6672},{"EARLY_PHASE1":6673,"PHASE1":6675,"PHASE2":6677,"PHASE3":6683,"PHASE4":6685,"NA":6687},{"trials":6674,"activeCount":103},[],{"trials":6676,"activeCount":103},[],{"trials":6678,"activeCount":103},[6679],{"nctId":6658,"briefTitle":6659,"status":115,"phases":6680,"primaryCompletion":3303,"completion":3303,"start":4451,"enrollment":6661,"conditions":6681,"interventions":6682},[92],[3963],[6649,6664],{"trials":6684,"activeCount":103},[],{"trials":6686,"activeCount":103},[],{"trials":6688,"activeCount":103},[],{"intervention":6690,"totalTrials":241,"cells":6691},"Lidocaine in SphenoCath device",{"EARLY_PHASE1":6692,"PHASE1":6694,"PHASE2":6696,"PHASE3":6710,"PHASE4":6712,"NA":6714},{"trials":6693,"activeCount":103},[],{"trials":6695,"activeCount":103},[],{"trials":6697,"activeCount":103},[6698],{"nctId":6699,"briefTitle":6700,"status":211,"phases":6701,"primaryCompletion":6702,"completion":6703,"start":6704,"enrollment":151,"conditions":6705,"interventions":6708},"NCT04650282","Sphenopalatine Ganglion Block for Headache After Concussion",[92],"2021-04-01","2021-04-06","2021-03-18",[6706,6707],"Concussion","Headache",[6690,6709],"Saline Solution in SphenoCath device",{"trials":6711,"activeCount":103},[],{"trials":6713,"activeCount":103},[],{"trials":6715,"activeCount":103},[],{"intervention":6709,"totalTrials":241,"cells":6717},{"EARLY_PHASE1":6718,"PHASE1":6720,"PHASE2":6722,"PHASE3":6728,"PHASE4":6730,"NA":6732},{"trials":6719,"activeCount":103},[],{"trials":6721,"activeCount":103},[],{"trials":6723,"activeCount":103},[6724],{"nctId":6699,"briefTitle":6700,"status":211,"phases":6725,"primaryCompletion":6702,"completion":6703,"start":6704,"enrollment":151,"conditions":6726,"interventions":6727},[92],[6706,6707],[6690,6709],{"trials":6729,"activeCount":103},[],{"trials":6731,"activeCount":103},[],{"trials":6733,"activeCount":103},[],{"intervention":6735,"totalTrials":241,"cells":6736},"6R BH4",{"EARLY_PHASE1":6737,"PHASE1":6739,"PHASE2":6741,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6738,"activeCount":103},[],{"trials":6740,"activeCount":103},[],{"trials":6742,"activeCount":103},[6743],{"nctId":6744,"briefTitle":6745,"status":115,"phases":6746,"primaryCompletion":4927,"completion":4927,"start":1496,"enrollment":1060,"conditions":6747,"interventions":6750},"NCT00625820","Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria",[92],[6748,6749],"Kidney Disease","Albuminuria",[6735],{"trials":6752,"activeCount":103},[],{"trials":6754,"activeCount":103},[],{"trials":6756,"activeCount":103},[],{"intervention":6758,"totalTrials":241,"cells":6759},"WNT974",{"EARLY_PHASE1":6760,"PHASE1":6762,"PHASE2":6764,"PHASE3":6774,"PHASE4":6776,"NA":6778},{"trials":6761,"activeCount":103},[],{"trials":6763,"activeCount":103},[],{"trials":6765,"activeCount":103},[6766],{"nctId":6767,"briefTitle":6768,"status":281,"phases":6769,"primaryCompletion":6770,"enrollment":103,"conditions":6771,"interventions":6773},"NCT02649530","A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",[92],"2018-07",[6772],"Squamous Cell Carcinoma, Head And Neck",[6758],{"trials":6775,"activeCount":103},[],{"trials":6777,"activeCount":103},[],{"trials":6779,"activeCount":103},[],{"intervention":6781,"totalTrials":241,"cells":6782},"Venetoclax",{"EARLY_PHASE1":6783,"PHASE1":6785,"PHASE2":6787,"PHASE3":6799,"PHASE4":6801,"NA":6803},{"trials":6784,"activeCount":103},[],{"trials":6786,"activeCount":103},[],{"trials":6788,"activeCount":103},[6789],{"nctId":6790,"briefTitle":6791,"status":211,"phases":6792,"primaryCompletion":6793,"completion":6793,"start":6794,"enrollment":384,"conditions":6795,"interventions":6797},"NCT05780879","A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia",[92],"2025-08-16","2024-06-03",[6796],"Secondary Acute Myeloid Leukemia",[6781,6798],"FLAG or CLAG Protocol",{"trials":6800,"activeCount":103},[],{"trials":6802,"activeCount":103},[],{"trials":6804,"activeCount":103},[],{"intervention":6798,"totalTrials":241,"cells":6806},{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6811,"PHASE3":6817,"PHASE4":6819,"NA":6821},{"trials":6808,"activeCount":103},[],{"trials":6810,"activeCount":103},[],{"trials":6812,"activeCount":103},[6813],{"nctId":6790,"briefTitle":6791,"status":211,"phases":6814,"primaryCompletion":6793,"completion":6793,"start":6794,"enrollment":384,"conditions":6815,"interventions":6816},[92],[6796],[6781,6798],{"trials":6818,"activeCount":103},[],{"trials":6820,"activeCount":103},[],{"trials":6822,"activeCount":103},[],{"intervention":6824,"totalTrials":241,"cells":6825},"Dipyridamole 100 Milligram",{"EARLY_PHASE1":6826,"PHASE1":6828,"PHASE2":6830,"PHASE3":6844,"PHASE4":6846,"NA":6848},{"trials":6827,"activeCount":103},[],{"trials":6829,"activeCount":103},[],{"trials":6831,"activeCount":103},[6832],{"nctId":6833,"briefTitle":6834,"status":115,"phases":6835,"primaryCompletion":6836,"completion":6836,"start":6837,"enrollment":6838,"conditions":6839,"interventions":6843},"NCT04391179","Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19",[92],"2021-02-22","2020-05-31",99,[6840,3432,6841,6842],"COVID","Covid-19","SARS-CoV-2 Infection",[6824],{"trials":6845,"activeCount":103},[],{"trials":6847,"activeCount":103},[],{"trials":6849,"activeCount":103},[],{"intervention":1367,"totalTrials":241,"cells":6851},{"EARLY_PHASE1":6852,"PHASE1":6854,"PHASE2":6856,"PHASE3":6862,"PHASE4":6864,"NA":6866},{"trials":6853,"activeCount":103},[],{"trials":6855,"activeCount":103},[],{"trials":6857,"activeCount":103},[6858],{"nctId":1356,"briefTitle":1357,"status":115,"phases":6859,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":6860,"interventions":6861},[92],[1364],[1366,1367,1368,1369],{"trials":6863,"activeCount":103},[],{"trials":6865,"activeCount":103},[],{"trials":6867,"activeCount":103},[],{"intervention":1369,"totalTrials":241,"cells":6869},{"EARLY_PHASE1":6870,"PHASE1":6872,"PHASE2":6874,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6871,"activeCount":103},[],{"trials":6873,"activeCount":103},[],{"trials":6875,"activeCount":103},[6876],{"nctId":1356,"briefTitle":1357,"status":115,"phases":6877,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":6878,"interventions":6879},[92],[1364],[1366,1367,1368,1369],{"trials":6881,"activeCount":103},[],{"trials":6883,"activeCount":103},[],{"trials":6885,"activeCount":103},[],{"intervention":6887,"totalTrials":241,"cells":6888},"VSL#3",{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6903,"PHASE4":6905,"NA":6907},{"trials":6890,"activeCount":103},[],{"trials":6892,"activeCount":103},[],{"trials":6894,"activeCount":103},[6895],{"nctId":6896,"briefTitle":6897,"status":115,"phases":6898,"primaryCompletion":5055,"completion":5055,"start":6899,"enrollment":2477,"conditions":6900,"interventions":6902},"NCT00630838","Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)",[92],"2006-09",[6901],"Hirschsprung Disease",[6887],{"trials":6904,"activeCount":103},[],{"trials":6906,"activeCount":103},[],{"trials":6908,"activeCount":103},[],{"intervention":5284,"totalTrials":241,"cells":6910},{"EARLY_PHASE1":6911,"PHASE1":6913,"PHASE2":6915,"PHASE3":6921,"PHASE4":6923,"NA":6925},{"trials":6912,"activeCount":103},[],{"trials":6914,"activeCount":103},[],{"trials":6916,"activeCount":103},[6917],{"nctId":5276,"briefTitle":5277,"status":115,"phases":6918,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":1249,"conditions":6919,"interventions":6920},[91,92],[5282],[5284,277],{"trials":6922,"activeCount":103},[],{"trials":6924,"activeCount":103},[],{"trials":6926,"activeCount":103},[],{"intervention":6928,"totalTrials":241,"cells":6929},"PTK787",{"EARLY_PHASE1":6930,"PHASE1":6932,"PHASE2":6934,"PHASE3":6944,"PHASE4":6946,"NA":6948},{"trials":6931,"activeCount":103},[],{"trials":6933,"activeCount":103},[],{"trials":6935,"activeCount":103},[6936],{"nctId":6937,"briefTitle":6938,"status":115,"phases":6939,"primaryCompletion":2371,"completion":6940,"start":6941,"enrollment":1343,"conditions":6942,"interventions":6943},"NCT00134355","Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer",[92],"2007-03","2005-07",[25],[6928],{"trials":6945,"activeCount":103},[],{"trials":6947,"activeCount":103},[],{"trials":6949,"activeCount":103},[],{"intervention":6951,"totalTrials":241,"cells":6952},"Tissue Repair Cells",{"EARLY_PHASE1":6953,"PHASE1":6955,"PHASE2":6957,"PHASE3":6966,"PHASE4":6968,"NA":6970},{"trials":6954,"activeCount":103},[],{"trials":6956,"activeCount":103},[],{"trials":6958,"activeCount":103},[6959],{"nctId":6960,"briefTitle":6961,"status":115,"phases":6962,"primaryCompletion":4715,"completion":5293,"start":4703,"enrollment":5336,"conditions":6963,"interventions":6965},"NCT00755911","Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy",[91,92],[6964],"Alveolar Bone Loss",[6951],{"trials":6967,"activeCount":103},[],{"trials":6969,"activeCount":103},[],{"trials":6971,"activeCount":103},[],{"intervention":6973,"totalTrials":241,"cells":6974},"Hydroxychloroquine lower dose",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6991,"PHASE4":6993,"NA":6995},{"trials":6976,"activeCount":103},[],{"trials":6978,"activeCount":103},[],{"trials":6980,"activeCount":103},[6981],{"nctId":6982,"briefTitle":6983,"status":211,"phases":6984,"primaryCompletion":6985,"completion":6985,"start":6986,"enrollment":620,"conditions":6987,"interventions":6989},"NCT04120883","Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)",[91,92],"2024-08-05","2020-02-25",[6988],"Retinitis Pigmentosa",[6973,6990],"Hydroxychloroquine higher dose",{"trials":6992,"activeCount":103},[],{"trials":6994,"activeCount":103},[],{"trials":6996,"activeCount":103},[],{"intervention":6990,"totalTrials":241,"cells":6998},{"EARLY_PHASE1":6999,"PHASE1":7001,"PHASE2":7003,"PHASE3":7009,"PHASE4":7011,"NA":7013},{"trials":7000,"activeCount":103},[],{"trials":7002,"activeCount":103},[],{"trials":7004,"activeCount":103},[7005],{"nctId":6982,"briefTitle":6983,"status":211,"phases":7006,"primaryCompletion":6985,"completion":6985,"start":6986,"enrollment":620,"conditions":7007,"interventions":7008},[91,92],[6988],[6973,6990],{"trials":7010,"activeCount":103},[],{"trials":7012,"activeCount":103},[],{"trials":7014,"activeCount":103},[],{"intervention":7016,"totalTrials":241,"cells":7017},"zileuton",{"EARLY_PHASE1":7018,"PHASE1":7020,"PHASE2":7022,"PHASE3":7033,"PHASE4":7035,"NA":7037},{"trials":7019,"activeCount":103},[],{"trials":7021,"activeCount":103},[],{"trials":7023,"activeCount":103},[7024],{"nctId":7025,"briefTitle":7026,"status":115,"phases":7027,"primaryCompletion":7028,"completion":7028,"start":7029,"enrollment":4428,"conditions":7030,"interventions":7031},"NCT00262405","Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis",[92],"2007-05","2001-01",[5353],[7016,7032],"azathioprine\u002Fprednisone",{"trials":7034,"activeCount":103},[],{"trials":7036,"activeCount":103},[],{"trials":7038,"activeCount":103},[],{"intervention":7032,"totalTrials":241,"cells":7040},{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7045,"PHASE3":7051,"PHASE4":7053,"NA":7055},{"trials":7042,"activeCount":103},[],{"trials":7044,"activeCount":103},[],{"trials":7046,"activeCount":103},[7047],{"nctId":7025,"briefTitle":7026,"status":115,"phases":7048,"primaryCompletion":7028,"completion":7028,"start":7029,"enrollment":4428,"conditions":7049,"interventions":7050},[92],[5353],[7016,7032],{"trials":7052,"activeCount":103},[],{"trials":7054,"activeCount":103},[],{"trials":7056,"activeCount":103},[],{"intervention":7058,"totalTrials":241,"cells":7059},"Aastrom BRCs",{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7064,"PHASE3":7074,"PHASE4":7076,"NA":7078},{"trials":7061,"activeCount":103},[],{"trials":7063,"activeCount":103},[],{"trials":7065,"activeCount":103},[7066],{"nctId":7067,"briefTitle":7068,"status":115,"phases":7069,"primaryCompletion":486,"completion":486,"start":7070,"enrollment":251,"conditions":7071,"interventions":7073},"NCT00980278","Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation",[91,92],"2010-03",[7072],"Tooth Loss",[7058],{"trials":7075,"activeCount":103},[],{"trials":7077,"activeCount":103},[],{"trials":7079,"activeCount":103},[],{"intervention":7081,"totalTrials":241,"cells":7082},"Fludarabine",{"EARLY_PHASE1":7083,"PHASE1":7085,"PHASE2":7087,"PHASE3":7098,"PHASE4":7100,"NA":7102},{"trials":7084,"activeCount":103},[],{"trials":7086,"activeCount":103},[],{"trials":7088,"activeCount":103},[7089],{"nctId":7090,"briefTitle":7091,"status":115,"phases":7092,"primaryCompletion":214,"completion":7093,"start":6940,"enrollment":1330,"conditions":7094,"interventions":7096},"NCT00623935","Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia",[92],"2015-11",[7095],"Acute Myelogenous Leukemia",[7081,7097],"Busulfan",{"trials":7099,"activeCount":103},[],{"trials":7101,"activeCount":103},[],{"trials":7103,"activeCount":103},[],{"intervention":7097,"totalTrials":241,"cells":7105},{"EARLY_PHASE1":7106,"PHASE1":7108,"PHASE2":7110,"PHASE3":7116,"PHASE4":7118,"NA":7120},{"trials":7107,"activeCount":103},[],{"trials":7109,"activeCount":103},[],{"trials":7111,"activeCount":103},[7112],{"nctId":7090,"briefTitle":7091,"status":115,"phases":7113,"primaryCompletion":214,"completion":7093,"start":6940,"enrollment":1330,"conditions":7114,"interventions":7115},[92],[7095],[7081,7097],{"trials":7117,"activeCount":103},[],{"trials":7119,"activeCount":103},[],{"trials":7121,"activeCount":103},[],{"intervention":5950,"totalTrials":241,"cells":7123},{"EARLY_PHASE1":7124,"PHASE1":7126,"PHASE2":7128,"PHASE3":7134,"PHASE4":7136,"NA":7138},{"trials":7125,"activeCount":103},[],{"trials":7127,"activeCount":103},[],{"trials":7129,"activeCount":103},[7130],{"nctId":5942,"briefTitle":5943,"status":281,"phases":7131,"primaryCompletion":5945,"completion":5946,"start":5947,"enrollment":103,"conditions":7132,"interventions":7133},[92],[717],[5933,5950,5951,5952],{"trials":7135,"activeCount":103},[],{"trials":7137,"activeCount":103},[],{"trials":7139,"activeCount":103},[],{"intervention":5951,"totalTrials":241,"cells":7141},{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7152,"PHASE4":7154,"NA":7156},{"trials":7143,"activeCount":103},[],{"trials":7145,"activeCount":103},[],{"trials":7147,"activeCount":103},[7148],{"nctId":5942,"briefTitle":5943,"status":281,"phases":7149,"primaryCompletion":5945,"completion":5946,"start":5947,"enrollment":103,"conditions":7150,"interventions":7151},[92],[717],[5933,5950,5951,5952],{"trials":7153,"activeCount":103},[],{"trials":7155,"activeCount":103},[],{"trials":7157,"activeCount":103},[],{"intervention":5952,"totalTrials":241,"cells":7159},{"EARLY_PHASE1":7160,"PHASE1":7162,"PHASE2":7164,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7161,"activeCount":103},[],{"trials":7163,"activeCount":103},[],{"trials":7165,"activeCount":103},[7166],{"nctId":5942,"briefTitle":5943,"status":281,"phases":7167,"primaryCompletion":5945,"completion":5946,"start":5947,"enrollment":103,"conditions":7168,"interventions":7169},[92],[717],[5933,5950,5951,5952],{"trials":7171,"activeCount":103},[],{"trials":7173,"activeCount":103},[],{"trials":7175,"activeCount":103},[],{"intervention":7177,"totalTrials":241,"cells":7178},"Tumor lysate-pulsed dendritic cell (DC) vaccine",{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7183,"PHASE3":7194,"PHASE4":7196,"NA":7198},{"trials":7180,"activeCount":103},[],{"trials":7182,"activeCount":103},[],{"trials":7184,"activeCount":103},[7185],{"nctId":7186,"briefTitle":7187,"status":115,"phases":7188,"primaryCompletion":7189,"completion":358,"start":296,"enrollment":713,"conditions":7190,"interventions":7193},"NCT00405327","A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation",[92],"2009-06",[939,7191,7192],"Neuroblastoma","Wilm's Tumor",[7177],{"trials":7195,"activeCount":103},[],{"trials":7197,"activeCount":103},[],{"trials":7199,"activeCount":103},[],{"intervention":7201,"totalTrials":241,"cells":7202},"Pirfenidone",{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7220,"PHASE4":7222,"NA":7224},{"trials":7204,"activeCount":103},[],{"trials":7206,"activeCount":103},[],{"trials":7208,"activeCount":103},[7209],{"nctId":7210,"briefTitle":7211,"status":211,"phases":7212,"primaryCompletion":7213,"completion":7214,"start":7215,"enrollment":5336,"conditions":7216,"interventions":7219},"NCT03473340","Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)",[92],"2021-07-23","2021-08-20","2018-04-27",[7217,7218],"Disorder Related to Lung Transplantation","Chronic Lung Allograft Dysfunction",[7201],{"trials":7221,"activeCount":103},[],{"trials":7223,"activeCount":103},[],{"trials":7225,"activeCount":103},[],{"intervention":7227,"totalTrials":241,"cells":7228},"Flumazenil",{"EARLY_PHASE1":7229,"PHASE1":7231,"PHASE2":7233,"PHASE3":7243,"PHASE4":7245,"NA":7247},{"trials":7230,"activeCount":103},[],{"trials":7232,"activeCount":103},[],{"trials":7234,"activeCount":103},[7235],{"nctId":7236,"briefTitle":7237,"status":115,"phases":7238,"primaryCompletion":7239,"completion":7239,"start":7240,"enrollment":758,"conditions":7241,"interventions":7242},"NCT03462641","Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm",[91,92],"2021-06-04","2018-03-09",[4101],[7227],{"trials":7244,"activeCount":103},[],{"trials":7246,"activeCount":103},[],{"trials":7248,"activeCount":103},[],{"intervention":3100,"totalTrials":241,"cells":7250},{"EARLY_PHASE1":7251,"PHASE1":7253,"PHASE2":7255,"PHASE3":7261,"PHASE4":7263,"NA":7265},{"trials":7252,"activeCount":103},[],{"trials":7254,"activeCount":103},[],{"trials":7256,"activeCount":103},[7257],{"nctId":3093,"briefTitle":3094,"status":281,"phases":7258,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":103,"conditions":7259,"interventions":7260},[92],[25],[3100,3101,3084],{"trials":7262,"activeCount":103},[],{"trials":7264,"activeCount":103},[],{"trials":7266,"activeCount":103},[],{"intervention":3101,"totalTrials":241,"cells":7268},{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7273,"PHASE3":7279,"PHASE4":7281,"NA":7283},{"trials":7270,"activeCount":103},[],{"trials":7272,"activeCount":103},[],{"trials":7274,"activeCount":103},[7275],{"nctId":3093,"briefTitle":3094,"status":281,"phases":7276,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":103,"conditions":7277,"interventions":7278},[92],[25],[3100,3101,3084],{"trials":7280,"activeCount":103},[],{"trials":7282,"activeCount":103},[],{"trials":7284,"activeCount":103},[],{"intervention":7286,"totalTrials":241,"cells":7287},"Tofacitinib",{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7304,"PHASE4":7306,"NA":7308},{"trials":7289,"activeCount":103},[],{"trials":7291,"activeCount":103},[],{"trials":7293,"activeCount":103},[7294],{"nctId":7295,"briefTitle":7296,"status":115,"phases":7297,"primaryCompletion":7298,"completion":7299,"start":7300,"enrollment":394,"conditions":7301,"interventions":7303},"NCT03274076","Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)",[91,92],"2019-04-08","2019-11-15","2017-09-25",[7302,3380],"Systemic Sclerosis",[7286],{"trials":7305,"activeCount":103},[],{"trials":7307,"activeCount":103},[],{"trials":7309,"activeCount":103},[],{"intervention":7311,"totalTrials":241,"cells":7312},"ifosfamide and doxorubicin vs gemcitabine and docetaxel",{"EARLY_PHASE1":7313,"PHASE1":7315,"PHASE2":7317,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7314,"activeCount":103},[],{"trials":7316,"activeCount":103},[],{"trials":7318,"activeCount":103},[7319],{"nctId":7320,"briefTitle":7321,"status":115,"phases":7322,"primaryCompletion":6246,"completion":858,"start":306,"enrollment":12,"conditions":7323,"interventions":7325},"NCT00189137","Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma",[92],[7324],"Sarcoma, Soft Tissue",[7311],{"trials":7327,"activeCount":103},[],{"trials":7329,"activeCount":103},[],{"trials":7331,"activeCount":103},[],{"intervention":1150,"totalTrials":241,"cells":7333},{"EARLY_PHASE1":7334,"PHASE1":7336,"PHASE2":7338,"PHASE3":7344,"PHASE4":7346,"NA":7348},{"trials":7335,"activeCount":103},[],{"trials":7337,"activeCount":103},[],{"trials":7339,"activeCount":103},[7340],{"nctId":1143,"briefTitle":1144,"status":115,"phases":7341,"primaryCompletion":1146,"completion":936,"start":1147,"enrollment":34,"conditions":7342,"interventions":7343},[92],[1128],[1150,234],{"trials":7345,"activeCount":103},[],{"trials":7347,"activeCount":103},[],{"trials":7349,"activeCount":103},[],{"intervention":7351,"totalTrials":241,"cells":7352},"SOC Carboplatin",{"EARLY_PHASE1":7353,"PHASE1":7355,"PHASE2":7357,"PHASE3":7370,"PHASE4":7372,"NA":7374},{"trials":7354,"activeCount":103},[],{"trials":7356,"activeCount":103},[],{"trials":7358,"activeCount":103},[7359],{"nctId":7360,"briefTitle":7361,"status":115,"phases":7362,"primaryCompletion":7363,"completion":7364,"start":7365,"enrollment":557,"conditions":7366,"interventions":7368},"NCT02784288","Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer",[92],"2020-07-10","2022-07-12","2016-10-31",[7367],"Oropharyngeal Squamous Cell Cancer",[7351,7369],"SOC Paclitaxel",{"trials":7371,"activeCount":103},[],{"trials":7373,"activeCount":103},[],{"trials":7375,"activeCount":103},[],{"intervention":7369,"totalTrials":241,"cells":7377},{"EARLY_PHASE1":7378,"PHASE1":7380,"PHASE2":7382,"PHASE3":7388,"PHASE4":7390,"NA":7392},{"trials":7379,"activeCount":103},[],{"trials":7381,"activeCount":103},[],{"trials":7383,"activeCount":103},[7384],{"nctId":7360,"briefTitle":7361,"status":115,"phases":7385,"primaryCompletion":7363,"completion":7364,"start":7365,"enrollment":557,"conditions":7386,"interventions":7387},[92],[7367],[7351,7369],{"trials":7389,"activeCount":103},[],{"trials":7391,"activeCount":103},[],{"trials":7393,"activeCount":103},[],{"intervention":7395,"totalTrials":241,"cells":7396},"carfilzomib, lenalidomide plus dexamethasone",{"EARLY_PHASE1":7397,"PHASE1":7399,"PHASE2":7401,"PHASE3":7409,"PHASE4":7411,"NA":7413},{"trials":7398,"activeCount":103},[],{"trials":7400,"activeCount":103},[],{"trials":7402,"activeCount":103},[7403],{"nctId":7404,"briefTitle":7405,"status":115,"phases":7406,"primaryCompletion":4715,"completion":3303,"start":1567,"enrollment":1377,"conditions":7407,"interventions":7408},"NCT01029054","Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma",[91,92],[1486],[7395,7395],{"trials":7410,"activeCount":103},[],{"trials":7412,"activeCount":103},[],{"trials":7414,"activeCount":103},[],{"intervention":7416,"totalTrials":241,"cells":7417},"Riboflavin",{"EARLY_PHASE1":7418,"PHASE1":7420,"PHASE2":7422,"PHASE3":7432,"PHASE4":7434,"NA":7436},{"trials":7419,"activeCount":103},[],{"trials":7421,"activeCount":103},[],{"trials":7423,"activeCount":103},[7424],{"nctId":7425,"briefTitle":7426,"status":115,"phases":7427,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":31,"conditions":7430,"interventions":7431},"NCT02622386","The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis",[92],"2020-04-06","2016-08-11",[2997],[7416],{"trials":7433,"activeCount":103},[],{"trials":7435,"activeCount":103},[],{"trials":7437,"activeCount":103},[],{"intervention":289,"totalTrials":241,"cells":7439},{"EARLY_PHASE1":7440,"PHASE1":7442,"PHASE2":7444,"PHASE3":7450,"PHASE4":7452,"NA":7454},{"trials":7441,"activeCount":103},[],{"trials":7443,"activeCount":103},[],{"trials":7445,"activeCount":103},[7446],{"nctId":279,"briefTitle":280,"status":281,"phases":7447,"primaryCompletion":283,"start":284,"enrollment":103,"conditions":7448,"interventions":7449},[92],[286],[288,234,289,199,290],{"trials":7451,"activeCount":103},[],{"trials":7453,"activeCount":103},[],{"trials":7455,"activeCount":103},[],{"intervention":942,"totalTrials":241,"cells":7457},{"EARLY_PHASE1":7458,"PHASE1":7460,"PHASE2":7462,"PHASE3":7468,"PHASE4":7470,"NA":7472},{"trials":7459,"activeCount":103},[],{"trials":7461,"activeCount":103},[],{"trials":7463,"activeCount":103},[7464],{"nctId":931,"briefTitle":932,"status":115,"phases":7465,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":7466,"interventions":7467},[92],[939,940],[43,942],{"trials":7469,"activeCount":103},[],{"trials":7471,"activeCount":103},[],{"trials":7473,"activeCount":103},[],{"intervention":7475,"totalTrials":241,"cells":7476},"Fluoxetine",{"EARLY_PHASE1":7477,"PHASE1":7479,"PHASE2":7481,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7478,"activeCount":103},[],{"trials":7480,"activeCount":103},[],{"trials":7482,"activeCount":103},[7483],{"nctId":7484,"briefTitle":7485,"status":115,"phases":7486,"primaryCompletion":5986,"completion":5986,"start":1361,"enrollment":273,"conditions":7487,"interventions":7488},"NCT01545843","Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression",[92],[16],[7475],{"trials":7490,"activeCount":103},[],{"trials":7492,"activeCount":103},[],{"trials":7494,"activeCount":103},[],{"intervention":7496,"totalTrials":241,"cells":7497},"AG 6013736",{"EARLY_PHASE1":7498,"PHASE1":7500,"PHASE2":7502,"PHASE3":7510,"PHASE4":7512,"NA":7514},{"trials":7499,"activeCount":103},[],{"trials":7501,"activeCount":103},[],{"trials":7503,"activeCount":103},[7504],{"nctId":7505,"briefTitle":7506,"status":115,"phases":7507,"primaryCompletion":239,"completion":7189,"start":6941,"enrollment":99,"conditions":7508,"interventions":7509},"NCT00176748","Treatment for Patients With Metastatic Thyroid Cancer",[92],[6037],[7496],{"trials":7511,"activeCount":103},[],{"trials":7513,"activeCount":103},[],{"trials":7515,"activeCount":103},[],{"intervention":7517,"totalTrials":241,"cells":7518},"Bob's Red Mill®",{"EARLY_PHASE1":7519,"PHASE1":7521,"PHASE2":7523,"PHASE3":7534,"PHASE4":7536,"NA":7538},{"trials":7520,"activeCount":103},[],{"trials":7522,"activeCount":103},[],{"trials":7524,"activeCount":103},[7525],{"nctId":7526,"briefTitle":7527,"status":115,"phases":7528,"primaryCompletion":7529,"completion":7529,"start":7530,"enrollment":4558,"conditions":7531,"interventions":7533},"NCT02763033","Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients",[92],"2025-12-29","2017-04-26",[7532],"Hematopoietic Stem Cell Transplantation",[7517],{"trials":7535,"activeCount":103},[],{"trials":7537,"activeCount":103},[],{"trials":7539,"activeCount":103},[],{"intervention":7541,"totalTrials":241,"cells":7542},"Dimethyl fumarate",{"EARLY_PHASE1":7543,"PHASE1":7545,"PHASE2":7547,"PHASE3":7560,"PHASE4":7562,"NA":7564},{"trials":7544,"activeCount":103},[],{"trials":7546,"activeCount":103},[],{"trials":7548,"activeCount":103},[7549],{"nctId":7550,"briefTitle":7551,"status":115,"phases":7552,"primaryCompletion":1360,"completion":7553,"start":7554,"enrollment":7555,"conditions":7556,"interventions":7559},"NCT02438137","Dimethyl Fumarate for Obstructive Sleep Apnea",[92],"2016-05","2015-05",65,[4383,7557,7558],"OSA","Sleep Apnea",[7541],{"trials":7561,"activeCount":103},[],{"trials":7563,"activeCount":103},[],{"trials":7565,"activeCount":103},[],{"intervention":7567,"totalTrials":241,"cells":7568},"Cyproheptadine",{"EARLY_PHASE1":7569,"PHASE1":7571,"PHASE2":7573,"PHASE3":7583,"PHASE4":7585,"NA":7587},{"trials":7570,"activeCount":103},[],{"trials":7572,"activeCount":103},[],{"trials":7574,"activeCount":103},[7575],{"nctId":7576,"briefTitle":7577,"status":211,"phases":7578,"primaryCompletion":3473,"completion":3473,"start":3232,"enrollment":804,"conditions":7579,"interventions":7581},"NCT01675050","A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain",[92],[7580],"Functional Abdominal Pain",[7567,7582],"sugar pill",{"trials":7584,"activeCount":103},[],{"trials":7586,"activeCount":103},[],{"trials":7588,"activeCount":103},[],{"intervention":7582,"totalTrials":241,"cells":7590},{"EARLY_PHASE1":7591,"PHASE1":7593,"PHASE2":7595,"PHASE3":7601,"PHASE4":7603,"NA":7605},{"trials":7592,"activeCount":103},[],{"trials":7594,"activeCount":103},[],{"trials":7596,"activeCount":103},[7597],{"nctId":7576,"briefTitle":7577,"status":211,"phases":7598,"primaryCompletion":3473,"completion":3473,"start":3232,"enrollment":804,"conditions":7599,"interventions":7600},[92],[7580],[7567,7582],{"trials":7602,"activeCount":103},[],{"trials":7604,"activeCount":103},[],{"trials":7606,"activeCount":103},[],{"intervention":7608,"totalTrials":241,"cells":7609},"GM-CSF",{"EARLY_PHASE1":7610,"PHASE1":7612,"PHASE2":7614,"PHASE3":7624,"PHASE4":7626,"NA":7628},{"trials":7611,"activeCount":103},[],{"trials":7613,"activeCount":103},[],{"trials":7615,"activeCount":103},[7616],{"nctId":7617,"briefTitle":7618,"status":115,"phases":7619,"primaryCompletion":7620,"completion":7189,"start":2493,"enrollment":7621,"conditions":7622,"interventions":7623},"NCT00201409","A Randomized Trial of GM-CSF in Patients With ALI\u002FARDS",[92],"2009-05",132,[2968],[7608],{"trials":7625,"activeCount":103},[],{"trials":7627,"activeCount":103},[],{"trials":7629,"activeCount":103},[],{"intervention":7631,"totalTrials":241,"cells":7632},"Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.",{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7637,"PHASE3":7648,"PHASE4":7650,"NA":7652},{"trials":7634,"activeCount":103},[],{"trials":7636,"activeCount":103},[],{"trials":7638,"activeCount":103},[7639],{"nctId":7640,"briefTitle":7641,"status":211,"phases":7642,"primaryCompletion":7643,"completion":7643,"start":7644,"enrollment":4428,"conditions":7645,"interventions":7647},"NCT03345550","OPTIMA-TBI Pilot Study",[92],"2021-07-27","2017-09-12",[7646],"Mild Traumatic Brain Injury",[7631],{"trials":7649,"activeCount":103},[],{"trials":7651,"activeCount":103},[],{"trials":7653,"activeCount":103},[],{"intervention":5541,"totalTrials":241,"cells":7655},{"EARLY_PHASE1":7656,"PHASE1":7658,"PHASE2":7660,"PHASE3":7666,"PHASE4":7668,"NA":7670},{"trials":7657,"activeCount":103},[],{"trials":7659,"activeCount":103},[],{"trials":7661,"activeCount":103},[7662],{"nctId":5533,"briefTitle":5534,"status":115,"phases":7663,"primaryCompletion":5536,"completion":4599,"start":5537,"enrollment":28,"conditions":7664,"interventions":7665},[92],[5539],[5541,300,1141],{"trials":7667,"activeCount":103},[],{"trials":7669,"activeCount":103},[],{"trials":7671,"activeCount":103},[],{"intervention":1383,"totalTrials":241,"cells":7673},{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7684,"PHASE4":7686,"NA":7688},{"trials":7675,"activeCount":103},[],{"trials":7677,"activeCount":103},[],{"trials":7679,"activeCount":103},[7680],{"nctId":1371,"briefTitle":1372,"status":115,"phases":7681,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":7682,"interventions":7683},[91,92],[1379,1380,1381],[1383,850],{"trials":7685,"activeCount":103},[],{"trials":7687,"activeCount":103},[],{"trials":7689,"activeCount":103},[],{"intervention":7691,"totalTrials":241,"cells":7692},"Lidocaine",{"EARLY_PHASE1":7693,"PHASE1":7695,"PHASE2":7697,"PHASE3":7707,"PHASE4":7709,"NA":7711},{"trials":7694,"activeCount":103},[],{"trials":7696,"activeCount":103},[],{"trials":7698,"activeCount":103},[7699],{"nctId":7700,"briefTitle":7701,"status":115,"phases":7702,"primaryCompletion":7703,"completion":7703,"start":2409,"enrollment":31,"conditions":7704,"interventions":7706},"NCT02872012","Cryoanesthesia for Intravitreal Injections",[91,92],"2018-06",[7705],"Ocular Anesthesia",[7691],{"trials":7708,"activeCount":103},[],{"trials":7710,"activeCount":103},[],{"trials":7712,"activeCount":103},[],{"intervention":7714,"totalTrials":241,"cells":7715},"Bexxar",{"EARLY_PHASE1":7716,"PHASE1":7718,"PHASE2":7720,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7717,"activeCount":103},[],{"trials":7719,"activeCount":103},[],{"trials":7721,"activeCount":103},[7722],{"nctId":7723,"briefTitle":7724,"status":211,"phases":7725,"primaryCompletion":1125,"completion":7726,"start":2410,"enrollment":336,"conditions":7727,"interventions":7728},"NCT01389076","Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma",[92],"2016-06",[844],[7714,7729],"Low Dose Methotrexate",{"trials":7731,"activeCount":103},[],{"trials":7733,"activeCount":103},[],{"trials":7735,"activeCount":103},[],{"intervention":7729,"totalTrials":241,"cells":7737},{"EARLY_PHASE1":7738,"PHASE1":7740,"PHASE2":7742,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7739,"activeCount":103},[],{"trials":7741,"activeCount":103},[],{"trials":7743,"activeCount":103},[7744],{"nctId":7723,"briefTitle":7724,"status":211,"phases":7745,"primaryCompletion":1125,"completion":7726,"start":2410,"enrollment":336,"conditions":7746,"interventions":7747},[92],[844],[7714,7729],{"trials":7749,"activeCount":103},[],{"trials":7751,"activeCount":103},[],{"trials":7753,"activeCount":103},[],{"intervention":7755,"totalTrials":241,"cells":7756},"beta-carotene, vitamins C and E, magnesium",{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7771,"PHASE4":7773,"NA":7775},{"trials":7758,"activeCount":103},[],{"trials":7760,"activeCount":103},[],{"trials":7762,"activeCount":103},[7763],{"nctId":7764,"briefTitle":7765,"status":115,"phases":7766,"primaryCompletion":284,"completion":284,"start":7767,"enrollment":6546,"conditions":7768,"interventions":7770},"NCT00808470","Micronutrients to Prevent Noise-induced Hearing Loss",[92],"2008-10",[7769],"Noise-Induced Hearing Loss",[7755],{"trials":7772,"activeCount":103},[],{"trials":7774,"activeCount":103},[],{"trials":7776,"activeCount":103},[],{"intervention":7778,"totalTrials":241,"cells":7779},"Functional Magnetic Resonance Imaging (fMRI) using Propofol",{"EARLY_PHASE1":7780,"PHASE1":7782,"PHASE2":7784,"PHASE3":7795,"PHASE4":7797,"NA":7799},{"trials":7781,"activeCount":103},[],{"trials":7783,"activeCount":103},[],{"trials":7785,"activeCount":103},[7786],{"nctId":7787,"briefTitle":7788,"status":115,"phases":7789,"primaryCompletion":7790,"completion":7790,"start":7791,"enrollment":200,"conditions":7792,"interventions":7794},"NCT05495945","Ultrasonic Deep Brain Stimulation During Anesthetic Sedation",[92],"2023-10-07","2022-08-26",[7793],"Mental Function",[7778],{"trials":7796,"activeCount":103},[],{"trials":7798,"activeCount":103},[],{"trials":7800,"activeCount":103},[],{"intervention":7802,"totalTrials":241,"cells":7803},"Ropivacaine",{"EARLY_PHASE1":7804,"PHASE1":7806,"PHASE2":7808,"PHASE3":7820,"PHASE4":7822,"NA":7824},{"trials":7805,"activeCount":103},[],{"trials":7807,"activeCount":103},[],{"trials":7809,"activeCount":103},[7810],{"nctId":7811,"briefTitle":7812,"status":115,"phases":7813,"primaryCompletion":2474,"completion":7814,"start":7815,"enrollment":1343,"conditions":7816,"interventions":7819},"NCT05625802","Erector Spinae Plane Block for Uncomplicated Renal Colic",[92],"2024-02-02","2023-02-08",[7817,7818],"Renal Colic","Kidney Stone",[7802],{"trials":7821,"activeCount":103},[],{"trials":7823,"activeCount":103},[],{"trials":7825,"activeCount":103},[],{"intervention":7827,"totalTrials":241,"cells":7828},"Optison",{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7842,"PHASE4":7844,"NA":7846},{"trials":7830,"activeCount":103},[],{"trials":7832,"activeCount":103},[],{"trials":7834,"activeCount":103},[7835],{"nctId":7836,"briefTitle":7837,"status":281,"phases":7838,"primaryCompletion":6244,"completion":1545,"start":7839,"enrollment":103,"conditions":7840,"interventions":7841},"NCT02061163","Contrast-Enhanced Ultrasound in Human Crohn's Disease",[91,92],"2015-02",[3720],[7827],{"trials":7843,"activeCount":103},[],{"trials":7845,"activeCount":103},[],{"trials":7847,"activeCount":103},[],{"intervention":301,"totalTrials":241,"cells":7849},{"EARLY_PHASE1":7850,"PHASE1":7852,"PHASE2":7854,"PHASE3":7860,"PHASE4":7862,"NA":7864},{"trials":7851,"activeCount":103},[],{"trials":7853,"activeCount":103},[],{"trials":7855,"activeCount":103},[7856],{"nctId":292,"briefTitle":293,"status":115,"phases":7857,"primaryCompletion":295,"completion":296,"start":297,"enrollment":28,"conditions":7858,"interventions":7859},[92],[25],[300,301,199],{"trials":7861,"activeCount":103},[],{"trials":7863,"activeCount":103},[],{"trials":7865,"activeCount":103},[],{"intervention":7867,"totalTrials":241,"cells":7868},"Gleevec",{"EARLY_PHASE1":7869,"PHASE1":7871,"PHASE2":7873,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7870,"activeCount":103},[],{"trials":7872,"activeCount":103},[],{"trials":7874,"activeCount":103},[7875],{"nctId":7876,"briefTitle":7877,"status":115,"phases":7878,"primaryCompletion":5654,"completion":1114,"start":7879,"enrollment":451,"conditions":7880,"interventions":7882},"NCT00156286","Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC",[92],"2002-03",[7881],"Small Cell Lung Cancer",[7867],{"trials":7884,"activeCount":103},[],{"trials":7886,"activeCount":103},[],{"trials":7888,"activeCount":103},[],{"intervention":1322,"totalTrials":241,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7892,"activeCount":103},[],{"trials":7894,"activeCount":103},[],{"trials":7896,"activeCount":103},[7897],{"nctId":1313,"briefTitle":1314,"status":115,"phases":7898,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":804,"conditions":7899,"interventions":7900},[92],[1320],[255,1322],{"trials":7902,"activeCount":103},[],{"trials":7904,"activeCount":103},[],{"trials":7906,"activeCount":103},[],{"intervention":7908,"totalTrials":241,"cells":7909},"Treatment-inhaled tPA",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7927,"PHASE4":7929,"NA":7931},{"trials":7911,"activeCount":103},[],{"trials":7913,"activeCount":103},[],{"trials":7915,"activeCount":103},[7916],{"nctId":7917,"briefTitle":7918,"status":115,"phases":7919,"primaryCompletion":7920,"completion":7921,"start":7922,"enrollment":557,"conditions":7923,"interventions":7926},"NCT02315898","Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis",[92],"2021-03-05","2023-06-30","2018-03-19",[7924,7925,22],"Plastic Bronchitis","Protein-Losing Enteropathies",[7908],{"trials":7928,"activeCount":103},[],{"trials":7930,"activeCount":103},[],{"trials":7932,"activeCount":103},[],{"intervention":7934,"totalTrials":241,"cells":7935},"Cyclophosphamide and Sirolimus",{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7951,"PHASE4":7953,"NA":7955},{"trials":7937,"activeCount":103},[],{"trials":7939,"activeCount":103},[],{"trials":7941,"activeCount":103},[7942],{"nctId":7943,"briefTitle":7944,"status":115,"phases":7945,"primaryCompletion":7946,"completion":2953,"start":7947,"enrollment":349,"conditions":7948,"interventions":7950},"NCT00743509","A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma",[92],"2010-04","2008-08",[7949],"Osteosarcoma",[7934],{"trials":7952,"activeCount":103},[],{"trials":7954,"activeCount":103},[],{"trials":7956,"activeCount":103},[],{"intervention":761,"totalTrials":241,"cells":7958},{"EARLY_PHASE1":7959,"PHASE1":7961,"PHASE2":7963,"PHASE3":7969,"PHASE4":7971,"NA":7973},{"trials":7960,"activeCount":103},[],{"trials":7962,"activeCount":103},[],{"trials":7964,"activeCount":103},[7965],{"nctId":753,"briefTitle":754,"status":115,"phases":7966,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":7967,"interventions":7968},[92],[729],[63,761],{"trials":7970,"activeCount":103},[],{"trials":7972,"activeCount":103},[],{"trials":7974,"activeCount":103},[],{"intervention":2404,"totalTrials":241,"cells":7976},{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7981,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7978,"activeCount":103},[],{"trials":7980,"activeCount":103},[],{"trials":7982,"activeCount":103},[7983],{"nctId":2397,"briefTitle":2398,"status":211,"phases":7984,"primaryCompletion":2400,"completion":2401,"start":1273,"enrollment":1044,"conditions":7985,"interventions":7986},[91,92],[1251],[2404,277,221],{"trials":7988,"activeCount":103},[],{"trials":7990,"activeCount":103},[],{"trials":7992,"activeCount":103},[],{"intervention":7994,"totalTrials":241,"cells":7995},"Iodine I 131 Tositumomab",{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8010,"PHASE4":8012,"NA":8014},{"trials":7997,"activeCount":103},[],{"trials":7999,"activeCount":103},[],{"trials":8001,"activeCount":103},[8002],{"nctId":8003,"briefTitle":8004,"status":115,"phases":8005,"primaryCompletion":3473,"completion":8006,"start":8007,"enrollment":713,"conditions":8008,"interventions":8009},"NCT00135200","Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma",[92],"2024-09-04","2005-08",[1486],[7994],{"trials":8011,"activeCount":103},[],{"trials":8013,"activeCount":103},[],{"trials":8015,"activeCount":103},[],{"intervention":8017,"totalTrials":241,"cells":8018},"Romidepsin",{"EARLY_PHASE1":8019,"PHASE1":8021,"PHASE2":8023,"PHASE3":8034,"PHASE4":8036,"NA":8038},{"trials":8020,"activeCount":103},[],{"trials":8022,"activeCount":103},[],{"trials":8024,"activeCount":103},[8025],{"nctId":8026,"briefTitle":8027,"status":211,"phases":8028,"primaryCompletion":8029,"completion":8029,"start":8030,"enrollment":1209,"conditions":8031,"interventions":8032},"NCT03547700","Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)",[91,92],"2020-08-27","2018-09-26",[1633],[8017,8033],"Ixazomib",{"trials":8035,"activeCount":103},[],{"trials":8037,"activeCount":103},[],{"trials":8039,"activeCount":103},[],{"intervention":8033,"totalTrials":241,"cells":8041},{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8046,"PHASE3":8052,"PHASE4":8054,"NA":8056},{"trials":8043,"activeCount":103},[],{"trials":8045,"activeCount":103},[],{"trials":8047,"activeCount":103},[8048],{"nctId":8026,"briefTitle":8027,"status":211,"phases":8049,"primaryCompletion":8029,"completion":8029,"start":8030,"enrollment":1209,"conditions":8050,"interventions":8051},[91,92],[1633],[8017,8033],{"trials":8053,"activeCount":103},[],{"trials":8055,"activeCount":103},[],{"trials":8057,"activeCount":103},[],{"intervention":8059,"totalTrials":241,"cells":8060},"Alpha-1-Antitrypsin",{"EARLY_PHASE1":8061,"PHASE1":8063,"PHASE2":8065,"PHASE3":8074,"PHASE4":8076,"NA":8078},{"trials":8062,"activeCount":103},[],{"trials":8064,"activeCount":103},[],{"trials":8066,"activeCount":103},[8067],{"nctId":8068,"briefTitle":8069,"status":115,"phases":8070,"primaryCompletion":1646,"completion":8071,"start":486,"enrollment":557,"conditions":8072,"interventions":8073},"NCT01700036","A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease",[92],"2018-10-26",[1402],[8059],{"trials":8075,"activeCount":103},[],{"trials":8077,"activeCount":103},[],{"trials":8079,"activeCount":103},[],{"intervention":8081,"totalTrials":241,"cells":8082},"PEG-IFN-a2b",{"EARLY_PHASE1":8083,"PHASE1":8085,"PHASE2":8087,"PHASE3":8095,"PHASE4":8097,"NA":8099},{"trials":8084,"activeCount":103},[],{"trials":8086,"activeCount":103},[],{"trials":8088,"activeCount":103},[8089],{"nctId":8090,"briefTitle":8091,"status":211,"phases":8092,"primaryCompletion":213,"completion":3401,"start":4599,"enrollment":1569,"conditions":8093,"interventions":8094},"NCT00573378","Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia",[92],[6046],[8081],{"trials":8096,"activeCount":103},[],{"trials":8098,"activeCount":103},[],{"trials":8100,"activeCount":103},[],{"intervention":1393,"totalTrials":241,"cells":8102},{"EARLY_PHASE1":8103,"PHASE1":8105,"PHASE2":8107,"PHASE3":8113,"PHASE4":8115,"NA":8117},{"trials":8104,"activeCount":103},[],{"trials":8106,"activeCount":103},[],{"trials":8108,"activeCount":103},[8109],{"nctId":1385,"briefTitle":1386,"status":115,"phases":8110,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":8111,"interventions":8112},[91,92],[716],[1393,850,851],{"trials":8114,"activeCount":103},[],{"trials":8116,"activeCount":103},[],{"trials":8118,"activeCount":103},[],{"intervention":8120,"totalTrials":241,"cells":8121},"Pevonedistat",{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8126,"PHASE3":8136,"PHASE4":8138,"NA":8140},{"trials":8123,"activeCount":103},[],{"trials":8125,"activeCount":103},[],{"trials":8127,"activeCount":103},[8128],{"nctId":8129,"briefTitle":8130,"status":211,"phases":8131,"primaryCompletion":8132,"completion":8132,"start":8133,"enrollment":557,"conditions":8134,"interventions":8135},"NCT03228186","Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer",[92],"2021-11-04","2018-03-05",[791],[8120,1141],{"trials":8137,"activeCount":103},[],{"trials":8139,"activeCount":103},[],{"trials":8141,"activeCount":103},[],{"intervention":8143,"totalTrials":241,"cells":8144},"amifostine trihydrate",{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8149,"PHASE3":8159,"PHASE4":8161,"NA":8163},{"trials":8146,"activeCount":103},[],{"trials":8148,"activeCount":103},[],{"trials":8150,"activeCount":103},[8151],{"nctId":8152,"briefTitle":8153,"status":115,"phases":8154,"primaryCompletion":5528,"completion":7879,"start":8155,"conditions":8156,"interventions":8157},"NCT00005598","Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome",[92],"2000-10",[715],[8143,8158],"azacitidine",{"trials":8160,"activeCount":103},[],{"trials":8162,"activeCount":103},[],{"trials":8164,"activeCount":103},[],{"intervention":8158,"totalTrials":241,"cells":8166},{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8177,"PHASE4":8179,"NA":8181},{"trials":8168,"activeCount":103},[],{"trials":8170,"activeCount":103},[],{"trials":8172,"activeCount":103},[8173],{"nctId":8152,"briefTitle":8153,"status":115,"phases":8174,"primaryCompletion":5528,"completion":7879,"start":8155,"conditions":8175,"interventions":8176},[92],[715],[8143,8158],{"trials":8178,"activeCount":103},[],{"trials":8180,"activeCount":103},[],{"trials":8182,"activeCount":103},[],{"intervention":8184,"totalTrials":241,"cells":8185},"Somatropin",{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8199,"PHASE4":8201,"NA":8203},{"trials":8187,"activeCount":103},[],{"trials":8189,"activeCount":103},[],{"trials":8191,"activeCount":103},[8192],{"nctId":8193,"briefTitle":8194,"status":115,"phases":8195,"primaryCompletion":1645,"completion":1645,"start":7554,"enrollment":451,"conditions":8196,"interventions":8198},"NCT02420353","Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears",[92],[8197],"Rupture of Anterior Cruciate Ligament",[8184],{"trials":8200,"activeCount":103},[],{"trials":8202,"activeCount":103},[],{"trials":8204,"activeCount":103},[],{"intervention":8206,"totalTrials":241,"cells":8207},"Devimistat",{"EARLY_PHASE1":8208,"PHASE1":8210,"PHASE2":8212,"PHASE3":8223,"PHASE4":8225,"NA":8227},{"trials":8209,"activeCount":103},[],{"trials":8211,"activeCount":103},[],{"trials":8213,"activeCount":103},[8214],{"nctId":8215,"briefTitle":8216,"status":281,"phases":8217,"primaryCompletion":1082,"completion":1082,"start":8218,"enrollment":103,"conditions":8219,"interventions":8221},"NCT05926206","Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas",[91,92],"2023-07",[8220],"Metastatic Pancreatic Adenocarcinoma",[8206,8222],"Modified FOLFIRINOX",{"trials":8224,"activeCount":103},[],{"trials":8226,"activeCount":103},[],{"trials":8228,"activeCount":103},[],{"intervention":8222,"totalTrials":241,"cells":8230},{"EARLY_PHASE1":8231,"PHASE1":8233,"PHASE2":8235,"PHASE3":8241,"PHASE4":8243,"NA":8245},{"trials":8232,"activeCount":103},[],{"trials":8234,"activeCount":103},[],{"trials":8236,"activeCount":103},[8237],{"nctId":8215,"briefTitle":8216,"status":281,"phases":8238,"primaryCompletion":1082,"completion":1082,"start":8218,"enrollment":103,"conditions":8239,"interventions":8240},[91,92],[8220],[8206,8222],{"trials":8242,"activeCount":103},[],{"trials":8244,"activeCount":103},[],{"trials":8246,"activeCount":103},[],{"intervention":8248,"totalTrials":241,"cells":8249},"Cannabidiol",{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8254,"PHASE3":8265,"PHASE4":8267,"NA":8269},{"trials":8251,"activeCount":103},[],{"trials":8253,"activeCount":103},[],{"trials":8255,"activeCount":103},[8256],{"nctId":8257,"briefTitle":8258,"status":115,"phases":8259,"primaryCompletion":8260,"completion":8260,"start":8261,"enrollment":557,"conditions":8262,"interventions":8264},"NCT04754399","Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",[92],"2023-10-10","2021-04-16",[8263,19],"Arthralgia",[8248],{"trials":8266,"activeCount":103},[],{"trials":8268,"activeCount":103},[],{"trials":8270,"activeCount":103},[],{"intervention":8272,"totalTrials":241,"cells":8273},"Teriparatide",{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8278,"PHASE3":8289,"PHASE4":8291,"NA":8293},{"trials":8275,"activeCount":103},[],{"trials":8277,"activeCount":103},[],{"trials":8279,"activeCount":103},[8280],{"nctId":8281,"briefTitle":8282,"status":211,"phases":8283,"primaryCompletion":8284,"completion":7093,"start":8285,"enrollment":5803,"conditions":8286,"interventions":8288},"NCT01279187","The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone",[92],"2015-03","2011-02",[8287],"Implant",[8272],{"trials":8290,"activeCount":103},[],{"trials":8292,"activeCount":103},[],{"trials":8294,"activeCount":103},[],{"intervention":8296,"totalTrials":241,"cells":8297},"Ginger Root Extract",{"EARLY_PHASE1":8298,"PHASE1":8300,"PHASE2":8302,"PHASE3":8311,"PHASE4":8313,"NA":8315},{"trials":8299,"activeCount":103},[],{"trials":8301,"activeCount":103},[],{"trials":8303,"activeCount":103},[8304],{"nctId":8305,"briefTitle":8306,"status":115,"phases":8307,"primaryCompletion":8308,"completion":5986,"start":1568,"enrollment":404,"conditions":8309,"interventions":8310},"NCT01344538","Ginger for Colorectal Cancer Prevention",[92],"2011-05",[5657],[8296],{"trials":8312,"activeCount":103},[],{"trials":8314,"activeCount":103},[],{"trials":8316,"activeCount":103},[],{"intervention":8318,"totalTrials":241,"cells":8319},"FOLFIRINOX",{"EARLY_PHASE1":8320,"PHASE1":8322,"PHASE2":8324,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8321,"activeCount":103},[],{"trials":8323,"activeCount":103},[],{"trials":8325,"activeCount":103},[8326],{"nctId":8327,"briefTitle":8328,"status":115,"phases":8329,"primaryCompletion":8330,"completion":8331,"start":6155,"enrollment":738,"conditions":8332,"interventions":8333},"NCT01661088","A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients",[92],"2017-08-10","2019-08-30",[2374],[8318],{"trials":8335,"activeCount":103},[],{"trials":8337,"activeCount":103},[],{"trials":8339,"activeCount":103},[],{"intervention":8341,"totalTrials":241,"cells":8342},"Ultrasound guided platelet rich plasma",{"EARLY_PHASE1":8343,"PHASE1":8345,"PHASE2":8347,"PHASE3":8358,"PHASE4":8360,"NA":8362},{"trials":8344,"activeCount":103},[],{"trials":8346,"activeCount":103},[],{"trials":8348,"activeCount":103},[8349],{"nctId":8350,"briefTitle":8351,"status":115,"phases":8352,"primaryCompletion":3303,"completion":3303,"start":8353,"enrollment":404,"conditions":8354,"interventions":8357},"NCT01600326","A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection",[92],"2010-07",[8355,8356],"Tendinosis","Tendinitis",[8341],{"trials":8359,"activeCount":103},[],{"trials":8361,"activeCount":103},[],{"trials":8363,"activeCount":103},[],{"intervention":8365,"totalTrials":241,"cells":8366},"Neoadjuvant Cisplatin and Gemcitabine",{"EARLY_PHASE1":8367,"PHASE1":8369,"PHASE2":8371,"PHASE3":8379,"PHASE4":8381,"NA":8383},{"trials":8368,"activeCount":103},[],{"trials":8370,"activeCount":103},[],{"trials":8372,"activeCount":103},[8373],{"nctId":8374,"briefTitle":8375,"status":211,"phases":8376,"primaryCompletion":5280,"completion":5280,"start":2953,"enrollment":241,"conditions":8377,"interventions":8378},"NCT01663285","Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)",[92],[5608,275],[8365],{"trials":8380,"activeCount":103},[],{"trials":8382,"activeCount":103},[],{"trials":8384,"activeCount":103},[],{"intervention":8386,"totalTrials":241,"cells":8387},"Citalopram 20mg",{"EARLY_PHASE1":8388,"PHASE1":8390,"PHASE2":8392,"PHASE3":8402,"PHASE4":8404,"NA":8406},{"trials":8389,"activeCount":103},[],{"trials":8391,"activeCount":103},[],{"trials":8393,"activeCount":103},[8394],{"nctId":8395,"briefTitle":8396,"status":115,"phases":8397,"primaryCompletion":8398,"completion":8398,"start":6702,"enrollment":8399,"conditions":8400,"interventions":8401},"NCT04497168","Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease",[92],"2026-03-02",58,[4101],[8386],{"trials":8403,"activeCount":103},[],{"trials":8405,"activeCount":103},[],{"trials":8407,"activeCount":103},[],{"intervention":8409,"totalTrials":241,"cells":8410},"eflornithine",{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8427,"PHASE4":8429,"NA":8431},{"trials":8412,"activeCount":103},[],{"trials":8414,"activeCount":103},[],{"trials":8416,"activeCount":103},[8417],{"nctId":8418,"briefTitle":8419,"status":115,"phases":8420,"primaryCompletion":8421,"completion":8422,"start":8423,"enrollment":8424,"conditions":8425,"interventions":8426},"NCT00003076","Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus",[92],"2002-06","2005-10","1995-10",152,[264],[8409],{"trials":8428,"activeCount":103},[],{"trials":8430,"activeCount":103},[],{"trials":8432,"activeCount":103},[],{"intervention":6048,"totalTrials":241,"cells":8434},{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8436,"activeCount":103},[],{"trials":8438,"activeCount":103},[],{"trials":8440,"activeCount":103},[8441],{"nctId":6040,"briefTitle":6041,"status":281,"phases":8442,"primaryCompletion":283,"completion":6043,"start":6044,"enrollment":103,"conditions":8443,"interventions":8444},[91,92],[6046],[6048,6023],{"trials":8446,"activeCount":103},[],{"trials":8448,"activeCount":103},[],{"trials":8450,"activeCount":103},[],{"intervention":8452,"totalTrials":241,"cells":8453},"Functional Magnetic Resonance Imaging (fMRI) with propofol",{"EARLY_PHASE1":8454,"PHASE1":8456,"PHASE2":8458,"PHASE3":8470,"PHASE4":8472,"NA":8474},{"trials":8455,"activeCount":103},[],{"trials":8457,"activeCount":103},[],{"trials":8459,"activeCount":103},[8460],{"nctId":8461,"briefTitle":8462,"status":115,"phases":8463,"primaryCompletion":8464,"completion":8464,"start":8465,"enrollment":758,"conditions":8466,"interventions":8469},"NCT06403852","Investigating Near-Threshold Perception During Anesthetic Sedation",[92],"2025-10-03","2024-05-10",[4388,8467,8468],"Anesthesia","fMRI",[8452],{"trials":8471,"activeCount":103},[],{"trials":8473,"activeCount":103},[],{"trials":8475,"activeCount":103},[],{"intervention":8477,"totalTrials":241,"cells":8478},"MLN9708",{"EARLY_PHASE1":8479,"PHASE1":8481,"PHASE2":8483,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8480,"activeCount":103},[],{"trials":8482,"activeCount":103},[],{"trials":8484,"activeCount":103},[8485],{"nctId":8486,"briefTitle":8487,"status":115,"phases":8488,"primaryCompletion":1646,"completion":3761,"start":2984,"enrollment":200,"conditions":8489,"interventions":8491},"NCT02158975","Open-label, Phase II Study of MLN9708 in Patients With Relapsed\u002FRefractory Cutaneous and Peripheral T-cell Lymphomas",[92],[8490],"Lymphoma, T-Cell",[8477],{"trials":8493,"activeCount":103},[],{"trials":8495,"activeCount":103},[],{"trials":8497,"activeCount":103},[],{"intervention":8499,"totalTrials":241,"cells":8500},"Mitomycin C",{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8505,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8502,"activeCount":103},[],{"trials":8504,"activeCount":103},[],{"trials":8506,"activeCount":103},[8507],{"nctId":8508,"briefTitle":8509,"status":211,"phases":8510,"primaryCompletion":261,"completion":8511,"start":270,"enrollment":200,"conditions":8512,"interventions":8513},"NCT00271011","A Study of Mitomycin C, Irinotecan, and Cetuximab",[92],"2009-07",[5657],[8499,2361,8514],"Irinotecan.",{"trials":8516,"activeCount":103},[],{"trials":8518,"activeCount":103},[],{"trials":8520,"activeCount":103},[],{"intervention":8514,"totalTrials":241,"cells":8522},{"EARLY_PHASE1":8523,"PHASE1":8525,"PHASE2":8527,"PHASE3":8533,"PHASE4":8535,"NA":8537},{"trials":8524,"activeCount":103},[],{"trials":8526,"activeCount":103},[],{"trials":8528,"activeCount":103},[8529],{"nctId":8508,"briefTitle":8509,"status":211,"phases":8530,"primaryCompletion":261,"completion":8511,"start":270,"enrollment":200,"conditions":8531,"interventions":8532},[92],[5657],[8499,2361,8514],{"trials":8534,"activeCount":103},[],{"trials":8536,"activeCount":103},[],{"trials":8538,"activeCount":103},[],{"intervention":8540,"totalTrials":241,"cells":8541},"Dialysate Magnesium",{"EARLY_PHASE1":8542,"PHASE1":8544,"PHASE2":8546,"PHASE3":8557,"PHASE4":8559,"NA":8561},{"trials":8543,"activeCount":103},[],{"trials":8545,"activeCount":103},[],{"trials":8547,"activeCount":103},[8548],{"nctId":8549,"briefTitle":8550,"status":115,"phases":8551,"primaryCompletion":296,"completion":2371,"start":8552,"enrollment":738,"conditions":8553,"interventions":8556},"NCT00242164","Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis",[92],"2005-11",[8554,8555],"Chronic Kidney Disease","Arrhythmia",[8540],{"trials":8558,"activeCount":103},[],{"trials":8560,"activeCount":103},[],{"trials":8562,"activeCount":103},[],{"intervention":8564,"totalTrials":241,"cells":8565},"0.4% Retinol Cream",{"EARLY_PHASE1":8566,"PHASE1":8568,"PHASE2":8570,"PHASE3":8581,"PHASE4":8583,"NA":8585},{"trials":8567,"activeCount":103},[],{"trials":8569,"activeCount":103},[],{"trials":8571,"activeCount":103},[8572],{"nctId":8573,"briefTitle":8574,"status":115,"phases":8575,"completion":8576,"start":307,"enrollment":20,"conditions":8577,"interventions":8580},"NCT00272610","Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin",[92],"2002-02",[8578,8579],"Skin Aging","Purpura",[8564],{"trials":8582,"activeCount":103},[],{"trials":8584,"activeCount":103},[],{"trials":8586,"activeCount":103},[],{"intervention":8588,"totalTrials":241,"cells":8589},"carbidopa",{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8594,"PHASE3":8604,"PHASE4":8606,"NA":8608},{"trials":8591,"activeCount":103},[],{"trials":8593,"activeCount":103},[],{"trials":8595,"activeCount":103},[8596],{"nctId":8597,"briefTitle":8598,"status":115,"phases":8599,"primaryCompletion":8600,"completion":8600,"start":8601,"enrollment":3208,"conditions":8602,"interventions":8603},"NCT04325503","Neurobiological Drivers of Mobility Resilience: The Dopaminergic System",[91,92],"2022-06-30","2021-02-08",[5747],[8588],{"trials":8605,"activeCount":103},[],{"trials":8607,"activeCount":103},[],{"trials":8609,"activeCount":103},[],{"intervention":8611,"totalTrials":241,"cells":8612},"Hormone therapy or chemotherapy",{"EARLY_PHASE1":8613,"PHASE1":8615,"PHASE2":8617,"PHASE3":8627,"PHASE4":8629,"NA":8631},{"trials":8614,"activeCount":103},[],{"trials":8616,"activeCount":103},[],{"trials":8618,"activeCount":103},[8619],{"nctId":8620,"briefTitle":8621,"status":115,"phases":8622,"primaryCompletion":8623,"completion":8623,"start":8624,"enrollment":3208,"conditions":8625,"interventions":8626},"NCT03556904","FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)",[92],"2023-07-28","2018-12-10",[25],[8611],{"trials":8628,"activeCount":103},[],{"trials":8630,"activeCount":103},[],{"trials":8632,"activeCount":103},[],{"intervention":6075,"totalTrials":241,"cells":8634},{"EARLY_PHASE1":8635,"PHASE1":8637,"PHASE2":8639,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8636,"activeCount":103},[],{"trials":8638,"activeCount":103},[],{"trials":8640,"activeCount":103},[8641],{"nctId":6068,"briefTitle":6069,"status":281,"phases":8642,"primaryCompletion":6071,"completion":6071,"start":6072,"enrollment":103,"conditions":8643,"interventions":8644},[92],[903,5233],[6075,5963],{"trials":8646,"activeCount":103},[],{"trials":8648,"activeCount":103},[],{"trials":8650,"activeCount":103},[],{"intervention":8652,"totalTrials":241,"cells":8653},"Fludarabine\u002FBusulfan x 4 days",{"EARLY_PHASE1":8654,"PHASE1":8656,"PHASE2":8658,"PHASE3":8667,"PHASE4":8669,"NA":8671},{"trials":8655,"activeCount":103},[],{"trials":8657,"activeCount":103},[],{"trials":8659,"activeCount":103},[8660],{"nctId":8661,"briefTitle":8662,"status":211,"phases":8663,"primaryCompletion":5986,"completion":3035,"start":3597,"enrollment":336,"conditions":8664,"interventions":8666},"NCT00615589","Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen",[92],[1486,8665],"Plasma Cell Leukemia",[8652],{"trials":8668,"activeCount":103},[],{"trials":8670,"activeCount":103},[],{"trials":8672,"activeCount":103},[],{"intervention":8674,"totalTrials":241,"cells":8675},"Lamivudine",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8680,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8677,"activeCount":103},[],{"trials":8679,"activeCount":103},[],{"trials":8681,"activeCount":103},[8682],{"nctId":8683,"briefTitle":8684,"status":281,"phases":8685,"primaryCompletion":8686,"start":3401,"enrollment":103,"conditions":8687,"interventions":8689},"NCT01528865","Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma",[91,92],"2017-08",[8688],"Lymphoma",[8674,8690],"Tenofovir disoproxil fumarate",{"trials":8692,"activeCount":103},[],{"trials":8694,"activeCount":103},[],{"trials":8696,"activeCount":103},[],{"intervention":8690,"totalTrials":241,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":103},[],{"trials":8702,"activeCount":103},[],{"trials":8704,"activeCount":103},[8705],{"nctId":8683,"briefTitle":8684,"status":281,"phases":8706,"primaryCompletion":8686,"start":3401,"enrollment":103,"conditions":8707,"interventions":8708},[91,92],[8688],[8674,8690],{"trials":8710,"activeCount":103},[],{"trials":8712,"activeCount":103},[],{"trials":8714,"activeCount":103},[],{"intervention":1549,"totalTrials":241,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8721,"PHASE3":8727,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":103},[],{"trials":8720,"activeCount":103},[],{"trials":8722,"activeCount":103},[8723],{"nctId":1541,"briefTitle":1542,"status":281,"phases":8724,"primaryCompletion":1544,"completion":1544,"start":1545,"enrollment":103,"conditions":8725,"interventions":8726},[91,92],[1547],[1549,1468],{"trials":8728,"activeCount":103},[],{"trials":8730,"activeCount":103},[],{"trials":8732,"activeCount":103},[],{"intervention":8734,"totalTrials":241,"cells":8735},"ginger extract",{"EARLY_PHASE1":8736,"PHASE1":8738,"PHASE2":8740,"PHASE3":8752,"PHASE4":8754,"NA":8756},{"trials":8737,"activeCount":103},[],{"trials":8739,"activeCount":103},[],{"trials":8741,"activeCount":103},[8742],{"nctId":8743,"briefTitle":8744,"status":115,"phases":8745,"primaryCompletion":7028,"start":8746,"enrollment":8747,"conditions":8748,"interventions":8751},"NCT00064272","UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer",[92],"2003-05",180,[8749,8750],"Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific",[8734],{"trials":8753,"activeCount":103},[],{"trials":8755,"activeCount":103},[],{"trials":8757,"activeCount":103},[],{"intervention":2415,"totalTrials":241,"cells":8759},{"EARLY_PHASE1":8760,"PHASE1":8762,"PHASE2":8764,"PHASE3":8770,"PHASE4":8772,"NA":8774},{"trials":8761,"activeCount":103},[],{"trials":8763,"activeCount":103},[],{"trials":8765,"activeCount":103},[8766],{"nctId":2406,"briefTitle":2407,"status":115,"phases":8767,"primaryCompletion":1400,"completion":2409,"start":2410,"enrollment":2411,"conditions":8768,"interventions":8769},[92],[2374,2413],[277,2415,221],{"trials":8771,"activeCount":103},[],{"trials":8773,"activeCount":103},[],{"trials":8775,"activeCount":103},[],{"intervention":8777,"totalTrials":241,"cells":8778},"Ixmyelocel-T",{"EARLY_PHASE1":8779,"PHASE1":8781,"PHASE2":8783,"PHASE3":8794,"PHASE4":8796,"NA":8798},{"trials":8780,"activeCount":103},[],{"trials":8782,"activeCount":103},[],{"trials":8784,"activeCount":103},[8785],{"nctId":8786,"briefTitle":8787,"status":115,"phases":8788,"primaryCompletion":1683,"completion":1683,"start":3232,"enrollment":8789,"conditions":8790,"interventions":8793},"NCT01616953","Cell Therapy for Craniofacial Bone Defects",[91,92],18,[8791,8792],"Cleft Palate","Trauma",[8777],{"trials":8795,"activeCount":103},[],{"trials":8797,"activeCount":103},[],{"trials":8799,"activeCount":103},[],{"intervention":8801,"totalTrials":241,"cells":8802},"Lapatinib",{"EARLY_PHASE1":8803,"PHASE1":8805,"PHASE2":8807,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8804,"activeCount":103},[],{"trials":8806,"activeCount":103},[],{"trials":8808,"activeCount":103},[8809],{"nctId":8810,"briefTitle":8811,"status":211,"phases":8812,"primaryCompletion":296,"completion":4599,"start":8422,"enrollment":937,"conditions":8813,"interventions":8815},"NCT00239200","Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus",[92],[8814],"Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus",[8801],{"trials":8817,"activeCount":103},[],{"trials":8819,"activeCount":103},[],{"trials":8821,"activeCount":103},[],{"intervention":8823,"totalTrials":241,"cells":8824},"Palonosetron",{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8829,"PHASE3":8841,"PHASE4":8843,"NA":8845},{"trials":8826,"activeCount":103},[],{"trials":8828,"activeCount":103},[],{"trials":8830,"activeCount":103},[8831],{"nctId":8832,"briefTitle":8833,"status":211,"phases":8834,"primaryCompletion":5360,"completion":5360,"start":8835,"enrollment":99,"conditions":8836,"interventions":8840},"NCT00982995","Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients",[92],"2010-11",[8837,8838,8839],"Nausea","Vomiting","Terminally Ill",[8823],{"trials":8842,"activeCount":103},[],{"trials":8844,"activeCount":103},[],{"trials":8846,"activeCount":103},[],{"intervention":8848,"totalTrials":151,"cells":8849},"GI heptapeptide",{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8869,"PHASE3":8871,"PHASE4":8873,"NA":8875},{"trials":8851,"activeCount":103},[],{"trials":8853,"activeCount":103},[8854,8861],{"nctId":8855,"briefTitle":8856,"status":115,"phases":8857,"primaryCompletion":6044,"completion":6044,"start":3854,"enrollment":641,"conditions":8858,"interventions":8860},"NCT01630798","A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract",[91],[8859],"Barrett's Esophagus",[8848],{"nctId":8862,"briefTitle":8863,"status":115,"phases":8864,"primaryCompletion":3830,"completion":3830,"start":8285,"enrollment":738,"conditions":8865,"interventions":8868},"NCT01391208","Esophageal Protocol for Detection of Neoplasia in the Digestive Tract",[91],[8866,8867],"Barrett Esophagus","Esophageal Adenocarcinoma",[8848],{"trials":8870,"activeCount":103},[],{"trials":8872,"activeCount":103},[],{"trials":8874,"activeCount":103},[],{"trials":8876,"activeCount":103},[],{"intervention":8878,"totalTrials":241,"cells":8879},"Alemtuzumab",{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8893,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8881,"activeCount":103},[],{"trials":8883,"activeCount":103},[8884],{"nctId":8885,"briefTitle":8886,"status":211,"phases":8887,"primaryCompletion":213,"completion":213,"start":2356,"enrollment":99,"conditions":8888,"interventions":8892},"NCT00637390","A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian\u002FPrimary Peritoneal Cancer.",[91],[8889,8890,8891],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer",[8878],{"trials":8894,"activeCount":103},[],{"trials":8896,"activeCount":103},[],{"trials":8898,"activeCount":103},[],{"trials":8900,"activeCount":103},[],{"intervention":8902,"totalTrials":241,"cells":8903},"Regadenoson",{"EARLY_PHASE1":8904,"PHASE1":8906,"PHASE2":8916,"PHASE3":8918,"PHASE4":8920,"NA":8922},{"trials":8905,"activeCount":103},[],{"trials":8907,"activeCount":103},[8908],{"nctId":8909,"briefTitle":8910,"status":115,"phases":8911,"primaryCompletion":8912,"completion":8912,"start":4638,"enrollment":1994,"conditions":8913,"interventions":8915},"NCT01433705","Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers",[91],"2018-01-19",[8914],"Heart Disease",[8902],{"trials":8917,"activeCount":103},[],{"trials":8919,"activeCount":103},[],{"trials":8921,"activeCount":103},[],{"trials":8923,"activeCount":103},[],{"intervention":8925,"totalTrials":241,"cells":8926},"Intravenous (IV) hydrocortisone",{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8941,"PHASE3":8943,"PHASE4":8945,"NA":8947},{"trials":8928,"activeCount":103},[],{"trials":8930,"activeCount":103},[8931],{"nctId":8932,"briefTitle":8933,"status":115,"phases":8934,"primaryCompletion":8935,"completion":8935,"start":8936,"enrollment":8937,"conditions":8938,"interventions":8940},"NCT04852458","Glucocorticoid Administration After Traumatic Birth",[91],"2022-11-03","2021-05-21",133,[8939],"Traumatic Birth",[8925],{"trials":8942,"activeCount":103},[],{"trials":8944,"activeCount":103},[],{"trials":8946,"activeCount":103},[],{"trials":8948,"activeCount":103},[],{"intervention":8950,"totalTrials":241,"cells":8951},"Dendritic cell vaccination",{"EARLY_PHASE1":8952,"PHASE1":8954,"PHASE2":8964,"PHASE3":8966,"PHASE4":8968,"NA":8970},{"trials":8953,"activeCount":103},[],{"trials":8955,"activeCount":103},[8956],{"nctId":8957,"briefTitle":8958,"status":211,"phases":8959,"primaryCompletion":859,"completion":7946,"start":8960,"enrollment":804,"conditions":8961,"interventions":8963},"NCT00843830","A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma",[91],"2006-10",[8962],"Metastatic Pancreatic Carcinoma",[8950],{"trials":8965,"activeCount":103},[],{"trials":8967,"activeCount":103},[],{"trials":8969,"activeCount":103},[],{"trials":8971,"activeCount":103},[],{"intervention":8973,"totalTrials":241,"cells":8974},"Talazoparib",{"EARLY_PHASE1":8975,"PHASE1":8977,"PHASE2":8992,"PHASE3":8994,"PHASE4":8996,"NA":8998},{"trials":8976,"activeCount":103},[],{"trials":8978,"activeCount":103},[8979],{"nctId":8980,"briefTitle":8981,"status":115,"phases":8982,"primaryCompletion":8983,"completion":8984,"start":8985,"enrollment":251,"conditions":8986,"interventions":8990},"NCT04703920","Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",[91],"2024-12-01","2025-01-02","2021-03-04",[6183,8987,8988,8989],"Metastatic Castration-resistant Prostate Cancer","Metastatic Ovarian Carcinoma","Metastic or Unresectable Pancreatic Adenocarcinoma",[8973,8991],"Belinostat",{"trials":8993,"activeCount":103},[],{"trials":8995,"activeCount":103},[],{"trials":8997,"activeCount":103},[],{"trials":8999,"activeCount":103},[],{"intervention":8991,"totalTrials":241,"cells":9001},{"EARLY_PHASE1":9002,"PHASE1":9004,"PHASE2":9010,"PHASE3":9012,"PHASE4":9014,"NA":9016},{"trials":9003,"activeCount":103},[],{"trials":9005,"activeCount":103},[9006],{"nctId":8980,"briefTitle":8981,"status":115,"phases":9007,"primaryCompletion":8983,"completion":8984,"start":8985,"enrollment":251,"conditions":9008,"interventions":9009},[91],[6183,8987,8988,8989],[8973,8991],{"trials":9011,"activeCount":103},[],{"trials":9013,"activeCount":103},[],{"trials":9015,"activeCount":103},[],{"trials":9017,"activeCount":103},[],{"intervention":9019,"totalTrials":241,"cells":9020},"Peptide application",{"EARLY_PHASE1":9021,"PHASE1":9023,"PHASE2":9032,"PHASE3":9034,"PHASE4":9036,"NA":9038},{"trials":9022,"activeCount":103},[],{"trials":9024,"activeCount":103},[9025],{"nctId":9026,"briefTitle":9027,"status":115,"phases":9028,"primaryCompletion":214,"completion":3473,"start":3353,"enrollment":738,"conditions":9029,"interventions":9031},"NCT01722058","A Phase I In-Vivo Peptide Applied in the Right Colon",[91],[9030],"Colon Lesions",[9019],{"trials":9033,"activeCount":103},[],{"trials":9035,"activeCount":103},[],{"trials":9037,"activeCount":103},[],{"trials":9039,"activeCount":103},[],{"intervention":9041,"totalTrials":241,"cells":9042},"Zinc Acetate",{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9054,"PHASE3":9056,"PHASE4":9058,"NA":9060},{"trials":9044,"activeCount":103},[],{"trials":9046,"activeCount":103},[9047],{"nctId":9048,"briefTitle":9049,"status":115,"phases":9050,"primaryCompletion":6155,"completion":6155,"start":4703,"enrollment":1362,"conditions":9051,"interventions":9053},"NCT00696410","The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy",[91],[3281,9052],"Cardiomyopathies",[9041],{"trials":9055,"activeCount":103},[],{"trials":9057,"activeCount":103},[],{"trials":9059,"activeCount":103},[],{"trials":9061,"activeCount":103},[],{"intervention":2446,"totalTrials":241,"cells":9063},{"EARLY_PHASE1":9064,"PHASE1":9066,"PHASE2":9072,"PHASE3":9074,"PHASE4":9076,"NA":9078},{"trials":9065,"activeCount":103},[],{"trials":9067,"activeCount":103},[9068],{"nctId":2437,"briefTitle":2438,"status":115,"phases":9069,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":9070,"interventions":9071},[91],[2444],[2446,1489,2447,2448],{"trials":9073,"activeCount":103},[],{"trials":9075,"activeCount":103},[],{"trials":9077,"activeCount":103},[],{"trials":9079,"activeCount":103},[],{"intervention":2447,"totalTrials":241,"cells":9081},{"EARLY_PHASE1":9082,"PHASE1":9084,"PHASE2":9090,"PHASE3":9092,"PHASE4":9094,"NA":9096},{"trials":9083,"activeCount":103},[],{"trials":9085,"activeCount":103},[9086],{"nctId":2437,"briefTitle":2438,"status":115,"phases":9087,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":9088,"interventions":9089},[91],[2444],[2446,1489,2447,2448],{"trials":9091,"activeCount":103},[],{"trials":9093,"activeCount":103},[],{"trials":9095,"activeCount":103},[],{"trials":9097,"activeCount":103},[],{"intervention":2448,"totalTrials":241,"cells":9099},{"EARLY_PHASE1":9100,"PHASE1":9102,"PHASE2":9108,"PHASE3":9110,"PHASE4":9112,"NA":9114},{"trials":9101,"activeCount":103},[],{"trials":9103,"activeCount":103},[9104],{"nctId":2437,"briefTitle":2438,"status":115,"phases":9105,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":9106,"interventions":9107},[91],[2444],[2446,1489,2447,2448],{"trials":9109,"activeCount":103},[],{"trials":9111,"activeCount":103},[],{"trials":9113,"activeCount":103},[],{"trials":9115,"activeCount":103},[],{"intervention":9117,"totalTrials":241,"cells":9118},"Curosurf",{"EARLY_PHASE1":9119,"PHASE1":9121,"PHASE2":9131,"PHASE3":9133,"PHASE4":9135,"NA":9137},{"trials":9120,"activeCount":103},[],{"trials":9122,"activeCount":103},[9123],{"nctId":9124,"briefTitle":9125,"status":211,"phases":9126,"primaryCompletion":9127,"completion":9127,"start":6986,"enrollment":151,"conditions":9128,"interventions":9130},"NCT04181255","Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy",[91],"2020-06-12",[4707,9129],"Hypoplastic Left Heart Syndrome",[9117],{"trials":9132,"activeCount":103},[],{"trials":9134,"activeCount":103},[],{"trials":9136,"activeCount":103},[],{"trials":9138,"activeCount":103},[],{"intervention":9140,"totalTrials":241,"cells":9141},"Fluoride mouthwash",{"EARLY_PHASE1":9142,"PHASE1":9144,"PHASE2":9156,"PHASE3":9158,"PHASE4":9160,"NA":9162},{"trials":9143,"activeCount":103},[],{"trials":9145,"activeCount":103},[9146],{"nctId":9147,"briefTitle":9148,"status":115,"phases":9149,"primaryCompletion":9150,"completion":9150,"start":9151,"enrollment":451,"conditions":9152,"interventions":9154},"NCT04239872","Fluoride Retention in the Mouth of Older Adults",[91],"2021-04-05","2020-03-11",[9153],"Hyposalivation",[9140,9155],"Calcium and fluoride mouthwash",{"trials":9157,"activeCount":103},[],{"trials":9159,"activeCount":103},[],{"trials":9161,"activeCount":103},[],{"trials":9163,"activeCount":103},[],{"intervention":9155,"totalTrials":241,"cells":9165},{"EARLY_PHASE1":9166,"PHASE1":9168,"PHASE2":9174,"PHASE3":9176,"PHASE4":9178,"NA":9180},{"trials":9167,"activeCount":103},[],{"trials":9169,"activeCount":103},[9170],{"nctId":9147,"briefTitle":9148,"status":115,"phases":9171,"primaryCompletion":9150,"completion":9150,"start":9151,"enrollment":451,"conditions":9172,"interventions":9173},[91],[9153],[9140,9155],{"trials":9175,"activeCount":103},[],{"trials":9177,"activeCount":103},[],{"trials":9179,"activeCount":103},[],{"trials":9181,"activeCount":103},[],{"intervention":9183,"totalTrials":241,"cells":9184},"Irinotecan and Bortezomib",{"EARLY_PHASE1":9185,"PHASE1":9187,"PHASE2":9196,"PHASE3":9198,"PHASE4":9200,"NA":9202},{"trials":9186,"activeCount":103},[],{"trials":9188,"activeCount":103},[9189],{"nctId":9190,"briefTitle":9191,"status":115,"phases":9192,"primaryCompletion":3854,"completion":3854,"start":9193,"enrollment":8789,"conditions":9194,"interventions":9195},"NCT00644696","Study of Irinotecan and Bortezomib in Children With Recurrent\u002FRefractory Neuroblastoma",[91],"2008-04",[7191],[9183],{"trials":9197,"activeCount":103},[],{"trials":9199,"activeCount":103},[],{"trials":9201,"activeCount":103},[],{"trials":9203,"activeCount":103},[],{"intervention":9205,"totalTrials":241,"cells":9206},"KSP\u002FQRH dimer",{"EARLY_PHASE1":9207,"PHASE1":9209,"PHASE2":9218,"PHASE3":9220,"PHASE4":9222,"NA":9224},{"trials":9208,"activeCount":103},[],{"trials":9210,"activeCount":103},[9211],{"nctId":9212,"briefTitle":9213,"status":211,"phases":9214,"primaryCompletion":900,"completion":900,"start":9215,"enrollment":23,"conditions":9216,"interventions":9217},"NCT03852576","Phase 1B Study of KSP\u002FQRH Dimer for Detection of Neoplasia in the Esophagus",[91],"2019-05-09",[8866],[9205],{"trials":9219,"activeCount":103},[],{"trials":9221,"activeCount":103},[],{"trials":9223,"activeCount":103},[],{"trials":9225,"activeCount":103},[],{"intervention":1224,"totalTrials":241,"cells":9227},{"EARLY_PHASE1":9228,"PHASE1":9230,"PHASE2":9236,"PHASE3":9238,"PHASE4":9240,"NA":9242},{"trials":9229,"activeCount":103},[],{"trials":9231,"activeCount":103},[9232],{"nctId":1216,"briefTitle":1217,"status":211,"phases":9233,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":216,"conditions":9234,"interventions":9235},[91],[1222],[1224,255,1225],{"trials":9237,"activeCount":103},[],{"trials":9239,"activeCount":103},[],{"trials":9241,"activeCount":103},[],{"trials":9243,"activeCount":103},[],{"intervention":9245,"totalTrials":241,"cells":9246},"KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg",{"EARLY_PHASE1":9247,"PHASE1":9249,"PHASE2":9261,"PHASE3":9263,"PHASE4":9265,"NA":9267},{"trials":9248,"activeCount":103},[],{"trials":9250,"activeCount":103},[9251],{"nctId":9252,"briefTitle":9253,"status":115,"phases":9254,"primaryCompletion":9255,"completion":9255,"start":9256,"enrollment":251,"conditions":9257,"interventions":9259},"NCT03643068","Phase 1A Study of the Safety of KSP\u002FQRH Dimer",[91],"2018-10-27","2018-08-22",[9258],"Healthy Adults",[9245,9260],"KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg",{"trials":9262,"activeCount":103},[],{"trials":9264,"activeCount":103},[],{"trials":9266,"activeCount":103},[],{"trials":9268,"activeCount":103},[],{"intervention":9260,"totalTrials":241,"cells":9270},{"EARLY_PHASE1":9271,"PHASE1":9273,"PHASE2":9279,"PHASE3":9281,"PHASE4":9283,"NA":9285},{"trials":9272,"activeCount":103},[],{"trials":9274,"activeCount":103},[9275],{"nctId":9252,"briefTitle":9253,"status":115,"phases":9276,"primaryCompletion":9255,"completion":9255,"start":9256,"enrollment":251,"conditions":9277,"interventions":9278},[91],[9258],[9245,9260],{"trials":9280,"activeCount":103},[],{"trials":9282,"activeCount":103},[],{"trials":9284,"activeCount":103},[],{"trials":9286,"activeCount":103},[],{"intervention":9288,"totalTrials":241,"cells":9289},"L-arginine",{"EARLY_PHASE1":9290,"PHASE1":9292,"PHASE2":9301,"PHASE3":9303,"PHASE4":9305,"NA":9307},{"trials":9291,"activeCount":103},[],{"trials":9293,"activeCount":103},[9294],{"nctId":9295,"briefTitle":9296,"status":211,"phases":9297,"primaryCompletion":3303,"completion":3303,"start":2410,"enrollment":99,"conditions":9298,"interventions":9300},"NCT01485757","Prospective L-arginine Study",[91],[9299],"Heart Transplant",[9288],{"trials":9302,"activeCount":103},[],{"trials":9304,"activeCount":103},[],{"trials":9306,"activeCount":103},[],{"trials":9308,"activeCount":103},[],{"intervention":9310,"totalTrials":241,"cells":9311},"Quercetin",{"EARLY_PHASE1":9312,"PHASE1":9314,"PHASE2":9323,"PHASE3":9325,"PHASE4":9327,"NA":9329},{"trials":9313,"activeCount":103},[],{"trials":9315,"activeCount":103},[9316],{"nctId":9317,"briefTitle":9318,"status":115,"phases":9319,"primaryCompletion":858,"completion":858,"start":1125,"enrollment":700,"conditions":9320,"interventions":9322},"NCT01708278","Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)",[91],[9321],"Chronic Obstructive Pulmonary Disease",[9310],{"trials":9324,"activeCount":103},[],{"trials":9326,"activeCount":103},[],{"trials":9328,"activeCount":103},[],{"trials":9330,"activeCount":103},[],{"intervention":9332,"totalTrials":241,"cells":9333},"Multiplexed heptapeptides",{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9346,"PHASE3":9348,"PHASE4":9350,"NA":9352},{"trials":9335,"activeCount":103},[],{"trials":9337,"activeCount":103},[9338],{"nctId":9339,"briefTitle":9340,"status":115,"phases":9341,"primaryCompletion":9342,"completion":9342,"start":9343,"enrollment":5803,"conditions":9344,"interventions":9345},"NCT03589443","Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus",[91],"2019-02-04","2018-05-10",[8866],[9332],{"trials":9347,"activeCount":103},[],{"trials":9349,"activeCount":103},[],{"trials":9351,"activeCount":103},[],{"trials":9353,"activeCount":103},[],{"intervention":9355,"totalTrials":241,"cells":9356},"Veliparib",{"EARLY_PHASE1":9357,"PHASE1":9359,"PHASE2":9368,"PHASE3":9370,"PHASE4":9372,"NA":9374},{"trials":9358,"activeCount":103},[],{"trials":9360,"activeCount":103},[9361],{"nctId":9362,"briefTitle":9363,"status":115,"phases":9364,"primaryCompletion":1376,"completion":9365,"start":1359,"enrollment":308,"conditions":9366,"interventions":9367},"NCT01477489","Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer",[91],"2017-10",[19],[9355],{"trials":9369,"activeCount":103},[],{"trials":9371,"activeCount":103},[],{"trials":9373,"activeCount":103},[],{"trials":9375,"activeCount":103},[],{"intervention":9377,"totalTrials":241,"cells":9378},"Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L",{"EARLY_PHASE1":9379,"PHASE1":9381,"PHASE2":9393,"PHASE3":9395,"PHASE4":9397,"NA":9399},{"trials":9380,"activeCount":103},[],{"trials":9382,"activeCount":103},[9383],{"nctId":9384,"briefTitle":9385,"status":115,"phases":9386,"primaryCompletion":9387,"completion":9388,"start":1438,"enrollment":37,"conditions":9389,"interventions":9392},"NCT01811992","Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma",[91],"2019-02","2021-01",[9390,9391],"Malignant Glioma","Glioblastoma Multiforme",[9377],{"trials":9394,"activeCount":103},[],{"trials":9396,"activeCount":103},[],{"trials":9398,"activeCount":103},[],{"trials":9400,"activeCount":103},[],{"intervention":9402,"totalTrials":241,"cells":9403},"grape seed extract",{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9420,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9405,"activeCount":103},[],{"trials":9407,"activeCount":103},[9408],{"nctId":9409,"briefTitle":9410,"status":115,"phases":9411,"primaryCompletion":9412,"completion":9413,"start":213,"enrollment":394,"conditions":9414,"interventions":9419},"NCT01185067","Physiological Effects of Grape Seed Extract in Diastolic Heart Failure",[91],"2013-11-04","2014-02-24",[9415,9416,9417,30,9418],"Diastolic Heart Failure","Hypertensive Heart Disease","Heart Failure With Preserved Ejection Fraction","Oxidative Stress",[9402],{"trials":9421,"activeCount":103},[],{"trials":9423,"activeCount":103},[],{"trials":9425,"activeCount":103},[],{"trials":9427,"activeCount":103},[],{"intervention":5393,"totalTrials":241,"cells":9429},{"EARLY_PHASE1":9430,"PHASE1":9432,"PHASE2":9438,"PHASE3":9440,"PHASE4":9442,"NA":9444},{"trials":9431,"activeCount":103},[],{"trials":9433,"activeCount":103},[9434],{"nctId":5385,"briefTitle":5386,"status":115,"phases":9435,"primaryCompletion":5388,"completion":5389,"start":5390,"enrollment":1209,"conditions":9436,"interventions":9437},[91],[19],[312,5393,5394],{"trials":9439,"activeCount":103},[],{"trials":9441,"activeCount":103},[],{"trials":9443,"activeCount":103},[],{"trials":9445,"activeCount":103},[],{"intervention":9447,"totalTrials":241,"cells":9448},"Candida albicans antigen",{"EARLY_PHASE1":9449,"PHASE1":9451,"PHASE2":9466,"PHASE3":9468,"PHASE4":9470,"NA":9472},{"trials":9450,"activeCount":103},[],{"trials":9452,"activeCount":103},[9453],{"nctId":9454,"briefTitle":9455,"status":115,"phases":9456,"primaryCompletion":9457,"completion":9458,"start":9459,"enrollment":557,"conditions":9460,"interventions":9463},"NCT02889159","Immunologic Profile of Chronically Photodamaged Skin",[91],"2023-02-09","2023-02-23","2016-06-06",[9461,9462],"Photoaged Skin","Normal Skin",[9447,9464,9465],"histamine phosphate","imiquimod 5% cream",{"trials":9467,"activeCount":103},[],{"trials":9469,"activeCount":103},[],{"trials":9471,"activeCount":103},[],{"trials":9473,"activeCount":103},[],{"intervention":9464,"totalTrials":241,"cells":9475},{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9484,"PHASE3":9486,"PHASE4":9488,"NA":9490},{"trials":9477,"activeCount":103},[],{"trials":9479,"activeCount":103},[9480],{"nctId":9454,"briefTitle":9455,"status":115,"phases":9481,"primaryCompletion":9457,"completion":9458,"start":9459,"enrollment":557,"conditions":9482,"interventions":9483},[91],[9461,9462],[9447,9464,9465],{"trials":9485,"activeCount":103},[],{"trials":9487,"activeCount":103},[],{"trials":9489,"activeCount":103},[],{"trials":9491,"activeCount":103},[],{"intervention":9465,"totalTrials":241,"cells":9493},{"EARLY_PHASE1":9494,"PHASE1":9496,"PHASE2":9502,"PHASE3":9504,"PHASE4":9506,"NA":9508},{"trials":9495,"activeCount":103},[],{"trials":9497,"activeCount":103},[9498],{"nctId":9454,"briefTitle":9455,"status":115,"phases":9499,"primaryCompletion":9457,"completion":9458,"start":9459,"enrollment":557,"conditions":9500,"interventions":9501},[91],[9461,9462],[9447,9464,9465],{"trials":9503,"activeCount":103},[],{"trials":9505,"activeCount":103},[],{"trials":9507,"activeCount":103},[],{"trials":9509,"activeCount":103},[],{"intervention":1768,"totalTrials":241,"cells":9511},{"EARLY_PHASE1":9512,"PHASE1":9514,"PHASE2":9520,"PHASE3":9522,"PHASE4":9524,"NA":9526},{"trials":9513,"activeCount":103},[],{"trials":9515,"activeCount":103},[9516],{"nctId":1762,"briefTitle":1763,"status":211,"phases":9517,"primaryCompletion":1765,"completion":1765,"start":618,"enrollment":700,"conditions":9518,"interventions":9519},[91],[25],[1768,1529],{"trials":9521,"activeCount":103},[],{"trials":9523,"activeCount":103},[],{"trials":9525,"activeCount":103},[],{"trials":9527,"activeCount":103},[],{"intervention":9529,"totalTrials":241,"cells":9530},"Aliskerin\u002FValsartan and Rampiril",{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9542,"PHASE3":9544,"PHASE4":9546,"NA":9548},{"trials":9532,"activeCount":103},[],{"trials":9534,"activeCount":103},[9535],{"nctId":9536,"briefTitle":9537,"status":281,"phases":9538,"primaryCompletion":5986,"completion":5986,"start":8285,"enrollment":103,"conditions":9539,"interventions":9541},"NCT01432106","The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan\u002FAliskiren in African American Patients With Hypertension and the Metabolic Syndrome",[91],[30,9540],"Metabolic Syndrome",[9529],{"trials":9543,"activeCount":103},[],{"trials":9545,"activeCount":103},[],{"trials":9547,"activeCount":103},[],{"trials":9549,"activeCount":103},[],{"intervention":9551,"totalTrials":241,"cells":9552},"KSP-910638G, 0.4 mg",{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9566,"PHASE3":9568,"PHASE4":9570,"NA":9572},{"trials":9554,"activeCount":103},[],{"trials":9556,"activeCount":103},[9557],{"nctId":9558,"briefTitle":9559,"status":115,"phases":9560,"primaryCompletion":9561,"completion":9561,"start":9562,"enrollment":251,"conditions":9563,"interventions":9564},"NCT03161418","Study of the Safety of KSP Heptapeptide (KSP-910638G)",[91],"2017-09-20","2017-06-21",[9258],[9551,9565],"KSP-910638G, 1.2 mg",{"trials":9567,"activeCount":103},[],{"trials":9569,"activeCount":103},[],{"trials":9571,"activeCount":103},[],{"trials":9573,"activeCount":103},[],{"intervention":9565,"totalTrials":241,"cells":9575},{"EARLY_PHASE1":9576,"PHASE1":9578,"PHASE2":9584,"PHASE3":9586,"PHASE4":9588,"NA":9590},{"trials":9577,"activeCount":103},[],{"trials":9579,"activeCount":103},[9580],{"nctId":9558,"briefTitle":9559,"status":115,"phases":9581,"primaryCompletion":9561,"completion":9561,"start":9562,"enrollment":251,"conditions":9582,"interventions":9583},[91],[9258],[9551,9565],{"trials":9585,"activeCount":103},[],{"trials":9587,"activeCount":103},[],{"trials":9589,"activeCount":103},[],{"trials":9591,"activeCount":103},[],{"intervention":9593,"totalTrials":241,"cells":9594},"FORTEO",{"EARLY_PHASE1":9595,"PHASE1":9597,"PHASE2":9607,"PHASE3":9609,"PHASE4":9611,"NA":9613},{"trials":9596,"activeCount":103},[],{"trials":9598,"activeCount":103},[9599],{"nctId":9600,"briefTitle":9601,"status":115,"phases":9602,"primaryCompletion":8511,"completion":8511,"start":306,"enrollment":557,"conditions":9603,"interventions":9606},"NCT00277706","Impact of Parathyroid Hormone (PTH) on Osseous Cavity",[91],[9604,9605],"Bone Loss","Periodontitis",[9593],{"trials":9608,"activeCount":103},[],{"trials":9610,"activeCount":103},[],{"trials":9612,"activeCount":103},[],{"trials":9614,"activeCount":103},[],{"intervention":9616,"totalTrials":241,"cells":9617},"QRH-882260",{"EARLY_PHASE1":9618,"PHASE1":9620,"PHASE2":9628,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9619,"activeCount":103},[],{"trials":9621,"activeCount":103},[9622],{"nctId":9623,"briefTitle":9624,"status":115,"phases":9625,"primaryCompletion":1436,"completion":1436,"start":7093,"enrollment":738,"conditions":9626,"interventions":9627},"NCT02574858","Study of the Safety of QRH-882260 Heptapeptide",[91],[9258],[9616],{"trials":9629,"activeCount":103},[],{"trials":9631,"activeCount":103},[],{"trials":9633,"activeCount":103},[],{"trials":9635,"activeCount":103},[],{"intervention":9637,"totalTrials":151,"cells":9638},"[18F]4F-MHPG",{"EARLY_PHASE1":9639,"PHASE1":9658,"PHASE2":9660,"PHASE3":9662,"PHASE4":9664,"NA":9666},{"trials":9640,"activeCount":103},[9641,9651],{"nctId":9642,"briefTitle":9643,"status":115,"phases":9644,"primaryCompletion":1436,"completion":283,"start":3401,"enrollment":713,"conditions":9645,"interventions":9647},"NCT02669563","An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients",[90],[9646],"Cardiomyopathy",[9637,9648,9649,9650],"[18F]3F-PHPG","[13N]ammonia","[11C]HED",{"nctId":9652,"briefTitle":9653,"status":115,"phases":9654,"primaryCompletion":1436,"completion":1436,"start":8284,"enrollment":713,"conditions":9655,"interventions":9657},"NCT02385877","Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines",[90],[9656],"Autonomic Peripheral Nervous System Diseases",[9637,9648],{"trials":9659,"activeCount":103},[],{"trials":9661,"activeCount":103},[],{"trials":9663,"activeCount":103},[],{"trials":9665,"activeCount":103},[],{"trials":9667,"activeCount":103},[],{"intervention":9648,"totalTrials":151,"cells":9669},{"EARLY_PHASE1":9670,"PHASE1":9680,"PHASE2":9682,"PHASE3":9684,"PHASE4":9686,"NA":9688},{"trials":9671,"activeCount":103},[9672,9676],{"nctId":9642,"briefTitle":9643,"status":115,"phases":9673,"primaryCompletion":1436,"completion":283,"start":3401,"enrollment":713,"conditions":9674,"interventions":9675},[90],[9646],[9637,9648,9649,9650],{"nctId":9652,"briefTitle":9653,"status":115,"phases":9677,"primaryCompletion":1436,"completion":1436,"start":8284,"enrollment":713,"conditions":9678,"interventions":9679},[90],[9656],[9637,9648],{"trials":9681,"activeCount":103},[],{"trials":9683,"activeCount":103},[],{"trials":9685,"activeCount":103},[],{"trials":9687,"activeCount":103},[],{"trials":9689,"activeCount":103},[],{"intervention":9691,"totalTrials":241,"cells":9692},"Crest Cavity Protection toothpaste",{"EARLY_PHASE1":9693,"PHASE1":9707,"PHASE2":9709,"PHASE3":9711,"PHASE4":9713,"NA":9715},{"trials":9694,"activeCount":103},[9695],{"nctId":9696,"briefTitle":9697,"status":115,"phases":9698,"primaryCompletion":9699,"completion":2692,"start":9700,"enrollment":451,"conditions":9701,"interventions":9703},"NCT05601154","Fluoride in Saliva After Use of Fluoride Toothpastes Followed by Fluoride Mouthrinses",[90],"2024-11-04","2023-03-23",[9702],"Dental Caries",[9691,9704,9705,9706],"Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse","Colgate PreviDent 5000+ toothpaste","Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse",{"trials":9708,"activeCount":103},[],{"trials":9710,"activeCount":103},[],{"trials":9712,"activeCount":103},[],{"trials":9714,"activeCount":103},[],{"trials":9716,"activeCount":103},[],{"intervention":9704,"totalTrials":241,"cells":9718},{"EARLY_PHASE1":9719,"PHASE1":9725,"PHASE2":9727,"PHASE3":9729,"PHASE4":9731,"NA":9733},{"trials":9720,"activeCount":103},[9721],{"nctId":9696,"briefTitle":9697,"status":115,"phases":9722,"primaryCompletion":9699,"completion":2692,"start":9700,"enrollment":451,"conditions":9723,"interventions":9724},[90],[9702],[9691,9704,9705,9706],{"trials":9726,"activeCount":103},[],{"trials":9728,"activeCount":103},[],{"trials":9730,"activeCount":103},[],{"trials":9732,"activeCount":103},[],{"trials":9734,"activeCount":103},[],{"intervention":9705,"totalTrials":241,"cells":9736},{"EARLY_PHASE1":9737,"PHASE1":9743,"PHASE2":9745,"PHASE3":9747,"PHASE4":9749,"NA":9751},{"trials":9738,"activeCount":103},[9739],{"nctId":9696,"briefTitle":9697,"status":115,"phases":9740,"primaryCompletion":9699,"completion":2692,"start":9700,"enrollment":451,"conditions":9741,"interventions":9742},[90],[9702],[9691,9704,9705,9706],{"trials":9744,"activeCount":103},[],{"trials":9746,"activeCount":103},[],{"trials":9748,"activeCount":103},[],{"trials":9750,"activeCount":103},[],{"trials":9752,"activeCount":103},[],{"intervention":9706,"totalTrials":241,"cells":9754},{"EARLY_PHASE1":9755,"PHASE1":9761,"PHASE2":9763,"PHASE3":9765,"PHASE4":9767,"NA":9769},{"trials":9756,"activeCount":103},[9757],{"nctId":9696,"briefTitle":9697,"status":115,"phases":9758,"primaryCompletion":9699,"completion":2692,"start":9700,"enrollment":451,"conditions":9759,"interventions":9760},[90],[9702],[9691,9704,9705,9706],{"trials":9762,"activeCount":103},[],{"trials":9764,"activeCount":103},[],{"trials":9766,"activeCount":103},[],{"trials":9768,"activeCount":103},[],{"trials":9770,"activeCount":103},[],{"intervention":9649,"totalTrials":241,"cells":9772},{"EARLY_PHASE1":9773,"PHASE1":9779,"PHASE2":9781,"PHASE3":9783,"PHASE4":9785,"NA":9787},{"trials":9774,"activeCount":103},[9775],{"nctId":9642,"briefTitle":9643,"status":115,"phases":9776,"primaryCompletion":1436,"completion":283,"start":3401,"enrollment":713,"conditions":9777,"interventions":9778},[90],[9646],[9637,9648,9649,9650],{"trials":9780,"activeCount":103},[],{"trials":9782,"activeCount":103},[],{"trials":9784,"activeCount":103},[],{"trials":9786,"activeCount":103},[],{"trials":9788,"activeCount":103},[],{"intervention":9650,"totalTrials":241,"cells":9790},{"EARLY_PHASE1":9791,"PHASE1":9797,"PHASE2":9799,"PHASE3":9801,"PHASE4":9803,"NA":9805},{"trials":9792,"activeCount":103},[9793],{"nctId":9642,"briefTitle":9643,"status":115,"phases":9794,"primaryCompletion":1436,"completion":283,"start":3401,"enrollment":713,"conditions":9795,"interventions":9796},[90],[9646],[9637,9648,9649,9650],{"trials":9798,"activeCount":103},[],{"trials":9800,"activeCount":103},[],{"trials":9802,"activeCount":103},[],{"trials":9804,"activeCount":103},[],{"trials":9806,"activeCount":103},[],{"intervention":9808,"totalTrials":241,"cells":9809},"Pazopanib",{"EARLY_PHASE1":9810,"PHASE1":9820,"PHASE2":9822,"PHASE3":9824,"PHASE4":9826,"NA":9828},{"trials":9811,"activeCount":103},[9812],{"nctId":9813,"briefTitle":9814,"status":115,"phases":9815,"primaryCompletion":9816,"completion":9816,"start":7726,"enrollment":713,"conditions":9817,"interventions":9819},"NCT02729194","Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",[90],"2017-09",[9818],"Carcinoma, Renal Cell",[9808],{"trials":9821,"activeCount":103},[],{"trials":9823,"activeCount":103},[],{"trials":9825,"activeCount":103},[],{"trials":9827,"activeCount":103},[],{"trials":9829,"activeCount":103},[],{"intervention":9831,"totalTrials":241,"cells":9832},"MPDL3280A",{"EARLY_PHASE1":9833,"PHASE1":9842,"PHASE2":9844,"PHASE3":9846,"PHASE4":9848,"NA":9850},{"trials":9834,"activeCount":103},[9835],{"nctId":9836,"briefTitle":9837,"status":115,"phases":9838,"primaryCompletion":9839,"completion":9839,"start":858,"enrollment":1569,"conditions":9840,"interventions":9841},"NCT02463994","A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC",[90],"2018-11-07",[791],[9831],{"trials":9843,"activeCount":103},[],{"trials":9845,"activeCount":103},[],{"trials":9847,"activeCount":103},[],{"trials":9849,"activeCount":103},[],{"trials":9851,"activeCount":103},[],{"intervention":9853,"totalTrials":241,"cells":9854},"Erlotinib",{"EARLY_PHASE1":9855,"PHASE1":9866,"PHASE2":9868,"PHASE3":9870,"PHASE4":9872,"NA":9874},{"trials":9856,"activeCount":103},[9857],{"nctId":9858,"briefTitle":9859,"status":281,"phases":9860,"primaryCompletion":9861,"start":3302,"enrollment":103,"conditions":9862,"interventions":9864},"NCT02277457","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",[90],"2021-06",[9863],"Non-Small Cell Lung Cancer",[9853,9865],"Crizotinib",{"trials":9867,"activeCount":103},[],{"trials":9869,"activeCount":103},[],{"trials":9871,"activeCount":103},[],{"trials":9873,"activeCount":103},[],{"trials":9875,"activeCount":103},[],{"intervention":9865,"totalTrials":241,"cells":9877},{"EARLY_PHASE1":9878,"PHASE1":9884,"PHASE2":9886,"PHASE3":9888,"PHASE4":9890,"NA":9892},{"trials":9879,"activeCount":103},[9880],{"nctId":9858,"briefTitle":9859,"status":281,"phases":9881,"primaryCompletion":9861,"start":3302,"enrollment":103,"conditions":9882,"interventions":9883},[90],[9863],[9853,9865],{"trials":9885,"activeCount":103},[],{"trials":9887,"activeCount":103},[],{"trials":9889,"activeCount":103},[],{"trials":9891,"activeCount":103},[],{"trials":9893,"activeCount":103},[],{"intervention":9895,"totalTrials":241,"cells":9896},"3-[18F]Fluoro-para-hydroxyphenethylguanidine",{"EARLY_PHASE1":9897,"PHASE1":9908,"PHASE2":9910,"PHASE3":9912,"PHASE4":9914,"NA":9916},{"trials":9898,"activeCount":103},[9899],{"nctId":9900,"briefTitle":9901,"status":115,"phases":9902,"primaryCompletion":9903,"completion":9903,"start":9904,"enrollment":727,"conditions":9905,"interventions":9906},"NCT04510311","Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors",[90],"2024-12-31","2020-10-19",[769],[9895,9907],"[123I] metaiodobenzylguanidine",{"trials":9909,"activeCount":103},[],{"trials":9911,"activeCount":103},[],{"trials":9913,"activeCount":103},[],{"trials":9915,"activeCount":103},[],{"trials":9917,"activeCount":103},[],{"intervention":9907,"totalTrials":241,"cells":9919},{"EARLY_PHASE1":9920,"PHASE1":9926,"PHASE2":9928,"PHASE3":9930,"PHASE4":9932,"NA":9934},{"trials":9921,"activeCount":103},[9922],{"nctId":9900,"briefTitle":9901,"status":115,"phases":9923,"primaryCompletion":9903,"completion":9903,"start":9904,"enrollment":727,"conditions":9924,"interventions":9925},[90],[769],[9895,9907],{"trials":9927,"activeCount":103},[],{"trials":9929,"activeCount":103},[],{"trials":9931,"activeCount":103},[],{"trials":9933,"activeCount":103},[],{"trials":9935,"activeCount":103},[],{"intervention":9937,"totalTrials":241,"cells":9938},"OrthoNovum 1\u002F35",{"EARLY_PHASE1":9939,"PHASE1":9951,"PHASE2":9953,"PHASE3":9955,"PHASE4":9957,"NA":9959},{"trials":9940,"activeCount":103},[9941],{"nctId":9942,"briefTitle":9943,"status":115,"phases":9944,"primaryCompletion":7703,"completion":7703,"start":3472,"enrollment":17,"conditions":9945,"interventions":9950},"NCT02155777","Why do Oral Contraceptives Prevent Ovarian Cancer?",[90],[9946,9947,9948,9949],"Ovarian Cancer Risk","Risk-reducing Surgery","Fallopian Tube Fimbriae","Ovarian Cortical Inclusion Cysts",[9937],{"trials":9952,"activeCount":103},[],{"trials":9954,"activeCount":103},[],{"trials":9956,"activeCount":103},[],{"trials":9958,"activeCount":103},[],{"trials":9960,"activeCount":103},[],{"intervention":9962,"totalTrials":241,"cells":9963},"Potato starch",{"EARLY_PHASE1":9964,"PHASE1":9973,"PHASE2":9975,"PHASE3":9977,"PHASE4":9979,"NA":9981},{"trials":9965,"activeCount":103},[9966],{"nctId":9967,"briefTitle":9968,"status":115,"phases":9969,"primaryCompletion":1765,"completion":1765,"start":9970,"enrollment":1569,"conditions":9971,"interventions":9972},"NCT04552418","Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors",[90],"2021-06-02",[1334],[9962],{"trials":9974,"activeCount":103},[],{"trials":9976,"activeCount":103},[],{"trials":9978,"activeCount":103},[],{"trials":9980,"activeCount":103},[],{"trials":9982,"activeCount":103},[],{"intervention":9984,"totalTrials":241,"cells":9985},"Atezolizumab",{"EARLY_PHASE1":9986,"PHASE1":9996,"PHASE2":9998,"PHASE3":10000,"PHASE4":10002,"NA":10004},{"trials":9987,"activeCount":103},[9988],{"nctId":9989,"briefTitle":9990,"status":211,"phases":9991,"primaryCompletion":9992,"completion":9992,"start":2994,"enrollment":241,"conditions":9993,"interventions":9994},"NCT03208712","Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy",[90],"2018-08-02",[729],[9984,9995],"Radium-223",{"trials":9997,"activeCount":103},[],{"trials":9999,"activeCount":103},[],{"trials":10001,"activeCount":103},[],{"trials":10003,"activeCount":103},[],{"trials":10005,"activeCount":103},[],{"intervention":9995,"totalTrials":241,"cells":10007},{"EARLY_PHASE1":10008,"PHASE1":10014,"PHASE2":10016,"PHASE3":10018,"PHASE4":10020,"NA":10022},{"trials":10009,"activeCount":103},[10010],{"nctId":9989,"briefTitle":9990,"status":211,"phases":10011,"primaryCompletion":9992,"completion":9992,"start":2994,"enrollment":241,"conditions":10012,"interventions":10013},[90],[729],[9984,9995],{"trials":10015,"activeCount":103},[],{"trials":10017,"activeCount":103},[],{"trials":10019,"activeCount":103},[],{"trials":10021,"activeCount":103},[],{"trials":10023,"activeCount":103},[],{"intervention":10025,"totalTrials":241,"cells":10026},"Inactive supplement",{"EARLY_PHASE1":10027,"PHASE1":10043,"PHASE2":10045,"PHASE3":10047,"PHASE4":10049,"NA":10051},{"trials":10028,"activeCount":103},[10029],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10032,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10035,"interventions":10036},"NCT04620252","Effect of Chewing a Calcium Supplement Before Fluoride Rinse on Salivary Fluoride",[90],"2022-03-31","2021-02-01",[9702],[10025,10037,10038,10039,10040,10041,10042],"Tricalcium phosphate supplement","Calcium carbonate supplement","Calcium citrate supplement","Inactive supplement and fluoride mouthwash","Calcium carbonate supplement and fluoride mouthwash","Calcium citrate supplement and fluoride mouthwash",{"trials":10044,"activeCount":103},[],{"trials":10046,"activeCount":103},[],{"trials":10048,"activeCount":103},[],{"trials":10050,"activeCount":103},[],{"trials":10052,"activeCount":103},[],{"intervention":10037,"totalTrials":241,"cells":10054},{"EARLY_PHASE1":10055,"PHASE1":10061,"PHASE2":10063,"PHASE3":10065,"PHASE4":10067,"NA":10069},{"trials":10056,"activeCount":103},[10057],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10058,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10059,"interventions":10060},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10062,"activeCount":103},[],{"trials":10064,"activeCount":103},[],{"trials":10066,"activeCount":103},[],{"trials":10068,"activeCount":103},[],{"trials":10070,"activeCount":103},[],{"intervention":10038,"totalTrials":241,"cells":10072},{"EARLY_PHASE1":10073,"PHASE1":10079,"PHASE2":10081,"PHASE3":10083,"PHASE4":10085,"NA":10087},{"trials":10074,"activeCount":103},[10075],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10076,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10077,"interventions":10078},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10080,"activeCount":103},[],{"trials":10082,"activeCount":103},[],{"trials":10084,"activeCount":103},[],{"trials":10086,"activeCount":103},[],{"trials":10088,"activeCount":103},[],{"intervention":10039,"totalTrials":241,"cells":10090},{"EARLY_PHASE1":10091,"PHASE1":10097,"PHASE2":10099,"PHASE3":10101,"PHASE4":10103,"NA":10105},{"trials":10092,"activeCount":103},[10093],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10094,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10095,"interventions":10096},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10098,"activeCount":103},[],{"trials":10100,"activeCount":103},[],{"trials":10102,"activeCount":103},[],{"trials":10104,"activeCount":103},[],{"trials":10106,"activeCount":103},[],{"intervention":10040,"totalTrials":241,"cells":10108},{"EARLY_PHASE1":10109,"PHASE1":10115,"PHASE2":10117,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10110,"activeCount":103},[10111],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10112,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10113,"interventions":10114},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10116,"activeCount":103},[],{"trials":10118,"activeCount":103},[],{"trials":10120,"activeCount":103},[],{"trials":10122,"activeCount":103},[],{"trials":10124,"activeCount":103},[],{"intervention":10041,"totalTrials":241,"cells":10126},{"EARLY_PHASE1":10127,"PHASE1":10133,"PHASE2":10135,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10128,"activeCount":103},[10129],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10130,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10131,"interventions":10132},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10134,"activeCount":103},[],{"trials":10136,"activeCount":103},[],{"trials":10138,"activeCount":103},[],{"trials":10140,"activeCount":103},[],{"trials":10142,"activeCount":103},[],{"intervention":10042,"totalTrials":241,"cells":10144},{"EARLY_PHASE1":10145,"PHASE1":10151,"PHASE2":10153,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10146,"activeCount":103},[10147],{"nctId":10030,"briefTitle":10031,"status":115,"phases":10148,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":8789,"conditions":10149,"interventions":10150},[90],[9702],[10025,10037,10038,10039,10040,10041,10042],{"trials":10152,"activeCount":103},[],{"trials":10154,"activeCount":103},[],{"trials":10156,"activeCount":103},[],{"trials":10158,"activeCount":103},[],{"trials":10160,"activeCount":103},[],{"intervention":10162,"totalTrials":241,"cells":10163},"Cardiac PET scan w\u002F18F-Fluorodeoxyglucose and rubidium-82",{"EARLY_PHASE1":10164,"PHASE1":10175,"PHASE2":10177,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10165,"activeCount":103},[10166],{"nctId":10167,"briefTitle":10168,"status":115,"phases":10169,"primaryCompletion":10170,"completion":10170,"start":284,"enrollment":404,"conditions":10171,"interventions":10174},"NCT02003456","Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging",[90],"2014-08",[10172,10173],"Ischemic Heart Disease","Myocardial Infarction",[10162],{"trials":10176,"activeCount":103},[],{"trials":10178,"activeCount":103},[],{"trials":10180,"activeCount":103},[],{"trials":10182,"activeCount":103},[],{"trials":10184,"activeCount":103},[],{"intervention":1141,"totalTrials":1569,"cells":10186},{"EARLY_PHASE1":10187,"PHASE1":10189,"PHASE2":10195,"PHASE3":10247,"PHASE4":10249,"NA":10251},{"trials":10188,"activeCount":103},[],{"trials":10190,"activeCount":103},[10191],{"nctId":1563,"briefTitle":1564,"status":211,"phases":10192,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":10193,"interventions":10194},[91],[1571,25,275,729],[1573,1574],{"trials":10196,"activeCount":103},[10197,10204,10208,10212,10216,10222,10226,10230,10236,10243],{"nctId":10198,"briefTitle":10199,"status":211,"phases":10200,"primaryCompletion":3473,"completion":10201,"start":6940,"enrollment":37,"conditions":10202,"interventions":10203},"NCT00480857","Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy",[92],"2014-07",[25],[1141],{"nctId":1131,"briefTitle":1132,"status":115,"phases":10205,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1136,"conditions":10206,"interventions":10207},[92],[1138],[1140,1141,221,234],{"nctId":2386,"briefTitle":2387,"status":211,"phases":10209,"primaryCompletion":261,"completion":213,"start":873,"enrollment":804,"conditions":10210,"interventions":10211},[92],[2390],[221,2361,222,1141],{"nctId":5533,"briefTitle":5534,"status":115,"phases":10213,"primaryCompletion":5536,"completion":4599,"start":5537,"enrollment":28,"conditions":10214,"interventions":10215},[92],[5539],[5541,300,1141],{"nctId":10217,"briefTitle":10218,"status":115,"phases":10219,"primaryCompletion":3049,"completion":271,"start":2372,"enrollment":394,"conditions":10220,"interventions":10221},"NCT00151047","Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer",[92],[25],[1119,1141],{"nctId":8129,"briefTitle":8130,"status":211,"phases":10223,"primaryCompletion":8132,"completion":8132,"start":8133,"enrollment":557,"conditions":10224,"interventions":10225},[92],[791],[8120,1141],{"nctId":5983,"briefTitle":5984,"status":211,"phases":10227,"primaryCompletion":5986,"completion":3302,"start":358,"enrollment":3133,"conditions":10228,"interventions":10229},[92],[5988],[1140,1141],{"nctId":10231,"briefTitle":10232,"status":115,"phases":10233,"primaryCompletion":4311,"completion":5359,"start":5414,"enrollment":766,"conditions":10234,"interventions":10235},"NCT00148070","Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer",[92],[6183],[1141],{"nctId":10237,"briefTitle":10238,"status":115,"phases":10239,"primaryCompletion":7947,"completion":8353,"start":10240,"enrollment":557,"conditions":10241,"interventions":10242},"NCT00148122","A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer",[92],"2002-11",[362],[1141,1119],{"nctId":5409,"briefTitle":5410,"status":115,"phases":10244,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":336,"conditions":10245,"interventions":10246},[92],[5416],[1141,312],{"trials":10248,"activeCount":103},[],{"trials":10250,"activeCount":103},[],{"trials":10252,"activeCount":103},[10253],{"nctId":10254,"briefTitle":10255,"status":115,"phases":10256,"primaryCompletion":10257,"completion":3783,"start":10258,"enrollment":738,"conditions":10259,"interventions":10260},"NCT00156312","Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine",[95],"2005-05","2003-07",[19],[1141,1119],{"intervention":1119,"totalTrials":5573,"cells":10262},{"EARLY_PHASE1":10263,"PHASE1":10265,"PHASE2":10267,"PHASE3":10292,"PHASE4":10294,"NA":10296},{"trials":10264,"activeCount":103},[],{"trials":10266,"activeCount":103},[],{"trials":10268,"activeCount":103},[10269,10273,10277,10281,10288],{"nctId":1111,"briefTitle":1112,"status":211,"phases":10270,"primaryCompletion":1114,"completion":271,"start":1115,"conditions":10271,"interventions":10272},[92],[1117],[234,277,1119],{"nctId":5651,"briefTitle":5652,"status":115,"phases":10274,"primaryCompletion":5654,"completion":2356,"start":5655,"enrollment":394,"conditions":10275,"interventions":10276},[92],[5657],[2376,1119,5340],{"nctId":10217,"briefTitle":10218,"status":115,"phases":10278,"primaryCompletion":3049,"completion":271,"start":2372,"enrollment":394,"conditions":10279,"interventions":10280},[92],[25],[1119,1141],{"nctId":10282,"briefTitle":10283,"status":211,"phases":10284,"primaryCompletion":10257,"completion":215,"start":8155,"enrollment":404,"conditions":10285,"interventions":10287},"NCT00176787","Radiation Therapy With Capecitabine in Rectal Cancer",[92],[10286],"Rectal Cancer",[1119],{"nctId":10237,"briefTitle":10238,"status":115,"phases":10289,"primaryCompletion":7947,"completion":8353,"start":10240,"enrollment":557,"conditions":10290,"interventions":10291},[92],[362],[1141,1119],{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[10298,10302],{"nctId":10254,"briefTitle":10255,"status":115,"phases":10299,"primaryCompletion":10257,"completion":3783,"start":10258,"enrollment":738,"conditions":10300,"interventions":10301},[95],[19],[1141,1119],{"nctId":10303,"briefTitle":10304,"status":211,"phases":10305,"completion":8007,"start":5528,"conditions":10306,"interventions":10307},"NCT00176735","Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer",[95],[2374],[1119],{"intervention":222,"totalTrials":216,"cells":10309},{"EARLY_PHASE1":10310,"PHASE1":10312,"PHASE2":10314,"PHASE3":10336,"PHASE4":10338,"NA":10340},{"trials":10311,"activeCount":103},[],{"trials":10313,"activeCount":103},[],{"trials":10315,"activeCount":103},[10316,10320,10324,10328,10332],{"nctId":209,"briefTitle":210,"status":211,"phases":10317,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":10318,"interventions":10319},[92],[218],[220,199,221,222],{"nctId":5330,"briefTitle":5331,"status":115,"phases":10321,"primaryCompletion":5333,"completion":5334,"start":5335,"enrollment":5336,"conditions":10322,"interventions":10323},[92],[5338],[5340,222,1254,5321],{"nctId":1244,"briefTitle":1245,"status":115,"phases":10325,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":10326,"interventions":10327},[91,92],[1251],[255,1253,222,1254],{"nctId":257,"briefTitle":258,"status":115,"phases":10329,"primaryCompletion":260,"completion":261,"start":262,"conditions":10330,"interventions":10331},[92],[264],[199,221,222],{"nctId":2386,"briefTitle":2387,"status":211,"phases":10333,"primaryCompletion":261,"completion":213,"start":873,"enrollment":804,"conditions":10334,"interventions":10335},[92],[2390],[221,2361,222,1141],{"trials":10337,"activeCount":103},[],{"trials":10339,"activeCount":103},[],{"trials":10341,"activeCount":103},[10342],{"nctId":355,"briefTitle":356,"status":115,"phases":10343,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":10344,"interventions":10345},[95],[362],[199,234,221,222],{"intervention":2361,"totalTrials":216,"cells":10347},{"EARLY_PHASE1":10348,"PHASE1":10350,"PHASE2":10352,"PHASE3":10379,"PHASE4":10381,"NA":10383},{"trials":10349,"activeCount":103},[],{"trials":10351,"activeCount":103},[],{"trials":10353,"activeCount":103},[10354,10358,10364,10368,10372],{"nctId":2353,"briefTitle":2354,"status":115,"phases":10355,"primaryCompletion":1438,"completion":1683,"start":2356,"enrollment":2357,"conditions":10356,"interventions":10357},[92],[275],[2360,221,2361],{"nctId":10359,"briefTitle":10360,"status":115,"phases":10361,"primaryCompletion":261,"completion":4450,"start":2460,"enrollment":758,"conditions":10362,"interventions":10363},"NCT00148109","Trial of Cetuximab in Patients With Metastatic and\u002For Locally Advanced Soft Tissue and Bony Sarcomas",[92],[939],[2361,2361],{"nctId":2386,"briefTitle":2387,"status":211,"phases":10365,"primaryCompletion":261,"completion":213,"start":873,"enrollment":804,"conditions":10366,"interventions":10367},[92],[2390],[221,2361,222,1141],{"nctId":8508,"briefTitle":8509,"status":211,"phases":10369,"primaryCompletion":261,"completion":8511,"start":270,"enrollment":200,"conditions":10370,"interventions":10371},[92],[5657],[8499,2361,8514],{"nctId":10373,"briefTitle":10374,"status":211,"phases":10375,"primaryCompletion":10376,"completion":10376,"start":1494,"enrollment":31,"conditions":10377,"interventions":10378},"NCT00904345","Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)",[92],"2020-12",[362],[2361],{"trials":10380,"activeCount":103},[],{"trials":10382,"activeCount":103},[],{"trials":10384,"activeCount":103},[10385],{"nctId":10386,"briefTitle":10387,"status":115,"phases":10388,"primaryCompletion":10389,"completion":10389,"start":4427,"enrollment":836,"conditions":10390,"interventions":10392},"NCT01663259","Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients",[95],"2019-09",[2332,10391],"HPV",[2361],{"intervention":10394,"totalTrials":1343,"cells":10395},"Metformin",{"EARLY_PHASE1":10396,"PHASE1":10398,"PHASE2":10400,"PHASE3":10416,"PHASE4":10418,"NA":10437},{"trials":10397,"activeCount":103},[],{"trials":10399,"activeCount":103},[],{"trials":10401,"activeCount":103},[10402,10409],{"nctId":10403,"briefTitle":10404,"status":115,"phases":10405,"primaryCompletion":2692,"completion":2692,"start":6246,"enrollment":1390,"conditions":10406,"interventions":10408},"NCT01750567","A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL",[92],[10407],"Relapsed Chronic Lymphocytic Leukemia",[10394],{"nctId":10410,"briefTitle":10411,"status":115,"phases":10412,"primaryCompletion":1682,"completion":6013,"start":4451,"enrollment":360,"conditions":10413,"interventions":10415},"NCT01579812","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",[92],[10414],"Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[10394],{"trials":10417,"activeCount":103},[],{"trials":10419,"activeCount":103},[10420,10430],{"nctId":10421,"briefTitle":10422,"status":115,"phases":10423,"primaryCompletion":10424,"completion":10425,"start":10426,"enrollment":10427,"conditions":10428,"interventions":10429},"NCT04625946","Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation",[94],"2025-07-01","2025-08-10","2021-01-19",117,[3963],[10394],{"nctId":10431,"briefTitle":10432,"status":115,"phases":10433,"primaryCompletion":10434,"completion":9816,"start":10201,"enrollment":5868,"conditions":10435,"interventions":10436},"NCT02069379","Endogenous Opioid Activity and Affective State in Insulin Resistant Women",[94],"2017-03-24",[16,3017,9540],[10394],{"trials":10438,"activeCount":103},[10439],{"nctId":10440,"briefTitle":10441,"status":115,"phases":10442,"primaryCompletion":10443,"completion":10443,"start":3596,"enrollment":3208,"conditions":10444,"interventions":10446},"NCT00670800","Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome",[95],"2009-08",[10445],"Polycystic Ovary Syndrome",[10394],{"intervention":1499,"totalTrials":99,"cells":10448},{"EARLY_PHASE1":10449,"PHASE1":10451,"PHASE2":10453,"PHASE3":10463,"PHASE4":10465,"NA":10467},{"trials":10450,"activeCount":103},[],{"trials":10452,"activeCount":103},[],{"trials":10454,"activeCount":103},[10455,10459],{"nctId":2456,"briefTitle":2457,"status":115,"phases":10456,"primaryCompletion":2459,"completion":1073,"start":2460,"enrollment":557,"conditions":10457,"interventions":10458},[92],[1486],[2463,1499,1489],{"nctId":1491,"briefTitle":1492,"status":115,"phases":10460,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":120,"conditions":10461,"interventions":10462},[91,92],[1486],[1488,1453,1489,1499],{"trials":10464,"activeCount":103},[],{"trials":10466,"activeCount":103},[],{"trials":10468,"activeCount":103},[10469],{"nctId":2490,"briefTitle":2491,"status":115,"phases":10470,"primaryCompletion":239,"completion":1073,"start":2493,"enrollment":404,"conditions":10471,"interventions":10472},[95],[1486],[2496,1499,1489],{"intervention":10474,"totalTrials":99,"cells":10475},"Duloxetine",{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10491,"PHASE4":10493,"NA":10506},{"trials":10477,"activeCount":103},[],{"trials":10479,"activeCount":103},[],{"trials":10481,"activeCount":103},[10482],{"nctId":10483,"briefTitle":10484,"status":115,"phases":10485,"primaryCompletion":10486,"completion":10486,"start":10487,"enrollment":3354,"conditions":10488,"interventions":10490},"NCT01912612","Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain",[92],"2019-06-28","2013-10-30",[10489],"Pain",[10474],{"trials":10492,"activeCount":103},[],{"trials":10494,"activeCount":103},[10495],{"nctId":10496,"briefTitle":10497,"status":115,"phases":10498,"primaryCompletion":10499,"completion":10500,"start":10501,"enrollment":10502,"conditions":10503,"interventions":10505},"NCT04870957","The Back Pain Consortium Research Program Study",[94],"2024-10-15","2025-04-14","2021-06-09",494,[10504],"Chronic Low-back Pain",[10474],{"trials":10507,"activeCount":103},[10508],{"nctId":10509,"briefTitle":10510,"status":115,"phases":10511,"primaryCompletion":8835,"completion":4451,"start":7767,"enrollment":3133,"conditions":10512,"interventions":10513},"NCT01028352","Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain",[95],[19],[10474],{"intervention":353,"totalTrials":151,"cells":10515},{"EARLY_PHASE1":10516,"PHASE1":10526,"PHASE2":10528,"PHASE3":10530,"PHASE4":10532,"NA":10534},{"trials":10517,"activeCount":103},[10518],{"nctId":10519,"briefTitle":10520,"status":281,"phases":10521,"primaryCompletion":10522,"completion":10522,"start":10523,"enrollment":103,"conditions":10524,"interventions":10525},"NCT03235869","Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma",[90],"2023-03-01","2018-03-01",[800],[353],{"trials":10527,"activeCount":103},[],{"trials":10529,"activeCount":103},[],{"trials":10531,"activeCount":103},[],{"trials":10533,"activeCount":103},[],{"trials":10535,"activeCount":103},[10536],{"nctId":343,"briefTitle":344,"status":115,"phases":10537,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":10538,"interventions":10539},[95],[351],[234,199,353],{"intervention":10541,"totalTrials":151,"cells":10542},"Sertraline",{"EARLY_PHASE1":10543,"PHASE1":10545,"PHASE2":10547,"PHASE3":10549,"PHASE4":10551,"NA":10553},{"trials":10544,"activeCount":103},[],{"trials":10546,"activeCount":103},[],{"trials":10548,"activeCount":103},[],{"trials":10550,"activeCount":103},[],{"trials":10552,"activeCount":103},[],{"trials":10554,"activeCount":103},[10555,10565],{"nctId":10556,"briefTitle":10557,"status":115,"phases":10558,"primaryCompletion":8284,"completion":8284,"start":8353,"enrollment":10559,"conditions":10560,"interventions":10564},"NCT01160588","Brain Markers of Anxiety Disorders and SSRI\u002FCBT Treatment in Children and Adolescents",[],156,[10561,10562,10563],"Social Phobia","Generalized Anxiety Disorder","Separation Anxiety Disorder",[10541],{"nctId":10566,"briefTitle":10567,"status":115,"phases":10568,"primaryCompletion":8308,"completion":2952,"start":2356,"enrollment":530,"conditions":10569,"interventions":10571},"NCT00872131","Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder",[],[10570],"Anxiety Disorders",[10541],{"intervention":3407,"totalTrials":151,"cells":10573},{"EARLY_PHASE1":10574,"PHASE1":10576,"PHASE2":10578,"PHASE3":10580,"PHASE4":10582,"NA":10588},{"trials":10575,"activeCount":103},[],{"trials":10577,"activeCount":103},[],{"trials":10579,"activeCount":103},[],{"trials":10581,"activeCount":103},[],{"trials":10583,"activeCount":103},[10584],{"nctId":3398,"briefTitle":3399,"status":115,"phases":10585,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":31,"conditions":10586,"interventions":10587},[94],[22,3405],[3407,3385],{"trials":10589,"activeCount":103},[10590],{"nctId":10591,"briefTitle":10592,"status":115,"phases":10593,"primaryCompletion":10594,"completion":10595,"start":3830,"enrollment":10596,"conditions":10597,"interventions":10598},"NCT01852344","Behavioral Differences in Effortful Control",[95],"2013-06-05","2017-04-24",108,[22],[3407],{"intervention":2496,"totalTrials":151,"cells":10600},{"EARLY_PHASE1":10601,"PHASE1":10603,"PHASE2":10605,"PHASE3":10611,"PHASE4":10613,"NA":10615},{"trials":10602,"activeCount":103},[],{"trials":10604,"activeCount":103},[],{"trials":10606,"activeCount":103},[10607],{"nctId":2456,"briefTitle":2457,"status":115,"phases":10608,"primaryCompletion":2459,"completion":1073,"start":2460,"enrollment":557,"conditions":10609,"interventions":10610},[92],[1486],[2463,1499,1489],{"trials":10612,"activeCount":103},[],{"trials":10614,"activeCount":103},[],{"trials":10616,"activeCount":103},[10617],{"nctId":2490,"briefTitle":2491,"status":115,"phases":10618,"primaryCompletion":239,"completion":1073,"start":2493,"enrollment":404,"conditions":10619,"interventions":10620},[95],[1486],[2496,1499,1489],{"intervention":2483,"totalTrials":151,"cells":10622},{"EARLY_PHASE1":10623,"PHASE1":10625,"PHASE2":10627,"PHASE3":10629,"PHASE4":10635,"NA":10637},{"trials":10624,"activeCount":103},[],{"trials":10626,"activeCount":103},[],{"trials":10628,"activeCount":103},[],{"trials":10630,"activeCount":103},[10631],{"nctId":2471,"briefTitle":2472,"status":211,"phases":10632,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":2477,"conditions":10633,"interventions":10634},[93],[2479],[2481,1489,2482,2483,2484],{"trials":10636,"activeCount":103},[],{"trials":10638,"activeCount":103},[10639],{"nctId":10640,"briefTitle":10641,"status":211,"phases":10642,"primaryCompletion":10643,"completion":10643,"start":3035,"enrollment":99,"conditions":10644,"interventions":10646},"NCT01625923","A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis",[95],"2019-06",[10645],"Idiopathic Gastroparesis",[2483],{"intervention":10648,"totalTrials":151,"cells":10649},"Anastrozole",{"EARLY_PHASE1":10650,"PHASE1":10652,"PHASE2":10654,"PHASE3":10663,"PHASE4":10665,"NA":10667},{"trials":10651,"activeCount":103},[],{"trials":10653,"activeCount":103},[],{"trials":10655,"activeCount":103},[10656],{"nctId":10657,"briefTitle":10658,"status":211,"phases":10659,"primaryCompletion":4715,"completion":6044,"start":873,"enrollment":5362,"conditions":10660,"interventions":10661},"NCT00555477","Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure",[92],[19],[10662],"anastrozole",{"trials":10664,"activeCount":103},[],{"trials":10666,"activeCount":103},[],{"trials":10668,"activeCount":103},[10669],{"nctId":10670,"briefTitle":10671,"status":115,"phases":10672,"primaryCompletion":3854,"completion":3353,"start":8511,"enrollment":20,"conditions":10673,"interventions":10674},"NCT01814397","Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients",[],[19,10489,8263],[10648,10675,10676],"exemestane","letrozole",{"intervention":10678,"totalTrials":241,"cells":10679},"Behavior intervention of uphill exercise",{"EARLY_PHASE1":10680,"PHASE1":10682,"PHASE2":10684,"PHASE3":10686,"PHASE4":10688,"NA":10690},{"trials":10681,"activeCount":103},[],{"trials":10683,"activeCount":103},[],{"trials":10685,"activeCount":103},[],{"trials":10687,"activeCount":103},[],{"trials":10689,"activeCount":103},[],{"trials":10691,"activeCount":103},[10692],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10695,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10699,"interventions":10701},"NCT03930758","Preventing Diabetic Osteoporosis With Exercise",[95],"2012-12-05","2012-12-20","2009-10-08",[10700],"Diabetes Mellitus, Type 2",[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],"Dietary intervention of exercise before the meal","Dietary intervention of uphill exercise","Dietary intervention of exercise after the meal","Behavior intervention of downhill exercise","Behavioral intervention of downhill exercise","Behavioral intervention of sedentary no-exercise trial","Dietary intervention of eating two meals",{"intervention":10702,"totalTrials":241,"cells":10710},{"EARLY_PHASE1":10711,"PHASE1":10713,"PHASE2":10715,"PHASE3":10717,"PHASE4":10719,"NA":10721},{"trials":10712,"activeCount":103},[],{"trials":10714,"activeCount":103},[],{"trials":10716,"activeCount":103},[],{"trials":10718,"activeCount":103},[],{"trials":10720,"activeCount":103},[],{"trials":10722,"activeCount":103},[10723],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10724,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10725,"interventions":10726},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10703,"totalTrials":241,"cells":10728},{"EARLY_PHASE1":10729,"PHASE1":10731,"PHASE2":10733,"PHASE3":10735,"PHASE4":10737,"NA":10739},{"trials":10730,"activeCount":103},[],{"trials":10732,"activeCount":103},[],{"trials":10734,"activeCount":103},[],{"trials":10736,"activeCount":103},[],{"trials":10738,"activeCount":103},[],{"trials":10740,"activeCount":103},[10741],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10742,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10743,"interventions":10744},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10704,"totalTrials":241,"cells":10746},{"EARLY_PHASE1":10747,"PHASE1":10749,"PHASE2":10751,"PHASE3":10753,"PHASE4":10755,"NA":10757},{"trials":10748,"activeCount":103},[],{"trials":10750,"activeCount":103},[],{"trials":10752,"activeCount":103},[],{"trials":10754,"activeCount":103},[],{"trials":10756,"activeCount":103},[],{"trials":10758,"activeCount":103},[10759],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10760,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10761,"interventions":10762},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10705,"totalTrials":241,"cells":10764},{"EARLY_PHASE1":10765,"PHASE1":10767,"PHASE2":10769,"PHASE3":10771,"PHASE4":10773,"NA":10775},{"trials":10766,"activeCount":103},[],{"trials":10768,"activeCount":103},[],{"trials":10770,"activeCount":103},[],{"trials":10772,"activeCount":103},[],{"trials":10774,"activeCount":103},[],{"trials":10776,"activeCount":103},[10777],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10778,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10779,"interventions":10780},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10706,"totalTrials":241,"cells":10782},{"EARLY_PHASE1":10783,"PHASE1":10785,"PHASE2":10787,"PHASE3":10789,"PHASE4":10791,"NA":10793},{"trials":10784,"activeCount":103},[],{"trials":10786,"activeCount":103},[],{"trials":10788,"activeCount":103},[],{"trials":10790,"activeCount":103},[],{"trials":10792,"activeCount":103},[],{"trials":10794,"activeCount":103},[10795],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10796,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10797,"interventions":10798},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10707,"totalTrials":241,"cells":10800},{"EARLY_PHASE1":10801,"PHASE1":10803,"PHASE2":10805,"PHASE3":10807,"PHASE4":10809,"NA":10811},{"trials":10802,"activeCount":103},[],{"trials":10804,"activeCount":103},[],{"trials":10806,"activeCount":103},[],{"trials":10808,"activeCount":103},[],{"trials":10810,"activeCount":103},[],{"trials":10812,"activeCount":103},[10813],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10814,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10815,"interventions":10816},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10708,"totalTrials":241,"cells":10818},{"EARLY_PHASE1":10819,"PHASE1":10821,"PHASE2":10823,"PHASE3":10825,"PHASE4":10827,"NA":10829},{"trials":10820,"activeCount":103},[],{"trials":10822,"activeCount":103},[],{"trials":10824,"activeCount":103},[],{"trials":10826,"activeCount":103},[],{"trials":10828,"activeCount":103},[],{"trials":10830,"activeCount":103},[10831],{"nctId":10693,"briefTitle":10694,"status":115,"phases":10832,"primaryCompletion":10696,"completion":10697,"start":10698,"enrollment":394,"conditions":10833,"interventions":10834},[95],[10700],[10678,10702,10703,10704,10705,10702,10706,10704,10707,10708],{"intervention":10836,"totalTrials":241,"cells":10837},"Cozaar",{"EARLY_PHASE1":10838,"PHASE1":10840,"PHASE2":10842,"PHASE3":10844,"PHASE4":10846,"NA":10848},{"trials":10839,"activeCount":103},[],{"trials":10841,"activeCount":103},[],{"trials":10843,"activeCount":103},[],{"trials":10845,"activeCount":103},[],{"trials":10847,"activeCount":103},[],{"trials":10849,"activeCount":103},[10850],{"nctId":10851,"briefTitle":10852,"status":211,"phases":10853,"primaryCompletion":5280,"completion":5280,"start":4189,"enrollment":804,"conditions":10854,"interventions":10857},"NCT01390181","The Effect of Losartan in Bicuspid Aortic Valve Patients",[95],[10855,10856],"Bicuspid Aortic Valve","Thoracic Aortic Aneurysm",[10836],{"intervention":10859,"totalTrials":241,"cells":10860},"GIFT",{"EARLY_PHASE1":10861,"PHASE1":10863,"PHASE2":10865,"PHASE3":10867,"PHASE4":10869,"NA":10871},{"trials":10862,"activeCount":103},[],{"trials":10864,"activeCount":103},[],{"trials":10866,"activeCount":103},[],{"trials":10868,"activeCount":103},[],{"trials":10870,"activeCount":103},[],{"trials":10872,"activeCount":103},[10873],{"nctId":10874,"briefTitle":10875,"status":115,"phases":10876,"primaryCompletion":10877,"completion":10425,"start":10878,"enrollment":10879,"conditions":10880,"interventions":10882},"NCT05552664","The Genetic Information and Family Testing (GIFT) Study",[95],"2025-07-10","2022-10-24",3002,[10881],"Cancer",[10859],{"intervention":10884,"totalTrials":241,"cells":10885},"Topical 17-beta estradiol in ethanol\u002Fpropylene glycol",{"EARLY_PHASE1":10886,"PHASE1":10888,"PHASE2":10890,"PHASE3":10892,"PHASE4":10894,"NA":10896},{"trials":10887,"activeCount":103},[],{"trials":10889,"activeCount":103},[],{"trials":10891,"activeCount":103},[],{"trials":10893,"activeCount":103},[],{"trials":10895,"activeCount":103},[],{"trials":10897,"activeCount":103},[10898],{"nctId":10899,"briefTitle":10900,"status":115,"phases":10901,"primaryCompletion":215,"completion":215,"start":306,"enrollment":8424,"conditions":10902,"interventions":10904},"NCT00113100","Mechanisms of Skin Repair by Topical Estrogen",[95],[10903],"Skin Wrinkling",[10884],{"intervention":10906,"totalTrials":241,"cells":10907},"Esmolol",{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10912,"PHASE3":10914,"PHASE4":10916,"NA":10918},{"trials":10909,"activeCount":103},[],{"trials":10911,"activeCount":103},[],{"trials":10913,"activeCount":103},[],{"trials":10915,"activeCount":103},[],{"trials":10917,"activeCount":103},[],{"trials":10919,"activeCount":103},[10920],{"nctId":10921,"briefTitle":10922,"status":281,"phases":10923,"primaryCompletion":3303,"completion":1436,"start":10201,"enrollment":103,"conditions":10924,"interventions":10926},"NCT01232400","Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage",[95],[10925],"Subarachnoid Hemorrhage",[10906],{"intervention":10928,"totalTrials":241,"cells":10929},"Venlafaxine HCl",{"EARLY_PHASE1":10930,"PHASE1":10932,"PHASE2":10934,"PHASE3":10936,"PHASE4":10938,"NA":10940},{"trials":10931,"activeCount":103},[],{"trials":10933,"activeCount":103},[],{"trials":10935,"activeCount":103},[],{"trials":10937,"activeCount":103},[],{"trials":10939,"activeCount":103},[],{"trials":10941,"activeCount":103},[10942],{"nctId":10943,"briefTitle":10944,"status":115,"phases":10945,"primaryCompletion":3830,"completion":3232,"start":4703,"enrollment":1249,"conditions":10946,"interventions":10948},"NCT00735670","Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury",[95],[10947],"Spinal Cord Injury",[10928],{"intervention":10950,"totalTrials":241,"cells":10951},"DPYD or UGT1A1 variants",{"EARLY_PHASE1":10952,"PHASE1":10954,"PHASE2":10956,"PHASE3":10958,"PHASE4":10960,"NA":10962},{"trials":10953,"activeCount":103},[],{"trials":10955,"activeCount":103},[],{"trials":10957,"activeCount":103},[],{"trials":10959,"activeCount":103},[],{"trials":10961,"activeCount":103},[],{"trials":10963,"activeCount":103},[10964],{"nctId":10965,"briefTitle":10966,"status":115,"phases":10967,"primaryCompletion":10968,"completion":10968,"start":10969,"enrollment":713,"conditions":10970,"interventions":10971},"NCT05583422","Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy",[],"2024-06-17","2023-08-18",[10881],[10950],{"intervention":10973,"totalTrials":241,"cells":10974},"Anesthetics, Dissociative",{"EARLY_PHASE1":10975,"PHASE1":10977,"PHASE2":10979,"PHASE3":10981,"PHASE4":10983,"NA":10985},{"trials":10976,"activeCount":103},[],{"trials":10978,"activeCount":103},[],{"trials":10980,"activeCount":103},[],{"trials":10982,"activeCount":103},[],{"trials":10984,"activeCount":103},[],{"trials":10986,"activeCount":103},[10987],{"nctId":10988,"briefTitle":10989,"status":211,"phases":10990,"primaryCompletion":7554,"completion":7554,"start":3597,"enrollment":713,"conditions":10991,"interventions":10993},"NCT02196259","Anesthesia and Functional Connectivity: An Analysis of fMRI Changes",[95],[10992],"Changes in Brain Network Connectivity",[10973],{"intervention":10995,"totalTrials":241,"cells":10996},"Fluorescein",{"EARLY_PHASE1":10997,"PHASE1":10999,"PHASE2":11001,"PHASE3":11003,"PHASE4":11005,"NA":11007},{"trials":10998,"activeCount":103},[],{"trials":11000,"activeCount":103},[],{"trials":11002,"activeCount":103},[],{"trials":11004,"activeCount":103},[],{"trials":11006,"activeCount":103},[],{"trials":11008,"activeCount":103},[11009],{"nctId":11010,"briefTitle":11011,"status":211,"phases":11012,"primaryCompletion":11013,"completion":11013,"start":11014,"enrollment":6546,"conditions":11015,"interventions":11019},"NCT03220711","Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon",[95],"2022-06-02","2017-07-28",[11016,11017,11018],"Colonic Dysplasia","Adenomatous Polyps","Irritable Bowel Disease",[10995],{"intervention":11021,"totalTrials":241,"cells":11022},"Exenatide",{"EARLY_PHASE1":11023,"PHASE1":11025,"PHASE2":11027,"PHASE3":11029,"PHASE4":11031,"NA":11033},{"trials":11024,"activeCount":103},[],{"trials":11026,"activeCount":103},[],{"trials":11028,"activeCount":103},[],{"trials":11030,"activeCount":103},[],{"trials":11032,"activeCount":103},[],{"trials":11034,"activeCount":103},[11035],{"nctId":11036,"briefTitle":11037,"status":115,"phases":11038,"primaryCompletion":3853,"completion":3853,"start":4703,"enrollment":10,"conditions":11039,"interventions":11042},"NCT00855439","Evaluation of Exenatide in Patients With Diabetic Neuropathy",[95],[11040,11041],"Type 2 Diabetes Mellitus","Diabetic Peripheral Neuropathy",[11021,11043],"Glargine",{"intervention":11043,"totalTrials":241,"cells":11045},{"EARLY_PHASE1":11046,"PHASE1":11048,"PHASE2":11050,"PHASE3":11052,"PHASE4":11054,"NA":11056},{"trials":11047,"activeCount":103},[],{"trials":11049,"activeCount":103},[],{"trials":11051,"activeCount":103},[],{"trials":11053,"activeCount":103},[],{"trials":11055,"activeCount":103},[],{"trials":11057,"activeCount":103},[11058],{"nctId":11036,"briefTitle":11037,"status":115,"phases":11059,"primaryCompletion":3853,"completion":3853,"start":4703,"enrollment":10,"conditions":11060,"interventions":11061},[95],[11040,11041],[11021,11043],{"intervention":11063,"totalTrials":241,"cells":11064},"B-TCP + 0.3 mg\u002Fml rhPDGF-BB in buffer",{"EARLY_PHASE1":11065,"PHASE1":11067,"PHASE2":11069,"PHASE3":11071,"PHASE4":11073,"NA":11075},{"trials":11066,"activeCount":103},[],{"trials":11068,"activeCount":103},[],{"trials":11070,"activeCount":103},[],{"trials":11072,"activeCount":103},[],{"trials":11074,"activeCount":103},[],{"trials":11076,"activeCount":103},[11077],{"nctId":11078,"briefTitle":11079,"status":115,"phases":11080,"primaryCompletion":3049,"completion":2459,"start":4740,"enrollment":8747,"conditions":11081,"interventions":11082},"NCT01530126","Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain",[95],[9605],[11063,11083,11084],"B-TCP + 1.0 mg\u002Fml rhPDGF-BB in buffer","B-TCP +buffer",{"intervention":11083,"totalTrials":241,"cells":11086},{"EARLY_PHASE1":11087,"PHASE1":11089,"PHASE2":11091,"PHASE3":11093,"PHASE4":11095,"NA":11097},{"trials":11088,"activeCount":103},[],{"trials":11090,"activeCount":103},[],{"trials":11092,"activeCount":103},[],{"trials":11094,"activeCount":103},[],{"trials":11096,"activeCount":103},[],{"trials":11098,"activeCount":103},[11099],{"nctId":11078,"briefTitle":11079,"status":115,"phases":11100,"primaryCompletion":3049,"completion":2459,"start":4740,"enrollment":8747,"conditions":11101,"interventions":11102},[95],[9605],[11063,11083,11084],{"intervention":11084,"totalTrials":241,"cells":11104},{"EARLY_PHASE1":11105,"PHASE1":11107,"PHASE2":11109,"PHASE3":11111,"PHASE4":11113,"NA":11115},{"trials":11106,"activeCount":103},[],{"trials":11108,"activeCount":103},[],{"trials":11110,"activeCount":103},[],{"trials":11112,"activeCount":103},[],{"trials":11114,"activeCount":103},[],{"trials":11116,"activeCount":103},[11117],{"nctId":11078,"briefTitle":11079,"status":115,"phases":11118,"primaryCompletion":3049,"completion":2459,"start":4740,"enrollment":8747,"conditions":11119,"interventions":11120},[95],[9605],[11063,11083,11084],{"intervention":11122,"totalTrials":241,"cells":11123},"Curosurf®",{"EARLY_PHASE1":11124,"PHASE1":11126,"PHASE2":11128,"PHASE3":11130,"PHASE4":11132,"NA":11134},{"trials":11125,"activeCount":103},[],{"trials":11127,"activeCount":103},[],{"trials":11129,"activeCount":103},[],{"trials":11131,"activeCount":103},[],{"trials":11133,"activeCount":103},[],{"trials":11135,"activeCount":103},[11136],{"nctId":11137,"briefTitle":11138,"status":281,"phases":11139,"primaryCompletion":284,"start":3830,"enrollment":103,"conditions":11140,"interventions":11142},"NCT01537354","Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome",[95],[11141],"Respiratory Distress Syndrome",[11122,11143],"Survanta®",{"intervention":11143,"totalTrials":241,"cells":11145},{"EARLY_PHASE1":11146,"PHASE1":11148,"PHASE2":11150,"PHASE3":11152,"PHASE4":11154,"NA":11156},{"trials":11147,"activeCount":103},[],{"trials":11149,"activeCount":103},[],{"trials":11151,"activeCount":103},[],{"trials":11153,"activeCount":103},[],{"trials":11155,"activeCount":103},[],{"trials":11157,"activeCount":103},[11158],{"nctId":11137,"briefTitle":11138,"status":281,"phases":11159,"primaryCompletion":284,"start":3830,"enrollment":103,"conditions":11160,"interventions":11161},[95],[11141],[11122,11143],{"intervention":11163,"totalTrials":241,"cells":11164},"Anesthetics, Intravenous",{"EARLY_PHASE1":11165,"PHASE1":11167,"PHASE2":11169,"PHASE3":11171,"PHASE4":11173,"NA":11175},{"trials":11166,"activeCount":103},[],{"trials":11168,"activeCount":103},[],{"trials":11170,"activeCount":103},[],{"trials":11172,"activeCount":103},[],{"trials":11174,"activeCount":103},[],{"trials":11176,"activeCount":103},[11177],{"nctId":11178,"briefTitle":11179,"status":11180,"phases":11181,"primaryCompletion":1682,"start":283,"enrollment":641,"conditions":11182,"interventions":11184},"NCT02659228","Assessing Covert Consciousness in Unresponsive Patients","UNKNOWN",[95],[11183],"Consciousness Disorders",[11163],{"intervention":11186,"totalTrials":241,"cells":11187},"Lubiprostone",{"EARLY_PHASE1":11188,"PHASE1":11190,"PHASE2":11192,"PHASE3":11194,"PHASE4":11196,"NA":11198},{"trials":11189,"activeCount":103},[],{"trials":11191,"activeCount":103},[],{"trials":11193,"activeCount":103},[],{"trials":11195,"activeCount":103},[],{"trials":11197,"activeCount":103},[],{"trials":11199,"activeCount":103},[11200],{"nctId":11201,"briefTitle":11202,"status":115,"phases":11203,"primaryCompletion":5986,"completion":5986,"start":8835,"enrollment":641,"conditions":11204,"interventions":11206},"NCT01162863","Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation",[95],[3937,11205],"Constipation",[11186],{"intervention":11208,"totalTrials":241,"cells":11209},"Heparin will be used for needle priming",{"EARLY_PHASE1":11210,"PHASE1":11212,"PHASE2":11214,"PHASE3":11216,"PHASE4":11218,"NA":11220},{"trials":11211,"activeCount":103},[],{"trials":11213,"activeCount":103},[],{"trials":11215,"activeCount":103},[],{"trials":11217,"activeCount":103},[],{"trials":11219,"activeCount":103},[],{"trials":11221,"activeCount":103},[11222],{"nctId":11223,"briefTitle":11224,"status":211,"phases":11225,"primaryCompletion":6703,"completion":11226,"start":11227,"enrollment":151,"conditions":11228,"interventions":11231},"NCT04764396","Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies",[95],"2021-07-06","2021-03-12",[11229,11230],"Pancreas","Mass Lesion",[11208,11232],"Saline",{"intervention":11232,"totalTrials":241,"cells":11234},{"EARLY_PHASE1":11235,"PHASE1":11237,"PHASE2":11239,"PHASE3":11241,"PHASE4":11243,"NA":11245},{"trials":11236,"activeCount":103},[],{"trials":11238,"activeCount":103},[],{"trials":11240,"activeCount":103},[],{"trials":11242,"activeCount":103},[],{"trials":11244,"activeCount":103},[],{"trials":11246,"activeCount":103},[11247],{"nctId":11223,"briefTitle":11224,"status":211,"phases":11248,"primaryCompletion":6703,"completion":11226,"start":11227,"enrollment":151,"conditions":11249,"interventions":11250},[95],[11229,11230],[11208,11232],{"intervention":11252,"totalTrials":241,"cells":11253},"Dietary manipulation",{"EARLY_PHASE1":11254,"PHASE1":11256,"PHASE2":11258,"PHASE3":11260,"PHASE4":11262,"NA":11264},{"trials":11255,"activeCount":103},[],{"trials":11257,"activeCount":103},[],{"trials":11259,"activeCount":103},[],{"trials":11261,"activeCount":103},[],{"trials":11263,"activeCount":103},[],{"trials":11265,"activeCount":103},[11266],{"nctId":11267,"briefTitle":11268,"status":115,"phases":11269,"primaryCompletion":11270,"completion":11271,"start":11272,"enrollment":620,"conditions":11273,"interventions":11275},"NCT03922685","Effects of Diet and Exercise on Circadian Glycemia",[95],"2017-08-31","2019-04","2016-09-01",[11274],"Glucose Intolerance",[11252,11252],{"intervention":11277,"totalTrials":241,"cells":11278},"tretinoin",{"EARLY_PHASE1":11279,"PHASE1":11281,"PHASE2":11283,"PHASE3":11285,"PHASE4":11287,"NA":11289},{"trials":11280,"activeCount":103},[],{"trials":11282,"activeCount":103},[],{"trials":11284,"activeCount":103},[],{"trials":11286,"activeCount":103},[],{"trials":11288,"activeCount":103},[],{"trials":11290,"activeCount":103},[11291],{"nctId":11292,"briefTitle":11293,"status":115,"phases":11294,"primaryCompletion":11295,"completion":11296,"start":11297,"enrollment":8747,"conditions":11298,"interventions":11301},"NCT00003598","UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia",[95],"2001-03","2009-11","1999-01",[11299,11300],"Cervical Cancer","Precancerous\u002FNonmalignant Condition",[11277],{"intervention":11303,"totalTrials":241,"cells":11304},"Aromatase inhibitor",{"EARLY_PHASE1":11305,"PHASE1":11307,"PHASE2":11309,"PHASE3":11311,"PHASE4":11313,"NA":11315},{"trials":11306,"activeCount":103},[],{"trials":11308,"activeCount":103},[],{"trials":11310,"activeCount":103},[],{"trials":11312,"activeCount":103},[],{"trials":11314,"activeCount":103},[],{"trials":11316,"activeCount":103},[11317],{"nctId":11318,"briefTitle":11319,"status":115,"phases":11320,"primaryCompletion":11321,"completion":11321,"start":11322,"enrollment":11323,"conditions":11324,"interventions":11327},"NCT05700006","Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging",[],"2026-02-26","2022-07-25",94,[11325,8263,11326],"Breast Neoplasm Female","Aging",[11303],{"intervention":11329,"totalTrials":241,"cells":11330},"Fenofibrate",{"EARLY_PHASE1":11331,"PHASE1":11333,"PHASE2":11335,"PHASE3":11337,"PHASE4":11339,"NA":11341},{"trials":11332,"activeCount":103},[],{"trials":11334,"activeCount":103},[],{"trials":11336,"activeCount":103},[],{"trials":11338,"activeCount":103},[],{"trials":11340,"activeCount":103},[],{"trials":11342,"activeCount":103},[11343],{"nctId":11344,"briefTitle":11345,"status":115,"phases":11346,"primaryCompletion":5537,"completion":5537,"start":7029,"enrollment":641,"conditions":11347,"interventions":11349},"NCT00422396","Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis",[95],[11348],"Hypertriglyceridemia With the Metabolic Syndrome",[11329],{"intervention":11351,"totalTrials":241,"cells":11352},"Intravenous Sedatives with or Without Analgesia",{"EARLY_PHASE1":11353,"PHASE1":11355,"PHASE2":11357,"PHASE3":11359,"PHASE4":11361,"NA":11363},{"trials":11354,"activeCount":103},[],{"trials":11356,"activeCount":103},[],{"trials":11358,"activeCount":103},[],{"trials":11360,"activeCount":103},[],{"trials":11362,"activeCount":103},[],{"trials":11364,"activeCount":103},[11365],{"nctId":11366,"briefTitle":11367,"status":115,"phases":11368,"primaryCompletion":11369,"completion":11369,"start":11370,"enrollment":20,"conditions":11371,"interventions":11374},"NCT05756439","Hemodynamic Changes During Implant Surgery with Intravenous Conscious Sedation",[],"2022-05-26","2022-02-03",[11372,11373],"Blood Pressure","Dental Anxiety",[11351,11375],"No IV sedation",{"intervention":11375,"totalTrials":241,"cells":11377},{"EARLY_PHASE1":11378,"PHASE1":11380,"PHASE2":11382,"PHASE3":11384,"PHASE4":11386,"NA":11388},{"trials":11379,"activeCount":103},[],{"trials":11381,"activeCount":103},[],{"trials":11383,"activeCount":103},[],{"trials":11385,"activeCount":103},[],{"trials":11387,"activeCount":103},[],{"trials":11389,"activeCount":103},[11390],{"nctId":11366,"briefTitle":11367,"status":115,"phases":11391,"primaryCompletion":11369,"completion":11369,"start":11370,"enrollment":20,"conditions":11392,"interventions":11393},[],[11372,11373],[11351,11375],{"intervention":11395,"totalTrials":241,"cells":11396},"11C-sarcosine",{"EARLY_PHASE1":11397,"PHASE1":11399,"PHASE2":11401,"PHASE3":11403,"PHASE4":11405,"NA":11407},{"trials":11398,"activeCount":103},[],{"trials":11400,"activeCount":103},[],{"trials":11402,"activeCount":103},[],{"trials":11404,"activeCount":103},[],{"trials":11406,"activeCount":103},[],{"trials":11408,"activeCount":103},[11409],{"nctId":11410,"briefTitle":11411,"status":115,"phases":11412,"primaryCompletion":11413,"completion":11413,"start":1683,"enrollment":451,"conditions":11414,"interventions":11415},"NCT02462447","Carbon-11 Labeled Sarcosine in Prostate Cancer",[],"2017-02-08",[25],[11395,11416],"11C-choline",{"intervention":11416,"totalTrials":241,"cells":11418},{"EARLY_PHASE1":11419,"PHASE1":11421,"PHASE2":11423,"PHASE3":11425,"PHASE4":11427,"NA":11429},{"trials":11420,"activeCount":103},[],{"trials":11422,"activeCount":103},[],{"trials":11424,"activeCount":103},[],{"trials":11426,"activeCount":103},[],{"trials":11428,"activeCount":103},[],{"trials":11430,"activeCount":103},[11431],{"nctId":11410,"briefTitle":11411,"status":115,"phases":11432,"primaryCompletion":11413,"completion":11413,"start":1683,"enrollment":451,"conditions":11433,"interventions":11434},[],[25],[11395,11416],{"intervention":11436,"totalTrials":241,"cells":11437},"fluorescence in situ hybridization",{"EARLY_PHASE1":11438,"PHASE1":11440,"PHASE2":11442,"PHASE3":11444,"PHASE4":11446,"NA":11448},{"trials":11439,"activeCount":103},[],{"trials":11441,"activeCount":103},[],{"trials":11443,"activeCount":103},[],{"trials":11445,"activeCount":103},[],{"trials":11447,"activeCount":103},[],{"trials":11449,"activeCount":103},[11450],{"nctId":11451,"briefTitle":11452,"status":115,"phases":11453,"primaryCompletion":2975,"completion":271,"start":11454,"enrollment":530,"conditions":11455,"interventions":11458},"NCT00900094","UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer",[],"2000-06",[19,5657,264,11456,11457,8889,2374],"Liver Cancer","Lung Cancer",[11436,11459,11460],"polymerase chain reaction","protein expression analysis",{"intervention":11459,"totalTrials":241,"cells":11462},{"EARLY_PHASE1":11463,"PHASE1":11465,"PHASE2":11467,"PHASE3":11469,"PHASE4":11471,"NA":11473},{"trials":11464,"activeCount":103},[],{"trials":11466,"activeCount":103},[],{"trials":11468,"activeCount":103},[],{"trials":11470,"activeCount":103},[],{"trials":11472,"activeCount":103},[],{"trials":11474,"activeCount":103},[11475],{"nctId":11451,"briefTitle":11452,"status":115,"phases":11476,"primaryCompletion":2975,"completion":271,"start":11454,"enrollment":530,"conditions":11477,"interventions":11478},[],[19,5657,264,11456,11457,8889,2374],[11436,11459,11460],{"intervention":11460,"totalTrials":241,"cells":11480},{"EARLY_PHASE1":11481,"PHASE1":11483,"PHASE2":11485,"PHASE3":11487,"PHASE4":11489,"NA":11491},{"trials":11482,"activeCount":103},[],{"trials":11484,"activeCount":103},[],{"trials":11486,"activeCount":103},[],{"trials":11488,"activeCount":103},[],{"trials":11490,"activeCount":103},[],{"trials":11492,"activeCount":103},[11493],{"nctId":11451,"briefTitle":11452,"status":115,"phases":11494,"primaryCompletion":2975,"completion":271,"start":11454,"enrollment":530,"conditions":11495,"interventions":11496},[],[19,5657,264,11456,11457,8889,2374],[11436,11459,11460],{"intervention":11498,"totalTrials":241,"cells":11499},"Paclitaxel 80mg\u002Fm2 weekly x 12 weeks",{"EARLY_PHASE1":11500,"PHASE1":11502,"PHASE2":11504,"PHASE3":11506,"PHASE4":11508,"NA":11510},{"trials":11501,"activeCount":103},[],{"trials":11503,"activeCount":103},[],{"trials":11505,"activeCount":103},[],{"trials":11507,"activeCount":103},[],{"trials":11509,"activeCount":103},[],{"trials":11511,"activeCount":103},[11512],{"nctId":11513,"briefTitle":11514,"status":115,"phases":11515,"primaryCompletion":11516,"completion":11516,"start":3853,"enrollment":641,"conditions":11517,"interventions":11518},"NCT02338115","Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients",[],"2016-12-20",[19],[11498],{"intervention":11520,"totalTrials":241,"cells":11521},"sincalide",{"EARLY_PHASE1":11522,"PHASE1":11524,"PHASE2":11526,"PHASE3":11528,"PHASE4":11530,"NA":11532},{"trials":11523,"activeCount":103},[],{"trials":11525,"activeCount":103},[],{"trials":11527,"activeCount":103},[],{"trials":11529,"activeCount":103},[],{"trials":11531,"activeCount":103},[],{"trials":11533,"activeCount":103},[11534],{"nctId":11535,"briefTitle":11536,"status":115,"phases":11537,"completion":8421,"start":11538,"enrollment":11539,"conditions":11540,"interventions":11541},"NCT00004414","Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis",[95],"1997-09",252,[5189],[11520],{"intervention":11543,"totalTrials":241,"cells":11544},"Estradiol",{"EARLY_PHASE1":11545,"PHASE1":11547,"PHASE2":11549,"PHASE3":11551,"PHASE4":11553,"NA":11555},{"trials":11546,"activeCount":103},[],{"trials":11548,"activeCount":103},[],{"trials":11550,"activeCount":103},[],{"trials":11552,"activeCount":103},[],{"trials":11554,"activeCount":103},[],{"trials":11556,"activeCount":103},[11557],{"nctId":11558,"briefTitle":11559,"status":115,"phases":11560,"primaryCompletion":1135,"completion":1135,"start":11561,"enrollment":404,"conditions":11562,"interventions":11564},"NCT01046643","Early Menopause Hormone Treatment and Cognition",[95],"2010-05",[11563],"Menopausal Syndrome",[11543,11565,11566],"Progesterone (P10) x90","Progesterone (P10) x10",{"intervention":11565,"totalTrials":241,"cells":11568},{"EARLY_PHASE1":11569,"PHASE1":11571,"PHASE2":11573,"PHASE3":11575,"PHASE4":11577,"NA":11579},{"trials":11570,"activeCount":103},[],{"trials":11572,"activeCount":103},[],{"trials":11574,"activeCount":103},[],{"trials":11576,"activeCount":103},[],{"trials":11578,"activeCount":103},[],{"trials":11580,"activeCount":103},[11581],{"nctId":11558,"briefTitle":11559,"status":115,"phases":11582,"primaryCompletion":1135,"completion":1135,"start":11561,"enrollment":404,"conditions":11583,"interventions":11584},[95],[11563],[11543,11565,11566],{"intervention":11566,"totalTrials":241,"cells":11586},{"EARLY_PHASE1":11587,"PHASE1":11589,"PHASE2":11591,"PHASE3":11593,"PHASE4":11595,"NA":11597},{"trials":11588,"activeCount":103},[],{"trials":11590,"activeCount":103},[],{"trials":11592,"activeCount":103},[],{"trials":11594,"activeCount":103},[],{"trials":11596,"activeCount":103},[],{"trials":11598,"activeCount":103},[11599],{"nctId":11558,"briefTitle":11559,"status":115,"phases":11600,"primaryCompletion":1135,"completion":1135,"start":11561,"enrollment":404,"conditions":11601,"interventions":11602},[95],[11563],[11543,11565,11566],{"intervention":10675,"totalTrials":241,"cells":11604},{"EARLY_PHASE1":11605,"PHASE1":11607,"PHASE2":11609,"PHASE3":11611,"PHASE4":11613,"NA":11615},{"trials":11606,"activeCount":103},[],{"trials":11608,"activeCount":103},[],{"trials":11610,"activeCount":103},[],{"trials":11612,"activeCount":103},[],{"trials":11614,"activeCount":103},[],{"trials":11616,"activeCount":103},[11617],{"nctId":10670,"briefTitle":10671,"status":115,"phases":11618,"primaryCompletion":3854,"completion":3353,"start":8511,"enrollment":20,"conditions":11619,"interventions":11620},[],[19,10489,8263],[10648,10675,10676],{"intervention":10676,"totalTrials":241,"cells":11622},{"EARLY_PHASE1":11623,"PHASE1":11625,"PHASE2":11627,"PHASE3":11629,"PHASE4":11631,"NA":11633},{"trials":11624,"activeCount":103},[],{"trials":11626,"activeCount":103},[],{"trials":11628,"activeCount":103},[],{"trials":11630,"activeCount":103},[],{"trials":11632,"activeCount":103},[],{"trials":11634,"activeCount":103},[11635],{"nctId":10670,"briefTitle":10671,"status":115,"phases":11636,"primaryCompletion":3854,"completion":3353,"start":8511,"enrollment":20,"conditions":11637,"interventions":11638},[],[19,10489,8263],[10648,10675,10676],{"intervention":11640,"totalTrials":241,"cells":11641},"Trivalent Influenza Vaccine",{"EARLY_PHASE1":11642,"PHASE1":11644,"PHASE2":11646,"PHASE3":11648,"PHASE4":11650,"NA":11652},{"trials":11643,"activeCount":103},[],{"trials":11645,"activeCount":103},[],{"trials":11647,"activeCount":103},[],{"trials":11649,"activeCount":103},[],{"trials":11651,"activeCount":103},[],{"trials":11653,"activeCount":103},[11654],{"nctId":11655,"briefTitle":11656,"status":115,"phases":11657,"primaryCompletion":5293,"completion":3232,"start":213,"enrollment":11658,"conditions":11659,"interventions":11661},"NCT01264601","Safe Administration of Flu Vaccine to Egg Allergic Children",[95],31,[11660],"Egg Allergy",[11640],{"intervention":11663,"totalTrials":241,"cells":11664},"Nicotine patches",{"EARLY_PHASE1":11665,"PHASE1":11667,"PHASE2":11669,"PHASE3":11671,"PHASE4":11673,"NA":11675},{"trials":11666,"activeCount":103},[],{"trials":11668,"activeCount":103},[],{"trials":11670,"activeCount":103},[],{"trials":11672,"activeCount":103},[],{"trials":11674,"activeCount":103},[],{"trials":11676,"activeCount":103},[11677],{"nctId":11678,"briefTitle":11679,"status":115,"phases":11680,"primaryCompletion":461,"completion":461,"start":3671,"enrollment":11681,"conditions":11682,"interventions":11685},"NCT00534404","A Randomized Trial of Internet Access to Nicotine Patches",[95],2485,[11683,11684],"Smoking Cessation","Tobacco Use Disorder",[11663],{"intervention":11687,"totalTrials":241,"cells":11688},"Nicotine patches 21 mg",{"EARLY_PHASE1":11689,"PHASE1":11691,"PHASE2":11693,"PHASE3":11695,"PHASE4":11697,"NA":11699},{"trials":11690,"activeCount":103},[],{"trials":11692,"activeCount":103},[],{"trials":11694,"activeCount":103},[],{"trials":11696,"activeCount":103},[],{"trials":11698,"activeCount":103},[],{"trials":11700,"activeCount":103},[11701],{"nctId":11702,"briefTitle":11703,"status":115,"phases":11704,"primaryCompletion":1438,"completion":1438,"start":3473,"enrollment":11705,"conditions":11706,"interventions":11707},"NCT01923467","Project Quit: Positive vs. Negative Offers of an Online Stop Smoking Program",[95],767,[11683],[11687],{"intervention":11709,"totalTrials":241,"cells":11710},"anastrozole, letrozole, exemestane",{"EARLY_PHASE1":11711,"PHASE1":11713,"PHASE2":11715,"PHASE3":11717,"PHASE4":11719,"NA":11721},{"trials":11712,"activeCount":103},[],{"trials":11714,"activeCount":103},[],{"trials":11716,"activeCount":103},[],{"trials":11718,"activeCount":103},[],{"trials":11720,"activeCount":103},[],{"trials":11722,"activeCount":103},[11723],{"nctId":11724,"briefTitle":11725,"status":115,"phases":11726,"primaryCompletion":10170,"completion":10170,"start":1567,"enrollment":11727,"conditions":11728,"interventions":11729},"NCT01896050","Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",[],115,[19,8263,27],[11709,11730],"Tamoxifen",{"intervention":11730,"totalTrials":241,"cells":11732},{"EARLY_PHASE1":11733,"PHASE1":11735,"PHASE2":11737,"PHASE3":11739,"PHASE4":11741,"NA":11743},{"trials":11734,"activeCount":103},[],{"trials":11736,"activeCount":103},[],{"trials":11738,"activeCount":103},[],{"trials":11740,"activeCount":103},[],{"trials":11742,"activeCount":103},[],{"trials":11744,"activeCount":103},[11745],{"nctId":11724,"briefTitle":11725,"status":115,"phases":11746,"primaryCompletion":10170,"completion":10170,"start":1567,"enrollment":11727,"conditions":11747,"interventions":11748},[],[19,8263,27],[11709,11730],{"intervention":11750,"totalTrials":241,"cells":11751},"Ocrelizumab",{"EARLY_PHASE1":11752,"PHASE1":11754,"PHASE2":11756,"PHASE3":11758,"PHASE4":11760,"NA":11762},{"trials":11753,"activeCount":103},[],{"trials":11755,"activeCount":103},[],{"trials":11757,"activeCount":103},[],{"trials":11759,"activeCount":103},[],{"trials":11761,"activeCount":103},[],{"trials":11763,"activeCount":103},[11764],{"nctId":11765,"briefTitle":11766,"status":115,"phases":11767,"primaryCompletion":11768,"completion":11768,"start":11769,"enrollment":3133,"conditions":11770,"interventions":11771},"NCT04459988","Mechanistic Study of Ocrevus",[],"2022-10-25","2020-07-01",[3331],[11750],{"intervention":11773,"totalTrials":241,"cells":11774},"Pentasa 500 mg capsule x 2 with 240 mL water; single dose",{"EARLY_PHASE1":11775,"PHASE1":11777,"PHASE2":11779,"PHASE3":11781,"PHASE4":11783,"NA":11785},{"trials":11776,"activeCount":103},[],{"trials":11778,"activeCount":103},[],{"trials":11780,"activeCount":103},[],{"trials":11782,"activeCount":103},[],{"trials":11784,"activeCount":103},[],{"trials":11786,"activeCount":103},[11787],{"nctId":11788,"briefTitle":11789,"status":115,"phases":11790,"primaryCompletion":3302,"completion":11791,"start":3025,"enrollment":404,"conditions":11792,"interventions":11794},"NCT01999400","Correlation of Mesalamine Pharmacokinetics With Local Availability",[95],"2017-04",[11793],"Local Drug Concentration in Gastrointestinal Tract",[11773,11795,11796,11797],"Apriso 375 mg capsule x 3 with 240 mL water; single dose","Lialda 1200 mg tablet x 1 with 240 mL water; single dose","Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose",{"intervention":11795,"totalTrials":241,"cells":11799},{"EARLY_PHASE1":11800,"PHASE1":11802,"PHASE2":11804,"PHASE3":11806,"PHASE4":11808,"NA":11810},{"trials":11801,"activeCount":103},[],{"trials":11803,"activeCount":103},[],{"trials":11805,"activeCount":103},[],{"trials":11807,"activeCount":103},[],{"trials":11809,"activeCount":103},[],{"trials":11811,"activeCount":103},[11812],{"nctId":11788,"briefTitle":11789,"status":115,"phases":11813,"primaryCompletion":3302,"completion":11791,"start":3025,"enrollment":404,"conditions":11814,"interventions":11815},[95],[11793],[11773,11795,11796,11797],{"intervention":11796,"totalTrials":241,"cells":11817},{"EARLY_PHASE1":11818,"PHASE1":11820,"PHASE2":11822,"PHASE3":11824,"PHASE4":11826,"NA":11828},{"trials":11819,"activeCount":103},[],{"trials":11821,"activeCount":103},[],{"trials":11823,"activeCount":103},[],{"trials":11825,"activeCount":103},[],{"trials":11827,"activeCount":103},[],{"trials":11829,"activeCount":103},[11830],{"nctId":11788,"briefTitle":11789,"status":115,"phases":11831,"primaryCompletion":3302,"completion":11791,"start":3025,"enrollment":404,"conditions":11832,"interventions":11833},[95],[11793],[11773,11795,11796,11797],{"intervention":11797,"totalTrials":241,"cells":11835},{"EARLY_PHASE1":11836,"PHASE1":11838,"PHASE2":11840,"PHASE3":11842,"PHASE4":11844,"NA":11846},{"trials":11837,"activeCount":103},[],{"trials":11839,"activeCount":103},[],{"trials":11841,"activeCount":103},[],{"trials":11843,"activeCount":103},[],{"trials":11845,"activeCount":103},[],{"trials":11847,"activeCount":103},[11848],{"nctId":11788,"briefTitle":11789,"status":115,"phases":11849,"primaryCompletion":3302,"completion":11791,"start":3025,"enrollment":404,"conditions":11850,"interventions":11851},[95],[11793],[11773,11795,11796,11797],{"intervention":11853,"totalTrials":241,"cells":11854},"Efudex",{"EARLY_PHASE1":11855,"PHASE1":11857,"PHASE2":11859,"PHASE3":11861,"PHASE4":11863,"NA":11865},{"trials":11856,"activeCount":103},[],{"trials":11858,"activeCount":103},[],{"trials":11860,"activeCount":103},[],{"trials":11862,"activeCount":103},[],{"trials":11864,"activeCount":103},[],{"trials":11866,"activeCount":103},[11867],{"nctId":11868,"briefTitle":11869,"status":115,"phases":11870,"completion":11871,"start":6941,"enrollment":34,"conditions":11872,"interventions":11875},"NCT00121511","The Effect of Efudex Treatment on Photoaged Skin",[95],"2007-07",[11873,11874],"Photo-aging","Keratosis",[11853],{"intervention":11877,"totalTrials":241,"cells":11878},"Procedure: Regional phenylephrine arterial",{"EARLY_PHASE1":11879,"PHASE1":11881,"PHASE2":11883,"PHASE3":11885,"PHASE4":11887,"NA":11889},{"trials":11880,"activeCount":103},[],{"trials":11882,"activeCount":103},[],{"trials":11884,"activeCount":103},[],{"trials":11886,"activeCount":103},[],{"trials":11888,"activeCount":103},[],{"trials":11890,"activeCount":103},[11891],{"nctId":11892,"briefTitle":11893,"status":211,"phases":11894,"primaryCompletion":8835,"completion":8835,"start":4851,"enrollment":8789,"conditions":11895,"interventions":11896},"NCT00356265","Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide",[95],[8554,30],[11877],{"intervention":11898,"totalTrials":241,"cells":11899},"Amiodarone and cardioversion",{"EARLY_PHASE1":11900,"PHASE1":11902,"PHASE2":11904,"PHASE3":11906,"PHASE4":11908,"NA":11910},{"trials":11901,"activeCount":103},[],{"trials":11903,"activeCount":103},[],{"trials":11905,"activeCount":103},[],{"trials":11907,"activeCount":103},[],{"trials":11909,"activeCount":103},[],{"trials":11911,"activeCount":103},[11912],{"nctId":11913,"briefTitle":11914,"status":115,"phases":11915,"completion":4704,"start":10240,"enrollment":2193,"conditions":11916,"interventions":11917},"NCT00272636","Radiofrequency Catheter Ablation for Chronic Atrial Fibrillation",[95],[3963],[11898],{"intervention":11919,"totalTrials":241,"cells":11920},"Single dose of ibuprofen",{"EARLY_PHASE1":11921,"PHASE1":11923,"PHASE2":11925,"PHASE3":11927,"PHASE4":11929,"NA":11931},{"trials":11922,"activeCount":103},[],{"trials":11924,"activeCount":103},[],{"trials":11926,"activeCount":103},[],{"trials":11928,"activeCount":103},[],{"trials":11930,"activeCount":103},[],{"trials":11932,"activeCount":103},[11933],{"nctId":11934,"briefTitle":11935,"status":115,"phases":11936,"primaryCompletion":3761,"completion":6013,"start":1389,"enrollment":1362,"conditions":11937,"interventions":11938},"NCT02806869","Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment",[95],[2743],[11919],{"intervention":11940,"totalTrials":241,"cells":11941},"Levothyroxine",{"EARLY_PHASE1":11942,"PHASE1":11944,"PHASE2":11946,"PHASE3":11948,"PHASE4":11950,"NA":11952},{"trials":11943,"activeCount":103},[],{"trials":11945,"activeCount":103},[],{"trials":11947,"activeCount":103},[],{"trials":11949,"activeCount":103},[],{"trials":11951,"activeCount":103},[],{"trials":11953,"activeCount":103},[11954],{"nctId":11955,"briefTitle":11956,"status":115,"phases":11957,"primaryCompletion":11958,"completion":11959,"start":3149,"enrollment":11960,"conditions":11961,"interventions":11965},"NCT03134976","Wound Complications in Head and Neck Surgery",[],"2020-04-01","2020-05-01",51,[11962,362,11963,1138,11964],"Hypothyroidism; Surgery","Wound Heal","Laryngeal Fistula",[11940],{"intervention":11967,"totalTrials":241,"cells":11968},"ISOFLURANE- Experimental Arm",{"EARLY_PHASE1":11969,"PHASE1":11971,"PHASE2":11973,"PHASE3":11975,"PHASE4":11977,"NA":11979},{"trials":11970,"activeCount":103},[],{"trials":11972,"activeCount":103},[],{"trials":11974,"activeCount":103},[],{"trials":11976,"activeCount":103},[],{"trials":11978,"activeCount":103},[],{"trials":11980,"activeCount":103},[11981],{"nctId":11982,"briefTitle":11983,"status":115,"phases":11984,"primaryCompletion":11985,"completion":11985,"start":486,"enrollment":641,"conditions":11986,"interventions":11987},"NCT01911195","Reconstructing Consciousness and Cognition",[95],"2015-02-09",[1723],[11967],{"intervention":11989,"totalTrials":241,"cells":11990},"Amlodipine Besylate",{"EARLY_PHASE1":11991,"PHASE1":11993,"PHASE2":11995,"PHASE3":11997,"PHASE4":11999,"NA":12001},{"trials":11992,"activeCount":103},[],{"trials":11994,"activeCount":103},[],{"trials":11996,"activeCount":103},[],{"trials":11998,"activeCount":103},[],{"trials":12000,"activeCount":103},[],{"trials":12002,"activeCount":103},[12003],{"nctId":12004,"briefTitle":12005,"status":281,"phases":12006,"primaryCompletion":12007,"completion":12007,"start":12008,"enrollment":103,"conditions":12009,"interventions":12010},"NCT03722381","Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis",[],"2020-01-30","2020-01",[622,623],[11989],{"intervention":12012,"totalTrials":241,"cells":12013},"Teriflunomide",{"EARLY_PHASE1":12014,"PHASE1":12016,"PHASE2":12018,"PHASE3":12020,"PHASE4":12022,"NA":12024},{"trials":12015,"activeCount":103},[],{"trials":12017,"activeCount":103},[],{"trials":12019,"activeCount":103},[],{"trials":12021,"activeCount":103},[],{"trials":12023,"activeCount":103},[],{"trials":12025,"activeCount":103},[12026],{"nctId":12027,"briefTitle":12028,"status":115,"phases":12029,"primaryCompletion":12030,"completion":12030,"start":12031,"enrollment":404,"conditions":12032,"interventions":12034},"NCT03464448","Mechanistic Studies of Teriflunomide in RRMS",[],"2021-10-13","2018-04-17",[12033],"Relapsing Remitting Multiple Sclerosis",[12012],{"intervention":12036,"totalTrials":241,"cells":12037},"Iodine tincture",{"EARLY_PHASE1":12038,"PHASE1":12040,"PHASE2":12042,"PHASE3":12044,"PHASE4":12046,"NA":12048},{"trials":12039,"activeCount":103},[],{"trials":12041,"activeCount":103},[],{"trials":12043,"activeCount":103},[],{"trials":12045,"activeCount":103},[],{"trials":12047,"activeCount":103},[],{"trials":12049,"activeCount":103},[12050],{"nctId":12051,"briefTitle":12052,"status":115,"phases":12053,"primaryCompletion":1567,"completion":11296,"start":1496,"enrollment":12054,"conditions":12055,"interventions":12057},"NCT01216761","A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions",[95],3879,[12056],"Bacteremia",[12036,12058,12059],"Chlorhexidine gluconate","Povidone iodine",{"intervention":12058,"totalTrials":241,"cells":12061},{"EARLY_PHASE1":12062,"PHASE1":12064,"PHASE2":12066,"PHASE3":12068,"PHASE4":12070,"NA":12072},{"trials":12063,"activeCount":103},[],{"trials":12065,"activeCount":103},[],{"trials":12067,"activeCount":103},[],{"trials":12069,"activeCount":103},[],{"trials":12071,"activeCount":103},[],{"trials":12073,"activeCount":103},[12074],{"nctId":12051,"briefTitle":12052,"status":115,"phases":12075,"primaryCompletion":1567,"completion":11296,"start":1496,"enrollment":12054,"conditions":12076,"interventions":12077},[95],[12056],[12036,12058,12059],{"intervention":12059,"totalTrials":241,"cells":12079},{"EARLY_PHASE1":12080,"PHASE1":12082,"PHASE2":12084,"PHASE3":12086,"PHASE4":12088,"NA":12090},{"trials":12081,"activeCount":103},[],{"trials":12083,"activeCount":103},[],{"trials":12085,"activeCount":103},[],{"trials":12087,"activeCount":103},[],{"trials":12089,"activeCount":103},[],{"trials":12091,"activeCount":103},[12092],{"nctId":12051,"briefTitle":12052,"status":115,"phases":12093,"primaryCompletion":1567,"completion":11296,"start":1496,"enrollment":12054,"conditions":12094,"interventions":12095},[95],[12056],[12036,12058,12059],{"intervention":12097,"totalTrials":241,"cells":12098},"Rosiglitazone",{"EARLY_PHASE1":12099,"PHASE1":12101,"PHASE2":12103,"PHASE3":12105,"PHASE4":12107,"NA":12109},{"trials":12100,"activeCount":103},[],{"trials":12102,"activeCount":103},[],{"trials":12104,"activeCount":103},[],{"trials":12106,"activeCount":103},[],{"trials":12108,"activeCount":103},[],{"trials":12110,"activeCount":103},[12111],{"nctId":12112,"briefTitle":12113,"status":115,"phases":12114,"completion":2371,"start":8576,"enrollment":5803,"conditions":12115,"interventions":12116},"NCT00549874","Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes",[95],[584],[12097,12117],"Glyburide",{"intervention":12117,"totalTrials":241,"cells":12119},{"EARLY_PHASE1":12120,"PHASE1":12122,"PHASE2":12124,"PHASE3":12126,"PHASE4":12128,"NA":12130},{"trials":12121,"activeCount":103},[],{"trials":12123,"activeCount":103},[],{"trials":12125,"activeCount":103},[],{"trials":12127,"activeCount":103},[],{"trials":12129,"activeCount":103},[],{"trials":12131,"activeCount":103},[12132],{"nctId":12112,"briefTitle":12113,"status":115,"phases":12133,"completion":2371,"start":8576,"enrollment":5803,"conditions":12134,"interventions":12135},[95],[584],[12097,12117],{"intervention":12137,"totalTrials":241,"cells":12138},"Tazorac",{"EARLY_PHASE1":12139,"PHASE1":12141,"PHASE2":12143,"PHASE3":12145,"PHASE4":12147,"NA":12149},{"trials":12140,"activeCount":103},[],{"trials":12142,"activeCount":103},[],{"trials":12144,"activeCount":103},[],{"trials":12146,"activeCount":103},[],{"trials":12148,"activeCount":103},[],{"trials":12150,"activeCount":103},[12151],{"nctId":12152,"briefTitle":12153,"status":115,"phases":12154,"primaryCompletion":11296,"completion":11296,"start":3783,"enrollment":557,"conditions":12155,"interventions":12158},"NCT00440024","The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance",[95],[12156,12157],"Sun-Damaged Skin","Retinoid Intolerance",[12137,12159,12160],"Dove Mild Cleanser","Dove Facial Moisturizer",{"intervention":12159,"totalTrials":241,"cells":12162},{"EARLY_PHASE1":12163,"PHASE1":12165,"PHASE2":12167,"PHASE3":12169,"PHASE4":12171,"NA":12173},{"trials":12164,"activeCount":103},[],{"trials":12166,"activeCount":103},[],{"trials":12168,"activeCount":103},[],{"trials":12170,"activeCount":103},[],{"trials":12172,"activeCount":103},[],{"trials":12174,"activeCount":103},[12175],{"nctId":12152,"briefTitle":12153,"status":115,"phases":12176,"primaryCompletion":11296,"completion":11296,"start":3783,"enrollment":557,"conditions":12177,"interventions":12178},[95],[12156,12157],[12137,12159,12160],{"intervention":12160,"totalTrials":241,"cells":12180},{"EARLY_PHASE1":12181,"PHASE1":12183,"PHASE2":12185,"PHASE3":12187,"PHASE4":12189,"NA":12191},{"trials":12182,"activeCount":103},[],{"trials":12184,"activeCount":103},[],{"trials":12186,"activeCount":103},[],{"trials":12188,"activeCount":103},[],{"trials":12190,"activeCount":103},[],{"trials":12192,"activeCount":103},[12193],{"nctId":12152,"briefTitle":12153,"status":115,"phases":12194,"primaryCompletion":11296,"completion":11296,"start":3783,"enrollment":557,"conditions":12195,"interventions":12196},[95],[12156,12157],[12137,12159,12160],{"intervention":12198,"totalTrials":241,"cells":12199},"MRI with Multihance",{"EARLY_PHASE1":12200,"PHASE1":12202,"PHASE2":12204,"PHASE3":12206,"PHASE4":12208,"NA":12210},{"trials":12201,"activeCount":103},[],{"trials":12203,"activeCount":103},[],{"trials":12205,"activeCount":103},[],{"trials":12207,"activeCount":103},[],{"trials":12209,"activeCount":103},[],{"trials":12211,"activeCount":103},[12212],{"nctId":12213,"briefTitle":12214,"status":115,"phases":12215,"primaryCompletion":3401,"completion":3401,"start":3473,"enrollment":4558,"conditions":12216,"interventions":12218},"NCT02226666","Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration",[],[12217],"Liver Tumor",[12198,12219],"MRI with Eovist",{"intervention":12219,"totalTrials":241,"cells":12221},{"EARLY_PHASE1":12222,"PHASE1":12224,"PHASE2":12226,"PHASE3":12228,"PHASE4":12230,"NA":12232},{"trials":12223,"activeCount":103},[],{"trials":12225,"activeCount":103},[],{"trials":12227,"activeCount":103},[],{"trials":12229,"activeCount":103},[],{"trials":12231,"activeCount":103},[],{"trials":12233,"activeCount":103},[12234],{"nctId":12213,"briefTitle":12214,"status":115,"phases":12235,"primaryCompletion":3401,"completion":3401,"start":3473,"enrollment":4558,"conditions":12236,"interventions":12237},[],[12217],[12198,12219],{"intervention":12239,"totalTrials":241,"cells":12240},"Lotemax",{"EARLY_PHASE1":12241,"PHASE1":12243,"PHASE2":12245,"PHASE3":12247,"PHASE4":12249,"NA":12251},{"trials":12242,"activeCount":103},[],{"trials":12244,"activeCount":103},[],{"trials":12246,"activeCount":103},[],{"trials":12248,"activeCount":103},[],{"trials":12250,"activeCount":103},[],{"trials":12252,"activeCount":103},[12253],{"nctId":12254,"briefTitle":12255,"status":115,"phases":12256,"primaryCompletion":6044,"completion":7839,"start":2952,"enrollment":1044,"conditions":12257,"interventions":12259},"NCT01695668","Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%",[95],[12258],"Dry Eyes",[12239,12260],"Restasis",{"intervention":12260,"totalTrials":241,"cells":12262},{"EARLY_PHASE1":12263,"PHASE1":12265,"PHASE2":12267,"PHASE3":12269,"PHASE4":12271,"NA":12273},{"trials":12264,"activeCount":103},[],{"trials":12266,"activeCount":103},[],{"trials":12268,"activeCount":103},[],{"trials":12270,"activeCount":103},[],{"trials":12272,"activeCount":103},[],{"trials":12274,"activeCount":103},[12275],{"nctId":12254,"briefTitle":12255,"status":115,"phases":12276,"primaryCompletion":6044,"completion":7839,"start":2952,"enrollment":1044,"conditions":12277,"interventions":12278},[95],[12258],[12239,12260],{"intervention":12280,"totalTrials":241,"cells":12281},"Growth-sparing instrumentation and titanium levels",{"EARLY_PHASE1":12282,"PHASE1":12284,"PHASE2":12286,"PHASE3":12288,"PHASE4":12290,"NA":12292},{"trials":12283,"activeCount":103},[],{"trials":12285,"activeCount":103},[],{"trials":12287,"activeCount":103},[],{"trials":12289,"activeCount":103},[],{"trials":12291,"activeCount":103},[],{"trials":12293,"activeCount":103},[12294],{"nctId":12295,"briefTitle":12296,"status":115,"phases":12297,"primaryCompletion":12298,"completion":12298,"start":12299,"enrollment":23,"conditions":12300,"interventions":12302},"NCT04069637","Serum and Urine Titanium Levels in Children With Early Onset Scoliosis Treated With Growth-Sparing Instrumentation",[],"2022-07-19","2019-11-07",[12301],"Early-Onset Scoliosis Deformity of Spine",[12280],{"intervention":12304,"totalTrials":241,"cells":12305},"hyperinsulinemic-euglycemic clamp",{"EARLY_PHASE1":12306,"PHASE1":12308,"PHASE2":12310,"PHASE3":12312,"PHASE4":12314,"NA":12316},{"trials":12307,"activeCount":103},[],{"trials":12309,"activeCount":103},[],{"trials":12311,"activeCount":103},[],{"trials":12313,"activeCount":103},[],{"trials":12315,"activeCount":103},[],{"trials":12317,"activeCount":103},[12318],{"nctId":12319,"briefTitle":12320,"status":115,"phases":12321,"primaryCompletion":12322,"completion":12322,"start":2409,"enrollment":251,"conditions":12323,"interventions":12324},"NCT02717832","Protection Against Insulin Resistance in Obesity",[95],"2019-08-09",[27,3017],[12304],{"intervention":12326,"totalTrials":241,"cells":12327},"growth hormone treatment",{"EARLY_PHASE1":12328,"PHASE1":12330,"PHASE2":12332,"PHASE3":12334,"PHASE4":12336,"NA":12338},{"trials":12329,"activeCount":103},[],{"trials":12331,"activeCount":103},[],{"trials":12333,"activeCount":103},[],{"trials":12335,"activeCount":103},[],{"trials":12337,"activeCount":103},[],{"trials":12339,"activeCount":103},[12340],{"nctId":12341,"briefTitle":12342,"status":115,"phases":12343,"primaryCompletion":4715,"completion":3401,"start":5536,"enrollment":5336,"conditions":12344,"interventions":12345},"NCT00355784","Growth Hormone as a Determinant of Weight Regulation",[95],[27],[12326],{"intervention":12347,"totalTrials":241,"cells":12348},"CelTx™",{"EARLY_PHASE1":12349,"PHASE1":12351,"PHASE2":12353,"PHASE3":12355,"PHASE4":12357,"NA":12359},{"trials":12350,"activeCount":103},[],{"trials":12352,"activeCount":103},[],{"trials":12354,"activeCount":103},[],{"trials":12356,"activeCount":103},[],{"trials":12358,"activeCount":103},[],{"trials":12360,"activeCount":103},[12361],{"nctId":12362,"briefTitle":12363,"status":115,"phases":12364,"primaryCompletion":859,"completion":859,"start":3596,"enrollment":4428,"conditions":12365,"interventions":12367},"NCT01134081","Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts",[95],[12366],"Gingival Recession",[12347]]